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The purpose of this study is to evaluate the association between sustained-release 
morphine (Avinza®), and performance on neuropsychological tests assessing short-
term memory, information processing, and motor skills in chronic pain patients, while 
controlling for stages of pain model variables and the effects of benzodiazepines.  
A convenience sampling procedure was utilized to enroll a sample of patients who 
had a trial of short-acting narcotic analgesics for their chronic non-malignant pain.   
Enrolled patients were treated with long-acting morphine Avinza.®  Patient interviews 
were conducted at enrollment and one-month follow-up.  A total of 129 patients were 
enrolled in the study.   Mean pain intensity ratings at the highest, lowest, and average 
levels in the previous week were lower at follow-up (10.90, 4.56. 7.64) than at 
baseline (12.71, 6.76, 10.01) respectively.  Reduction in pain levels was associated 
 viii
with a corresponding reduction in levels of pain unpleasantness, pain suffering, and 
pain behaviors.  The models evaluating the associations between the stages of pain 
model variables, morphine dose, benzodiazepine dose, and digit span test (chi square 
= 147.79, p = 0.76), digit symbol test (chi square = 128.06, p = 0.5), and paced 
auditory serial attention test fit the data well (chi square = 160.39, p = 0.85).  There 
was a statistically significant inverse association between frequency of pain behaviors 
and digit span test scores at baseline (-0.49, p = 0.01).  Although the association 
between pain behaviors and digit symbol test scores (- 17. 0 %, p  = 0.09) and paced 
auditory serial addition test scores (-4.0%, p = .28) at baseline were not statistically 
significant, a large negative effect was found.  At follow-up, the association between 
pain behaviors and digit span test was positive and not significant.  The negative 
association between frequency of pain behaviors and digit symbol test scores (-4.4%, 
p = 0.67 ) and paced auditory serial addition test scores (-2.8%, p = 0.21) at follow-up 
were considerably weaker.  There were no significant association between opioid 
dose and cognitive function test scores.  Opioid therapy, particularly, sustained-
release morphine therapy (Avinza) does not contribute to cognitive impairment in 
chronic pain patients. 
   
 ix
Table of Contents 
List of Figures ..................................................................................................xiii 
List of Tables.....................................................................................................xv 
Chapter 1: Background and Introduction .........................................................1 
1.1 Introduction............................................................................................................. 1 
1.2 Purpose of the Study............................................................................................... 2 
1.3 Literature Review ................................................................................................... 3 
1.3.1 Definition of Chronic Pain .............................................................................. 3 
1.3.2 Epidemiology and Economics of Chronic Non-malignant Pain (CNMP) .. 3 
1.3.3 Chronic Pain Syndrome – Diagnostic Criteria ............................................. 5 
1.3.4 Pain Management Guidelines ......................................................................... 7 
1.3.4.1 Guidelines for Opioid Therapy in Chronic Non-malignant Pain Patients
................................................................................................................................... 10 
1.3.5 Treatment Options for Chronic Pain Syndrome Patients.......................... 10 
1.3.6 Opioids in Chronic Non-Malignant Pain..................................................... 12 
1.3.6.1 Narcotic Analgesic Classification .............................................................. 12 
1.3.6.2 Disadvantages of Narcotic Analgesics....................................................... 13 
1.3.6.3 Long-Acting Narcotic Analgesic Therapy ................................................ 16 
1.3.6.4 Morphine Sulfate Extended Release (Avinza): ........................................ 17 
1.3.7 Studies Assessing Safety and Efficacy of Opioid Therapy in Chronic Non-
Malignant Pain ........................................................................................................ 19 
1.3.7.1 Summary of Studies Examining the Safety and Efficacy of Opioid 
Therapy in Chronic Non-Malignant Pain............................................................. 36 
1.3.8 Mechanisms of Pain ....................................................................................... 37 
1.3.8.1 The Gate Control Theory (GCT)............................................................... 38 
1.3.8.2 Neuromatrix Theory................................................................................... 39 
1.3.9 Neuropsychological Functioning .................................................................. 40 
1.3.10 Neuropsychological Tests Used to Assess Memory and Function Among 
Pain Patients ............................................................................................................ 41 
1.3.10.1 Attention Tests .......................................................................................... 41 
1.3.10.2 Visual, Visuomotor, and Auditory Tests................................................. 46 
1.3.10.3 Language Tests.......................................................................................... 48 
1.3.10.4 Memory Tests ............................................................................................ 48 
1.3.10.5 Executive Functions and Motor Performance Tests.............................. 49 
1.3.11 Cognitive—Affective Model of the Interruptive Function of Pain.......... 54 
1.3.12 Cognitive Function in Chronic Pain Patients............................................ 56 
1.3.13 Effects of Experimentally Induced Pain on Attention.............................. 69 
1.3.14 Effects of Opioids on Cognition in Healthy Subjects................................ 75 
Effects on Motor Tasks and Reaction Times: ...................................................... 75 
Effects on Sustained Attention: ............................................................................. 77 
Effects on Complex Psychomotor Performance: ................................................. 77 
Effects on Memory (Delayed Recall): ................................................................... 78 
1.3.15 Effects of Opioids on Cognitive Ability in Chronic Non -Malignant Pain 
(CNMP) Patients ..................................................................................................... 84 
 x
1.3.16 Effects of Opioids on Cognitive Function in Patients with Cancer Pain 91 
Chapter 2: Study Objectives and Theoretical Framework.............................94 
2.1 Study Objectives.................................................................................................... 94 
2.2 Theoretical Framework for Study....................................................................... 95 
2.2.1 Stages of Pain Model...................................................................................... 95 
2.3 Key Model Variables ............................................................................................ 97 
2.3.1 Stage I.............................................................................................................. 97 
2.3.2 Stage II ............................................................................................................ 98 
2.3.3 Stage III........................................................................................................... 99 
2.3.4 Stage IV......................................................................................................... 101 
2.3.5 Narcotic Analgesics...................................................................................... 103 
2.3.6 Benzodiazepines ........................................................................................... 103 
2.3.7 Association between Exogenous Variables and Stages of Pain Model.... 105 
2.3.7.1 Ethnicity..................................................................................................... 105 
2.3.7.2 Age.............................................................................................................. 106 
2.3.7.3 Gender........................................................................................................ 107 
2.3.8 Dependent Variables – Measures of Attention.......................................... 107 
2.3.8.1 Digit Span and Digit Symbol Subtest of the Wechsler Adult Intelligence 
Scale –III (WAIS-III)............................................................................................ 108 
2.3.8.2 Paced Auditory Serial Attention Test (PASAT) ................................ 108 
2.4 Hypothesis........................................................................................................ 113 
2.4.1 Hypothesis for Digit Span Model ............................................................... 113 
2.4.2 Hypothesis for Digit Symbol Model ........................................................... 116 
2.4.3 Hypothesis for Paced Auditory Serial Addition Test Model ................... 119 
Chapter 3: Methodology.................................................................................121 
3.1 Study Design........................................................................................................ 121 
3.2 Sample Characteristics....................................................................................... 127 
3.2.1 Patient Recruitment..................................................................................... 127 
3.2.2 Sample Size Calculations............................................................................. 128 
3.3 Instruments.......................................................................................................... 131 
3.3.8 Neuropsychological Tests ............................................................................ 136 
3.3.8.1 Digit Span Test .......................................................................................... 137 
3.3.8.2 Digit Symbol Test...................................................................................... 138 
3.3.8.3 Paced Auditory Serial Addition Test ...................................................... 138 
3.4 Data Analysis....................................................................................................... 140 
3.4.1 Analyses Plan................................................................................................ 140 
3.4.2 Goodness of Fit Statistics ............................................................................ 141 
3.4.3 Advantages of Causal Modeling and Path Analysis: ................................ 143 
Chapter 4: Results ..........................................................................................145 
4.1 Data Screening .................................................................................................... 145 
4.1.1 Missing Data ................................................................................................. 145 
4.1.2 Outliers.......................................................................................................... 146 
4.1.3 Normality ...................................................................................................... 147 
4.2 Sample Description ............................................................................................. 150 
 xi
4.2.1 Adverse Events ............................................................................................. 150 
4.2.2 Demographic Characteristics ..................................................................... 151 
4.2.3 Duration of Chronic Non-Malignant Pain................................................. 154 
4.2.4 Payment Source............................................................................................ 154 
4.2.5 Diagnoses ...................................................................................................... 155 
4.3 Results of Key Model Variables......................................................................... 159 
4.3.1 Morphine Equivalent Dose (MED)............................................................. 159 
4.3.2 Valium Equivalent Dose (VED).................................................................. 166 
4.3.3 Pain Intensity (PI) ........................................................................................ 170 
4.3.4 Pain Unpleasantness (PU) ........................................................................... 172 
4.3.5 Pain Suffering (PS) ...................................................................................... 175 
4.3.5.1 Negative Emotions .................................................................................... 175 
4.3.5.2 Negative Beliefs ......................................................................................... 178 
4.3.6 Pain Behaviors (PB)..................................................................................... 182 
4.3.6.4 Pain Contingent Down Time.................................................................... 191 
4.3.7 Digit Span Test (DST).................................................................................. 195 
4.3.8 Digit Symbol Test (DSYT)........................................................................... 197 
4.3.9 Paced Auditory Serial Addition Test (PASAT)......................................... 199 
4.4 Beck Depression Inventory (BDI)...................................................................... 202 
4.5 Structural Equation Modeling........................................................................... 205 
4.5.1 Overview of Modeling Approach ............................................................... 207 
4.5.2 Baseline Stages of Pain Model - Original................................................... 208 
4.5.3 Baseline Stages of Pain Model - Modified.................................................. 211 
4.5.4 Follow-up Stages of Pain Model – Modification 2 .................................... 215 
4.6 Two-Wave Models .............................................................................................. 220 
4.6.1 Stages of Pain – Two Wave Model ............................................................. 222 
4.6.2 Hypothesized Study Model.......................................................................... 224 
4.6.2.1 Autocorrelated Errors .............................................................................. 227 
4.6.3 Hypothesized Digit Span Test (DST) Model.............................................. 228 
4.6.3.1 Hypothesis Testing – Digit Span Model .................................................. 231 
4.6.4 Hypothesized Digit Symbol Test (DSYT) Model....................................... 239 
4.6.4.1 Hypothesis Testing – Digit Symbol Model.............................................. 242 
4.6.5 Hypothesized Paced Auditory Serial Addition Test (PASAT) Model..... 251 
4.6.5.1 Hypothesis Testing – Paced Auditory Serial Addition Test.................. 254 
Chapter 5: Discussion and Conclusion ........................................................264 
5.1 Study Withdrawals ............................................................................................. 264 
5.2 Key model Variables........................................................................................... 265 
5.2.1 Morphine Equivalent Dose (MED)............................................................. 265 
5.2.2 Valium Equivalent Dose (VED).................................................................. 265 
5.2.3 Pain Intensity................................................................................................ 266 
5.2.4 Pain Unpleasantness .................................................................................... 267 
5.2.5 Pain Suffering............................................................................................... 267 
5.2.5.1 Negative Emotions ................................................................................ 267 
5.2.5.2 Negative Beliefs ..................................................................................... 267 
 xii
5.2.6 Pain Behaviors.............................................................................................. 268 
5.2.7 Digit Span Test (DST).................................................................................. 268 
5.2.8 Digit Symbol Test (DSYT)........................................................................... 270 
5.2.9 Paced Auditory Serial Addition Test (PASAT)......................................... 271 
5.3 Stages of Pain Model........................................................................................... 273 
5.3.1 Pain Intensity and Pain Unpleasantness .................................................... 274 
5.3.2 Pain Suffering............................................................................................... 274 
5.3.3 Pain Behaviors.............................................................................................. 275 
5.4 Hypothesized Models .......................................................................................... 279 
5.4.1 Association between Morphine Equivalent Dose and Tests of Cognitive 
Function (DST, DSYT, and PASAT) .................................................................. 279 
5.4.2 Association between Valium Equivalent Dose, DST, DSYT, and PASAT
................................................................................................................................. 281 
5.4.3 Association between Pain Intensity, DST, DSYT and PASAT ................ 284 
5.4.4. Association between Pain Suffering, DST, DSYT, and PASAT ............. 285 
5.4.5 Association between Pain Behaviors, DST, DSYT, and PASAT ............. 287 
5.4.6 Association between Age, DST, DSYT, and PASAT ................................ 294 
5.4.7 Association between Gender and Pain Unpleasantness ........................... 295 
5.4.8 Association between Pain Suffering and Ethnicity ................................... 296 
5.5 Limitations........................................................................................................... 297 
5.6 Conclusion ........................................................................................................... 299 
Appendix A......................................................................................................302 
Appendix B......................................................................................................310 
Appendix C......................................................................................................312 
Appendix D......................................................................................................319 
Appendix E ......................................................................................................329 
Appendix F ......................................................................................................332 
Appendix G......................................................................................................334 
Bibliography....................................................................................................337 
VITA..................................................................................................................351 
 
 xiii
List of Figures 
 
Figure 1.1 – The World Health Organization Analgesic Ladder .....................................7 
 
Figure 1.2 Cards Presenting Dominant and Non-Dominant Information......................... 60 
 
Figure 2.1 Stages of Pain Model....................................................................................... 95 
 
Figure 2.2 Structural Equation Model Depicting Associations between Demographics 
(age, gender, ethnicity), Stages of Pain Model Variables, Narcotic and Benzodiazepine 
Dose, and the Dependent Variable (cognitive function test score) at Baseline .............. 110 
 
Figure 2.3- Proposed Two-wave Path Diagram with Digit Span Test as the Dependent 
Variable........................................................................................................................... 112 
 
Figure 2.4- Proposed Two-wave Path Diagram with Digit Symbol Test as the Dependent 
Variable........................................................................................................................... 115 
 
Figure 2.5- Proposed Two-wave Path Diagram with Paced Auditory Serial Addition Test 
as the Dependent Variable .............................................................................................. 118 
 
Figure 3.1 – Division of Responsibilities and Point of Contact between Patients and 
Researcher....................................................................................................................... 125 
 
Figure 3.2 – Flow Chart of Study Protocol, Enrollment Criteria, Baseline and Follow-up 
Assessments .................................................................................................................... 126 
 
Figure 4.1 – Components of a Structural Equation Model ............................................. 206 
 
Figure 4.2 Standardized Parameter Estimates of Original Baseline Stages of Pain 
Confirmatory Factor Model ............................................................................................ 210 
 
Figure 4.3 Unstandardized Parameter Estimates of Baseline Stages of Pain Confirmatory 
Factor Model – Modification 1 ....................................................................................... 213 
 
Figure 4.4 Unstandardized Parameter Estimates of  Baseline Stages of Pain Confirmatory 
Factor Model – Modification 2 ....................................................................................... 214 
 
Figure 4.5 Unstandardized Parameter Estimates of Follow-up Stages of Pain 
Confirmatory Factor Model – Modification 2 ................................................................ 216 
 
Figure 4.6 Unstandardized Parameter Estimates of Baseline Stages of Pain Confirmatory 
Factor Model – Final Model ........................................................................................... 217 
 
 xiv
Figure 4.7 Unstandardized Parameter Estimates of Follow-up Stages of Pain 
Confirmatory Factor Model – Final Model .................................................................... 218 
 
Figure 4.8 Unstandardized Parameter Estimates of the Two-Wave Stages of Pain 
Confirmatory Factor Model – Final Model .................................................................... 223 
 
Figure 4.9 Hypothesized Two-Wave Digit Span Test Structural Model........................ 230 
 
Figure 4.10  Hypothesized Two-Wave Digit Symbol Test Measurement Model .......... 241 
 
Figure 4.11 Hypothesized Two-Wave PASAT  Measurement Model ........................... 253 
 
Figure 5.3 Plot of Baseline & Follow-up Digit Span Test Scores by Pain Behavior 
Composite at Baseline..................................................................................................... 288 
 
Figure 5.4 Plot of Baseline & Follow-up Digit Span Test Scores by Pain Behavior 
Composite at Follow-up.................................................................................................. 288 
 
Figure 5.5 Plot of Baseline & Follow-up Digit Symbol Test Scores by Pain Behavior 
Composite at Baseline..................................................................................................... 290 
 
Figure 5.6 Plot of Baseline & Follow-up Digit Symbol Test Scores by Pain Behavior 
Composite at Follow-up.................................................................................................. 290 
 
Figure 5.7 Plot of Baseline & Follow-up PASAT 2.4  Scores by Pain Behavior 
Composite at Baseline..................................................................................................... 292 
 
Figure 5.8 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain Behavior 
Composite at Follow-up.................................................................................................. 292 
 
Figure 5.9 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain Behavior 
Composite at Baseline..................................................................................................... 293 
 
Figure 5.10 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain Behavior 
Composite at Follow-up.................................................................................................. 293 
 
 
 
 
 
 xv
List of Tables 
 
Table 1.1  Equianalgesic Doses of Centrally Acting Opioid Doses Compared to Morphine
........................................................................................................................................... 18 
 
Table 1.2  Summary of Commonly Used Cognitive Tests in Literature Review............. 52 
 
Table 1.2  (Continued) Summary of Commonly Used Cognitive Tests in Literature 
Review .............................................................................................................................. 53 
 
Table 3.1 - Division of Responsibilities between Physician/Clinic Staff and Researcher at 
Clinic Site........................................................................................................................ 124 
 
Table 3.2.  Summary of Studies with Relevant Effect Size Estimates ........................... 130 
 
Table 3.3 - Drug Dose Conversion Equivalent to 60mg Diazepam (Valium)................ 136 
 
Table 2.3 – Mean Number of Correct Responses at Each Age Range ........................... 139 
 
Table 4.1 – All Reasons for Subject Loss and Sample Size of Patients in the DSTa, 
DSYTb, and PASATc Models ......................................................................................... 147 
 
Table 4.2 Variance Estimates of Indicators Included in the Hypothesized Study Model for 
Data obtained from Evaluable Patients at Baseline and Follow-up................................ 149 
 
Table 4.3 – Number and Proportion of Patients who Completed the Study, Dropped Out, 
and Failed to Follow-up.................................................................................................. 150 
 
Table 4.4 – Total Counts of Each Adverse Event or Reason Provided by Patients who 
Dropped Out of the Study (N =30) ................................................................................. 151 
 
Table 4.5 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients by 
Demographic Characteristics: Age, Gender, Race/Ethnicity, and Education Level....... 153 
 
Table 4.6 - Distribution of Sample by Duration of Pain  for Enrolled, Evaluable, and 
Non-Evaluable Patients................................................................................................... 154 
 
Table 4.7 - Distribution of Sample by Payment Source  for Enrolled, Evaluable, and Non-
Evaluable Patients........................................................................................................... 155 
 
Table 4.8 Total Count of Each Diagnosis for which Evaluable (N = 84) and Non-
Evaluable (N = 40) Patients were Treated at the Study Site........................................... 157 
 
 xvi
Table 4.8 (Continued)  Total Count of Each Diagnosis for which Evaluable (N = 84) and 
Non-Evaluable(N = 40) Patients were Treated at the Study Site.................................... 158 
 
Table 4.9 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients by Brand of 
Primary  Short-Acting Narcotic Analgesic Used to Treat Pain at Baseline ................... 161 
 
Table 4.10 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients by Brand of  
Secondary Short-Acting Narcotic Analgesic Used to Treat Pain at Baseline ................ 162 
 
Table 4.11 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients by Average 
Daily Morphine Equivalent Dose (MED) of Short-Acting Narcotic Analgesic at Baseline
......................................................................................................................................... 163 
 
Table 4.12 Distribution of Evaluable Patients by Average Daily Morphine Equivalent 
Dose (MED) of Avinza, Short-Acting Breakthrough Narcotic Analgesic, and Total 
Narcotic Analgesic at Follow-up .................................................................................... 165 
 
Table 4.13 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients by Brand of  
Benzodiazepine Medication at Baseline ......................................................................... 167 
 
Table 4.14 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients who Use  
Benzodiazepine Medications by Duration of Use .......................................................... 169 
 
Table 4.15 Distribution of Enrolled, Evaluable, and Non-Evaluable Benzodiazepine 
Users by Valium Equivalent Dose at Baseline ............................................................... 170 
 
Table 4.16 Means and Standard Deviations for Items Assessing Highest, Lowest, and 
Usual Pain Intensity Levels for Enrolled, Evaluable, and Non-Evaluable Patients at 
Baseline and Follow-up .................................................................................................. 172 
 
Table 4.17 Means and Standard Deviations for Items Assessing Highest, Lowest, and 
Usual Pain Unpleasantness (PU)  Levels for Enrolled, Evaluable, and Non-Evaluable 
Patients at Baseline and Follow-up................................................................................. 175 
 
Table 4.18 Means and Standard Deviations for Items Assessing Negative Emotions for 
Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ............... 178 
 
Table 4.19 Means and Standard Deviations for Items Assessing Negative Beliefs  for 
Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ............... 181 
 
Table 4.20 Frequency Distribution and Descriptive Statistics of Pain Behaviors at Home  
for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ......... 184 
 
 xvii
Table 4.21 Frequency Distribution and Descriptive Statistics of Social Reinforcement of 
Pain Behavior for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and 
Follow-up........................................................................................................................ 187 
 
Table 4.22 Frequency Distribution and Descriptive Statistics of Home or Family Related 
Responsibilities for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and 
Follow-up........................................................................................................................ 190 
 
Table 4.23 Frequency Distribution and Descriptive Statistics of Pain Contingent Down 
Tine  for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up 192 
Table 4.24 Frequency Distribution and Descriptive Statistics of Observed Pain Behaviors 
for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ......... 194 
 
Table 4.25 Frequency Distribution and Descriptive Statistics of Digit Span Test for 
Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ............... 197 
 
Table 4.26 Frequency Distribution and Descriptive Statistics of Digit Symbol for 
Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up ............... 199 
 
Table 4.27 Frequency Distribution and Descriptive Statistics of Paced Auditory Serial 
Addition Test  for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and 
Follow-up........................................................................................................................ 201 
 
Table 4.28 Comparison between a Normal Sample and Evaluable Patients at Baseline and 
Follow-up on the Mean Number of Correct Responses to the PASAT 2.4 and 2.0 by Age 
Group .............................................................................................................................. 202 
 
Table 4.29  Frequency Distribution and Descriptive Statistics of Beck Depression 
Inventory for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline and Follow-up
......................................................................................................................................... 204 
 
Table 4.30 Cutoff Values for Fit Indices ........................................................................ 207 
 
Table 4.31 Comparison of Factor Loadings for Pain Intensity, Pain Unpleasantness, Pain 
Suffering, and Pain Behavior Constructs between Current Study and Wade et al. Study
......................................................................................................................................... 209 
 
Table 4.32 Goodness of Fit Statistics for the Stages of Pain Model............................... 211 
 
Table 4.34 Measurement Error Variance Estimates of Single Indicators Utilized in the 
Hypothesized Models...................................................................................................... 226 
 
 xviii
Table 4.35  Goodness of Fit Indices for the Hypothesized DST, DSYT, and PASAT 
Models............................................................................................................................. 228 
 
Table 4.36 Table of Unstandardized Model Equations and Squared Multiple Correlations 
for the Hypothesized Digit Span Model ......................................................................... 229 
 
Table 4.37 Summary of Hypothesized Relationships for the Digit Span Model............ 232 
 
Table 4.38 Table of Unstandardized Model Equations and Squared Multiple Correlations 
for the Modified Digit Symbol Model ............................................................................ 240 
 
Table 4.39 Summary of Hypothesized Relationships for the Digit Symbol Model ....... 243 
 
Table 4.40 Table of Unstandardized Model Equations and Squared Multiple Correlations 
of Paced Auditory Serial Addition Test Model .............................................................. 252 
 
Table 4.41 Summary of Hypothesized Relationships for the Paced Auditory Serial 
Addition Test Model ....................................................................................................... 255 
 
Table 5.1 Mean Baseline and Follow-up Scores of Evaluable Patients with Scores that 
were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) the Mean Sample 
Baseline Digits Span Forwards and Backwards Test Scores.......................................... 270 
 
Table 5.2 Mean Baseline and Follow-up Scores of Evaluable Patients with Scores that 
were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) the Mean Sample 
Baseline Digits Symbol Test Scores ............................................................................... 271 
 
Table 5.3 Mean Baseline and Follow-up Scores of Evaluable Patients with Scores that 
were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) the Mean Sample 
Baseline PASAT 2.4 and 2.0 Scores............................................................................... 272 
 1
Chapter 1: Background and Introduction 
1.1 Introduction  
 
The number of people in the United States that suffer from pain is estimated to 
be in the range of 35 to 75 million.1 Numerous therapeutic and non-therapeutic 
strategies have been applied in the management of pain.  Narcotic analgesics 
(opioids) are often utilized in chronic pain as a last resort when all other pharmaco-
therapeutic options have failed. 
The use of opioids in the treatment of chronic non-malignant pain (CNMP) is 
not without debate or controversy.  There is a lack of conclusive evidence regarding 
the risks and benefits of opioid therapy in the management of CNMP.2  Results from 
a study about physician attitudes towards use of opioids in CNMP showed that 42 
percent, 57 percent, and 75 percent of respondents would never prescribe long acting 
schedule II opioids to patients with post herpetic neuralgia, chronic low back pain, 
and chronic daily headache, respectively.3  Cognitive impairment due to opioids is 
often cited as a cause for concern; this study outlines a proposal to examine the issue 
further. 
A number of studies have found that pain, in addition to opioid use is 
associated with cognitive dysfunction.4,5,6,7,8  This study questions whether pain 
                                                 
1 Walsh NE et al.  Cited by: Wade JB, Hart RP.  Attention and the stages of pain processing.  Pain 
Medicine.  2002;3:30-38. 
2 Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic non malignant pain.  Journal of 
Family Practice. 2001;50:145-159. 
3 Ibid. 
4 Hart RP, Martelli MF, Zasler ND.  Chronic pain and neuropsychological functioning.  Neuropsychology 
Review.  2000;10:131-149.  
5 Schwartz DP, Barth JT, Dane JR, Drenan SE, DeGood DE, Rowlingson JC.  Cognitive deficits in chronic 
pain patients with and without a history of head/neck injury: development of a brief screening battery. 
Clinical Journal of  Pain.  1987;3:94-101. 
6 Dufton BD.  Cognitive failure and chronic pain.  International Journal of Psychiatry in Medicine.  
1989;19:291-297. 
7 Eccleston C.  Chronic pain and distraction: An experimental investigation into the role of sustained and 
shifting attention in the processing of chronic persistent pain.  Behavior Research and Therapy.  
1995;33:391-405. 
8 Eccleston C, Crombez G, Aldrich S, Stannard C.  Attention and somatic awareness in chronic pain.  Pain.  
1997;72:209-215. 
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control with long-acting morphine, particularly Avinza® is associated with an 
improvement in cognitive symptoms.  “Studies examining opioid-related cognitive 
dysfunction in chronic non-malignant pain are limited, and overall they provide a 
conflicting series of results.  Regarding the choice among stronger opioids, there is 
little evidence to suggest that one opioid is superior to any other regarding cognitive 
side effects with the exception of meperidine and perhaps methadone.”9  A review of 
five controlled studies in the treatment of chronic pain with opioid analgesics showed 
inconsistent results on outcome variables such as “disability,” “emotional distress,” 
“quality of life,” and “psychological or functional impairment.”10 
1.2 Purpose of the Study 
 
Opioid use on a chronic basis may be associated with some cognitive 
impairment.  There are very few studies that have examined the effects of opioid use 
on cognitive impairment in chronic pain patients.  Furthermore, only one study has 
examined this association for long-acting narcotic analgesics.  None of these studies 
have utilized a theoretical framework to address this complex issue.  The purpose of 
this study is to utilize the stages of pain model to assess cognitive function in chronic 
non-malignant pain patients who are stabilized on long acting narcotic analgesic 
therapy.  
                                                 
9 Lawlor PG.  The panorama of opioid-related cognitive dysfunction in patients with cancer.  Cancer. 2002: 
94:1836-1853. 
10 Dickinson BD, Altman RD, Nielsen NH, Williams MA.  Use of opioids to treat chronic, noncancer pain.  
The Western Journal of Medicine.  2000;172:107-115. 
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1.3 Literature Review  
 
1.3.1 Definition of Chronic Pain 
 
Pain is an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage, or both.11  Pain that 
persists for a period of three months is often referred to as being chronic.12  
Additionally, pain that remains untreated or uncontrolled beyond an anticipated 
duration may also qualify as persistent pain.13  Chronic pain has been characterized as 
an illness rather than a disease and it encompasses physical discomfort, psychological 
suffering, activity limitation, and psychosocial difficulties.14 
A consensus statement issued by the the American Academy of Pain Medicine 
(AAPM) and the American Pain Society (APS) states that there are no nationally 
accepted clinical practice guidelines for the management of CNMP.  Despite the 
availability of various therapeutic, surgical, and behavioral interventions for the 
management of non-cancer pain, the condition is often left untreated or under treated.  
Inadequate treatment contributes to excessive utilization of health services, reduced 
productivity, and poor quality of life (QOL).15 
 
1.3.2 Epidemiology and Economics of Chronic Non-malignant Pain (CNMP) 
 
According to a World Health Organization (WHO) survey, 22 percent 
(1196/5438) of patients sampled reported experiencing persistent pain defined as pain 
                                                 
11 Merskey H, Bogduk N, eds.  Classification of chronic pain: Descriptions of chronic pain syndromes and 
definitions of chronic pain syndromes and definitions of pain terms.  2nd ed.  Seattle, WA: IASP Press; 
1993:3-4. 
12 Andersson GBJ.  Epidemiological features of chronic low back pain.  Lancet.  1999;354:581-585. 
13 Weitz MA, Burke SM.   Persistent pain in long term care: overcoming barriers to improve resident care.  
The Consultant Pharmacist.  2002;17(SupplB):3-9. 
14 Turk DC, Monarch ES.  Biopsychosocial perspective on chronic pain.  In: Turk DC, Gatchel RJ, eds.  
Psychological approaches to pain management.  New York, NY:The Guilford Press;2002. 
15 American Pain Society.  The Use of opioids for the treatment of chronic pain.  A consensus statement 
from American Academy of Pain Medicine and American Pain Society.   Available at: 
http://www.ampainsoc.org/advocacy/opioids.htm.  Accessed on Feb 22, 2003. 
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that persisted for six or more months in a year.16  Back pain, headache, and joint pain 
were reported to occur most frequently.  Participants also indicated that pain 
interfered with numerous activities and was associated with depression.  Results from 
a follow-up study showed that 49.2 percent of these patients continued to meet the 
criteria for persistent pain.  Pain at two or more sites, depressed mood, and age 
(greater than 40) were factors predictive of a poor outcome.17  In a review of several 
international studies, Maniadakis and Gray reported that the prevalence of back pain 
at any given time ranges from 12-35 percent in the population.18  Approximately 30 
percent of the population in industrialized nations experience chronic pain of some 
form at a given time, and nearly half of the sufferers experience partial or complete 
disability.19  Back pain ranks second in the United States (US) as a reason for visits to 
the physician, and is the fifth leading cause of hospitalizations.20 
A cost-of-illness study in the United Kingdom (UK) estimated the direct costs 
of back pain to be £1632 million, of which physiotherapy (37%) and utilization of 
hospital services (31%) accounted for majority of the costs.21  In 1990, the direct 
costs of back pain were estimated to be $24.3 billion in the United States.22 
In 1991, costs due to absenteeism and disability payments in the Netherlands 
were estimated at $US 4.6 billion and $US 1.5 billion.23  The human capital approach 
and the friction cost method were used to estimate productivity losses.  In 1998, 
indirect costs (time lost from work and caregiver time) to the UK health system due 
to back pain were estimated to be £ 5018 million.24  In the United States, 
                                                 
16 Gureje O, Von Korpff M, Simon GE, Gater R.  Persistent pain and well being: a World Health 
Organization study in primary care.  Journal of the American Medical Association.  1998;280:146-151. 
17 Gureje O, Simon GE, Von Korpff M.  A cross-national study of the course of persistent pain in primary 
care.  Pain.  2001;92:195-200. 
18 Maniadakis N, Grey A.  The economic burden of back pain in the UK.  Pain.  2000;84:95-103. 
19 Loeser JD.  Economic implications of pain management.  Acta Anaesthesiologica Scandinavica.  
1999;43:957-959. 
20 Andersson GBJ.  Epidemiological features of chronic low back pain.  Lancet.  1999;354:581-585. 
21 Ibid. 
22 Frymoyer JW, Cars Varil WL.  Cited by: Hemmila HM.  Quality of life and cost of care of back pain 
patient.  Spine.  2002;27:647-653. 
23 Hutubessy RCW, Van Tulder MW, Vondeling H, Bouter LM.  Indirect costs of pain in the Netherlands: a 
comparison of the human capital method with the friction cost method.  Pain.  1999;80:201-207 
24 Maniadakis N, Grey A.  The economic burden of back pain in the UK.  Pain.  2000;84:95-103. 
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approximately 2 percent of injured workers receive disability payments each year due 
to chronic back pain.25  Indirect costs in 1990 ranged from $75-100 billion. 
Outcomes among many individuals with chronic pain do not improve even 
after diagnosis and treatment, indicating a poor understanding of the pathological 
causes of pain.  Chronic pain is often under treated in both ambulatory and long-term 
care settings.  Untreated pain can cause several undesirable effects such as anxiety, 
agitation, depression, cognitive dysfunction, and a variety of activity limitations.26  
Poor QOL and diminished functional ability are commonly observed among these 
individuals.  It has been reported that back pain significantly limits activity in the 
younger population (less than 45 years).27  Pain being a multidimensional experience 
adversely affects physical functioning, psychological functioning, and social 
functioning.28  
The complex nature of pain and the difficulties associated in determining the 
causal factors that are associated with chronic pain limit the development and use of 
standardized treatment protocols and algorithms.  In addition to causal factors and 
variations in treatment patterns, patient response to therapy and ultimate satisfaction 
with the treatment varies greatly from one patient to another.  The need for cost-
consciousness and the focus on consumer satisfaction in healthcare necessitate the 
measurement of health related quality of life (HRQOL) and other treatment related 
outcomes among patients suffering from chronic pain. 
 
1.3.3 Chronic Pain Syndrome – Diagnostic Criteria 
 
 The following is a list of characteristics that can be used to identify a chronic 
pain syndrome (CPS) patient:  
                                                 
25 Andersson GBJ.  Epidemiological features of chronic low back pain.  Lancet.  1999;354:581-585. 
26 Weitz MA, Burke SM.   Persistent pain in long term care: overcoming barriers to improve resident care.  
The Consultant Pharmacist.  2002;17SupplB:3-9. 
27 Loeser JD.  Economic implications of pain management.  Acta Anaesthesiologica Scandinavica.  
1999;43:957-959. 
28 Marcus DA. Treatment of chronic nonmalignant pain.  American Family Physician.  2000;61:1331-1440. 
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 (a) reports of persistent (i.e., at least three months duration) pain, which may be 
consistent with or significantly out of proportion to physical findings; 
 (b) demonstrates or has demonstrated a progressive deterioration in ability to function 
at home, socially, and at work; 
 (c) shows or has shown a progressive increase in health care utilization (such as 
repeated physical evaluations, diagnostic tests, requests for pain medications, and/or 
invasive medical procedures); 
 (d) demonstrates mood disturbance; and 
 (e) exhibits clinically significant anger and hostility.29 
 According to this definition, any patient that presents with persistent pain, and 
two additional characteristics listed above may be categorized as a CPS patient.  
Patients with a history of excess utilization or deterioration in function that has 
stabilized in the recent past are also CPS candidates. 
 The appropriate management of any disease state is based on established 
algorithms that are primarily developed on the basis of observation in clinical 
practice, empirical evidence based on randomized trials and additional studies, and 
expert opinion.  Evidence-based guidelines serve as a critical roadmap in making 
assessments and developing treatment strategies.  Practice guidelines play an 
important role in standardizing the level of care patients receive and enable 
comparisons across different groups of patients.  “Guidelines, which have been 
developed for opioid therapy in patients with chronic non-cancer pain, are based on 
empirical clinical judgment or consensus and have not been validated in large 
prospective clinical trials.”30 
                                                 
29 Sanders SH, Harden RN, Benson SE, Vicente PJ.  Clinical practice guidelines for chronic non-malignant 
pain syndrome patients II: An evidence-based approach.  Journal of Back and Musculoskeletal 
Rehabilitation. 1999;13:47-58. 
30 Nedeljkovik SS, Wasan A, Jamison RN.  Assessment of efficacy of long-term opioid therapy in pain 
patients with substance abuse potential.  The Clinical Journal of Pain.  2002;18:S39-S51. 
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1.3.4 Pain Management Guidelines 
 
The World Health Organization’s analgesic ladder has been widely accepted 
as a useful tool in the management of acute pain and cancer-related pain.  In the 
absence of specific guidelines, this tool has also been widely utilized for the 
management of chronic non-malignant pain.  The following figure is a representation 
of the WHO analgesic ladder: 
 
Figure 1.1 – The World Health Organization Analgesic Ladder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment with acetaminophen and non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen is widely accepted as first-line therapy in the 
management of pain.  Milder opioid analgesic agents such as codeine are 
recommended in Step 2, while the more potent narcotic analgesics (morphine, 
oxycodone) are reserved for step 3.31  Adjuvant therapy with antidepressants, 
anticonvulsants and muscle relaxants is also commonly observed in practice. 
                                                 
31 Vielvoye-KerkmeerAPE, Mattern C, Uitendaal MP.  Transdermal fentanyl in opioid-naive cancer pain 
patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naïve 
patients and a group using codeine.  Journal of Pain and Symptom Management.  2000;19:185-192. 
STEP 1 
Goal 
Freedom from Pain
Step 1 – Non-opioids +/- adjuvant 
therapy 
Step 2 – opioids for mild to moderate 
pain, +/- non-opioids, +/- adjuvant 
therapy 
STEP 2 
Step 3 – opioids for moderate to severe 
pain, +/- non-opioids, +/- adjuvant 
therapy 
STEP 3 
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The National Guideline Clearinghouse ™ (NGC™), an initiative of the Agency 
for Healthcare Research and Quality (AHRQ) is a widely accepted source of clinical 
practice guidelines.  AHRQ lists numerous guidelines that recommend opioids as an 
effective tool for the management of pain arising out of various mechanisms:32,33 ,34 
1. Nociceptive pain - Nociceptive pain occurs subsequent to tissue damage caused 
by  injury, and has a more defined pathology.35  Painful stimuli are transmitted via 
nerve fibers to the central nervous system (CNS).  Pharmacologic interventions such 
as nerve blocks and various analgesic agents are most commonly used to treat 
nociceptive pain.36  
2. Neuropathic pain – Usually the pathological processes surrounding neuropathic 
pain may not be evident; however, the peripheral or central nervous systems play a 
role in the condition.  Pain occurs in the absence of any obvious tissue damage.  
Neuropathic pain may also occur secondary to previous tissue damage, and is difficult 
to treat.37  This form of pain is also associated with allodynia and hyperalgesia, which 
refer to pain in response to stimuli that do not normally elicit a painful response and a 
lowered tolerance for pain, respectively.38  In addition to opioids, patients find 
adjuvant therapy with antidepressants and anticonvulsants to be beneficial.39 
Neuropathic pain has also been classified further as being nociceptive or non-
nociceptive.  Nociceptive nerve pain occurs in response to damage to the nerve axon 
                                                 
32 Washington State Department of Labor and Industries. Guidelines for outpatient prescription of oral 
opioids for injured workers with chronic, noncancer pain. Olympia (WA): Washington State Department of 
Labor and Industries; 2002 Aug. 21 p. 
33 Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, 
mechanisms, and treatment recommendations. Archives of Neurolology. 2003;60:1524-1534 
34 Registered Nurses Association of Ontario (RNAO). Assessment and management of pain. Toronto (ON): 
Registered Nurses Association of Ontario (RNAO); 2002 Nov. 142 p 
35 Cimino C.  Painful Neurological Syndromes.  In: Aronoff GM.  Evaluation and Treatment of Chronic 
Pain. Baltimore, MD.  Williams and Wilkins.  1992. MD.  
36 Burke SM, Weitz MA.  Persistent pain in long term care: pathophysiologic mechanisms and treatment 
strategies.  The Consultant Pharmacist.  2002;17SupplB:10-17. 
37 Cimino C.  Painful Neurological Syndromes.  In: Aronoff GM.  Evaluation and Treatment of Chronic 
Pain. Baltimore, MD.  Williams and Wilkins.  1992. 
38 Burke SM, Weitz MA.  Persistent pain in long term care: pathophysiologic mechanisms and treatment 
strategies.  The Consultant Pharmacist.  2002;17SupplB:10-17. 
39 American Geriatric Society Panel on Chronic Pain.  The management of chronic pain in older persons.  
Geriatrics.  1998;53(suppl 3):S8-S24. 
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(inner information pathway of the nerve cell) or “depolarization of unmyelinated C-
fibers” which is secondary to tissue damage.  Non-nociceptive nerve pain occurs in 
response to lesions in the CNS, pain is usually associated with superficial tissues, and 
is not accompanied by inflammation.  The variable response associated with opioid 
therapy in neuropathic pain may be indicative of the differences in underlying 
mechanisms.  Consequently, debate about the clinical utility of opioids in neuropathic 
pain has been inconclusive.  However, it is believed that opioid analgesics may be 
more effective in neuropathic pain syndromes that are nociceptive in nature.40   
3. Mixed Nociceptive and Neuropathic pain – Examples of mixed pain syndromes 
include chronic recurrent headaches and vasculopathic pain syndromes.   The 
underlying pathophysiology of these conditions is often unknown and treatment 
approaches are highly variable.41  Consequently, treatment outcomes are highly 
unpredictable. 
4. Psychogenic pain – Affective dimensions such as anxiety, fear, depression (i.e., 
emotions) and cognitive factors contribute to the occurrence of psychogenic pain.  
Psychiatric interventions may be useful in such situations.42  Opioids are not 
recommended for use in these patients. 
 Failure of other therapeutic alternatives (NSAIDs, etc.) in opioid-naïve patients 
is also an indication for the use of narcotic analgesics in patients with chronic pain.  
Typically for opioid-naïve patients with unbearable pain, short-acting opioid 
medications such as hydrocodone or oxycodone (10 to 15mg), hydromorphone (2 to 
4mg), codeine (30 to 60mg) and morphine (15 to 30mg) may be initiated.  In addition 
to opioids, the use of antidepressants among pain patients has resulted in improved 
outcomes.  Research has consistently shown that multidisciplinary approaches to the 
management of chronic pain are not only suitable but also preferred.  However, there 
is little consensus regarding “patient selection and exclusion criteria,” utilization of 
                                                 
40 Dellemijn PL, Vanneste JAL.  Randomised double-blind active-placebo-controlled crossover trial of 
intravenous fentanyl in neuropathic pain.  The Lancet.  1997;349:753-758. 
41 Ibid. 
42 Burke SM, Weitz MA.  Persistent pain in long term care: pathophysiologic mechanisms and treatment 
strategies.  The Consultant Pharmacist.  2002; 17(suppl B):10-18. 
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narcotic analgesics and sedative-hypnotics, and use of invasive techniques or 
implantation of devices across guidelines.43  
 
1.3.4.1 Guidelines for Opioid Therapy in Chronic Non-malignant Pain Patients 
  
 The American Academy of Pain Management (AAPM) and the American Pain 
Society (APS) advocate the use of a comprehensive plan for practitioners treating 
pain with opioids.44  The New Hampshire Board of Medicine G recommends a 
similar strategy.45   
 The plan involves conducting extensive patient-history evaluations, setting 
goals with periodic reviews, obtaining informed consent, keeping detailed records, 
and complying with state and board licensure requirements.   
Other guidelines state that long-acting narcotic medications are effective 
pharmacological treatments for chronic persistent pain.46,47  Management of episodic 
pain with short-acting narcotic medications contribute to improving outcomes.  
Adverse-events such as constipation and nausea that may arise from treatment with 
opioids must be treated and carefully monitored. 
 
1.3.5 Treatment Options for Chronic Pain Syndrome Patients 
 
 Sanders and colleagues utilized an evidence-based approach to document the 
usefulness of various treatment modalities in the treatment of chronic pain 
                                                 
43 Sanders SH, Rucker KS and Anderson KO et al., Clinical practice guidelines for chronic non-malignant 
pain syndrome patients.  Journal of Back and Musculoskeletal Rehabilitation. 1995;5:115–120. 
44 American  Pain Society.  The Use of opioids for the treatment of chronic pain.  A consensus statement 
from American Academy of Pain Medicine and American Pain Society.  Available at: 
http://www.ampainsoc.org/advocacy/opioids.htm.  Accessed on Feb 22, 2003. 
45 New Hampshire Medical Society.  Guidelines for the use of controlled substances in the treatment of 
pain.  Available at: http://www.nhms.org/advocacy/pain.html.  Accessed on November 11, 2002 
46 Washington State Department of Labor and Industries. Guidelines for outpatient prescription of oral 
opioids for injured workers with chronic, noncancer pain. Olympia (WA): Washington State Department of 
Labor and Industries; 2002 Aug. 21 p. 
47 Burke SM, Weitz MA.  Persistent pain in long term care:pathophysiologic mechanisms and treatment 
strategies.  The Consultant Pharmacist.  2002;17(SupplB):10-18. 
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syndrome.48  In order for a particular recommendation or therapy to be included as 
part of the guideline, the therapy must have been evaluated in at least two well-
designed, prospective research studies with large samples (n ≥ 200).  Similarly, a 
meta-analysis demonstrating effectiveness of a treatment modality was considered to 
meet evidence criteria.  
 NSAIDs, antidepressants, and anticonvulsants are believed to be useful in the 
management of chronic painful conditions.  The literature review elicited promising 
yet inconclusive evidence about the usefulness of opioids and sedative-hypnotics 
among CPS patients.  According to Sanders et al., there is a need for studies 
evaluating the long-term efficacy and safety of opioids and sedative-hypnotics among 
patients with chronic pain syndromes.  There is a need for well-controlled, 
randomized trials evaluating various outcomes including cognitive function among 
various groups of CPS patients.  “If long-term opioid or sedative-hypnotic 
medications are considered with chronic non-malignant pain syndrome patients, they 
should be applied only when there is clear evidence that they do not impair the patient 
but produce significant and sustained improvement in function.”49   
 Physical and occupational therapy play an important role in restoring function, 
however, evidence indicates that the effects of these interventions are not sustained.  
These interventions are very important in helping patients improve posture, strength, 
and flexibility.  Various behavioral and psychological interventions have consistently 
proven to be effective in certain groups of CPS patients and are of extreme 
importance.  Programs that provide vocational guidance and techniques to cope with 
disability can enable functional restoration, but these services are often separate than 
those provided by a physician.50 
 The literature indicates that trigger point injections, botulinum toxin injections, 
and nerve block injections are of limited utility and should not be used routinely in 
CPS patients.  Systematic, well-controlled studies evaluating long-term outcomes of 
                                                 
48 Sanders SH, Rucker KS and Anderson KO et al., Clinical practice guidelines for chronic non-malignant 
pain syndrome patients. Journal of Back and Musculoskeletal Rehabilitation. 1995;5:115–120. 
49 Ibid. 
50 Ibid. 
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nerve blocks in this population are needed.  Surgery is not recommended in the 
absence of “progressive neurological deficits, such as loss of bladder/bowel function 
or paralysis,” or spine instability that must be corrected, or other findings such as 
“new lesions” in the patient.51 
 Physicians must educate patients with various aspects of their condition.  In 
order to achieve optimal outcomes, patients must independently chart their progress, 
while discussing any barriers that might limit treatment success with the physician.  
The primary goals of treatment include improvement in patient’s functional status and 
better ability to manage their pain.  Even though patients on medications may exhibit 
a lack of subjective pain relief, the aforementioned goals of functional restoration 
should be stressed upon.  Some other treatment objectives include minimizing 
abuse/overuse and dependence on pain medications (particularly opioids and sedative 
hypnotics), increasing rate at which patients return to work and other social activities, 
reducing pain intensity, and reducing utilization costs associated with the pain 
condition. 
1.3.6 Opioids in Chronic Non-Malignant Pain 
 
1.3.6.1 Narcotic Analgesic Classification 
 
The narcotic analgesics are classified as agonists (oxycodone, morphine, 
fentanyl), and mixed agonist-antagonists, which are antagonists with analgesic action 
at the opiate receptors (buprenorphine, butorphanol, nalbuphine).  This classification 
is based on the site of action of opioid analgesics: µ, δ, and κ receptors.  Activation of 
µ receptors produces analgesia, respiratory depression, reduced GI motility, and 
euphoria, while activation of κ receptors produces analgesia, dysphoria, and 
psychotomimetic effects.  Effect of δ receptor activation in humans is not clear.52 
According to a clinical update published by the International Association for 
the Study of Pain in 1995, there was very little scientific evidence about the relative 
                                                 
51 Ibid. 
52 Drug Facts and Comparisons.  57th Edition.  2003.  Facts and Comparisons.  St. Louis, MO. 2003. 
 
 13
risks and benefits of opioid therapy in chronic non-malignant pain.53  In reference to 
opioid therapy, the organization continues to maintain that “we are still looking for a 
balanced approach, and outcomes-based guidelines remain only a hope for the 
future.”54  
Use of opioids among cancer patients has produced successful outcomes with 
limited adverse effects.  The limited negative health outcomes such as analgesic 
tolerance, physical dependence, and addiction among cancer patients spurred 
speculation about the usefulness of opioid analgesics in other patient groups.55  
Despite the positive evidence regarding opioids in cancer pain, there is considerable 
controversy surrounding the use of narcotic analgesics in chronic pain conditions of 
non-malignant origin.  Proponents of opioid use in these patients believe that political 
pressure, strict regulatory oversight, and an exaggerated fear of addiction and other 
side-effects have limited the use of these drugs, contributing to the under treatment of 
pain.56  Despite the controversy, 90 percent of all opioid prescriptions in the United 
States are intended for pain relief in non-malignant chronic pain.57 
 
1.3.6.2 Disadvantages of Narcotic Analgesics 
 
Several adverse effects such as cognitive impairment, sedation, respiratory 
depression, nausea, constipation, edema, and hypogonadism have been associated 
with the use of opioids.58  Cognitive impairment, respiratory depression, tolerance, 
abuse, and dependence associated with narcotic analgesics are the main factors 
implicated in the controversy surrounding opioid-therapy prescribed in the treatment 
of chronic non-cancer pain. 
                                                 
53 International Association for the Study of Pain.  Opioids for chronic noncancer pain.  1995;3. Available 
at:: http://www.iasp-pain.org/PCU95c.html. Accessed on February 22.2003. 
54 International Association for the Study of Pain.The future: will pain be abolished or just pain specialists.  
2000;8.  Available at:: http://www.iasp-pain.org/PCU00-6.html.  Accessed on October 11, 2002. 
55 Portenoy RK.  Opioid therapy for chronic nonmalignant pain: a review of the critical issues.  Journal of 
Pain and Symptom Management.  1996;11:203-217. 
56 American Geriatric Society Panel on Chronic Pain.  The management of chronic pain in older persons.  
Geriatrics.  1998;53(suppl 3):S8-S24. 
57 Brookoff D.  Chronic pain:. The case for opiods.  Hospital Practice.  2000;35;69-72,75-76,81-84. 
58 Bartleson JD..Evidence for and against the use of opioid analgesics for chronic nonmalignant low back 
pain: a review.  Pain Medicine.  2002;3:260-271. 
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Respiratory depression secondary to opioid use is not generally observed in 
clinical settings.  Studies have shown that opioids produce different effects in the 
laboratory setting (pain free subjects) as compared to clinical settings.59  It is believed 
that among patients, pain impulses are transmitted to respiratory centers, thereby 
inhibiting the depressive effect of opioids.  In the case of healthy subjects (no pain) or 
situations wherein pain relief is brought about, for example, by a nerve block, impulse 
transmission is prevented, which could then result in respiratory depression with an 
equianalgesic opioid dose.  Thus, pain serves as a physiological antagonist to opioid 
depressant effects.  The upward titration of an opioid dose is safe provided the patient 
is experiencing pain.60   
“Tolerance is a state of adaptation in which exposure to a drug induces 
changes that result in a diminution of one or more of the drug’s effects over time.”61  
Tolerance may develop to both the analgesic and respiratory depressive effects of 
opioids; however, tolerance usually develops quicker in the latter case.  There are no 
maximum opioid analgesic dose limits that have been established. 
“Addiction is a primary, chronic, neurobiologic disease, with genetic, 
psychosocial, and environmental factors influencing its development and 
manifestations.”62  Addiction is characterized by impaired control, compulsive 
behavior, craving, and persistence with behaviors that are harmful.63  In addition to 
brain chemistry, genetics and social/environmental cues play a role in the 
development of addictive behaviors.  “Family history of addiction,” “temperament,” 
“poor support,” and “drug availability,” contribute to the development of addiction.64  
The literature lacks well-controlled studies that examine the potential for addiction 
with the long-term use of opioid analgesics.  In the few studies that examine addiction 
                                                 
59 McQuay H.  Opioids in pain management.  Lancet.  1999;253:2229-2232 
60 Hanks GW.  Pain, the physiological antagonist of opioid analgesics.   Lancet.  1984;323:1477-1478. 
61 Liaison Committee on Pain and Addiction.  Definitions related to the use of opioids for the treatment of 
pain.  American Pain Society.  Available at: http://www.ampainsoc.org/advocacy/opioids2.htm, Accessed, 
January 21, 2003. 
62 Ibid. 
63 Nedeljkovic SS, Wasan A, Jamison RN.  Assessment of efficacy of long-term opioid therapy in pain 
patients with substance abuse potential.  The Clinical Journal of Pain.  2002;18:S39-S51. 
64 Ibid 
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rates, the proportion of chronic non-cancer pain patients who develop addiction is 
very small.  Most patients who develop addiction also have a history of substance 
abuse.  
“Substance abuse is the use of any substance(s) for non-therapeutic purposes; 
or use of medication for purposes other than those for which it is prescribed.”65  
Abuse associated with opioid use is of concern.  Important issues to consider are the 
misuse of prescription opioids and the diversion of these drugs.  An evaluation of 
overall prescribing patterns can serve as a guide to the existence and extent of the 
diversion problem.  Patient histories with regard to pain history, drug abuse, and other 
pertinent information must be recorded.  It is critical that all opioid prescribing be 
maintained by a single physician.  Routine follow-ups to assess patient progress and 
medication use may also serve to identify problems with medication abuse.66   
Data from the Drug Abuse Warning Network between 1990 and 1996 showed 
that use of opioids (fentanyl, morphine, meperidine, hydromorphone, and oxycodone) 
increased dramatically, except for meperidine.  The number of drug abuse mentions 
as a proportion of use declined from 5.1 percent in 1990 to 3.8 percent in 1996.67 
Pain patients often present with several psychiatric comorbidities.  
Retrospective data obtained through the Veteran’s Administration (VA, n = 50) and a 
primary care clinic (PCC, n = 48) showed that the lifetime prevalence rates for 
depression (44% and 54%), anxiety (20% and 21%), alcohol abuse and/or 
dependence (46% and 31%), and narcotic abuse/dependence (18% and 38%) 
respectively, were substantial.68  The highest rates of abuse were associated with 
oxycodone.  A history of lifetime substance use disorder was strongly associated with 
abuse of narcotic analgesics. 
                                                 
65 The Federation of State Medical Boards of the Unites States, Inc.  Model guidelines for the use of 
controlled substances for the treatment of pain.  Available at: http://www.csam-
asam.org/pain_treatment_guidelines.htm.  Accessed, January 31, 2003. 
66 International Association for the Study of Pain.  Opioids for chronic noncancer pain.  1995;3.  Available 
at: http://www.iasp-pain.org/PCU95c.html.  Accessed, October 11,2002. 
67 Joransons DE, Ryan KM, Gilson AM, Dahl JL.  Trends in medical use and abuse of opioid analgesics.  
JAMA.  2000;283:1710-1719. 
68 Carrington M, Engles-Horton LL, Weber MB, et al.  Use of opioid medications for chronic noncancer 
pain syndromes in primary care.  Journal of General Internal Medicine.  2002;17:173-179. 
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Prolonged opioid therapy or large doses may cause neurotoxicity, which is 
characterized by cognitive impairment, cognitive failure, severe sedation, 
hallucinosis, myoclonus, seizures and hyperalgesia.69  However, these symptoms are 
typically observed in extremely sick, dehydrated patients and in patients with renal 
impairment.   
 
1.3.6.3 Long-Acting Narcotic Analgesic Therapy 
 
Opioids that are available as prolonged delivery dosage forms (e.g., 
Oxycontin®, Avinza®, Duragesic®) have an improved safety profile compared to the 
short-acting opioid agents.  Sustained release therapy is indicated for those patients 
with a successful trial on short-acting opioid agents.70  Dosage should be adjusted to 
be similar to the average daily dose of the short-acting agent that provided adequate 
pain relief.  There are numerous advantages associated with long-acting opioid 
dosage formulations:  withdrawal and rebound symptoms are avoided; sedative 
effects that might occur after administration of short-acting agents are avoided due to 
optimal titration; normal sleeping patterns can be restored; optimal serum levels of 
drug are achieved thereby avoiding sub/supra analgesic doses; adherence to regimen 
is easier; abuse potential is minimized; patients can achieve greater control thereby 
allowing them to focus attention away from pain.  Empiric evidence suggests that 
abuse associated with opioid analgesics has increased from 1997 to 2002.71  However, 
the proportion of drug abuse mentions for hydrocodone (a short-acting narcotic) were 
higher when compared with either fentanyl, oxycodone, or morphine.  This study did 
not distinguish between long-acting and immediate release forms of morphine and 
fentanyl.  Sustained release dosage forms may be more useful and preferred as 
                                                 
69 Brevik H.  Opioids in cancer and chronic non-cancer pain therapy – indications and controversies.  Acta 
Anaesthesiologica Scandinavica.  2001;45:1059-1066. 
70 Ibid. 
71 Gilson AM, Ryan KM, Joranson DE, Dahl JL.  A reassessment of trends in the medical use and abuse of 
opioid analgesics and implications for diversion control:1997-2002.  Journal of Pain and Symptom 
Management.  2004;28:176-188. 
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compared to short-acting opioid agents.72  In this study, the effect, the effect long-
acting morphine, namely, Avinza® on various measures of pain and cognitive status 
will be examined. 
The following steps are recommended when patients currently on opioids are 
being converted to the controlled release formulation: 
 
1. Using standard conversion ratio estimates (see table below), multiply the mg/day 
of the previous opioids by the appropriate multiplication factors to obtain the 
equivalent total daily dose of oral morphine. 
2. Round down to a dose that is appropriate for the capsule strengths available (30, 
60, 90, 120 mg Avinza capsules) 
3. Discontinue all other around-the-clock opioid drugs when controlled-release 
Avinza therapy is initiated.73 
 
 
1.3.6.4 Morphine Sulfate Extended Release (Avinza): 
 
Morphine-3-glucoronide  and morphine-6-glucoronide are the active 
metabolites of morphine sulfate.  MS Contin is the most widely used formulation of 
controlled release morphine.  Avinza (morphine sulfate extended-release) capsules 
received marketing approval from the FDA March 2002 for “the once-daily treatment 
of chronic, moderate-to-severe pain in patients who require continuous, around-the-
clock therapy for an extended period of time.”74  The drug delivery system is a 
technological advance as the capsule contains morphine in an immediate release form 
and a sustained release form.  Once a stable plasma level of morphine is attained, the 
sustained release beads deliver the drug over a 24-hour period.  Avinza is available in 
30, 60, 90, and 100 mg capsules.  A pharmacokinetic comparison between Avinza 
and MS Contin showed that Avinza provides maximum concentrations over a longer 
                                                 
72 Bartleson JD..Evidence for and against the use of opioid analgesics for chronic nonmalignant low back 
pain: a review.  Pain Medicine.  2002;3:260-271. 
73 Ibid 
74 Elan Corporation.  FDA Approves Once-Daily Avinza (Extended Release Morphine) For Chronic 
Moderate-to-Severe Pain.  
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256B830048A246.  Accessed: Jun 
8, 2003. 
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period of time with minimal fluctuations in concentration levels.75 From a clinical 
perspective, a stable concentration of morphine has been associated with lower levels 
of pain intensity in chronic pain patients.  The following directions must be followed 
when converting from conventional immediate-release oral morphine to 
controlled/extended/sustained release oral morphine: Administer 50 percent of the 
total daily morphine dose every 12 hours; one third of total daily dose administered 
every eight hours (MS Contin and extended release tablets only); or the full daily 
morphine dose every 24 hours (Kadian only).76  The last conversion criteria can also 
be extended to Avinza. 
 
 
Table 1.1  Equianalgesic Doses of Centrally Acting 
Opioid Doses Compared to Morphine 
Drug Dose (mg) 
oral77,78,79 
Conversion 
Factor 
Morphine 30 1 
Codeine 200 0.15 
Hydrocodone 30 1 
Hydromorphone 
(Dilaudid) 
7.5 4 
Levorphanol 1 30 
Methadone 4 7.5 
Oxycodone 20 1.5 
Oral transmucosal 
fentanyl citrate 
(Actiq) 
1 30 
Propoxyphene 130 0.23 
Tramadol (Ultram) 150 0.2 
                                                 
75 Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J.  Steady-state pharmacokinetic 
comparison of a new, extended-release, once-daily morphine formulation, AvinzaTM and a twice-daily 
controlled-release morphine formulation in patients with chronic moderate to severe pain. Journal of Pain 
and Symptom Management.  2002;23:292-300. 
76 Drug Facts and Comparisons.  57th Edition.  Facts and Comparisons.  St. Louis, MO. 2003. 
77 Ibid 
78 CPSO Task Force on CNMP. Evidence-based recommendations for medical management of chronic 
non-malignant pain: reference guide for clinicians.  College of Physicians and Surgeons of Ontario 
(CPSO).  Ontario, Canada;2000. 
79 American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 4th ed. 
Glenview, IL: American Pain Society; 1999. 
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1.3.7 Studies Assessing Safety and Efficacy of Opioid Therapy in Chronic Non-
Malignant Pain 
 
Evidence from a few studies indicate that non-malignant pain patients 
presenting at multidisciplinary clinics may find limited improvement with narcotic 
use and some may even benefit with elimination of narcotic therapy.  McNairy and 
colleagues classified a sample of 50 chronic pain patients based on medication use as 
non-abusers (n = 14), abusers (n = 15), and dependent users (n=21).80  The authors 
concluded that the two latter groups demonstrated impaired cognitive function.  
Finlayson et al. examined long-term outcomes in chronic pain patients that were 
treated for substance dependency.81  Follow-up survey results showed that more 
patients who persisted with treatment for dependency (n = 34) reported improved 
work and social relationships as compared to those that discontinued treatment (n = 
16).  Reports of pain in the two groups showed no differences.  At two-years, two 
patients who discontinued treatment reported being pain-free. However, there are 
numerous limitations associated with these studies.  Patients in these studies were 
abusers or dependent users of prescription narcotics.  The results are not generalizable 
to the entire population of pain patients.  While one study reported pain levels at 
follow-up, McNairy and colleagues did not address pain as an outcome measure.  
Finally, the use of other drugs (e.g., benzodiazepines) that produce significant 
cognitive impairment was not reported.  The conclusion that chronic pain patients 
may benefit from the discontinuation of opioid therapy seems erroneous in light of 
these limitations. 
Results of studies documenting the efficacy of opioid therapy in neuropathic 
pain have shown a variable response.   Portenoy concludes that opioid therapy may 
not be generally indicated; however, individual differences, and the possibility of a 
                                                 
80 McNairy SL, Maruta T, Ivnik RJ, Swanson DW, Ilstrup DM.  Prescription medication dependence and 
neuropsychologic function.  Pain.  1984;18:169-177. 
81 Finlayson RE, Maruta T, Morse RM, Martin MA.  Substance dependence and chronic pain: experience 
with treatment and follow-up results.  Pain.  1986;26:175-180. 
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favorable outcome substantiate the use of narcotic analgesics.82  More recent evidence 
indicates that neuropathic pain is responsive to opioid therapy.   
A review of studies examining the efficacy of narcotic analgesics in chronic 
pain indicates that these drugs have an important role in the management of chronic 
non-malignant pain, particularly after other therapeutic options have been exhausted.  
These studies are presented in a reverse chronological order below: 
 The morphine responsiveness, efficacy, and tolerability in patients with non-
tumor associated pain (MONTAS) trial was a prospective, double-blind, placebo 
controlled, crossover trial in which non-tumor associated (NTAS) pain patients (n = 
49) were assigned to group I (10 and 30 mg doses of SR-morphine for one week 
followed by placebo in the second week) or group II (placebo was followed by SR-
morphine).83  Patients with neuropathic (n = 33) and nociceptive pain (n = 15) who 
had been exposed to a variety of treatment options without adequate relief 
participated in the trial, while one patient was not included due to a stroke prior to 
administration of study medication.  All of the patients had a “long history of severe 
pain,” “polymedication, many with step II opioids,” “a high incidence of increased 
disability and psychological disturbances, resulting in social and even financial 
problems.”  At the end of the trial, patients were categorized as responders if they 
reported a 50 percent improvement in pain or pain intensity was less than 5 on a 
numerical rating scale, pain was tolerable or minimal (visual rating scale < 3), and 
side effects were manageable while on morphine.  In order to be classified as a partial 
responder, side effects should have been manageable, while some pain relief was 
obtained due to placebo and inadequate pain relief was obtained due to study drug. 
Among patients that reported no pain/good analgesic response, 19 were on 
morphine while three were on placebo.  Mean improvement in pain intensity was 33 
percent for morphine compared to seven percent for placebo.  An approximately 
                                                 
82 Portenoy RK.  Opioid therapy for chronic nonmalignant pain: a review of the critical issues.  Journal of 
Pain and Symptom Management.  1996;11:203-217. 
83 Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G.  Morpine responsiveness, efficacy, and 
tolerability in patients with chronic non-tumor associated pain – results of a double-blind placebo-
controlled trial (MONTAS).  Pain.  2002;97:223-233. 
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equal number of patients on morphine (n = 17) and placebo (n =16) reported that pain 
was just tolerable.  Significantly more patients treated with morphine (n = 19, 40%) 
than with placebo (n = 1, 2%) were classified as responders.  In addition to pain 
intensity, improvements in affect, mood, and sleep quality were also observed.  A 
greater proportion of patients on morphine (58.0%) experienced side-effects as 
compared to those on placebo (22.0%), however, some of these side effects were also 
associated with opioid withdrawal and a greater reliance on rescue medication during 
the placebo phase.  Most patients (58.3%) relied on the maximum daily dose (180mg) 
of morphine allowed in the trial.  More patients with neuropathic pain (14 of 33, 
42%) were categorized as responders than patients with nociceptive pain (3 of 15, 
20%).  The proportion of partial responders was greater in the nociceptive pain group 
(40%) than in neuropathic pain group (33.33%).  In addition to analgesia, responders 
to morphine reported improvements in mood, sleep quality, pain disability, and scores 
on depression and exercise endurance improved as well.  “The sum score of central 
nervous system (CNS) complaints were increased only in the non-responders, but 
lowered in the response group and during morphine therapy.”84 
Attal and colleagues examined the efficacy of IV morphine in a sample of 
patients (n = 15) with central pain (neuropathic pain subsequent to stroke or spinal 
cord injury).85  Eligibility criteria included opioid-naive patients with moderate pain 
(>30/100 at baseline) that had persisted for six or more months.  The study utilized a 
double-blind placebo-controlled trial in which patients were either randomized to 
receive morphine (tolerability to the drug was assessed in a previous titration phase) 
or 0.9 percent saline.  Responders and partial responders to treatment were defined as 
those patients who reported 100 percent and 50 percent relief from pain, respectively.  
Patients treated with morphine reported on average that spontaneous pain reduced by 
46.42 percent 30 minutes after injection (mean = 61.6 mm, s.d. = 17   to mean = 
33mm, s.d. = 23), while patients receiving placebo reported a 24 percent reduction on 
                                                 
84 Ibid. 
85 Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D.  Effects of IV morphine in 
central pain.  Neurology.  2002;58:554-563. 
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average (mean = 69 mm, s.d. = 16.9   to mean = 52mm, s.d. = 19).  A greater 
proportion of patients treated with morphine (46%) achieved a 50 percent or greater 
reduction in pain as compared with placebo (13%). Among patients experiencing 
allodynia (n =10) at baseline, nine patients achieved a 50 percent or better reduction 
in pain intensity with morphine and three patients achieved this outcome with 
placebo.  Morphine did not improve tolerability to mechanically induced thermal or 
electric stimuli.  A total of 14 patients were successfully switched to sustained-release 
oral therapy with morphine, and six discontinued the treatment due to adverse effects.  
A significant reduction (mean difference = 20 mm, p = 0.03, n = 8) in pain intensity 
was reported on average at the end of four weeks of oral therapy.  Long-term 
followup (≥ one year) showed that only three patients continued to find relief with 
morphine while three discontinued due to side effects.  More patients discontinued 
treatment due to the concern about side-effects than lack of pain relief.  The results 
suggest that morphine is effective in some neuropathic pain syndrome patients, but 
long-term side effects may pose a problem for many patients. 
 A randomized cross-over trial was utilized to assess patient preference for either 
sustained release morphine (MS Contin) or transdermal fentanyl (Duragesic®).86  In 
order to be included in the trial, patients should have received opioids for six weeks 
and achieved moderate relief with a stable opioid dose for one week prior to the 
study.  Overall, a significantly greater number of patients either strongly preferred or 
preferred fentanyl patches (n = 138, 65%) over SR morphine (n = 58, 28%).  Better 
pain relief and ease of dosing were cited most commonly as advantages of fentanyl 
over morphine.  More patients on fentanyl rated pain relief as good or very good, 
regardless of whether patients experienced nociceptive pain (43/123, 35%), 
neuropathic pain (21/62, 34%), or mixed nociceptive and neuropathic pain (23/63, 
37%).  As per the corresponding classification, the proportion of patients that 
provided similar ratings with the use of SR morphine were 25 percent (15/59), 23 
percent (27/116), and 20 percent (12/59), respectively.  Average pain intensity ratings 
                                                 
86 Allan L, Hays H, Jensen NH, et al.  Randomised crossover trial of transdermal fentanyl and sustained 
release oral morphine for treating chronic non-cancer pain.  British Medical Journal.  2001;322:1-7. 
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were significantly lower (p < 0.001) with fentanyl (57.8 cm, range – 33.1 to 82.5) 
than with SR morphine (62.9, range – 41.2 to 84.6).  On average, patients receiving 
fentanyl provided significantly higher ratings on most SF-36 subscales, no significant 
differences in scores on the emotional subscales were observed.   Among patients 
who had no prior exposure to opioids, withdrawals and reports of adverse events for 
both drugs were similar. Among patients who had prior exposure to morphine, a 
greater number of withdrawals occurred when patients were treated with fentanyl 
first. It was concluded that the higher proportion of withdrawals occurred due to 
larger doses resulting in more unanticipated side-effects. 
Wilder-Smith et al. compared the effects of controlled release (CR) tramadol 
(n = 28),  (CR) dihydrocodeine (n = 29), and NSAIDs (n = 30) in patients with pain 
due to osteoarthritis.87  Opioid treatment groups were permitted to continue using 
corresponding immediate release formulations for breakthrough pain.  Patients in the 
opioid treatment arms provided higher pain intensity ratings than the control group at 
baseline.  Pain intensity at rest was significantly lower in the tramadol group (p = 
0.04).  Pain intensity ratings at baseline were significantly higher than those obtained 
during treatment.  Quality of sleep ratings improved from poor at baseline to “good” 
and “very good” for the dihydrocodeine and tramadol groups respectively on day 28.  
However, no significant group differences emerged on this outcome measure.  Pain 
due to osteoarthritis was adequately controlled with tramadol and dihydrocodeine.  
Use of breakthrough pain medication was limited.  
 Milligan and colleagues enrolled chronic non-malignant pain patients (n = 532) 
(persistent pain ≥ 6 weeks) who had a moderate response with opioids into an open-
label trial to assess the safety, efficacy, and preference of fentanyl transdermal patch 
over other opioids.88  A total of 301 patients (43%) completed the trial, which lasted 
                                                 
87 Wilder-Smith CH, Hill L,  Spargo K, Kalla A..  Treatment of severe pain from osteoarthritis with slow-
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transdermal fentanyl in the treatment of chronic noncancer pain. The Journal of Pain.  2001;2:197-204. 
 24
for 12 months.  Average dose of fentanyl used increased from 48 µg/hour to 90 
µg/hour in the last month of the trial.  The proportion (71%) of responders to opioids 
at the start of the study did not vary significantly from the proportion (67%) at the end 
of the study.  In response to items on the SF-36, more patients reported pain to have 
improved from very severe/severe to moderate at the end of the study.  Overall 
improvements in QOL (physical, social, and mental) were minor, yet fentanyl proved 
tolerable and produced analgesia among patients with nociceptive and neuropathic 
pain. 
 A medical record examination of primary care clinics in the Wisconsin area 
showed that a broad range of conditions such as low back/lumbar pain, arthritis, 
headache/migraine, neck/upper back, fibromyalgia, etc. are treated with narcotic 
analgesics.89  A total of 209 chronic pain patients were identified from a population of 
83,000 patients that received care at five centers.  The chronic pain patients received 
the following narcotic analgesics for at least three months:  Percocet (30%), Extended 
release morphine tablets (20%), Vicodin (14%), Tylenol #3 (14%), Oxycontin (11%), 
Oxycodone (10%), Methadone (8%), Darvon (9%).  (Proportion of narcotics used by 
these patients exceeds 100 since some patients used more than one narcotic 
medication).  A diagnosis of depression was confirmed in 37.8 percent of the sample 
(n = 79).  A significantly greater number of positive diagnoses for depression were 
made in individuals under age 60 and women. Depression, in addition to panic and 
anxiety disorders was most commonly associated with headaches/migraines.  Patients 
were most commonly treated with opioids for chronic pain due to lumbar/low back 
pain (37%), fibromyalgia (26%), and headache/migraine (23%).  The high prevalence 
of chronic pain in the US, relatively few patients (0.25%) with prescriptions for 
opioids in the population studies, and the increased acceptance of the use of opioids 
in chronic non-malignant pain patients led the authors to conclude that pain is under-
treated in the primary care setting examined for this study.  In addition to concerns 
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about side effects and addiction, “lack of knowledge regarding pain management,” 
inability to assess pain, and concern about regulatory authorities were cited as barriers 
to physician acceptance of long-term opioid therapy as an acceptable option in the 
treatment of chronic pain. 
 Roth and colleagues conducted a double-blind placebo-controlled trial in which 
patients with moderate to severe pain due to osteoarthritis were assigned to receive 
controlled release (CR) oxycodone 20mg/day (n  = 44), or 40 mg/day (n= 44), or 
placebo (n = 45).90  The trial extended for a period of 14 days, subsequent to which 
patients were enrolled in an open-label drug study with follow-up measures reported 
at 6, 12, and 18 month intervals.  A total of 39 patients discontinued therapy due to 
lack of pain relief; a significantly greater number of patients in the placebo group (n = 
22) dropped out of the study than in the treatment groups (n = 17).  A significantly 
higher proportion of patients discontinued treatment due to adverse effects from 
treatment (26/88) than from placebo (2/45).  Patients receiving the largest dose of CR 
oxycodone reported significant improvements over baseline pain intensity ratings 
than the two other groups at the end of two weeks.  Improvements in function 
(minimal functional impairment reported at baseline) were observed in the treatment 
groups, however, no statistical differences were detected in comparison with placebo.  
Among patients that continued the long-term trial, analgesic efficacy was observed 
for the length of the study (18 months) with a mean dose of 40mg/day of CR 
oxycodone.  Withdrawal of drug resulted in return of pain to baseline levels, which 
further established the effectiveness of treatment.  Improvements in sleep, sleep 
quality, and mood were also observed.   
 Taylor and colleagues conducted a retrospective review of 59 pain patients who 
were treated with methadone for an average duration of 18.4 months (s.d. = 28.5).91  
Of these patients, 14 remained on methadone (ON group), 19 were lost to follow-up, 
and 26 discontinued methadone treatment (OFF group).  Among patients in the OFF 
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group, the condition of three patients had resolved, six were non-compliant, eight did 
not achieve adequate pain relief, 12 experienced unmanageable side effects 
(peripheral edema and/or nausea), and four patients died.  (Total exceeds 26 since 
more than one patient discontinued treatment for multiple reasons.).  Only 50 percent 
(13/26) of patients that discontinued methadone sought and continued treatment with 
other opioids.  Although significantly (p < 0.05) more patients ON methadone were 
employed (53%) than those OFF methadone (23%), this comparison does not reflect 
the proportion of patients on other opioids who returned to work.   A general trend of 
dose increases were observed for all opioids indicating that long term opioid therapy 
would more often than not be accompanied by dose escalation.  Patients that were 
switched from methadone to other opioids continued to derive significant benefit 
from narcotic analgesic therapy.  The finding that more patients in the ON group were 
employed as compared to those in the OFF group prompted the authors to favor the 
use of long-acting opiod therapy in comparison with short-acting narcotic analgesic 
therapy from their practice experience: 
1. The finding may be a manifestation of the negative impact on employment of the 
dysphoria associated with the use of short-acting opioids; 
2. The relative disinterest of workers with dysphoria; 
3. The increased absolute number of pills taken by less functional patients; 
4. The utility of time-contingent dosing as opposed to symptom-based dosing.92 
 
 Caldwell et al. conducted a double-blind placebo-controlled trial to evaluate the 
effectiveness of CR oxycodone (Oxycontin® 10mg) and immediate release (IR) 
oxycodone-APAP (5/325mg) (Percocet® ) in patients with moderate to severe pain 
due to osteoarthritis (OA) that were unresponsive to NSAID therapy.93   All patients 
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(n = 167) underwent a titration phase (30 days) prior to the randomization phase in 
which the dose of Percocet (maximum dose – 12 tablets/day) was adjusted to achieve 
pain relief without significant side effects.  A total of 36 patients withdrew due to side 
effects and another 17 due to lack of analgesia.  Among patients that continued the 
trial, mean dose of IR oxycodone was 40mg/day.  Patients (n = 107) were randomized 
to one of three-treatment arms placebo (n = 36), Oxycontin (n = 34) (bid), and 
Percocet (n = 37) (qid).  Global assessments for pain intensity (0 = none, 1 = slight, 2 
= moderate, and 3 = severe) at joint determined to be most painful and quality of 
sleep (1 = very poor, 2 = poor, 3 = fair, 4 = good, 5 = excellent) were made.  Patients 
on placebo experienced a significantly greater (p < 0.0040) increase in pain intensity 
(mean increase = 1.00, sd = 0.13) than either Oxycontin (mean increase = 0.44, sd = 
0.13) or Percocet (mean increase = 0.49, sd = 0.11) than those reported at the end of 
titration phase.  Global quality of sleep ratings declined dramatically (p ≤ 0.0001) for 
the group receiving inactive treatment, while scores for groups receiving drug 
treatment showed no change.  The two active treatments seemed to produce 
comparable results with respect to pain intensity, but patients reported better quality 
sleep with the CR dosage form. 
 Chronic low back patients (n=33) without structural pathology for their 
condition, history of substance abuse, or psychiatric disease who were refractory to 
other treatment options (physical therapy, psychotherapy, intraspinal injections, and 
adjunctive medications) were enrolled into an opioid trial.94  Of these patients, five 
discontinued the trial due to side effects, seven did not respond to opioid therapy, and 
21 showed significant improvement in pain and disability from baseline (numerical 
rating scale mean  =  8.45, range 6 to 10; Oswestry disability scale score mean = 64, 
range – 42 to 88) to conclusion of trial (mean = 4.90, range – 0 to 8; mean = 50, range 
– 9 to 80).  Patients that obtained benefit from the trial received long-term opioid 
therapy (mean duration – 32 months).  A comparison between the responders (n = 21) 
and all the other patients (n =12) at the end of one-year showed that on average, pain 
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scores and disability scores improved by 3.6 and 13.8 points, respectively in the 
former group and remained stable in the latter group.  The author was unable to 
identify any specific variables that may have contributed to the analgesic efficacy of 
opioids in one group of patients  (n = 21) and the lack of effect in a similar subgroup 
(n =7). 
 Jamison et al. conducted a randomized, open-label, long-term study to evaluate 
the effectiveness of opioids in chronic non-malignant pain patients with moderately 
severe back pain (pain intensity ≥ 40 on scale ranging from 1 to 100).  In the first 
phase of the study, patients were randomized to one of three treatment regimens, i.e., 
naproxen (maximum daily dose – 1000mg), fixed dose oxycodone (Roxicodone® 
maximum daily dose – 20mg), and a titrated dose of oxycodone and SR morphine 
(Oramorph SR®).95  Patients were followed for 16 weeks after which all patients were 
eligible to receive oxycodone and SR morphine (maximum daily dose – 200mg) for 
an additional 16 week period.  In the final phase of the study, opioid dose was 
gradually tapered for 12 weeks, followed by a 4-week washout period, at the end of 
which final follow-up measures were obtained.  Information on pain intensity, sleep 
and activity, participation in activities with family, socioeconomic factors, and 
previous medication history was collected by using the Comprehensive Pain 
Evaluation Questionnaire (CPEQ), which is an amalgam of several exhaustive 
instruments.  Additionally, the SF-36 and the SCL90-R were administered at baseline 
and 1-year follow-up.   
 Of the 36 participants, 74.3 percent had undergone prior surgery to treat their 
low back pain.96  At baseline, the group receiving titrated doses of opioids reported 
greater number of hours reclining (df =16, F =4.65, P < 0.05) than the other groups.  
Side effects were common in the opioid treatment groups (p < 0.001), and 
characteristics of participants reporting frequent adverse events included more severe 
pain ratings at baseline (r = 0.44, p <0.01), higher likelihood of compensation (r = 
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0.36, p< 0.05), frequent users of nicotine products (r = 0.35, p < 0.05), and a 
sedentary lifestyle.  Although the NSAID group reported higher levels of anxiety, 
other emotional variables such as depression and irritability did not differ across 
groups.  At the end of 16 weeks, average pain intensity rating increased from 64.3 
(s.d. = 17.50) to 65.5 (s.d. = 19.5) in the naproxen group, and improved from 67.2 
(s.d. = 15.12) to 59.8 (s.d. = 16.65) in the fixed dose group and from 70.8 (s.d. = 
18.45) to 54.9 (s.d. = 15.87) in the SR morphine group.  Current pain intensity ratings 
did not change for the naproxen group, but reduced from 62.3 (s.d. = 17.83) and 68.2 
(s.d. = 23.25) to 55.3 (s.d. = 20.87) and 51.3 (s.d. = 18.98) in the oxycodone and SR 
morphine groups respectively.  Highest and lowest pain intensity ratings, anxiety, 
depression, and irritability scores were significantly lower for the opioid groups 
compared to the naproxen group.  There were no significant group differences in 
pain, mood, activity, and sleep at the end of the study period.  A consistent feature 
was that patients reported moderate levels of pain intensity at the end of the trial.  
Although opioids improved patient mood and pain, no significant impact was 
observed on the extent to which participation in activities increased. 
 Watson and Babul conducted a randomized, double-blind, placebo controlled, 
crossover trial that examined the effectiveness of sustained release oxycodone (10mg) 
in patients with postherpetic neuralgia.97  In addition to the study drug, patients were 
permitted to continue taking concurrent medications such as NSAIDs and 
antidepressants.  “ A previous study in postherpetic neuralgia suggested that standard 
deviations of 27mm (pain VAS) were reasonable to expect.  With the patient serving 
as his or her own control, and assuming a minimal correlation between responses in a 
single subject in the two treatment periods, a total of 30 completed patients would 
provide 80% power (β = 0.2) to detect a difference of 20mm in pain intensity VAS at 
a statistical significance of 0.05.”98   A total of 50 patients were enrolled, and 38 
completed the trial.  Patients served as their own controls and measures on pain 
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intensity (100mm VAS) and categorical pain intensity scale (0 -  no pain, 1 – mild 
pain, 2 – moderate pain, 3-severe pain, 4 – unbearable pain) were obtained at the end 
of each four-week interval.  Pain relief was measured on a six point scale (0 – pain 
worse, 1 – no relief, 2 – slight relief, 3 – moderate relief, 4 –a lot of relief, 5 – 
complete relief.).  A total of eight participants withdrew due to side-effects, five while 
on oxycodone and three while on placebo.  Reports of average pain intensity, both 
VAS (35mm +/- 25 vs 54mm +/-25mm) and categorical scale (1.7 +/- 0.7 vs 2.3 +/- 
0.7) were significantly lower (p < 0.001) during the fourth week for patients being 
treated with oxycodone than with placebo. Oxycodone rather than placebo was 
associated with greater pain relief and lower disability scores (p < 0.0001).  BDI 
scores remained unchanged throughout the trial.  Results from this study show that 
opioid analgesics (oxycontin) are effective in the management of neuropathic pain, 
particularly postherpetic neuralgia.    
 Dellemijn and Vannaste conducted a double-blind crossover trial to assess the 
efficacy of intravenous fentanyl in chronic pain patients (nociceptive nerve pain, 
deaffrentation pain, and mixed neuropathic pain).99  Patients experiencing pain due to 
trigeminal neuralgia or pain of ambiguous origin were not included in the study.  All 
patients reported baseline pain intensity scores and were then infused with fentanyl 
and diazeapam (inert placebo).  After one week (washout period), patients with 
moderate to severe pain (≥ 40 on NRS) were subsequently randomized to receive 
fentanyl (5µg/ml) and diazepam (0.2mg/ml).  All patients in group-1 (n = 26) 
received either the drug first or active placebo first, while patients in group-2 (n = 24) 
received drug (fentanyl - 5/ml) first or inactive placebo (saline) first.  Depression 
scores indicated that all patients were either severely (n = 44) or moderately (n = 6) 
depressed.  Although patients reported greater pain relief with fentanyl, no significant 
differences were detected in percent pain intensity difference (PID) or percent pain 
unpleasantness difference (PUD) between fentanyl, diazepam, or saline.  Average 
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dose of fentanyl and diazepam that was infused equaled 873µg (equivalent morphine 
dose – 70mg) and 52.1mg respectively, over five hours.  The proportion of 
respondents (≥ 50% pain relief) to fentanyl (65.4% and 50.0%) was significantly 
greater in group 1 and 2 respectively, than with diazepam (15.4%) or placebo (8.3%).  
No differences were apparent between diazepam and saline with respect to pain 
intensity. 
 Dellemijn and colleagues extended the previous study to examine long-term use 
of transdermal fentanyl by soliciting volunteers who successfully completed the trial 
reported above.  Only patients with chronic neuropathic pain were solicited for the 
trial.100  Pain intensity and unpleasantness evaluations were made for each of the 12 
weeks of the trial.  In addition to pain intensity and unpleasantness, self reported 
measures were obtained on the Zung depression scale, and a validated quality of life 
index that incorporated three dimensions: “symptom control,” “physical well-being,” 
and “psychological well being.”  At the end of this period patients were gradually 
weaned off fentanyl by lowering the dose to 25 µg/hour and then switching patients 
to 60mg/day sustained release morphine, which was finally discontinued.  A total of 
48 patients participated in the study, and 30 completed the trial.  Of these 30 patients, 
13 (43.33%) experienced greater than 50 percent relief in pain intensity, while the rest 
experienced less than 50 percent relief.  The greater relief in pain intensity was also 
associated with a reduction in psychological symptoms.  Among the nine patients 
who continued transdermal fentanyl therapy at the end of 2 years, average pain 
intensity difference was 47 percent, with 3 patients obtaining negligible pain relief.  
Patients adapted to the drug treatment within a week, which was accompanied by a 
corresponding reduction in side-effect severity and sedation.  Although many patients 
obtained substantial pain relief, a majority (82%) did not continue treatment with 
fentanyl.  Pain relief was not associated with QOL scores or ratings obtained on the 
Zung depression scale.  Side-effects of the treatment in many cases outweighed the 
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benefits of pain relief.  Successful treatment with intravenous fentanyl was a predictor 
of good outcome with transdermal therapy. 
 Moulin DE and colleagues conducted a randomized double-blind, placebo-
controlled trial to assess the effectiveness of SR morphine in chronic pain patients 
(persistent pain ≥ 6 months).101  Patients who were unresponsive to NSAIDs and 
tricyclic antidepressants (TCAs) with moderate pain ratings in the week prior to the 
trial (pain intensity ≥ 5 cm on a 10cm long VAS) were included in the trial.  Almost 
all patients (60/61) had used codeine in the past (mean dose- 126.5mg, mean duration 
– 32.3 months).  Patients were titrated upto a maximum dose of 60mg MS Contin bid 
for 3 weeks, followed by a maintenance dose in the evaluation phase, which lasted for 
6 weeks.  Benztropine was administered as placebo.  Following a two-week washout 
period, patients were crossed over to corresponding treatment and placebo arms.  The 
following subject-rated measures were obtained: SCL-90, Profile of Mood States 
(POMS), sickness impact profile (SIP), and the Pain Disability Index (PDI).  Impact 
on cognitive ability was assessed with the High Sensitivity Cognitive Screen.  Pain 
intensity, pain relief, and adverse effects, which were measured on a three-point scale 
that ranged from mild to severe, were obtained on a weekly basis. Psychological and 
functional status assessments were made at the end of titration, follow-up, and 
washout phases. “A sample size of 42 was determined to be sufficient to detect a 
difference of 1cm with a standard deviation of 2 cm to provide 90 percent power at 
the 0.05 significance level.”  Pain intensity ratings reduced significantly (p = 0.02) for 
the group treated with morphine first and the effects persisted with placebo.  Patients 
who were assigned to receive placebo first failed to respond to both treatments.  
Psychological and functional status assessments did not improve in response to 
treatment with morphine.  Prior exposure to codeine may have resulted in the limited 
usefulness of current therapy; however, the average morphine dose used in the study 
(83.5 mg) was equivalent to four times that of the average codeine dose (560 mg) that 
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patients were using before the trial. Morphine dose of 120mg per day did not 
adversely affect cognitive abilities such as memory, attention, and concentration. 
 Arkinstall and colleagues utilized a randomized double-blind, placebo-
controlled crossover study design, which showed that controlled release codeine 
(Codeine Contin®) on average was more effective than placebo in reducing pain 
intensity VAS scores (35 mm s.d. = 18 vs 49mm s.d. = 16mm) among a sample of 
chronic non-malignant pain patients.102  The amount of rescue medications for 
breakthrough pain was significantly lower while patients were on CR codeine than on 
placebo. 
 A 24-hour patient-controlled analgesia technique was used to assess the efficacy 
of IV morphine in nociceptive, neuropathic, and mixed pain of chronic non-malignant 
and cancer origin.103  Of the 22 patients included in the study, 12 achieved a good 
response (> 70mm pain relief on a 100mm VAS scale and few side effects), four 
patients achieved a moderate response (<70mm and >30mm pain relief at two or 
more assessment times), and the rest achieved a poor response (< 30mm pain relief 
and intolerable side effects).  Response to opioids was variable regardless of type of 
pain and source of pain suggesting that management of certain pain syndromes (e.g., 
neuropathic pain syndromes) with opioids should not be excluded as a possibility. 
 Bouckoms et al. conducted a retrospective review of 59 patients that had been 
prescribed narcotic analgesics for chronic nonmalignant pain a period of 36 
months.104  A total of 20 patients (34%) obtained complete relief and another 27 
patients (46%) obtained partial relief with narcotic analgesic use.  Nociceptive pain 
was responsive to opioids, while neuropathic pain, drug abuse, and comorbid 
depression were not associated with improvement in pain.  Comorbidities such as 
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major depression, personality disorder, and other psychiatric conditions were most 
commonly associated with the development of abuse and dependence. 
 Jadad et al. utilized a double-blind randomized crossover design to examine 
analgesic relief obtained by the administration of morphine sulphate solution 
administered intravenously (10mg/ml and 30mg/ml).105  Patients were administered 
either a 10mg/ml or 30mg/ml dose and controlled the rate of drug delivery.  Pain 
relief was measured by VAS, VAS for pain intensity, pain relief measured with a 
categorical scale at regular intervals during an eight hour period, and baseline 
measurements with McGill pain questionnaire were obtained.   The crossover dose 
was administered only when patients reported similar pain intensity as that at 
previous administration.  A total of 13 patients were enrolled in the study and 10 
completed both phases.  On average, 230 mg of MS was utilized by patients.  
Although patients with neuropathic pain experienced their symptoms longer than 
those patients with nociceptive pain, no significant differences were observed in other 
characteristics such as pain intensity, age, McGill pain score, and the number of 
words utilized by patients to describe their pain. Pain response to the higher dose of 
morphine sulphate was superior and more side-effects were experienced with the 
lower dose (31 vs 36), however, this difference in adverse effects was not significant.  
Common side-effects experienced by subjects were drowsiness, itchiness, and 
concentration difficulties.  It appears that both neuropathic and nociceptive pain are 
responsive to morphine; however, study results showed that patients with the latter 
type of pain achieved greater analgesic relief. 
 Tennant and colleagues published a report about 52 chronic non-malignant pain 
patients (mean age = 48.6 years) who were dependent on opioids and had been 
referred to the authors practice.106  This group of patients had exhausted a variety of 
other pharmacological and non-pharmacological treatment options without much 
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success.  Most patients (92.3%) experienced pain of known etiology, which was 
musculoskeletal in nature.  A majority of patients (88.5%) achieved adequate pain 
control, which was determined on the basis of patient self-reports and attending 
physician’s clinical judgment.  In this open label trial, pain was managed by either 
raising the original opioid dose, switching to a longer acting narcotic (methadone, 
oxycodone), combining low dose methadone with short-acting narcotic agents, or 
utilizing suppositories (hydromorphone/morphine).  A wide variety of narcotic 
analgesics such as oxycodone, methadone, codeine, propoxyphene, hydromorphone, 
meperidine, and hydrocodone were utilized in this group of patients. 
 A report on the use of opioid analgesics in two separate patient groups with 
chronic pain of non-cancer origin concluded that patients experience adequate but 
incomplete pain relief without substantial improvement in functional status.107  A 
majority of patients were treated with oxycodone (12/38), while other therapies 
included methadone, levorphanol, methadone/oxycodone,  propoxyphe, 
propoxyphene/oxycodone, meperidine, codeine, pentazocine, 
pentazocine/propoxyphene, levorphanol/codeine.  The report also suggested that 
patients undergoing long-term therapy might achieve better outcomes under the 
comprehensive supervision of one physician who assumes responsibility for 
management of these patients.  Physician-patient relationship as a predictor of 
outcome with opioid therapy is an additional variable that is typically not evaluated. 
 A retrospective study of pain patients that had been stabilized on opioids 
showed satisfactory outcomes among compliant patients.108  Noncompliant patients 
(n=18, 12%) were on less potent opioids (hydrocodone, codeine), displayed aberrant 
medication taking behavior, and reported limited pain relief.  The rate of return to 
work improved in the compliant group. 
 A review of the safety and efficacy of Oxycontin concluded that although the 
drug is superior to placebo, it has no clinical advantages over immediate release 
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oxycodone in the treatment of chronic non-malignant pain.109  However, both 
formulations are superior to non steroidal anti-inflammatory drugs (NSAIDs) in this 
regard. In three of six studies reviewed, participants experienced fewer side-effect 
with the controlled release formulation, however, the authors concluded  that SR 
oxycodone did not have a better side-effect profile than oxycodone.  Except for one 
study that assessed postoperative pain, studies comparing oxycontin with other 
opioids were conducted in cancer patients. In five studies that compared oxycontin 
with sustained release morphine, no differences were found in either analgesic 
efficacy or adverse event profiles.  The authors state that patients that have failed on a 
methadone trial received benefits from alternative opioid therapy suggesting that 
different narcotics, dosages, and dosage forms may produce different effects in any 
individual.  This strengthens the case for individualized evaluations for selection of 
appropriate opioid therapy. 
 
1.3.7.1 Summary of Studies Examining the Safety and Efficacy of Opioid Therapy 
in Chronic Non-Malignant Pain 
  
 This review indicates that regardless of the source of chronic pain, subgroups of 
patients with nociceptive, neuropathic, and osteoarthritis related pain obtain relief 
from the use of narcotic analgesics.  Specific criteria that separate responders and 
partial responders from non-responders have not been clearly identified.  Analgesic 
relief with opioid therapy is superior to that attained by NSAIDs.  However, patients 
experience a greater number of side-effects with opioid therapy.  Short-acting and 
long-acting analgesic therapies produce comparable analgesic relief.  The evidence 
suggesting an improved side-effect profile with long-acting therapy is limited.  
However, patients have reported improvements in sleep, sleep quality, and mood with 
long-acting opioid therapy.  Results from most of the studies examined suggested that 
patients tend to discontinue opioid therapy due to intolerable side-effects rather than 
lack of analgesia.  Nausea, vomiting, itching, and drowsiness are some of the most 
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commonly reported adverse effects.  Morphine doses upto 120 mg/day did not impair 
cognitive abilities of attention, memory, and concentration.110  Central nervous 
system symptoms were commonly apparent among patients that did not respond to 
opioid therapy.  Very few studies have reported improvements in functional status, 
participation in activities, or return to work among patients on opioid therapy.  A 
tabulated summary of the studies reviewed is listed in Appendix A.   
 
1.3.8 Mechanisms of Pain 
 
 A number of models have proposed mechanisms by which individuals 
experience pain.  The biomedical model is limited and defines illness narrowly on the 
basis of biological, physical, and chemical attributes.111  This model does not explain 
phenomena such as the presence of pain in the absence of pathology.  Models that are 
based on the psychological perspectives claim that such phenomena can be attributed 
to various psychogenic factors including motivation (financial, family attention, etc) 
and reinforcement, wherein individuals may have become sensitized to painful 
stimuli long after factors causing pain (damaged tissue) may have resolved.  Again, a 
disadvantage with the psychological perspective is the lack of an explanation for 
cases that are asymptomatic in the presence of obvious pathology.  Individual 
variations in response to therapy, failure of surgical and pharmacological 
interventions, and “the low association between impairment and disability” indicate 
that a combination of factors ranging from biological findings to cultural norms and 
social interactions, and psychological functioning contribute to an individual’s 
acceptance, response, and ability to cope with the condition. 
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1.3.8.1 The Gate Control Theory (GCT)  
 
 The GCT was proposed by Melzack and Wall in 1965 states that pain 
perception can be attributed to mechanical and psychological stimuli, and both factors 
play a role in altering response.112  The GCT states that pain does not only involve 
sensory perceptions, but also includes affective and cognitive dimensions.  The 
central nervous system plays a major role in the transmission and perception of pain 
suggesting that both psychological and somatic factors mediate pain.  According to 
the theory, transmission of pain impulses to the brain occurs through the smaller 
afferent fibers that connect with large fibers in the dorsal horn of the spinal cord.  The 
large fibers inhibit this transmission. If there is damage to large fibers, firing of slow 
impulses from the smaller fibers can lead to opening of the gate and perception of 
pain.  Large fiber activity produces an opposite effect closing the hypothetical gate. 
 The spinothalamic and spinoreticular tracts constitute the ascending system and 
transmit sensory nociceptive information to the thalamus.  The spinothalamic tract 
splits into the lateral branch and medial branch, which penetrate the brainstem 
reticular formation.  The lateral branch “is responsible for the sensory discrimination 
of the spatial, temporal, and magnitude characteristics of pain, while the medial 
branch is associated with few painful stimuli.”113  The spinoreticular tract also splits 
into two branches that reintegrate in the periaqueductal grey (PAG) where heat and 
mechanical stimuli are perceived.  Fibers that descend into the dorsal horn are 
believed to inhibit excitatory activity of impulses there. These fibers emerge primarily 
from the PAG and are capable of negating impulses that are generated by the afferent 
fibers.  The PAG (located in the midbrain) is believed to inhibit transmission of pain 
impulses in the dorsal horn.  The presence of enkephalin receptors in the PAG that 
bind with opioid like substances, stimulation of the PAG that causes release of 
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enkephalins and endorphins with analgesic properties, and the inhibitory effects that 
opioid antagonists have on this stimulation corroborate the above finding.114  
 Numerous brain structures such as the frontal cortex, the PAG, and brain 
reticular formation play a role in cognitive and motivational-affective activities.  
Numerous emotions, fears, and avoidance-behaviors that arise in pain patients can be 
contributed to the involvement of these structures in the transmission and perception 
of pain.  Prior to the GCT, pain research ignored the importance of cognitive 
processes, which were believed to occur secondary to pain.  The complex processes 
involved in the perception of pain make it important to incorporate variables such as 
past experiences, attention, and cognitive activities and their association with 
therapy.115 
 The mechanism of pain as explained by the GCT provided a sound theoretical 
foundation and stimulated significant research resulting in major therapeutic advances 
in behavioral, cognitive, psychological, and medical strategies.  Recent advances in 
technology have revealed some deficiencies in the GCT that have resulted in 
modifications to the theory.  Despite these data, the GCT continues to serve as a 
heuristic basis for studying pain as it continues to provide a “powerful summary of 
the phenomena observed in the spinal cord and brain, and has the capacity to explain 
many of the most mysterious and puzzling problems encountered in the clinic.”116 
 
1.3.8.2 Neuromatrix Theory   
 
Melzack, in 1999, proposed the neuromatrix theory, which incorporates theory of stress 
into the GCT.  The important features of this neuromatrix include a network of nerve 
fibers, genetic factors that define the neuromatrix, and prior sensory stimulation and 
learned behaviors that are capable of sensitizing and modifying the neuromatrix.  
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Collectively these factors are referred to as the “body-self neuromatrix.”  It is believed 
that the multidimensional nature of pain stems from these characteristics.  Nerve 
impulses that are transmitted by the “neural network” are responsible for pain perception, 
and are generated in response to both peripheral nociceptive stimuli and central inputs 
that are independent of the former.117    
 Under normal physiological conditions, the human body does not experience any 
stress.  Damage or injury to a tissue can cause stress and a disruption of normalcy 
triggering “neural,” “hormonal,” and “behavioral” mechanisms.  Typically, the injury 
heals and the body returns to normalcy.  However, stress that persists can compromise the 
“immune system and activate the limbic system.” Chronic pain syndromes may often 
develop in response to chronic stress that causes deregulation. 
 Differences in stress levels, the manifestation of those effects, and the variability in 
perception of pain occur due to unique neuromatrix characteristics and experiences.  
Although pain is believed to occur secondary to stress, augmentation of this pain by other 
acute stressors prevents the body from achieving homeostasis.  At the same time, pain 
itself, fear of pain, and concern about improvement contribute further to the abnormality, 
thereby perpetuating the cycle.  Continuous nociceptive input can result in structural and 
functional modifications of the neuromatrix.  CNS modifications may contribute to pain 
perception subsequent to healing of the original injury even in the absence of abnormal 
pathology. 
 
1.3.9 Neuropsychological Functioning 
 
 “Cognition comprises the brain’s powers to retrieve, process, store, integrate, 
and interpret information.”118 The ‘stages of pain’ model indicates that the latter two 
stages of pain, i.e., pain suffering and behavior contribute to impaired cognitive 
abilities in the chronic pain patient.  Numerous studies have examined the effects of 
both chronic pain and experimental pain on cognitive functioning.  Although not 
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definitive, opioids tend to have an adverse effect on motor tasks, but do not 
significantly impair non-motor tasks that test memory and verbal skills.  The 
following sections review the effects of pain (both chronic pain and experimental 
pain) on cognition and the effects of opioids on cognition among healthy and chronic 
pain patients. 
 In order to permit a better understanding of the empirical literature examining 
the association between experimental pain, chronic pain, opioid use and cognitive 
function, a description of the cognitive tests used most commonly in the literature are 
presented below: 
 
1.3.10 Neuropsychological Tests Used to Assess Memory and Function Among Pain 
Patients 
 
 According to Posner and Boies, attention is composed of three distinguishable 
components: “(1) a readiness to respond called forth by a specific warning event; (2) 
selectivity, which involves the focusing aspect of attention; and (3) a limited 
processing capacity.”119  Although the primary goal of treatment for an individual 
experiencing pain is to obtain analgesia, the benefits of relief obtained through 
treatment must not be outweighed by intolerable side-effects.   
The term vigilance has been used to describe sustained and focused attention (Lezak 
1995).  Successful completion of tasks involving vigilance is independent of age 
(≤80). 
 
1.3.10.1 Attention Tests 
 
1. Continuous Performance Test (CPT) – Rosvold et al., in 1956 originally 
developed the CPT as a measure of attention.120 Test takers are required to press a key 
when presented with a “target letter” such as “X” or when some other letter is 
presented right before the target letter, e.g., when Z is presented before target letter X.  
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Various forms of the test have been developed that utilize both auditory or visual 
stimuli.  Similarly, data can be collected as the number target stimuli missed or 
accounted for, reponse time to stimuli, etc.  According to Spreen and Strauss, the 
Connors’ CPT (1995) has been used extensively.  The standardized test takes 
approximately 14 minutes to complete and individuals are required to respond by 
pressing a key for all letters except ‘X’.  Six blocks of testing must be completed with 
each block consisting of 20 subblocks with three different interstimulus levels.  The 
computer software generates several results such as the number of “hits,” 
“omissions,” “commissions” (i.e., response frequency for unintended targets), “mean 
response time (RT) in milliseconds,” “attentiveness (d’)” (i.e., ability to discriminate 
between targets and non-targets), “risk taking (ß),” “hit RT block change” (i.e., 
change in RT from one test interval to the next),  “hit standard error (SE) block 
change” (i.e., standard error of change from one test interval to next), “hit RT 
interstimulus interval (ISI) change,” “hit SE ISI change,” and an overall index which 
is a weighted measure of all scores.  One study found a direct relationship between IQ 
performance, academic achievement and CPT scores.     
The test is associated with a variety of cognitive measures, for example, 
omissions correspond to deficits in sustained attention or vigilance while 
commissions correspond to impulsive behavior, lack of attention or memory deficits.  
Although the test provides a wide array of measures and is easily administered via a 
computer, reliability and validity data for Connor’s  CPT are not extensive.  CPT 
scores have not been very useful to distinguish patients that may systematically differ 
with respect to various diagnostic criteria.  The test can be ordered through Multi-
Health Systems Inc at a cost of $495 (Canadian). 
2. Paced Auditory Serial Addition Test (PASAT) – The PASAT is a measure of 
“information processing ability,” and measures “sustained and divided 
attention.”121,122 Patients are presented a series of 61 random numbers that range from 
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one to nine.  The objective of the test is to add pairs of numbers such that each 
number is added to the one immediately preceding it.  A total of four trials can be 
completed and the rate of digit presentation increases gradually from 2.4 seconds in 
the first trial to 1.2 seconds in the last.  Thus, a greater demand is placed on a 
subject’s information processing capability with each trial.  The test takes 15 to 20 
minutes to complete if all four trials are included.  Studies that have assessed the 
usefulness of the PASAT in brain injured individuals recommend it be used in high 
functioning patients compared to low functioning patients.123   
Performance scores across different trials are highly reliable (Cronbach’s 
alpha = 0.9).  For tests that are conducted within short time intervals, test retest 
correlations are ≥ 0.9.  There is a substantial body of evidence documenting the 
construct validity of the test.  If the proportion of errors exceeds 20 percent, the 
interpretation of this test as a measure of attention is compromised.  Practice effects 
have been noted, particularly if successive tests are administered within a week from 
each other.  Test tape along with scoring instruction is available from 
Neuropsychology Laboratory, University of Victoria, P.O. Box 1700, Victoria, BC 
BC V8W 2Y2, Canada at a cost $50 (Can), while The Psychological Corporation, San 
Antonio, TX-78204 offers a computerized version for $716.50 (US).  The PASAT is 
capable of detecting very subtle impairments in information processing ability, but 
the sensitivity of this test does not come without cost.  “Patients perceive this 
sensitive test as very stressful: most persons – whether cognitively intact or impaired 
– feel under great pressure and that they are failing, even when doing well.124” Thus, 
it is necessary to forewarn the patients about the demanding nature of the test. 
3. Symbol Digit Modalities Test – The test is a measure of visual scanning and 
tracking aspects of attention, and motor speed.  Patients are presented with several 
geometric designs from which they are required to identify symbols, and substitute 
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each symbol with a corresponding number.  Oral and written versions of the test are 
available.  A total of 5 minutes are required for the test.   It has been reported that 
frequent administration (eight test sessions at 2 to 4 week intervals) may result in 
practice effects; however, minimal effects have been observed with substantial gaps 
between subsequent tests.   Regardless of interval, test-retest correlations have ranged 
from 0.72 to 0.80.  Patient groups such as substance abusers, older adults that are 
sedentary, aging individuals, and those with head injuries have performed poorly on 
the test indicating impairment.  The SDMT is highly correlated with the Wechsler 
Digit Symbol Test (r = 0.62 to 0.91), and also captures aspects of performance 
measured by the Trail Making and choice reaction time tests.  Spreen and Strauss 
advocate caution with the use of this test among litigating patients.  The test kit is 
available at a cost of $60 (US). 
4. Visual Search and Attention Test (VSAT) – This test measures ability to maintain 
sustained attention and visually track targets/stimuli.  A total of four trials must be 
completed.  In the first two practice trials, subjects are presented with an arbitrary 
target, “letter” or “symbol” that must be crossed out.  In the test trials, patients are 
presented with a variety of symbols and letters in blue, red, and green ink.  The 
objective is to identify all the Hs and slashes in blue ink.    Each trial must be 
completed in 60 seconds. A total of about 6 minutes are required to complete test 
administration.  Scores are calculated by adding the number of correct hits in the 
allotted time.  “Percentile scores are used to interpret a patient’s performance on the 
VSAT.”125  The VSAT has low to moderate correlations with the PASAT (0.30) and 
Digit symbol test (0.65) indicating that it may not be a very effective tool to measure 
attention.  Psychological Assessment Resources provides the test at a cost of $58 
(US). 
5. Digit Span Subtest of the Wechsler Adult Intelligence Scale–III (WAIS-III) – The 
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tests comprises two parts, Digits forwards and backwards, and is a measure of span of 
short term recall.  The test consists of seven pairs of random numbers.126   In the digits 
forward test, subjects are required to repeat the numbers in the same sequence as the 
examiner. The procedure is followed until the patient fails to repeat correctly or 
successfully repeats a nine digit series of numbers.  Average raw score in the normal 
population is 6 (+/- 1).  Patients that score 5 or above are considered to have a normal 
span of attention, a span of 4 is indicative of borderline impairment, and a span of 3 
indicates impairment.127  The test primarily measures “efficiency of attention” also 
referred to as “freedom from distractability.” 
 In the digits backward test, the number sequences can range from two to eight 
digits.  Subjects repeat the sequence in the exact reverse order until failure or entire 
sequence is recalled correctly. A digit span of 4 and above is considered to be within 
normal limits, a span of 3 suggests some deficiency, and a span of 2 is indicative of a 
defect (upto age 60).  The digit backwards scores vary with education and age.  An 
average decline of 1-point below the normal may be expected for individuals above 
age 70.  “The ability to reverse digits, or to spell a word or recite a letter sequence 
backwards, is probably characteristic of normal cognitive function and language 
processes related to the brain’s normal function of temporal ordering.”128 
 The digits forward and backward tests should preferably be scored separately.  
A suboptimal performance on the digit backward test is more than likely an indication 
of impaired cognitive function.  Patients that perform poorly on the backward test 
may perform well on the digits forward test.  Thus, combining results from the two 
tests may lead to an inaccurate conclusion.  “For example, a  total score of 11 may be 
assumed to be normal, however a digits forward score of ‘8’ and a digits backward 
score of ‘3’ (total = 11) would be rarely observed in the normal population.”129  The 
reliability coefficients obtained from subsequent tests are high (range = 0.66 to 0.89) 
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with few practice effects.  An individual that correctly repeats eight and seven digits 
on the digits forward and backward test respectively is assumed to lie within the 
normal distribution, and thus prolonged testing may not be necessary.  
6. Digit Symbol Test of the WAIS-III – The test is similar to the digit symbol 
substitution test described above.  The test comprises a series of boxes labeled with 
random numbers ranging from one to nine, along with nine symbols that are also 
identified by numbers.  The subject’s task is to substitute the appropriate symbol for 
each corresponding number.130  The digit symbol test is a measure of ability to focus 
and maintain visual attention.  Individuals with motor difficulties or with impaired 
motor function tend to perform poorly on this test.  The test does not draw upon an 
individual’s intelligence, memory or learning ability.  The digit symbol does tap the 
following resources: motor persistence, sustained attention, response speed, and 
visuomotor coordination.  The test is reliable, which is evident from the high test-
retest reliability (range 0.82 to 0.88). Practice effects are negligible.  The digits 
symbol test is highly sensitive and “failures on this test may be the result of different 
factors or their interplay, or of a sore shoulder, or stiff fingers.” (Lezak 1995)  Age 
(greater than 60), gender (being male), and a lower education level are all associated 
with underachievement on the test.  
 
1.3.10.2 Visual, Visuomotor, and Auditory Tests 
 
1. Trail Making Test (TMT) – This test is also referred to as the Partington 
Pathways, can alternatively be administered as the Oral Trailmaking Test, Color 
Trails Test (CLT).  The tests are a measure of “speed of attention,” “sequencing,” 
“mental flexibility,” and “visual search and motor function.”131  The Oral 
Trailmaking Test does not assess the lattermost cognitive function.  The test is 
composed of two parts; in Part A, subjects are required to connect 25 circles that 
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enclose numbers located randomly on a page in a specified order.  In Part B, the 25 
circles contain either numbers or letters that must be connected alternatively.  Retests 
can be conducted by altering the sequence to minimize practice effects.  The CLT is 
designed to minimize language barriers associated with the TMT.  The circles are 
shaded as pink or yellow.  In Part 1, odd-numbers are assigned a pink shade and even 
numbers are shaded yellow, and subjects must alternate between colors.  In Part 2, 
numbers from 1 to 25 are presented two times with one series shaded pink and the 
other yellow.  “Subject is required to connect the numbers from 1 to 25 alternating 
between pink and yellow circles and disregarding the numbers in circles of alternate 
color.” 
An average of five to ten minutes is required to complete test administration. 
A ratio of the two test scores can also be computed.  Scoring for the TMT has evolved 
over the years.132  A 10-point scale which accounted for the amount of time taken to 
complete the test was used.  A patient who made three errors was instructed to stop 
working on the test.  Now, a patient who makes an error is instructed about the error 
and asked to correct it.  Performance scores are measured as the amount of time 
required to complete both parts of the test.  Although the errors are accounted by the 
amount of time required to make corrections, the reliability of the test is compromised 
since the rate at which corrections are pointed out and made is a function of the 
examiner.  Interrater reliability is at least 0.9 for both parts of the test.  Lezak reported 
reliabilites measured as the coefficient of concordance for parts A and B of the test to 
be 0.78 and 0.67 respectively on repeated administrations.  The interpretation of 
performance scores must take a patient’s age into account.  A correlation of 0.49 
between Part A and B of the TMT has been reported, indicating that the tests measure 
different aspects of cognitive function. 
2. Clock Drawing Test – The test has been used as a tool to screen for dementia.  
Involves either free hand drawing or utilizes worksheets with circles that are printed.  
The circle serves as a clockface and subjects are required to draw the clock hands 
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corresponding to the time.  A total of 5 minutes are required for the test.  A 
standardized scoring system is available.  This test has been used most commonly in 
patients with Alzheimer’s disease, since it is very easy to administer.  The test has 
been shown to accurately discriminate between healthy older adults, Alzheimer’s 
patients, and those with dementia and depression.   
 
1.3.10.3 Language Tests 
 
1. Controlled Oral Word Association Test – This test is also known as the FAS as it 
employs three letters F, A, and S, to test patients’ verbal fluency.133  The patient is 
required to list without repetition as many words for each letter during a one-minute 
interval. Proper nouns, numbers, and same words with different suffix endings are not 
allowed.  The frequency of words in a dictionary with the letters F, A, and S, 
increases sequentially. In order to assess semantic association, patients are asked to 
name things from a category after being presented with an example such as cat for the 
category of animals. Foods, grocery items, etc. are examples of other categories.134  
Patients are ranked on the basis of a percentile score that is age, gender, and 
education adjusted.  The interrater reliabilities are very high and test-retest reliability 
has ranged from 0.65 to 0.88 in adults. 
 
1.3.10.4 Memory Tests 
 
1. Rey-Osterrieth Complex Figure Test (CFT) – The purpose of this test is to assess 
visual memory and ability to reconstruct complex figures.135  Motor skills of subjects 
are also assessed.  Participants are presented with a diagram and are required to 
produce a copy of the image, and subsequently asked to draw the figure from 
memory.  Subjects may be asked to recall the figure either immediately or after 3 
minutes, and sometimes even longer time intervals.  It has been observed that few 
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differences exist between shortened and delayed testing for normal subjects, since 
most memory loss occurs within the first few minutes. If such a difference does 
occur, it is interpreted t have clinical significance.  This is true provided the delayed 
recalls are less than an hour.  A total of 10-15 minutes are required to complete test 
administration.  Each component of the figure is assigned a total point-value, and 
scores are assigned based on completeness, accuracy, distortion, etc.  When 
considering multiple raters, reliability scores have been reported as 0.8 or greater.  
The reliabilities for the various components have ranged from 0.14 to 0.96.   
2. California Verbal Learning Test (CVLT) – The purpose of the test is to gauge an 
understanding of techniques utilized to learn verbal material.  Additionally, the test is 
a good measure of the amount of verbal material that can be retained.  The test is 
administered over several trials.  Patients are presented with a shopping list 
containing 16 items (Includes a total of 4 categories each containing 4 items).  
Subjects are then presented an alternate list (2 categories are the same as above and 2 
are different) that serves as a distraction.  Participants are then subjected to an 
immediate and a 20-minute delayed recall of the first list. The test takes 
approximately 35 minutes to complete. Alternate short forms containing nine items 
have also been developed for use among memory-impaired older adults.   The CVLT 
has been shown to be internally consistent, and correlation scores for the various 
administrations have not been consistent ranging from 0.12 to 0.79. Interrater 
reliability is questionable.   
 
1.3.10.5 Executive Functions and Motor Performance Tests 
 
1. Stroop Test –  The Stroop test is a measure of ability to refocus attention and to  
respond in a manner that is atypical or deviates from the norm.136  The test has four 
trials and consists of three cards with information presented on them.  In the first trial, 
paticipants are asked to read a card containing color names (blue, green, etc) printed 
in black ink.  In task two, participants are required to read color names on a card 
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printed in colored ink.  In task 3, a card with boxes in various colors is presented and 
the participant identifies the color.  Trial four is similar to trial two except that 
participants must read the color of the print.  Administration of the test requires about 
five minutes.  Different parts of the test and subsequent test scores have showed high 
reliability (0.75 and greater).  Performance on this test is related to that on the Digit 
symbol, digit span, and block design test, and is measured as the amount of time 
required to name the colors.  Depressed and anxious patients have an impaired 
performance on the Stroop test.  The test is not useful in a sample of patients that is 
visually impaired. 
2. Finger Tapping Test (FTT) – This is a test of manual dexterity, and was also 
referred to as the Finger Oscillation Test.137  Subjects are simply asked to tap their 
index finger as fast as they can while keeping their palms flat against a pad.  The 
tapping speed for both the preferred and non-preferred hands is measured.  
Alcoholics, head-injury patients, and those in the early stages of dementia have 
performed poorly on the FTT.  In addition to motor function, “the speed, 
coordination, and pacing requirements” of the test can vary with “level of alertness, 
impaired ability to focus attention, or slowness of responses.” 
3. Purdue Pegboard Test – The pegboard test also measures manual dexterity.  The 
board consists of 2 sets of 25 grooves that run along the length of the board.138 
Subjects are required to place pins that are located at the top of the board in the 
groove.  The test consists of three trials requiring placement with preferred hand, non-
preferred hand, and both hands within a 30 second time limit.  Performance is 
measured as the number of pins successfully place. An additional fourth trial involves 
placing a pin, a washer, a collar, and another washer in order alternately with both 
hands.  A one-minute time limit is set for this test. 
One to two week retest reliabilities have been reported in the range of 0.63 to 
0.82.  Average scores for groups such as production workers and those seeking 
                                                 
137 Lezak MD.  Neuropsychological assessment.  Oxford University Press.  New York. 1983. 
138 Spreen O, Strauss E.  A compendium of neuropsychological tests.  Administration, norms, and 
commentary.  Oxford University Press.  New York. 1998. 
 51
production jobs have ranged from 15-19, 14.5-18, and 12-15.5 for right, left, and both 
hands respectively.139 
4. Grooved Pegboard Test – This test is more difficult than the Purdue test, as it 
utilizes a smaller board with grooves arranged in different directions.  The pegs are 
designed so that they have to be rotated to fit the groove correctly, thus making it a 
more sensitive measure of motor function.140 
5. Block Design Test of the WAIS –R – The test involves construction using blocks 
and tests visuospatial as well as motor capabilities.  Numerous patterns can be used to 
increase the level of task difficulty.  The time limit must be competed in either 1 or 2 
minutes depending on whether 4 blocks or 9 blocks, respectively are required in the 
construction.  Older individuals tend to perform the task more slowly.  Educations 
does not influence ability to construct designs.  Split  half reliabilities range from 0.82 
to 0.89, while test retest reliability coefficients ranged fro 0.73 (in older adults, mean 
age - 79±3.5) to 0.84. 
6. Hopkins Verbal Learning Test (HVLT) – The test consists of six lists, each list 
comprised of four semantically similar words in groups of three for a total of 12 
words.  Subjects are allowed to practice (3 trials) and then must identify 24 words 
with 12 words directly from the list, 6 others are associated with the original 12 and 
the last six are have no connection.141  
7. North American Adult Reading Test - This is a test of verbal ability.  Subjects are 
simply required to read a list of words that must be pronounced correctly.  The 
NAART is a test of assessing an individuals education level.  The underlying 
assumption of the test is that ability to read words is reflective of reading ability.  
This is not a commonly used test in neuropsychology.142 
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Table 1.2  Summary of Commonly Used Cognitive Tests in Literature Review 
TEST TIME 
(MINS) 
SINGLE 
COMPOSITE 
MEASURE 
ASPECT OF COGNITIVE 
FUNCTION 
RELIABILITY 
DATA 
CPT 
 
 
 
PASAT 
 
 
 
SDMT 
 
 
VSAT 
 
DSTF 
 
DSTB 
 
DSYT 
 
 
 
TM 
 A&B 
 
CDT 
 
14  
 
 
 
15-20 
 
 
 
5  
 
 
6  
 
2-3 
 
2-3  
 
1.5 
 
 
 
5-10 
 
 
5  
 
Multiple measures: # 
of hits, omissions, 
commisions 
 
 correct responses for 
each test series 
or mean score 
 
Time for completion 
 
 
# of correct hits 
 
Average raw score 
 
Average raw score 
 
# of correct 
responses 
 
 
Time required to 
complete test 
 
Standardized scoring 
system 
 
 
Vigilance, sustained attention, 
memory deficits. 
 
 
Sustained attention & information 
processing. 
 
 
Visual scanning & tracking, motor 
speed. 
 
Attention & visual tracking 
 
Immediate recall 
 
Temporal ordering 
 
Motor persistence, sustained 
attention, speed, and visuomotor 
coordination 
 
 Attention ,  mental flexibility, 
visual search, and motor function 
 
Distinguishes between healthy 
controls, dementia, and alzheimer’s 
patients 
 
Few studies have assessed 
reliability and validity 
 
 
Cronbach’s α = 0.9 
 
 
 
Test-retest corr – 0.72 to 0.80 
 
May not be a good measure of 
attention 
 
Reliability coeff – 0.66 to 0.89 
 
Reliability coeff – 0.66 to 0.89 
 
Test-retest reliabilities (range 
0.82 to 0.88) 
 
 
Correlation between A&B – 
0.49 
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Table 1.2  (Continued) Summary of Commonly Used Cognitive Tests in Literature Review 
COWA 
 
 
RO-
CFT 
 
CVLT 
 
 
ST 
 
 
 
FTT 
 
 
 
PGP 
 
 
 
One/  
letter 
 
10-15 
 
 
35  
 
 
5 
 
 
 
3-4 
 
 
 
2 
 
# of words 
 
 
completeness, 
accuracy, distortion. 
 
Numerous measures 
based on subtests 
 
Amount of time 
required to name 
colors 
 
Tapping speed 
dominant and non-
dominant hand 
 
# of pins correctly 
placed 
Verbal fluency 
Psychomotor function 
 
Visual memory 
 
 
Verbal memory 
 
 
Ability to refocus attention 
 
 
 
Test of manual dexterity 
 
 
 
Manual Dexterity and motor 
performance 
Test-retest reliability - 0.65 to 
0.88 
 
Reliabilities – 0.14-0.96 
 
 
Inter-rater  reliability 
questionable. 
 
High reliability among sub-
parts (≥ 0.75) 
 
 
 
 
 
 
Test-retest reliability - 0.63 to 
0.82 
 
CPT – Continuous Performance Test  PASAT – Paced Auditory Serial Attention Test,  SDMT – Symbol Digit Modalities Test, VSAT 
- Visual Search and Attention Test DSTF – Digits Span Test Forwards, DSTB – Digits Span Test Backwards,  DSYT – Digit Symbol 
Test, TM  A&B – Trail Making Test Part A&B CDT – Clock Drawing Test, COWA – Controlled Oral Word Association Test, RO-
CFT – Rey Osterrieth-Complex Figure Test, CVLT – California Verbal Learning Test, ST – Stroop Test, FTT – Finger Tapping Test, 
PGP – Purdue/Grooved Pegboard Test 
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Crombez, Eccleston and colleagues have argued that studies assessing the 
effects of various external stimuli (distractions) on pain perception have neglected the 
attentional deficits that pain itself can produce.143  In addition to disrupting normal 
day-to-day activities, pain can interfere with a variety of tasks that require 
concentration by drawing attention away from them.  Individuals experiencing pain 
bear an opportunity cost as their ability to focus attention on other tasks that require 
attention maybe compromised.  Such a conceptualization of pain offers an 
opportunity for the validation of data on pain-related attention and memory deficits 
obtained through self-reports and neuropsychological tests.  Numerous behavioral and 
activity measures can also be used to assess the interruptive nature of pain.  
Subsequent sections of this chapter are devoted to the effects of pain and opioids on 
cognitive impairment. 
 
1.3.11 Cognitive—Affective Model of the Interruptive Function of Pain 
  
 Attention can be defined as an individual’s capability to focus on multiple tasks.  
As the attention required by these multiple tasks exceeds a certain threshold, 
performance can diminish, cease, or become impaired.144  The pain literature does not 
offer a theoretical understanding of the manner in which pain can divert attention from 
other tasks, despite recognition that pain perception and behavior incorporate 
mechanisms of attention.  Human behaviors are driven by goals, and often these 
behaviors can be interrupted by insufficient information or other more important 
priorities.  It has been argued that attentional systems must be capable of responding to 
dangerous or novel situations as well.  Pain is one example of a danger that would 
trigger interruption of other tasks, as protecting the body from harm is recognized as a 
basic goal atop the hierarchy of all needs.   
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 In 1971, Walker concluded that students subjected to electrocutaneous stimuli 
found it difficult to focus on an attentionally demanding task.  Numerous studies have 
corroborated this finding.  Expectation of pain can also cause emotional distress.  
Pain is perceived as a threat and greater the threat potential of a stimulus, more likely 
is the possibility of task interruption.145   
 Several studies have tested distraction strategies that can be used to draw 
attention away from pain.  Low intensity rather than high intensity pain tended to 
respond to these strategies.  Distraction stimuli that were qualitatively similar to pain 
producing stimuli were no more effective than dissimilar distractions.  Distraction 
strategies with positive or pleasant emotional content were more successful at 
increasing pain threshold and tolerance as compared to anger or other unpleasant 
emotional content. 146  
 In the context of chronic pain, interruption is often expressed as somatization, 
higher utilization, depressive symptomology, and withdrawal from activity and social 
interactions.  Interruption according to this model may be a mechanism to escape 
from pain and pain producing stimuli rather than a pathological response to pain.147  
“Pain patients often report being unable to read, watch television or complete a 
simple task because of their inability to attend to the material or activity.”148  This 
lack of concentration also affects a pain patient’s ability to complete work-related 
responsibilities effectively.  Patients involved in jobs that are physically demanding 
find it extremely difficult to maintain employment.  They are advised to refrain from 
physically demanding tasks, and the inability to concentrate makes it challenging to 
train for jobs that require greater mental ability, thus making it difficult to find a new 
vocation 
. 
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1.3.12 Cognitive Function in Chronic Pain Patients 
 
 In one of the earliest studies to examine memory and concentration problems in 
pain patients, Jamison and colleagues collected information on a variety of measures 
such as the Symptom Checklist-90-R (SCL-90-R) and pain evaluation 
questionnaire.149  A five point rating scale (1 – not at all and 5-extremely) was used to 
assess the extent to which a patient felt depressed, anxious, or irritable.  Memory and 
concentration problems were assessed through two items rated on a 5-point scale on 
the SCL-90-R: 1) “how much are you bothered by trouble concentrating?’ and 2) how 
much are you bothered by trouble remembering things?”   
 Patients with a score of 2 or greater on these items (reflecting moderate to 
extreme concentration problems) were classified as one group (n = 198).  The group 
with no concentration and memory problems (n = 195) did not differ from the former 
on demographic variables such as age, gender, and marital status, or on intensity and 
duration of pain.  Patients with concentration troubles provided significantly higher 
ratings for depression, anxiety and irritability, reported a significantly greater number 
of conflicts within the home and experienced pain that worsened while sitting.  Fewer 
patients with memory troubles were satisfied with social activities (23.3% vs 35.1%, 
p < 0.01) and sexual activities (26.8% vs 47.2%, p < 0.001).  Except for work and 
shopping, patients with memory troubles reported a significantly greater interference 
in socializing, hobbies, exercise, sleeping, and sexual activities due to pain.  Only 30 
percent of the sampled patients were working, and this may have accounted for the 
lack of difference between the two groups with regard to work.  Pain patients are 
prone to complaining about cognitive deficits and the use of subjective reports may 
be a limitation.  Additionally, a global question about concentration and memory 
deficits provides little information about the extent and nature to which patients are 
affected.  The measures used in this study were not substantially validated and lacked 
suitable psychometric properties. 
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 Dufton utilized the Cognitive Failures Questionnaire (CFQ) to assess everyday 
cognitive skills of attention, perception, memory, and motor functioning.150  A total 
157 patients who had experienced pain for an average duration of 5.7 years completed 
the CFQ and BDI.  A median split on the CFQ score was used to create two groups, 
group 1 (n = 79) with an average score of 26.1, and group 2 (n =78) with an average 
score of 49.1 indicating a high level of cognitive inefficiency.  The groups did not 
differ significantly on pain descriptors, chronic nature of pain, prescription and OTC 
drugs, and a variety of daily activities (group 2 indicated that participation in daily 
activities was less desirable).  However, the high CFQ group scored significantly 
higher on the BDI (mean = 13.8) compared to the low CFQ group (mean = 8.6), the 
former score being indicative of mild depression.  These results do not elucidate the 
relationship between pain, cognitive inefficiency, and affective distress.  Pain patients 
are believed to experience a mild form of cognitive dysfunction and self-report 
measures utilized by Dufton and Jamison may not be sensitive enough to detect such 
impairment.  
 Kewman et al. administered the Neurobehavioral Cognitive Status Examination 
(NCSE) to 73 patients with musculoskeletal pain.151  The NCSE includes items that 
evaluate orientation, attention, language, functioning, visuospatial constructional 
abilities, memory, arithmetic calculation, and reasoning.  A total of 23 participants 
(32%) performed poorly with deficits observed most commonly in the following 
domains: attention (n = 3); memory (n = 13); calculation (n = 6); and test of similarity 
(n = 8).  Pain intensity (r = -0.475, p < 0.001) and interference in daily activities (r = -
0.304, p < 0.001) were significantly correlated with NCSE scores.  The relationship 
was not significant when emotional distress was added as a control variable, 
indicating that affective distress modifies the relationship.  The relationship between 
duration of pain and cognitive dysfunction approached significance, and higher 
education was associated with lower cognitive dysfunction.  It is argued that well 
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educated patients may be able to compensate for cognitive difficulties, thus leading to 
underestimations about the prevalence of neuropsychological impairment in these 
populations. 
 Schwartz and colleagues developed a battery of screening tests to assess 
cognitive impairment in chronic pain patients designed to minimize screening costs 
and time.152  The battery consisted of the Trails Part A & B, the controlled word 
association (CWA) test, and the paced auditory serial addition test (PASAT).  Results 
from the study showed that patients with chronic pain and history of trauma 
performed poorly on cognitive screening tests than pain patients without trauma.  
These differences were not significant, but a global impairment rating showed 
significant differences between the trauma (18 of 25) and non-trauma (4 of 17) 
patients.  The deficits are often subtle and therefore may not be detected, however, 
even these less than obvious deficits can affect activities that require attention and 
concentration.  Subsequent evaluation indicated that results from the battery 
correlated perfectly with comprehensive neuropsychological assessment tools. Heyer 
et al. evaluated the effect of pain on neuropsychological tests among patients that 
underwent spine surgery.153  A battery of tests designed to assess neuropsychological 
function were administered before surgery and one day post surgery.  The Trails Part 
A & B (measure visuomotor tracking and complex attention), Controlled Oral Word 
Association test (COWA), and the Rey Complex Figure were administered as they 
represented a broad assessment of cognitive function.  A standardized numeric 11-
point pain intensity rating scale was also administered (0- no pain and 10 – worst 
possible pain).  Post-operative pain correlated with test scores on the Rey Complex 
figure (r = -0.577, p = 0.004) and Trails A test (r = 0.527, p = 0.01).  Patients treated 
with centrally acting analgesics (Percocet and Morphine) post-operatively performed 
poorly on the COWA and Rey Complex Figure tests.  Results from this study suggest 
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that although chronic pain may not be associated with neuropsychological 
functioning, acute pain does show an association.  However, results from other 
studies have indicated otherwise.  Effects of anesthesia and trauma due to surgery 
were not controlled. 
 Eccleston conducted a series of three studies to assess the association between 
pain and attention.  Attention was assessed as a measure of time required to respond 
to information presented in the form of cards on a computer screen.  These cards 
resemble playing cards on which numbers ranging from one to nine are printed in 
regular pattern (Arabic numerals). The cards were identified on the basis of the digit 
value V (i.e., six and one for the cards shown below) or the number of digits N (i.e., 
four and nine for the cards shown below) printed on the card.154  In experiment one, 
participants (chronic pain patients, n = 20; controls, n =10) identified the numerical 
value (V) of the card (dominant information) followed by the number of digits (N) 
printed on the card (non-dominant information).  The amount of time needed for 
responding to non-dominant information usually increases.  The amount of time 
required to complete the task was much higher with the use of non-dominant 
information for both pain patients and controls.  It was concluded that persistent pain 
did not draw attention away from such a basic task.  It was further hypothesized that 
performance on a complex task would be impaired due to pain.  In experiment two, 
pairs of cards placed adjacent to each other were presented and subjects were asked to 
identify the card with larger values in one trial and larger number of digits in the 
second trial.   
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Figure 1.2 Cards Presenting Dominant and Non-Dominant 
Information 
 
 
 
 
 
 
 
       
 
 
 
 
 Amount of time required to complete the task was used as the dependent 
measure.  A 3x2x2 analysis of variance model [pain (3 categories) by task (2 
categories) by difficultly (2 categories)] was used.  Although main effects for all 
variables were significant, an interaction between pain levels and task was significant 
[F(2,33) =13.25, p < 0.01).  Patients with high intensity pain required the most time to 
complete the non-dominant task, i.e., time required to call the N printed on the cards.  
Chronic pain patients that reported high pain intensity on the VAS and numerical 
rating scale required a significantly greater amount of time to complete the 
recognition task than controls (p < 0.05) and those reporting low intensity pain  (p < 
0.05).155  
 In the second study of this series, Eccleston hypothesized that patients 
experiencing low intensity chronic pain are capable of switching attention back and 
forth between pain and task to be completed.  There is some degree of interference 
due to the pain, however, the duration and intensity is not large enough to 
systematically influence performance on the task.  The same procedure utilized for 
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experiment two in the previous study (Eccleston, 1994) was utilized in experiment 
one for this study.156  The non-dominant task is a test that requires attention 
processing that is similar to that of pain processing.  Results from a two-way 
ANOVA (pain X task) showed a significant interaction between the independent 
variables.  Patients reporting high intensity pain took significantly (p < 0.05) more 
time for the recognition task (non-dominant information) than controls and low 
intensity pain patients (median VAS ≤ 39.6 range 1- 75; median numerical rating 
scale ≤ 66, range 1-80).  Patients experiencing low intensity pain may be able to 
temporarily shift their attention to focus on the task at hand such as a test; scores on 
these tests do not reflect a substantial effect of low-intensity pain on cognitive 
function.  
 A competing hypothesis, namely, that these patients are experiencing 
psychoanalgesia at the time of task completions was suggested.  However, this 
suggestion cannot be empirically tested. In order to test the ability to switch theory, 
the experiment was modified by alternating between presentation of non-dominating 
and dominating information rapidly, without any cues.  This test was modified on the 
premise that the need to focus on two distinct tasks requiring attention that arise from 
the same stimuli places a greater burden on an individual’s ability to concentrate.  
Thus, it was hypothesized that if patients with low intensity pain did refocus their 
attention, such a demanding task would hamper their reaction time.  The results 
showed that patients with low intensity pain did not differ significantly from the 
control group lending support to the theory that these patients experienced 
distractional psychoanalgesia.  In conclusion, patients experiencing high intensity 
pain perform poorly on task requiring central attention as compared to low intensity 
pain patients or controls. 
 Eccleston et al. hypothesized that patients with high intensity chronic pain and 
high somatic awareness (greater number of health complaints in addition to pain) 
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were more likely to experience attention difficulties.157  Attention was assessed as a 
function of response time required to process dominant and non-dominant 
information as described above.  The results showed that patients with high intensity 
pain (n = 16, mean on VAS (100mm) = 60.5, sd = 12.9) and high somatic scores as 
obtained on the Modified Somatic Perceptions Questionnaire (MSPQ) experienced 
greater attention deficiencies than high intensity/low somatic (n =5), low 
intensity/high somatic (n =8), and low intensity/low somatic (n = 17) patient groups.  
These patients also experienced greater affective distress evidenced through 
significantly higher scores on the Zung Depression Scale {t(22) = 1.92, p < 0.04} and 
the Hospital and Anxiety Depression Scale Depression: {t(22) = 1.83, p < 0.04} and 
Anxiety {t(22) = 2.19, p < 0.02}. A large proportion of the sample utilized 
medications such benzodiazepines, opioids, and antidepressants.  Medication use was 
not associated with task performance.  High intensity/low somatic awareness group 
patients reported significantly [t(19) = -1.547, p = 0.07] higher pain intensities (mean 
= 68.0) than the high intensity/high somatic awareness group patients (mean = 58.1). 
Results from this study indicated that somatization, depression and other affect 
variables are associated with processes of attention. 
 Schnurr and McDonald examined memory difficulties in back and neck pain 
patients who were injured in vehicular accidents (n = 56) or at work (n = 27).158  
Patients that utilized psychotherapy services (n = 20) and general medical and dental 
patients (n = 24) served as controls.  The pain patients scored significantly higher on 
the Beck Depression Inventory (BDI) and [F(3,123) = 32.32, p < 0.0001] and the 
State-Trait Anxiety Inventory [f(3,123) = 22.90, p < 0.0001] indicating higher levels 
of depression and anxiety than control groups.  Average ratings on all three subscales 
of the Memory Observation Questionnaire-2 scales indicated that pain patients 
experienced significantly greater memory problems than the medical and dental 
controls.  Although average self-reported memory ratings for all pain patients were 
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lower than psychotherapy patients, these differences were not significant for all sub-
tests.  An analysis of covariance (ANCOVA) indicated that pain and control groups 
did not differ significantly on this measure after controlling for depression and 
anxiety.  Of the two covariates, depression significantly correlated with self-reported 
memory functioning.  However, ANCOVA results showed that average scores on the 
Chronic Pain Memory Complain Questionnaire  (CPMCQ) between pain and control 
groups differed significantly [F(3,119) = 3.44, p = 0.019] despite partialling out the 
effects of depression and anxiety.  Since no significant differences were observed 
between the two pain patient groups the authors believed that “ mild head injury 
would not appear to be the sole contributing factor to memory complaints in chronic 
pain patients.159”  Self –reported use of codeine and psychotropic drug use were not 
associated with memory problems. 
 Patients with persistent pain may code and recall information differently from 
healthy controls.  Studies evaluating recall bias in depressed patients and controls 
showed that the former tend to recall depressed words (used in a self-reference 
context) more easily than non-depressed words.  Pincus et al. hypothesized that 
chronic pain patients with pain-associated experiences and memories may be subject 
to a similar recall bias when presented with information containing pain stimuli.160  
The results from this study indicated that control subjects recall more information 
than pain sufferers {F(1,40) = 6.99, p = 0.01).  Pain patients, however, recall 
significantly more sensory pain information in reference to themselves than in 
reference to others and recall more neutral (everyday use words) information that is 
presented in reference to others.  Pincus and colleagues replicated these findings in 
another study and concluded that anxiety and depression did not influence this recall 
bias.161  However, the results also showed that words indicating painful stimuli do not 
draw attention away from pain patients and they perform similar to controls when 
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emotional distress is included as a control variable. The authors concluded that pain 
draws greater resources from activities that require effortful processing rather than 
automatic processing. 
 Assignments that involve automatic processing consume minimal resources of 
the brain and those that require effortful processing place a considerable strain on 
attention capacity.162  Automatic processes tend to occur at a subconscious level, do 
not draw on other cognitive resources, and can be characterized as occurring 
involuntarily.  Elaborative or effortful processes on the other hand draw on various 
mechanisms and resources that may be utilized for other mental activity, are critical 
for grasping knowledge, and are often voluntary.  Similarly, it has been suggested that 
pain hampers explicit memory, which is measured by using free recall techniques to a 
greater extent than implicit memory, which is measured using cueing techniques. 
 Townsend evaluated the effects of chronic pain on processing, memory, verbal 
functions (i.e., reading, writing, verbal memory, and temporal relationships), and 
nonverbal processing such as visuospatial information.163  Participants (n = 65) with a 
confirmed diagnosis of arthritis were enrolled and average age was 50.9 (s.d.= 13.3) 
years.  Patients reported high pain intensity (mean = 7.8, s.d. = 4.9) and fatigue (mean 
= 9.7, s.d. = 4.8) levels measured on a 10 cm VAS.  Patients had not utilized any 
opioid analgesics in the 24 hours prior to administration of tests. The following 
neuropsychological testing instruments were administered: The North American 
Adult Reading Test (NAART); the Mood Assessment Scale (MAS); PASAT; the 
Stroop test, parts D and C; Digit Span and Visual Memory Span (VMS) from the 
WMS-R; the California Verbal Learning Test (CVLT); word recall and stem 
completion task; CFQ; and parts of the Coping Strategies Questionnaire. 
 Except for a weak association with the Stroop test (r = 0.28, p < 0.05), self-
reported measures of cognitive dysfunction via the CFQ did not correlate with any of 
the scores obtained on neuropsychological tests.  Depression scores correlated with 
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CFQ scores (r = 0.59, p < 0.001), and no association was found between pain 
intensity and CFQ.  The Stroop C test and the semantic cluster ratio of the CVLT 
(measures of effortful processing) and Stroop D test (automatic processing) accounted 
for only 2 percent of the variance in pain intensity.  Pain intensity did not affect either 
explicit (measured by Free recall and CVLT trials A1-A5) or implicit memory in this 
sample, as these tests accounted for 2 percent and 3 percent of the variance 
respectively.  The Digit span and the PASAT (verbal function measures) and VMS 
(nonverbal processing) accounted for 3 percent of the variance in pain intensity.  
Thus, pain intensity did not impact cognitive function and only the Digit Span and the 
CVLT were significantly correlated with this measure.  This study was associated 
with several limitations.  Many patients rescheduled appointments due to severe pain. 
At the time of testing, pain may have not been substantial to affect cognitive 
processes. Since cognitive deficits may be mild to begin with, tests involving 
complex tasks may have been more suitable in this population.  The reviewed 
evidence indicates that pain intensity does not correlate with cognitive function; thus, 
the premise utilized in this study may be inappropriate.  In a more recent study, 
Pincus and Newman found that recall bias was significantly (p = 0.02) associated 
with utilization costs (referrals to specialists) for back pain.164   
 Sletvold and colleagues assessed neuropsychological functioning in a sample of 
fibromyalgia patients (n = 25), depressed patients (n = 22), and healthy controls.165  
Only FM patients reported pain intensities on a VAS. A 3-way multivariate analysis 
of covariance showed significant differences (p < 0.05) in cognitive ability scores for 
the three groups.  While the two patient groups did not differ significantly, FM group 
had significantly lower scores on the Digit symbol test  [F(1,40) = 5.6, p< 0.05], 
PASAT (presentation rate 2.4 seconds) [F(1,40) = 4.1, p< 0.05], PASAT 
(presentation rate 2.0 seconds) [F(1,40) = 4.1, p< 0.05], reaction time with left hand 
[F(1,40) = 4.1, p< 0.05], and reaction time with left hand utilizing an inhibiting 
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stimulus than the controls.  Depressed patients scored significantly worse than 
controls on these tests as well.  A subsequent analysis showed that FM (n = 11) 
patients with and without lifetime history of depression (n = 14) did not differ 
significantly on the cognitive test scores.  These results indicated that pain patients do 
experience cognitive dysfunction, and factors in addition to affect disorder are 
associated with this dysfunction.  Although medication use of depressed patients was 
assessed (no antidepressants, lithium carbonate, or neuroleptics agents used in 
previous month), this assessment was not performed for FM patients.   
 Landro and colleagues also reported results from the same groups of subjects on 
the Randt Memory Test, The Code Memory Test, The Word Fluency Task, The 
Kimura Recurring Recognition Figures Test, and the Incidental Memory Task, all 
tests of long term memory.166  The tests indicated that FM patients with a lifetime 
depressive disorder and depressed patients scored significantly lower on the  on the 
Randt Memory Test [F(1,40)= 6.1, p < 0.05]; [F(1,37) = 13.5, p < 0.001, 
respectively], Word Fluency Task [F(1,40) = 5.5, p < 0.05; [F(1,37) = 0.9, p < 0.001, 
respectively], and Code Memory Tests part  1 [F(1,40) = 7.6, p < 0.01; [F(1,37) = 
11.3, p < 0.01, respectively], and Code Memory Tests part 2 [F(1,40) = 8.6, p < 0.01; 
[F(1,37) = 5.3, p < 0.05, respectively].    
 Iezzi and colleagues tested a sample of chronic nonmalignant pain patients (n = 
73) on several neuropsychological tests including the Wechsler adult intelligence 
scale, the Wechsler memory scale – Revised, the Rey-Osterrieth figure test, the 
Stroop test, the Wisconsin card sorting test, the PASAT, the trail making test, form B, 
the design fluency test, the COWA, and the grooved pegboard test.167  A cluster 
analysis was used to classify patients as having high, moderate, or low levels of 
distress based on responses to the SCL-90-R.  Patients with low distress on average 
had more education (years) (low, n = 10, mean = 13.5, s.d. = 3.4),  (high, n = 27 mean 
= 11.6, s.d. = 2.5); (moderate, n = 36, mean = 12.7, s.d. = 2.3); and less pain duration 
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(low, mean = 65.7, s.d. = 70.7), (high, mean = 118.8 months, s.d. = 146.4); 
(moderate, mean = 59.1, s.d. = 42.2).  A multivariate analysis of variance showed 
significant differences between the groups on cognitive function tests.  Post hoc 
Scheffe’s test showed that the low and moderate distress groups performed 
significantly better than the high distress group on the Rey-Osterreith figure test (p < 
0.05), Stroop test (p < 0.05), PASAT (p < 0.05), and visual memory component of the 
Weschler memory scale (p < 0.005). The low distress group also outperformed (p < 
0.05) the high distress group on the Weschler adult intelligence scale.  The 
differences in education level and pain duration were not considered in the analyses; 
additionally high distress patients were believed to be on narcotic and psychotropic 
medications, and prior research has demonstrated that psychotropics impair 
performance on cognitive tests.   
 A recent study included a broad array of predictors such as demographics, pain 
severity and location, psychological distress, anxiety, quality of sleep, prescription 
drug use, and involvement in lawsuits on cognitive functioning.168  The Alertness 
Behavior subscale of the Sickness Impact profile was used to assess cognitive 
difficulties associated with completion of daily tasks.  Of 275 patients enrolled in the 
study, 64 (23.4%), 63 (23.1%), 51 (18.7%), and 56 (20.5%) chronic pain patients 
reported problems with forgetfulness, minor accidents, and difficulty with 
maintaining attention and completion of tasks, respectively.  Depression scores 
obtained through the BDI and use of antidepressant medications were significantly (p 
< 0.01) correlated with cognitive complaints, while the association with pain-related 
anxiety approached significance (p = 0.08).  These variables contributed 36 percent of 
the variance to patient reports of difficulties with daily tasks.  Use of narcotic 
analgesics did not seem to negatively affect cognitive abilities.   McCracken and 
Iverson state that the relationship “between cognitive impairment, opioid use, and 
depression in patients with chronic pain deserve further study.”169  
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 Grace and colleagues compared 30 fibromyalgia patients to an equal number of 
healthy controls on a series of neuropsychological tests including the Wechsler 
Memory Scale – Revised (WMS – R), Rey-Auditory Verbal Learning Test, PASAT, 
Symbol Digit Modalities Test (SDMT), Memory Observation Questionnaire, and pain 
severity scale of the Multidimensional Pain Questionnaire.170  A multivariate analysis 
of variance indicated that FM patients performed significantly (p < 0.0001) poorly 
compared to controls.  Healthy controls performed significantly (p < 0.05) better on 
the WMS – R and PASAT, while differences on the SDMT approached significance.  
Patients had greater trouble with tasks that required sustained attention.  Even though 
self-reports of attention deficits were greater for patients than controls, this difference 
was not reflected on objective testing.  Anxiety levels, and not pain severity was 
correlated significantly wth delayed recall, memory, and PASAT. 
 In contrast, some researchers have also hypothesized that cognitive functioning, 
in addition to pain and self-efficacy, contribute to mental health of pain patients.  
Shifren and colleagues have measures intellectual (cognitive) functioning by gauging 
performance on  tasks involving “working memory”, “speed of processing 
information,” “verbal ability,” and “reasoning.”171  It has been suggested that patients 
with higher levels of intellectual functioning can devise more suitable strategies to 
treat their condition better, and do not tend to focus on negative outcomes as much as 
individuals with limited cognitive abilities.   
 The following measures were used to assess intellectual functioning: free recall, 
reading and computation span tasks as indicators of working memory, letter and 
pattern comparison tasks as measures of perceptual speed, identification of synonyms 
to assess verbal ability, and letter set test as an indicator of reasoning.172  Mental 
health was assessed using the Center for Epidemiologic Studies Depression Scale 
(CES-D) and the Multiple Affect Adjective Checklist – Revised (MAACL-R-R), the 
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latter is capable of delineating positive affect from negative affect.  The structural 
equation model included pain, self-efficacy, and intellectual functioning, which 
explained 45 percent and 62 percent of variance in positive and negative affect, 
respectively.  Age and education influenced the dependent variable indirectly, 
through intellectual functioning.  Pain was related only with negative affect. 
 A review of the literature indicates that chronic nonmalignant pain patients 
experience mild cognitive deficits.  Deficits may be observed in the following areas: 
sustained attention, memory, arithmetic, and other tasks requiring concentration.  
Often, this association is mediated by numerous variables such as high intensity pain, 
depression, anxiety, and minimal participation in activities or lack of a desire to 
participate in various social activities.  Patient performance on the Digit Symbol test, 
PASAT, reaction time tests, Stroop tests, and some tests of memory seemed to have 
been impaired.  Many of the studies addressing cognitive appraisals in chronic pain 
patients have failed to examine the issue within a theoretical context.  The review 
above has demonstrated that numerous factors influence cognitive deficits among 
pain patients.  Pain also has been widely recognized as a multidimensional 
experience.  Thus, the study of cognitive function in patients with chronic 
nonmalignant pain deserves a systematic approach that is based on certain theoretical 
principles.   
 
1.3.13 Effects of Experimentally Induced Pain on Attention 
 
   The review above clearly indicates that pain has the ability to capture attention 
and draw attention away from a variety of tasks.  There is substantial documented 
evidence to indicate that attention-based cognitive coping strategies help chronic pain 
patients obtain analgesic relief through the modification of pain perception.173  
However, these effects have been demonstrated primarily in controlled laboratory 
settings.  Even though numerous studies have addressed the effects of various 
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distraction tasks, limited research has focused on the interruptive ability of 
experimentally induced pain on tasks.  In addition to stimuli that are threatening or 
noxious, it can be hypothesized that novel stimuli such as experimentally induced 
pain would also be capable of interfering with attention.    
 Crombez and colleagues tested two competing models regarding the effect of 
knowledge about impeding pain.174  According to one model, prior knowledge 
sensitizes individuals leading them to process information at an emotional rather than 
analytical level.  As a result, even the hint of a painful stimulus can be perceived as 
noxious if the message was thus perceived.  On the other hand, “cognitively oriented 
representation models” suggest that individuals are capable of structuring 
expectations so as to simulate an event very closely.  Such an accurate anticipation 
typically minimizes the actual impact of the event.  “Thus, when the objective 
stimulus is unambiguously painful, a pain warning may enhance the accuracy of the 
representation, which would result in a better match and consequently in a lesser 
impact.175”
 Crombez and colleagues studied the effects of painful stimuli (46◦ C) on the 
ability to discriminate between a low-pitched and high-pitched tone.176  In order to 
test the emotion-based and cognitive-based models, distractors such as slides with a 
picture and warmth stimuli were introduced.  A 2 X 2 design was employed; half of 
the participants (n = 42) were informed (temporal certain group) about the timing of 
distractor presentation while the other half were not.  Also one half (pain condition) 
of the participants were told that that warmth stimulus was intense and perceived as 
painful to most individuals.  Individuals expecting the painful stimulus provided 
lower intensity ratings for the heat stimuli (mean  = 20.67) than the other group (mean 
= 27.59).  It was reasoned that subjects in the pain group overestimated the pain 
intensity of the impending stimulus.  An opposite effect could have resulted if pain 
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intensities were underestimated, subjects may have perceived the stimuli to be 
intense.  Reaction time to the auditory task were slowed only by the heat distractor 
and not the slide distractor lending further support to the hypothesis that pain 
interferes with attention. 
 An experiment was used to determine the effects of painful/control stimuli on 
the ability to distinguish between a high pitched and low pitched tone.177  Subjects 
reported the pain stimuli to be intense and unpleasant (mean = -1.8) as compared to 
control stimulus (mean = 0.24, +5 = pleasant, -5 = unpleasant) {t (25), p < 0.001}, 
and subjects reported being significantly {t (25), p < 0.001} more distracted with pain 
stimuli (mean = 6.45) than with control stimulus (mean = 4.49).  Standard deviation 
scores were not reported.  Distraction was rated on an 11-point scale with 0 being 
“not at all distracted” and 10 being “very strongly distracted.”  Results from the study 
showed that painful stimuli produced significantly greater disruption in task 
completion than control stimuli.  Even though control stimuli increased reaction time 
for the completion of the auditory discrimination task, the effects were not as 
dramatic as those observed with the pain stimuli.  Stimuli were administered at three 
intervals and the extent of disruption continued to decline with subsequent stimuli so 
that no differences in reaction time were observed due to administration of either pain 
or control stimuli at interval three.  
 The authors draw on several theories to address the implications of the above 
results.  New stimuli trigger alarm systems that draw a significant amount of attention 
thereby increasing the amount of time required or the number of errors in the process 
of task completion.  Responses to these stimuli after they have lost their novelty are 
governed by motivational-affective systems, which utilize different mechanisms.  In 
this scenario, pain stimuli did not pose any imminent or long-term threat value; 
therefore, participants in the experiment were able to compensate for any attentional 
deficits and complete the task without much difficulty on subsequent attempts.  It has 
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also been recognized that processes involving attention compensate continuously to 
maintain coherence and are capable of minimizing the effects of any extraneous 
stimuli.  “It is remarkably difficult to demonstrate serious degradations in 
performance during the presence of stressors.”178  We saw here that participants were 
able to voluntarily focus attention on the task after adjusting to the pain stimulus. Pain 
intensity did cause interruption and subsequent reduction in response was due to the 
ability to compensate.  In the context of chronic pain where pain intensity may flare 
on occasions, and the distress and suffering arising from these stimuli and perceptions 
about harm associated with pain could affect the ability to refocus attention in these 
patients.  This pattern of interference can lead to deficiencies in several cognitive 
domains among chronic pain patients.179 
 Crombez and colleagues, in an effort to understand the effect of varying pain 
intensities on task interference and the process of recovery with respect to task 
interference administered electric stimuli to a sample of healthy volunteers (n = 24).  
It was observed that pain and control stimuli disrupted attention at first, measured by 
excess time and/or greater inaccuracy in the completion of an auditory task compared 
to baseline.  Results showed that on subsequent administration of stimuli, pain 
continued to disrupt attention while control stimulus did not distract from the task.  
Greater effort was required to  divert attention away from the pain stimulus.180  The 
pain stimulus continued to disrupt attention even at subsequent administrations, 
contrary to the findings presented above.  The authors suspected that methodological 
differences in the current study and that presented above (Crombez G et al., 1996) are 
responsible for this discrepancy.  Even though the effect of pain on task interference 
persisted, a gradual reduction in response times indicates that subjects can adapt to 
experimental pain stimuli. 
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 In another study, Crombez and colleagues subjected participants (n=37) to an 
elecrocutaneous stimulus and a control stimulus.181  The purpose of the study was to 
distinguish the extent to which threat of pain moderated subjects’ responses to an 
auditory discriminating task [high (1000 Hz) and low tones (250 Hz)].  A control 
group (n =19) was informed about the maximum intensity of stimulus that would be 
generated, while the threat group (n =18) was notified about the possibility of stimuli 
with fluctuating intensities.  The results indicated that electrocutaneous stimuli rather 
than control stimuli produced significantly higher reaction times in the high threat 
group than in the control group.  It has been postulated that fear of harmful 
consequences evoked by threats are capable of inducing avoidance behaviors.  For 
chronic pain patients that have developed a sense of fear of their condition, 
participation in activities/behaviors that can trigger pain are avoided and considerable 
attentions is devoted to a variety of triggers. 
 The effect of catstrophizing about pain on attention has also been examined.  
Prior research has suggested that patients who magnify the potential effects of pain 
and the threat pain poses are preoccupied with its effects and find it difficult to 
refocus attention on other tasks.  A similar task-oriented procedure as has been 
described above was utilized.182  A painful stimulus was delivered via electrodes to 
both arms, and participants were threatened by informing them about the delivery on 
an intense stimulus to one arm (right/left), while the other arm received a constant 
level of low-intensity stimulation.  Data on catastrophizing (Pain Catastrophizing 
Scale -PCS), negative, and positive emotions were also collected.  A median split 
based on PCS scores were used to identify catastrophizers (n = 20, mean = 23.05, s.d. 
= 5.47) fron non-catastrophizers (n = 23, mean = 9.52, s.d. = 4.47).  Catastrophizers 
were found to have greater levels of negative affect and lower levels of positive 
affect.  Ratings about intensity of threat stimulus provided by the two groups were 
similar.  Results indicated that task interference was pronounced for catastrophizers in 
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the presence of threat stimuli, however this effect was observed only at Time 1 and 
not during subsequent test administration.  Task interruption due to the low-intensity 
stimulus was pronounced in these individuals, who also rated the stimulus as being 
more intense and unpleasant.  These results indicate that catastrophizing does mediate 
the interruptive effect of pain.   
 In comparison to the laboratory setting, a real fear of pain may have more 
lasting effects than those observed in the present study.  A cross-sectional study about 
coping styles in chronic pain showed that avoidance behaviors were highly 
prevalent.183  Avoiders did not differ from pain confronters in either pathology or 
self-reports about pain intensity.  Avoidance behaviors are commonly observed in 
catastrophizers indicating an association between these behaviors and attention 
deficits.  A recent study conducted with healthy individuals indicates that the 
association between pain and fear may be spurious.184  The experimental procedure 
use to induce pain (inflating a sphygmomanometer cuff around the forearm) may 
have contributed to the results, as the stimuli may have not been perceived as 
harmful. 
 In summary, novel stimuli such as experimentally induced pain can interrupt 
attention.  Typically, individuals can adapt to successive stimuli and are capable of 
refocusing their attention.  It can be reasoned that pain stimuli in a laboratory setting 
do not have any lasting threat value, and are therefore incapable of capturing attention 
subsequently.  Factors such as the threat of pain, catastrophizing, and negative affect 
are associated with the interruption function of pain. 
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1.3.14 Effects of Opioids on Cognition in Healthy Subjects 
 
 There is extensive literature that documents the effectiveness of morphine and 
other opioids on cognitive status in health subjects.  A study that examined the effects 
of morphine in experimentally induced pain induced conducted as early as 1940 
concluded that feelings of calmness and satisfaction that may occur under normal 
conditions of morphine administration do not persist in the presence of painful 
stimuli.185  Numerous studies have examined the effects of opioids in healthy 
subjects.   
 Zacny has provided a comprerehensive review about the effects of opioids on 
psychomotor and cognitive functioning in humans.186 The review was structured to 
provide information about the type of opioids considered, studies examining 
psychomotor and cognitive effects of opioids, effects of opioid withdrawal in 
physically dependent subjects, and epidemiological aspects including the correlation 
between opioid use and accidents.  Studies reviewed examined the effects of 
morphine agonists (morphine, hydromorphone, heroin, merperidine, fentanyl, 
alfentanyl, and methadone), partial agonists (oxycodone and dihydrocodeine, 
propoxyphene, dextropropoxyphene, dipipanone, meptazinol, papaveratum, and 
dezocine), and mixed agonist-antagonists (buprenorphine, pentazocine, butorphanol, 
and nalbuphine). 
Effects on Motor Tasks and Reaction Times: 
 
 Among three studies with healthy subjects, morphine impaired reaction time 
(RT) measured as finger tapping in only one experiment.  Among chronic cancer pain 
patients, dose escalation was associated with increased reaction time measured by 
tapping rate. However, psychomotor effects subsided within a week.  Morphine doses 
of 10mg, 15mg, and 30 mg have been found to increase auditory reaction times.  Two 
studies examined the extent to which external stimuli (shock) modified cognitive 
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effects as measured by visual RT test.  Although morphine did produce a higher RT 
time than saline, there was no difference in RT time between groups administered 
morphine, shock, or a combination.  Surprisingly, combination of shock and 
morphine resulted in fewer disruptive effects than the administration of morphine 
alone.  The suggestion that morphine does not worsen, and may even improve pain-
induced impairment can be traced as far back as 1952.  
Of three studies that assessed the effects of IV fentanyl (20mg morphine equivalent 
dose), only results from one experiment showed an impaired performance on finger 
tapping.  Visuo-motor tracking in healthy subjects on fentanyl was impaired in one 
study (morphine equivalent dose – 10 mg) and unaffected in another (morphine 
equivalent dose – 5 mg) demonstrating a dose-response relationship.  Oxycodone 
(morphine equivalent dose – 9.1 mg) did not compromise finger tapping speed.187 
 
Effects on Information Processing  
 
 The Digit Symbol Substitution Test (DSST) was used to examine the effects of 
morphine (dose range – 0 to 10mg) in four different studies among healthy 
volunteers. Volunteers showed no impairment except in one study, and effects of the 
drug were not very strong when compared to placebo (only four fewer symbols were 
incorrectly substituted). In studies that evaluated the effects of 
morphine/hydromorphone (dose range – 0 to 30mg) on the DSST among opioid 
abusers, results were no different than those obtained with placebo.  The tests were 
performed with a maximum dose equivalent to 30mg of morphine.  In similar tests 
that were conducted among opioid dependent individuals, doses of either morphine or 
hydromorphone that ranged from 0.125 mg to 14mg equivalents of morphine 
produced no significant differences in performance compared to placebo.  Among 
studies (n = 7) that have examined the effects of 10mg morphine on the speed and 
accuracy of oral addition, written addition, arithmetic, and coding and all but one 
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have detected impairment in speed.  Only one study concluded that accuracy on a 
written addition test was compromised.188 
 Fentanyl administered via infusion impaired performance on the DSST among 
healthy volunteers, the relationship was dose-dependent.  A low dose of fentanyl 
(morphine equivalent dose – 5mg) administered as an injection and intramuscularly 
administered oxycodone (morphine equivalent dose – 9.1 mg) did not impair ability 
to perform on the DSST compared to placebo. 
 
Effects on Sustained Attention: 
 
 Sustained attention has been measured using RT tests that last for 5 to 10 
minutes.  In a comparison of intravenous infusion, oral, and sustained release dosage 
forms in healthy volunteers, only IV morphine impaired a sustained auditory task.  
Comparison between cancer patients (morphine dose range – 10 - 307 mg) and 
healthy controls (no drug) yielded impaired performance on a 10 minute auditory 
reaction time test.  Performance on tasks such as hidden figures test (complex pictures 
containing simpler ones to be identified) and penning numbers in the order presented 
have suffered after administration of morphine  in healthy volunteers.189   
 Considerably large doses of IV fentanly (morphine equivalent dose – 20 mg) 
and relatively small dose of oxycodone (morphine equivalent dose – 3 mg) 
administered subcutaneously (SC) did not affect performance on the symbol 
cancellation test.  
Effects on Complex Psychomotor Performance: 
 
 Morphine doses (as high as10mg) in healthy subjects have not impaired 
cognitive tasks such as complex tracking and ability to solve orally presented 
arithmetic problems in the presence of distraction.  The effects of (SC) oxycodone 
(morphine equivalent dose – 9.1 mg) on three complex cognitive tests were 
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evaluated: divided attention, tracking, and choice reaction time (CRT).  A negative 
effect on performance was observed only in the case of CRT.190 
Effects in Memory (Immediate Recall) 
One study (Digit Span Test) in healthy volunteers and four in opioid dependent 
individuals (Immediate Free Recall) found no impairment on tests due to morphine.  
In two studies conducted by the same author that utilized immediate free recall 
testing, IV fentanyl (morphine equivalent dose – 21mg) did not impair performance.  
A third study that assessed performance on free recall, Digit span, and the Benton 
visual retention tests found that IV fentanyl (morphine equivalent dose – 21mg) 
impaired performance only on the Digit Span. Test.  Another study found the 
opposite result (improved performance on Digit Span) in the case of SC oxycodone 
(morphine equivalent dose – 3 mg).191 
Effects on Memory (Delayed Recall): 
 Studies assessing delayed recall have found that morphine does not negatively 
affect recall, however, reading speed has been shown to be compromised. Neither 
fentanyl nor oxycodone in any of the studies reviewed were found to negatively affect 
delayed free recall.  Fentanyl has been shown to decrease reading speed.  
 Jarvik and colleagues examined the effects of morphine (10mg/70 kg body 
weight) on pain tolerance and psychomotor function measured by the Digit Symbol 
Substitution (DSS) test and the finger tapping test.192  Tests were administered at 
three time intervals: 45 minutes before and 45, 225 minutes after the dose.  The study 
included 20 subjects (10 monozygotic twin pairs) who were subjected to experimental 
pain using the cold pressor technique.  Morphine significantly (p < 0.05) increased 
pain tolerance.  Performance on the DSS improved significantly (p < 0.05) after 
administration of morphine as compared to placebo. Performance on the FTT 
declined significantly (p < 0.05) after session two with administration of both placebo 
and morphine.  In the case of DSS test, the authors cited practice effects as the reason 
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for improved performance, while in the case of FTT, fatigue was associated with the 
decline in performance. 
 A group of eight healthy volunteers were selected to examine the effects of 
placebo, 20mg dihydrocodeine, and D-Met2 Pro5-enkephalinamide (EA –3 and 10mg)  
each administered 2-3 weeks apart on pain tolerance and cognitive function.193  Pain 
was experimentally induced using a sub maximum effort tourniquet technique.  The 
following cognitive tests were administered: symbol cancellation test, digits forward 
and backward test, and the Guilford memory test.  Dihydrocodeine and EA 10mg 
enhanced pain threshold at 30 and 60-minute intervals.  As compared to placebo, 
performance on the symbol cancellation and digits forward and backwards test 
improved subsequent to administration of drugs.  Treatment did not produce an effect 
on the word fluency test. 
 Stacher and colleagues utilized electrical and thermal stimulation techniques to 
induce pain in a sample of 48 subjects to assess the analgesic effects of orally 
administered diclofenac sodium (75 and 150 mg), codeine (60mg), and placebo.194  
Psychomotor function was measured as a function of sensorimotor responsiveness 
and fine motor control.  Reaction time to acoustic stimuli was used to measure the 
former and subjects were required to complete a tracking task in order to assess motor 
control.  Diclofenac 150 mg, codeine 60mg, and diclofenac 75mg in this order 
significantly (p < 0.05) increased pain threshold and tolerance as compared to 
placebo.   As compared to placebo and diclofenac 150mg, reaction time to acoustic 
stimuli was significantly (p < 0.05) higher for diclofenac 75 mg and codeine 60mg.  
The effects of codeine on fine motor control were similar to that of placebo.  
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  Bradley and Nicholson assessed the cognitive effects of codeine (30, 60, and 
90mg) and triprolidine (10mg) on six healthy subjects.195  Cognitive functioning was 
assessed as performance on the following tests: visuo-motor coordination (VMC), 
dynamic visual acuity (DVA), complex reaction time (CRT), critical flicker fusion 
(CFF), and digit symbol substitution test (DSST).  Codeine (60 and 90mg doses) 
impaired performance on the VMC as measured by difference in mean scores 
obtained from the two test intervals (time 1 and time 2) as compared to mean score 
difference when placebo was administered.  Codeine 90mg and troprolidine impaired 
performance on the DVA.  Codeine did not affect performance on the CRT, CFF, and 
DSST.  Poor visuo-motor coordination was associated with nausea and not 
drowsiness or sedation. 
 A randomized double blind cross over single dose trial was used to assess the 
effects of morphine sulphate (10mg and 15mg), lorazepam (1mg), and placebo in 
twelve healthy subjects over a period of four weeks.196  Drug effects (baseline, 1, 2, 4, 
and 6 h after administration) were observed on the following cognitive function tests: 
simple reaction time, choice reaction time, number vigilance, (all 3 tests of attention) 
memory scanning, immediate and delayed word recall, word recognition, picture 
recognition (tests of memory), critical flicker fusion threshold (CFFT).  Compared to 
placebo, morphine sulphate (10mg and 15mg) significantly (p < 0.05) impaired 
performance on the delayed word recall and picture recognition test at the one-hour 
interval, and performance at subsequent intervals was not compromised.  
Performance on the CFFT declined steadily, and was significantly lower for both 
doses compared to placebo at the 4-hour interval.  Lorazepam impaired performance 
on all tests. 
 O’Neill and colleagues utilized a similar study design as described above to 
ascertain the cognitive effects of dextropropoxyphene napsylate 100mg, morphine 
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sulphate 10mg, lorazepam 0.5mg, and placebo in ten healthy subjects.197  Lorazepam 
significantly (p < 0.05) impaired reaction time on all tasks at time intervals ranging 
from four hours to 30 hours (list of tasks provided in Hanks GW et al. summary) 
except the digit vigilance task.  Dextropropoxyphene negatively affected performance 
on choice reaction time and picture recognition tests at several time intervals.  The 
effects of morphine in comparison were negligible.  Although accuracy on the choice 
reaction time improved significantly (p < 0.005), speed declined.  The improvement 
in accuracy had been observed  in their previous study (Hanks GW et al., 1995) as 
well.  Additionally morphine impaired speed on the simple reaction time (16 h, p = 
0.05, 36 h p < 0.01), negatively affected memory scanning sensitivity and speed (12h, 
p < 0.005; 16h, p < 0.02).  In light of the inconsistent results observed with morphine 
(stong mu agonist) in comparison with dextropropoxyphene (weak mu agonist), the 
authors concluded that larger doses of morphine may produce a more pronounced 
cognitive effect.  However, the results clearly indicate that in comparison to 
lorazepam, the effects of both strong and weak mu agonists on cognitive function are 
minor.  Larger doses of morphine taken chronically may be associated with a general 
slowing of reaction time; however, this effect in the context of a pain patient, the 
dosage form, and route of administration can be variable. 
 Conley and colleagues examined the effects of equianalgesic doses of morphine 
and Butarphanol administered intravaneously on psychomotor function.198  A total of 
13 subjects were examined in the presence of a painful stimulus (cold pressor) and a 
control condition.  While butarphanol impaired performance in both conditions, 
morphine did not impair performance on the Digit Symbol Substitution Test.  This 
may be explained by the different receptors that morphine (mu) and butarphanol 
(kappa) affect.   
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 Walker and Zacny found that oral morphine (40mg) did not impair performance 
on any psychomotor tests such as DSST, auditory reaction test, logical reasoning test, 
and locally developed short term and long term memory tests.199  However, this dose 
did cause sedative effects as measured by the penotobarbital-chlorpromazine-alcohol 
(PCAG) subscale of the addiction research center inventory (ARCI) used to 
distinguish various classes of psychoactive drugs.  Hill and Zacny examined the 
psychomotor effects of hydromorphone (0, 0.33, 0.65, 1.3mg/70kg) and morphine (5 
and 10mg/70kg) in a group of 17 health non-drug abusing subjects.200  A significantly 
(p < 0.05) lower score was obtained on the DSST for subjects on the largest dose of 
hydromorphone (Hydromorphone Dose –1.3mg/70kg, Mean DSST score = 42.3, sd 
=2.7) than when subjects were on saline (Mean DSST score = 46.3, sd = 2.2).  
According to the authors, the decline in performance is minimal in comparison to 
those observed with benzodiazepenes and other sedatives (15-20 fewer symbols).  
Subjects on morphine (10mg/70kg) performed comparably on the DSST (Mean score 
= 43.6, sd = 2.4), however, a 1.3mg/70kg dose of hydromorphone is equivalent to 
13.4mg of morphine.  Both drugs did not affect reaction time, hand-eye coordination, 
logical reasoning or memory processes.  
 In a recent study, Walker and colleagues examined the effects of administering 
increased doses of either morphine or nalbuphine (0, 2.5, 5, and 10mg/70kg), 
butorphanol (0, 0.5, 1, and 2 mg/70kg), pentazocine (0, 7.5, 15, and 0mg/70kg), or 
saline.201  Results showed that increasing doses of opioids (except for pentazocine) 
caused impaired performance on the DSST.  While the rate at which symbols were 
drawn were affected, accuracy was not compromised.  Cognitive impairment as 
assessed by decreasing number of symbols was observed after the fourth dose for 
morphine (6 fewer symbols) and nalbuphine (10 fewer symbols), and after third dose 
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of butorphanol (23 fewer symbols).  Butorphanol also affected hand-eye coordination 
to a greater extent than morphine and nalbuphine. Only butorphanol impaired 
perfomance on the logical reasoning test. 
 Most recently, Allen and colleagues compared the effects of placebo, ibuprofen, 
and a combination of hydrocodone bitartrate (7.5mg) and ibuprofen (200 mg) on 
sustained attention, concentration, and coordinated movement.202  Participants 
included 72 healthy males who were subjected to exercise induced muscle damage.  
The following cognitive tests were utilized: PASAT; tracking task (2 measures, i.e., 
percentage of time on track and total possible distance successfully tracked); and 
simple as well as complex reaction time.  It was observed that participants on 
combination therapy (mean = 58.06, SEM = +/- 0.85) obtained significantly (p < 
0.03) lower score for the percent of time on track compared to ibuprofen (mean = 
61.35, SEM = +/- 0.85), but not placebo (mean = 59.21, SEM = +/- 0.85).  Even 
though this group committed a significantly greater number of errors on simple 
reaction time task then the two other groups, they performed the task much faster as 
well, which may have contributed to the inaccuracy.  In conclusion, hydrocodone did 
not produce any systematic cognitive effects among participants.  
 Many of the studies examined here were one-time dose experiments or tested 
multiple doses over several weeks.  Based on the findings reported in these studies, it 
can be concluded that opioids (morphine, fentanyl, oxycodone, codeine, and 
hydromorphone) do not significantly impair cognitive status in healthy subjects.  
Impairments were observed most commonly in tests of motor function.  Tasks 
assessing attention, information processing, and memory were not hampered by these 
drugs except with very large doses.  
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1.3.15 Effects of Opioids on Cognitive Ability in Chronic Non -Malignant Pain 
(CNMP) Patients 
 
 The target population for the proposed study is chronic nonmalignant pain 
patients who will be treated with long-acting narcotic analgesics.  Thus, it is 
necessary to review the literature examining the effects of opioid use on cognitive 
status among CNMP patients.   
 McNairy and colleagues observed patients on narcotic analgesics that faced 
difficulty in focusing, understanding, and retaining instructions provided upon entry 
at a clinic.203  Observations were made over a three day period and patients controlled 
medication consumption frequency. The following cognitive function tests were 
administered:  Wechsler verbal performance, full scale IQs, digit symbol, and block 
design, which are subscales of the Wechsler test; tactual performance test (TPT), 
finger tapping test, grooved pegboard test,  and Rey’s auditory-verbal learning test 
(AVLT).  Patients were designated as non-abusers (mean daily dose = 2.36 mg), 
abusers (mean daily dose = 18.6 mg), or dependent users (mean daily dose = 32.3 
mg) based on narcotic analgesic consumption expressed as milligram equivalents of 
morphine.  On average, abusers (mean daily dose = 188 mg) and dependent users 
(mean daily dose = 520 mg) consumed significantly greater amounts of tranquilizers 
(expresses as milligram units of pentobarbital) than non abusers (mean daily dose = 
15mg).  The abuse-dependent groups were combined into one group for analyses, and 
demonstrated impaired performance on the digit symbol (p = 0.005), block design (p 
= 0.008), TPT – dominant, nondominant, both hands (p =0.006, p = 0.01, p = 0.014).  
The verbal test suggested that both groups did not display any aberrant memory or 
learning functioning. 
 Although the results of this study suggest that use of high dose narcotics is 
associated with cognitive impairment, several limitations are associated with the 
study methodology and analyses of data. Numerous (54) ANOVAs were conducted 
thereby inflating alpha error.  The authors did not utilize any corrective measures, 
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such as Bonferroni’s test to adjust for this inflation.  Abusers and dependent users 
utilized excess doses of narcotics and as such these patients cannot be compared to 
chronic pain patients without deviant drug taking behaviors.  The authors did not 
control for the use of tranquilizers which have repeatedly been shown to impair 
cognitive function.204  The authors conducted the study from a biased perspective 
since it was assumed that opioids cause cognitive impairment, and the results are a 
reflection of the patients selected and methodology used.   
 Lorenz, Beck, and Bromm examined the effects of sustained release morphine 
(initial dose = 30mg) and experimentally induced pain in six female patients with 
chronic nonmalignant pain (mean VAS pain intensity score = 7.3, s.d. = +/- 2.3).205  
At follow-up, patients reported substantial reduction in pain (mean VAS pain 
intensity score = 2.7, s.d. = +/- 2.1), while objective measures of cognitive function 
showed no change or minor improvement.    Long-term follow-up (> 1 year) showed 
that patients had substantially increased morphine doses, however pain was well 
controlled with few side-effects such as constipation and no problems associated with 
drowsiness and concentration. Experimentally induced pain did not affect cognitive 
ability.  Patients reported an improved mood along with feeling less stressed and 
depressed.  These results are consistent with the stages of pain model which suggests 
that pain suffering rather than intensity is correlated with cognitive impairment. 
 Haythornthwaite et al. evaluated the effect of long-acting opioid analgesics 
(methadone/SR-morphine) on cognitive function and depression.206  Subjects (n=19) 
included chronic pain patients (pain that persisted longer than 6 months) that had not 
improved in response to standard therapy.  The following assessments were made at 
baseline and follow-up: Multidimensional Pain Inventory (MPI), Symptom Checklist 
90-R (SCL-90-R), Beck Depression Inventory (BDI), Grooved Pegboard test, 
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Hopkins Verbal Learning Test (HVLT), the Trail Making Test (Part A), and the Digit 
Span subscale from the Wechsler Adult Intelligence Test – Revised (WAIS-R).  In 
addition to the experimental group, a sample of 10 patients receiving standard care 
served as a control group for the study.  Controls that utilized short-acting opioids on 
an as needed basis were put on a regular dosing pattern.  Patients in the treatment 
group rated their pain to be significantly more (p < 0.05) severe (mean = 5.30) than 
control group patients (mean = 4.43) at baseline.  An approximately equal proportion 
of patients in the treatment (79%, mean follow-up period –5.8 months) and control 
groups (80%, mean follow-up period – 3.0 months) reported using short acting 
opioids at baseline.   
 Mean improvement in pain severity was significantly greater for the group 
receiving long acting opioids (mean difference = -1.93) as compared to the usual care 
group (mean difference = -0.24) at the 95% level.  While only two patients in the 
usual care group reported increased ability to participate in work and leisure 
activities, nine patients in the treatment group reported such an improvement.  
Although no significant differences were observed between depression levels for the 
two groups, mean reduction in anxiety (-0.27) and hostility (-0.20) were significantly 
different than the mean increase in scores (0.13 and 0.31 respectively) for the two 
scales among control group patients.207 
 Mean scores on the Digit Symbol (DS) test improved significantly [F(1,25) = 
5.3, P<0.05] from baseline to follow up for the treatment group.  As compared to 
usual care patients who showed a drop in scores for the DS test (mean decline = -1.1), 
long acting opioid users showed a significant improvement in the Digit Symbol test 
scores at follow-up (mean improvement = 4.4).  No significant differences were 
observed on other cognitive function tests (grooved pegboard, Hopkins Verbal 
Learning Test, Trail Making Test- Part A&B, Digit Span Subscale) either between or 
                                                 
207 Ibid 
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within groups at follow-up.208  It can be speculated that more group differences would 
have emerged with a larger sample size. 
 The results indicated that reduction in pain severity was observed in patients 
responding to lower doses of long acting opioids.  A larger sample size would have 
enabled robust conclusions about the comparative effects of short and long acting 
opioids on cognitive function.  Follow-up period ranged from 3 to 5 months 
suggesting that the likelihood of improvement in cognitive test scores due to practice 
effects was minimal. The authors concluded that the improvement in performance on 
this cognitive test may be a function of the analgesic relief obtained due to the 
treatment.209   
 Francis examined the effect of opioid therapy on various aspects of cognitive 
functioning such as verbal learning and memory, short-term memory, visuomotor 
tracking, psychomotor speed and accuracy, and sustained attention.210  Pain intensity, 
depression, and opioid medications (hydrocodone, propoxyphene, and codeine) were 
considered as independent variables.  Pain intensity was assessed using a 11-point 
rating scale, and the Beck Depression Inventory was used to assess depression among 
patients.  Scores on all tests were obtained at baseline (when patients began treatment 
with opioids) and one month after opioid dose had been stabilized.  The results were 
analyzed by calculating change scores for each independent variable and cognitive 
function test score.  A regression equation was developed for each test with change in 
cognitive function test score as the dependent variable. 
 The California verbal Learning Test (CLVT) was used to measure verbal 
memory and included eight subtests.  Results from a t-test showed that scores on a 
total of six subtests (List A Trial 5, List B, Short Delay Free, Short Delay Cued, Long 
Delay Free, Long Delay Cued) improved significantly at follow-up.  However, only 
the regression model with List A Trial 1 subtest as the dependent measure was 
                                                 
208 Ibid 
209 Ibid 
210 Francis SE.  The effects of long term opioid therapy on neuropsychological functioning in chronic pain 
patients. California Institue of Integral Studies.  Dissertation.  June 1999; 130p. 
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significant.  Only the BDI accounted for a significant proportion of the variance (sr2 = 
0.166, p < 0.01) in test score change.  
 The Digit Span Forward and Backward is a measure of short term memory.  
Scores on the digit forward test declined (mean change = -0.22, p > 0.05),while 
scores on the digit backward improved (mean change = +0.22, p > 0.05).  The 
regression model showed that pain and opioid dose accounted for a significant 
proportion of the variance in the digit forward test.  Higher pain scores correlated 
with higher scored on the digit forward test, a result that was contrary to that 
hypothesized.  Larger opioid doses were associated lower scores on the test. 
 The Trailmaking tests Part A and B are a measure visuomotor tracking and 
complex attention.   A significant improvement in scores was observed for both Part 
A (mean change = -6.95, sd = 11.49, p < 0.001) and Part B (mean change = -13.55, sd 
= 42.19, p < 0.05).  None of the independent variables accounted for the variance in 
these measures. 
 The grooved pegboard test is a measure of psychomotor function and utilizes 
the dominant and non dominant hands to assess function.  The mean test scores at 
follow-up for the dominant hand improved and were significantly different from 
baseline (mean change = -5.12, sd = 10.89, p < 0.01).  Pain intensity, depression, and 
opioid dose did not account for any variance in psychomotor function. 
 The Continuous Performance Test (CPT) is a measure of sustained attention that 
incorporates five subtests.  None of the subtests showed a significant change in score 
from baseline to follow-up, and only depression accounted for 20 percent of the 
variance in the CPT Hit Reaction Time Standard Error (p < 0.01) and 24 percent of 
the variance in the CPT variability subtest. 
 Results from this study indicate that short-acting narcotic analgesics have 
minimal effects on cognitive function.  Patients were only prescribed short acting 
opioid agents such as hydrocodone, codeine, and propoxyphene.  Cognitive 
impairment is of greater importance in patients that are prescribed long-acting opioid 
agents.  As patients are maintained on a constant dose, their ability to focus at work, 
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drive, and participate in other activities is often questioned.  A related limitation with 
the previous study is the time of testing.  Often short-acting opioids produce 
deleterious effects within two hours of administration and the variability in dose may 
produce results that can be misleading.211  
 Sjogren et al. prospectively studied 40 chronic pain patients that had been 
stabilized on opioid therapy for at least two weeks.212  The following drugs were 
included in the study sustained release morphine (n = 23), methadone (n = 12), 
ketobemidone (n = 2), buprenorphine (n = 2), and tramadol (n = 1).  All doses were 
converted into an equianalgesic morphine dose, and median morphine dose used was 
60 mg.  Evaluations on neuropsychological tests (CRT, FTT, PASAT) were 
compared with a matched control group.   
 On the CRT test, a significantly (p = 0.022) slower reaction time was observed 
for patients than controls that had scores in the lowest percentile.  As compared to 
controls, patients performed poorly on the FTT [dominant hand (p = 0.008) and 
nondominant hand (p = 0.003)], as well as on the PASAT (p less than or equal to 
0.02).  Anxiety and depression measures did not correlate with test scores. 
 The authors concluded that treatment with long-term opioids negatively affects 
cognitive ability in nonmalignant pain patients as compared to a normal population.  
Since this study utilized a cross-sectional design, it is not possible to ascertain if 
patient condition had improved at all on opioid therapy.  The median age of patients 
and controls was 60 and 59 years respectively.  Patient characteristics such as age and 
extent of distress due to pain may have contributed to differences in cognitive 
abilities that were observed between the two groups.  The biggest drawback of this 
study is the utilization of a control group that is healthy as opposed to pain patients 
with similar characteristics that are not taking opioid medications.  Consequently, the 
                                                 
211 Saarilho-Kere U, Julkunem H, Mattilla J et al.  Cited by: Chapman SL, Byas-Smith MG, Reed BA.  
Effects of intermediate and long term use of opioids on cognition in patients with chronic pain.  The 
Clinical Journal of Pain.  2002;18:583-590. 
212 Sjogren P, Thomsen AB, Olsen AK.  Impaired neuropsychological performancein chronic nonmalignant 
pain patients receiving long-term oral opioid therapy.  Journal of Pain and Symptom Mangement.  
2000;19:100-108. 
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interpretation of these results in the context of a chronic nonmalignant pain patient 
population is limited.  A measure of performance prior to opioid use would have 
provided insight into the potential effects of pain on cognitive performance. 
 Driving is an important daily activity that pain patients on opioid therapy must 
be capable of performing in order to achieve a sense of return to normal function.  In 
a comparison of driving ability tested by means of a simulator, patients on chronic 
opioid analgesic therapy (COAT) performed significantly better than age matched 
cerebrally compromised patients (cerebrovascular accidents, traumatic brain injury, 
and anoxia).  Although COAT patients made errors on tasks that required speed and 
accuracy, the authors attributed the errors to hasty actions rather than impairment 
caused by drugs. 
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1.3.16 Effects of Opioids on Cognitive Function in Patients with Cancer Pain 
 
 Opiods are often used in the management of pain in cancer patients.  “The 
specific contribution of opioids to the cognitive impairment associated with advanced 
cancer is often difficult to evaluate owing to the frequent presence of multisystem 
impairment and the concurrent administration of other psychotropic medications.”213  
Characteristics such as disease severity, complications, and numerous medications 
associated with cancer can individually and collectively affect cognitive status.  
Additionally, a large proportion (60%) of cancer patients belong to the older age 
group (age ≥ 65).  These patients are particularly prone to experiencing pain, and 
cognitive functioning normally declines in elderly patients.  Thus, studies evaluating 
cognitive deficits due to opioids in the cancer population are plagued by numerous 
confounding variables. 
 Results from thee studies that utilized Continuous Reaction Time to examine the 
cognitive effects of opioids in cancer patients showed that test times were prolonged 
in groups that received the drug.  Opioid-naïve patients were more likely to exhibit 
delayed reaction times than those patients that had been stabilized on a dose.214  
Findings from this population cannot, however, be extended to other groups of 
patients experiencing pain of nonmalignant origin.  Multiple reasons, including 
susceptibility to cognitive dysfunction, older age, and numerous other disease-related 
factors prevent the extrapolation of these results. 
 Results of studies evaluating the effects of opioids on neuropsychological 
functioning must be interpreted taking into consideration factors such as dose 
variations, opioid type and route, frequency of dosing, and interval between 
administration of dose and neuropsychological testing.  
 Sjogren and colleagues assessed the effects of opioids, performance status, and 
pain on some facets of neuropsychological function in cancer pain patients (n =  
                                                 
213 Lawlor PG.  The Panorama of opioid-related cognitive dysfunction in patients with cancer: a critical 
literature appraisal.  Cancer.  2002;94:1836-1853. 
214 Ibid. 
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130).215  Potential confounding medications such as benzodiazepines, antidepressants, 
anticonvulsants, neuroleptics, etc were excluded from the trial.  Patient reported pain 
(no pain and intolerable pain were anchors) and sedation (quite alert and extremely 
tired were anchors) levels were obtained on a VAS.  The following tests were 
administered about 150 minutes after administration of morphine doses: continuous 
reaction time (CRT) which measures vigilance, finger tapping test (FTT), and paced 
auditory serial addition task (PASAT) which is associated with memory function.   
 Patients in the control group (n = 40) [karnofsky performance status (KPS) A] 
experienced no pain and did not receive opioids. Their scores on the psychomotor 
tests were not statistically different from matched healthy controls.   Comparisons 
were drawn between the control group and 4 other groups. Group 2  (n = 19) – KPS 
B, no pain, no opioids; Group 3 (n -  19) – KPS B pain no opioids; Group 4a (n = 31) 
-  KPS B, pain, opiods administered (average dose = 120 mg); Group 4b (n = 21) – no 
pain, opioid administered (average dose = 40mg).   
 As compared to other groups, patients in group 4a had the lowest score on all 
tests.  As compared to patients in the control group, patients in all groups except 3 
had significantly (p < 0.05) slower scores on the CRT test.  Performance on the FTT 
was significantly (p < 0.01) slower by patients in group 3 and 4a than patients in the 
control group.  Average scores on PASAT were significantly better for patients in 
group 4b versus group 4a, suggesting that pain may mediate working memory.  
However, since group 2 and 3 did not differ statistically, this conclusion may be 
erroneous especially among patients not treated with opioids.  Pooling data from the 
two opioid treated groups and untreated groups showed no differences on PASAT test 
scores, while combining groups with pain free patients (2 and 4b) and those still 
experiencing pain (3 and 4a) showed significantly better scores for the pain-free 
group.   
 Since patients receiving opioids had been stabilized on their doses for two 
weeks, the results suggest that long-term opioid use does not significantly affect 
                                                 
215 Sjogren P, Olsen AK, Thomsen AB, Dalberg J.  Neuropsychological performance in cancer patients; the 
role of oral opioids, pain and performance status.  Pain.  2000;86:237-245. 
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scores on cognitive function tests.  Cognitive tests were administered shortly after 
dose administration.  A spike in blood drug levels may have caused some side-effects 
such as drowsiness, thereby confounding the results of these tests. The results indicate 
that pain may mediate cognitive ability.   
 Clinicians that treat cancer patients with long-term opioid therapy have reported 
positive outcomes with this management strategy.  Contrary to expectations about 
adverse effects, problems such as sedation and cognitive impairment are not typically 
observed.216 
 The above literature has demonstrated that pain does impair neuropsychological 
functioning.  A number of factors such as anxiety, sleep disturbances, depression, and 
medication (opioid & benzodiazepine) use in pain patients contribute to abnormal 
cognitive functioning.  Results from various studies indicate that aspects of attention, 
memory, speed of processing, and executive control functions may often be disrupted 
due to chronic pain that is untreated/under treated.217  Treatment of the underlying 
pain would probably alleviate these problems, and restore homeostasis.   
                                                 
216 Galski T, Williams JB, Ehle HT.  Effects of opioids on driving ability.  Journal of Pain and Symptom 
Management.  2000;19:200-208. 
217 Nicholson K, Martelli MF, Zasler ND.  Does pain confound interpretation of neuropsychological test 
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Chapter 2: Study Objectives and Theoretical Framework 
 
 In this chapter, a statement of study objectives will be made.   The study 
objectives and observations from the literature review will serve as guide to develop the 
theoretical rationale for the study.   
 The stages of pain model (figure 2.1), which was developed in the 1990’s will 
be used as the underlying theoretical basis for the study.   The association between 
stages of pain model variables, exogenous variables (age, gender, and ethnicity), and 
endogenous variables (narcotic analgesic dose and benzodiazepine dose) will be 
discussed. 
  A path analytic framework will be used to model the relationships between the 
variables discussed above and measures of attention (digit span test, digit symbol test, 
and the paced auditory serial addition test), which will serve as the dependent 
variables.  A separate model for each dependent variable will be constructed.  Finally, 
hypothesis based on the modeled relationships will be proposed for each model. 
  
2.1 Study Objectives 
 
1. The primary purpose of this study is to examine the association between Avinza®  
and performance on neuropsychological tests in chronic non-malignant pain 
patients while controlling for other variables such as pain intensity, pain 
unpleasantness, pain suffering, pain behaviors, and benzodiazepine use.  More 
specifically, measures of attention associated with immediate recall (digit span 
forwards and backwards), sustained attention and information processing 
(PASAT), visual attention and motor persistence (digit symbol subtest of the 
WAIS-R) will be evaluated. 
 
2. To examine the association between benzodiazepine dose and performance on 
tests of cognitive function. 
 
3. To examine whether pain intensity and unpleasantness have an indirect influence 
on measures of attention mediated by pain suffering and pain behaviors. 
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4. To determine whether adequate pain control with Avinza influences the direct 
association between pain suffering and performance on tests of cognitive 
function. 
 
5. To determine whether adequate pain control with Avinza influences the direct 
association between pain behaviors and performance on tests of cognitive 
function. 
 
2.2 Theoretical Framework for Study 
 
The stages of pain model will serve as the theoretical basis for this study.  The rationale 
for using the stages of pain model will be discussed below. 
 
2.2.1 Stages of Pain Model 
 
 The sensory, affective, and cognitive dimensions of pain proposed in the Gate 
Control Theory (GCT) have been further evaluated and are believed to be composed 
of sub-parts that coincide with various stages of pain processing.218  
 Wade et al. have proposed a four-stage model of pain process.  The following 
figure presents an illustration of the model:219 
 
Figure 2.1 Stages of Pain Model 
 
 
 
 
 
 
 
 
 
                                                 
218 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
219 Wade JB, Hart RP.  Attention and the stages of pain processing.   Pain Medicine.  2002;3:30-38. 
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 “A theoretical scheme of dimensions and stages of pain may be useful in 
identifying the level at which therapeutic interventions exert their influence.”220  Wade 
and colleagues applied a linear structural relations (LISREL) approach to identify the 
structural relationship between the four pain stages, assess validity of latent constructs, 
and examine the predictive ability of the model.221  Pain intensity and unpleasantness 
were measured on a VAS with the following anchors: “no sensation” and “the most 
intense sensation imaginable”, and “not bad at all” and “the most intense bad feeling 
imaginable”, respectively.  Pain affect (emotional distress, i.e., depression, anxiety, 
frustration, fear, anger) and perception of impact on life (beliefs about interference with 
participation in desired activity, difficulty in enduring pain, ability to reduce pain, and 
likelihood of cure) were measured as indicators of stage 3 processing.  Pain-related 
behavior was measured by utilizing five items from the psychological pain inventory.  
Best fit was obtained after the dimension about “impact of pain on life” was dropped 
from the model.  A weak relationship was found between suffering and behavior.  The 
authors attributed the weak association to differences in measurement, i.e, visual 
analogue scales for all other items versus multiple rating methods for behavior items.  
Previous research has demonstrated that factors such as gender, age, and type of pain 
disorder do not significantly influence the modeled variables.222 
 In a recent study, the stages of pain model served as a heuristic to examine the 
association between chronic pain and cognitive function.  In order to assess cognitive 
function, the Digit Span (D.S.) test, which is a measure of immediate recall was used.  
The results from stepwise regression analysis indicated that depressed mood (r2 = 
0.04, p < 0.0001), interference due to pain (r2 = 0.03, p < 0.0001), and “solicitous 
behavior and change in daily activities” (r2 = 0.04, p < 0.0001) accounted for 
significant variance in attentional performance.   
                                                 
220 Ibid. 
221 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
222 Wade JB, Dougherty LM, Hart RP, Rafii A, Price DD.  A canonical correlation analysis of the influence 
of neuroticism and extraversion on chronic pain, suffering, and pain behavior.  Pain.  1992;51:67-73. 
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Wade and Hart suggest that follow-up studies utilizing the stages of pain model 
should utilize multiple measures of attention, working memory capacity, and 
information processing speed to gauge the association between cognitive function and 
chronic pain.223  Thus, the  purpose of this study is to evaluate the association 
between long-acting morphine (Avinza®), and performance on neuropsychological 
tests assessing short-term memory, information processing, and motor skills in 
chronic pain patients, while controlling for stages of pain model variables and the 
effects of benzodiazepines.   
2.3 Key Model Variables 
 
A detailed description of each variable included in the proposed study model, and 
the modeled relationships shall be examined below.  The ensuing discussion first presents 
a description of the stages of pain model variables.  This is followed by examining the 
association between demographic variables, medication use and the stages of pain model 
variables,  
 
2.3.1 Stage I 
 
The concept of stages of pain processing was introduced in the 1980s.  It is 
believed that pain perception can be characterized by four stages that are distinguishable 
in chronic pain patients.224  The first stage is described as pain intensity, which is 
indicative of responsiveness to nociceptive stimuli.  Visual analog scales (VAS), “verbal 
descriptor scaling methods,” and “other cross modality matching methods” have been 
used to measure perceived pain intensity.225 It is hypothesized that pain intensity does not 
influence attention directly, but the relationship is mediated through pain unpleasantness, 
pain suffering, and pain behaviors. 
                                                 
223 Wade JB, Hart RP.  Attention and the stages of pain processing.   Pain Medicine.  2002;3:30-38. 
224 Harkins SW, Price DD, Braith J.  Effects of extraversion and neuroticism on experimental pain, clinical 
pain, and illness behavior.  Pain.  1989;36:209-218. 
225 Wade JB, Dougherty LM, Hart Rp, Rafii A, Price DD.  A canonical correlation analysis of the influence 
of neuroticism and extraversion on chronic pain, suffering, and pain behavior.  Pain.  1992;51:67-73. 
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2.3.2 Stage II 
 
   The second stage of pain experience known as pain affect (unpleasantness) has 
been measured using sound psychometric theory.226  It is characterized by the 
continuous sensations of unpleasantness that are evoked in the presence of painful 
stimuli.227  Pain affect correlates closely with pain intensity, and is moderately 
associated with cognitive processing.  Pain affect has been validated by measuring 
response to both experimentally induced and clinical pain.  Pain affect, like pain 
intensity is measured with VAS; however, ratings have been demonstrated to measure 
different dimensions.228 Pain affect is also referred to as “Stage 1 affect.”229 Subjects 
who are exposed to experimental pain typically provide higher pain intensity ratings 
and lower pain affect ratings, while the opposite trend is observed in chronic pain 
populations.  This is indicative of the lack of concern for harmful or negative 
outcomes associated with experimental pain.  Pain intensity is independent of 
psychological factors that influence pain affect.230   
   Neurophysiological findings also indicate that perceived unpleasantness and 
affect due to noxious stimuli are associated with excitatory activity in a different 
region of the brain, namely the anterior cingulated cortex (ACC) and pain intensity is 
linked to activity in the primary somatosensory cortex.  Rainviille and Duncan 
concluded that the ACC is the most critical determinant in the perception of pain 
unpleasantness; however, various structures such as the somatosensory cortex, ACC, 
and PAG which are responsible for “encoding different aspects of pain” are 
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associated and “highly interactive.”231  These physical findings clearly substantiate 
the existence of two different stages in the perceptions of pain.  Rainville and 
colleagues have also demonstrated this difference experimentally through the use of 
hypnosis.232 
 According to Price and colleagues, pain that poses a threat to life or health (i.e., 
cancer pain, chronic pain) would influence affective ratings of pain to a greater extent 
than pain that is characterized as being less harmful (e.g., labor pain).233  Cancer, 
causalgia, upper back pain and low back pain patients provided significantly (p < 
0.05) higher affective pain ratings than sensory pain ratings, while labor pain patients 
provided significantly (p < 0.05) higher pain intensity ratings.  Labor pain patients 
who focused more on the pain than on the impending birth tended to provide higher 
affective ratings, thus lending further support to the hypothesis.   Various 
psychological and cognitive factors such as impact of pain on daily activities and 
future health, and perceived locus of control influence pain affect.  Differentiation 
between various pain ratings for various groups of pain patients can provide a sound 
basis for assessing the effects of different therapeutic strategies.  Both, pain intensity 
and pain unpleasantness are believed to influence measures of attention indirectly 
through pain suffering (stage III) and pain behaviors (stage (IV). 
 
2.3.3 Stage III 
 
 The third stage of pain experience (Stage 2 affect) is an expression of individual 
beliefs, mood and emotional distress.  Individual beliefs stem from past experiences 
and perceptions about the future.  Individuals have variable responses to their 
condition; some patients are significantly hampered by their pain while others prevent 
pain from disrupting their lifestyle.  Patients in whom symptoms flare or do not 
                                                 
231 Rainville P, Duncan GH.  Pain affect encoded in human anterior cingulated but not somatosensory 
cortex.  Science.  1997;277:968-971.  
232 Rainville P, Carrier B, Hofbauer RK, Bushnell MC, Duncan GH.  Dissociation of sensory and affective 
dimensions of pain using hypnotic modulation.  Pain.  1999;82:159-171. 
233 Price DD, Harkins SW, Baker C.  Sensory-affective relationships among different types of clinical and 
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subside form references to previous experiences associated with their pain.  
Additionally, patients can vary in their outlook about the potential consequences of 
chronic pain, which may either be realistic or exaggerated.  These evaluations 
contribute to pain suffering.  Negative evaluations about pain are expected to give rise 
to a variety of negative emotions.  Experiences with pain and its impact on lifestyle 
influence cognitive processes, which give rise to a variety of emotional responses.  
Accordingly, the third stage of pain processing has been referred to as suffering.  Pain 
experienced long after an injury has healed would remind an accident victim about 
the mishap and subsequent suffering.234   
 Wade and colleagues suggested that the emotional component of pain includes 
negative emotions such as fear, anxiety, frustration, and anger in addition to 
depression.235   Five visual analog rating scales describing each emotion were 
correlated with pain affect scores (pain unpleasantness –maximum, minimum, and 
usual) and depression scores obtained through the Beck Depression Inventory (BDI) 
and the depression scale of the Minnesota Multiphasic Personality Inventory (MMPI).  
A canonical correlation analysis indicated that negative emotions explained 11 
percent of the variance in pain unpleasantness (correlation was significant only for 
maximum  pain unpleasantness) and 33 percent of the variance in BDI scores.  A 
multiple regression analysis showed that anxiety and frustration predicted maximum 
pain unpleasantness; anxiety, frustration and anger predicted minimum pain 
unpleasantness; and only frustration predicted usual levels of pain unpleasantness.  
Depression and anger contributed significantly to BDI scores. It was interesting to 
note that none of the pain unpleasantness levels were predicted by depression ratings.  
These findings lend support to the hypothesis that pain unpleasantness and pain 
suffering are separate dimensions.  It can be argued that pain patients who are 
frustrated with their condition experience an increase in pain unpleasantness levels, 
which leads to psychological distress and depression.  Although the five VAS ratings 
                                                 
234 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
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correlated with the BDI, the authors suggest that these measures should not be used to 
substitute the BDI, which is a more reliable assessment of depression among pain 
patients. 
Depression is commonly prevalent among patients with chronic pain.  Reports 
about the incidence of depression in chronic pain vary tremendously ranging from 10 
percent to 90 percent.236,237  The large discrepancy may be attributable to the 
variability in criteria used to assess depression in chronic pain.238 
 Both pain and depression are separate, yet related normal physiologic responses 
designed to conserve energy and enable survival in the face of internal or external 
threats.  Depressive symptoms are linked to cytokines, which regulate the function of 
the immune system.  The depressive symptoms include “behavioral (restlessness, 
reduced activity, hypersomnia, social withdrawal), cognitive (lack of concentration, 
loss of interest), and affective (depressed mood, anhedonia) components,” which 
“represent a motivational state that promotes resistance to pathogens by resetting an 
organism’s priorities.”  In some situations, improper regulation of these mechanisms 
may result in motivational states that are repetitive and persistent.   Like depression, 
pain is a motivational process.  The involvement of the immune system and the 
inability to self-regulate cytokine mechanisms lead to the development of chronic 
syndromes.   
 
2.3.4 Stage IV 
 
 According to Loeser and Egan, behavior is the only observable aspect of these 
different stages of pain.239  Pain behavior can be measured either through self-reports 
or proxy reports, or by means of observation.  Inability or limited ability to work, 
partake in social and recreational activities, and perform daily tasks due to pain 
                                                 
236 Hendler N.  Depression caused by chronic pain.  Journal of Clinical Psychiatry.  1984;45:30-36. 
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239  Loeser JD, Egan KJ.  History and organization of the university of Washington multidisciplinary pain 
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constitute the construct of pain behavior.  It can be hypothesized that patients with 
high levels of self-efficacy exhibit positive behaviors and beliefs about their 
condition, which may be associated with improved outcomes. 
 Factors such as fear about pain and the degree to which pain can be controlled, 
or the lack of control contribute largely to anxiety, perception about increased pain 
intensity, and a requirement for excess medications.  Patients who have negative 
appraisals about their condition also limit their activities drastically to the extent that 
they become disabled.240 
 Avoidance of certain activities can lead to anticipatory perceptions about other 
activities that can potentially evoke pain, thereby causing anxiety.  Perceptions about 
illness and health are learned.  Pain is always accompanied by discomfort or 
unhappiness and is, therefore, inherently an emotional experience.  It has been 
estimated that 50 percent of chronic pain sufferers are depressed.  Lack of control and 
inability to partake in activity can contribute to depression.  Anger can contribute to 
perceived interference, pain intensity, and frequency of pain behaviors.  “The 
cognitive activity of chronic pain patients may contribute to the exacerbations, 
attenuation, or maintenance of pain, pain behavior, affective distress, and 
dysfunctional adjustment to chronic pain.”241  In addition to pain intensity, emotional 
disturbances as well as disruption of day to day activities may contribute to attention 
disruption in pain patients. 
 A sub-objective of this study will be to validate the factor analytic structure of 
the stages of pain model.  Thus, the variables used to develop the constructs (pain 
intensity, pain unpleasantness, pain suffering, and pain behaviors) will be measured 
using the same instruments utilized by Wade and colleagues.242  In order to validate 
the pain suffering construct, a multiple regression analysis will be performed by 
regressing BDI scores on the observed variables used to form the construct. 
                                                 
240 Bond MR.  Psychological issues in cancer and non-cancer conditions.  Acta Anaesthesiologica 
Scandanavica.  2001;45:1095-1099.  
241 Ibid. 
242 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
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2.3.5 Narcotic Analgesics 
It is hypothesized that pain intensity is predictive of narcotic dose; high pain 
intensity is positively correlated with a greater average daily narcotic dose.  In this 
study, patients with uncontrolled pain on short-acting narcotics will be initiated on 
Avinza®, a long-acting morphine agent.   Opioid rotation whereby patients are switched 
to a more potent opioid is a strategy employed to overcome lack of analgesia or 
intolerable side-effects including cognitive dysfunction.  Opioid switches require the 
calculation of equianalgesic dose ratios.  “An equianalgesic dose refers to a dose that 
yields roughly equivalent analgesia to the standard set in a given equianalgesic dose 
table.”243  Dose selection depends on the previous dose of the patient’s narcotic 
analgesic, relative potency of the drug being initiated, and characteristics of the opioid 
being discontinued.  In a study of cancer patients, similar dose ratios were required for 
rotation from morphine to methadone in both neuropathic and non-neuropathic pain 
patients.244   Although there is no defined upper extremity with regard to opioid dosing 
in the control of pain,245 most patients will be initiated on the lowest available Avinza 
dose (30mg).   
  The published literature reviewed in the previous section demonstrated a weak 
association between narcotic use and impaired attention among pain patients.  Thus, it 
is hypothesized that the correlation between narcotic dose and tests of attention is low.   
 
2.3.6 Benzodiazepines 
 Benzodiazepines are commonly prescribed in the management of chronic pain.246  
Often, chronic pain patients experience insomnia and benzodiazepines are useful in 
inducing sleep.  It is well documented that anxiety is highly prevalent in the population 
                                                 
243 Anderson R, Saiers JH, Abram S, Schlischt C.  Accuracy in equianalgesic dosing: conversion dilemmas.  
Journal of Pain and Symptom Management.  2001;21:397-406. 
244 Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic 
pain versus non-neuropathic pain.  Journal of Pain and Symptom Management.  1999;18:120-125. 
245 Anderson R, Saiers JH, Abram S, Schlischt C.  Accuracy in equianalgesic dosing: conversion dilemmas.  
Journal of Pain and Symptom Management.  2001;21:397-406. 
246 King SA, Strain JJ.  Benzodiazepine use by chronic pain patients.  The Clinical Journal of Pain.  
1990;6:143-147. 
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of chronic pain patients.  Further, anxiety is linked with other emotional symptoms such 
as depression, anger, frustration, and sleep disturbances.  Thus, benzodiazepines are 
prescribed to treat anxiety, or in conditions where anxiety is not a prominent symptom, 
their muscle relaxant properties could serve to provide analgesic relief.247  Despite these 
benefits, the use of benzodiazepines is associated with many disadvantages. 
According to Breggin, benzodiazepines have several toxic effects such as, sedation, 
hypnosis, cognitive dysfunction, agitation, anxiety, and other behavioral aberrations.248  
Benzodiazepines produce changes in normal behavior through two different modes of 
action.  Direct intoxication results in “impaired executive and cognitive function, 
including reduced judgment and impulse control.249”  Withdrawal of the drug or loss in 
efficacy results in rebound symptoms, which are responsible for emotional outbursts.  
Long-term users of benzodiazepines have impaired performance on tests of sustained 
attention.250   Recently, benzodiazepine use has been linked with anterograde amnesia.  
Subjects administered midazolam showed an impaired ability to learn; a dose-
dependent association was found between benzodiazepines and activity in regions of 
the brain association with information processing and memory.251  
Studies assessing the effects of benzodiazepines on cognitive function have showed that 
test scores often improve after withdrawal of benzodiazepines irrespective of duration 
of use.  These results further support the conclusion of a dose-response association 
between benzodiazepine use and performance on tests of cognitive function.252,253   
                                                 
247 Dellemijn PL, Fields HL.  Do benzodiazepines have a role in chronic pain management.  Pain.  
1994;57:137-152. 
248 Breggin PR.  Brain-disabling treatments in psychiatry: drugs, electroshock and the role of the FDA. 
Springer Publishing Company.  1997.  New York, NY.  
249 Ibid. 
250 Golombok S, Moodley P, Lader M.  Cognitve impairment in long-term benzodiazepine users.  
Psychological Medicine. 1988;18:365-74. 
251 Reinsel RA, Veselis RA, Dnistrian Am et al.  Midazolam increases cerebral blood flow in the left 
prefrontal cortex in a dose-dependent fashion.  The International Journal of NeuroPsychopharmacology.  
2000;3:117-127. 
252 Scheman J, Aker R, Covington E.  Cognitive effects of opioid and benzodiazepine weaning.  Abstract.  
American Pain Society. 2003;Poster# 859.  http://www.ampainsoc.org/abstract/2003/data/859/index.html.  
Accessed:Jun 11, 2003. 
253 Curran KC, Marks HN, Basoglu M.  Long-term effects of alprazolam on memory: a 3.5 year follow-up 
of agrophobia/panic patients.  Pschological Medicine.  1999;29:225-231. 
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Thus in assessing the effects of long-acting narcotic agents on cognitive impairment in 
chronic pain, the ideal research design would exclude all patients on benzodiazepines.  
However, numerous chronic non-malignant pain patients in clinical practice are 
maintained on benzodiazepines.  Eliminating these patients from the study would 
significantly limit the sample.  Therefore, benzodiazepine dose is included in the model 
as a control variable.  The effects of benzodiazepine on cognitive impairment will be 
controlled for statistically in the study model. 
 
2.3.7 Association between Exogenous Variables and Stages of Pain Model 
 
2.3.7.1 Ethnicity 
 
Previous studies have documented differences among various racial/ethnic 
groups about the meaning of pain to life and beliefs about pain and the ability to 
control it.254  Results from one study indicated a tendency among African-American 
and Italian patients to blame themselves for their condition.255  As compared to 
Whites, African Americans viewed being in pain as analogous to being ill.  The belief 
that pain is self-inflicted or a perception that magnifies the potential consequences of 
pain tend to be associated with pain-related fear and depression.256 
 More recently, the association between race/ethnicity and the chronic pain 
experience has been examined in the context of the stages of pain model.  Riley and 
colleagues used structural equation modeling techniques to examine differences 
between White (n = 1084) and African-American (n = 473) chronic pain patients 
across the model variables.257   African American chronic pain patients on average 
provided significantly higher usual pain unpleasantness levels [5.2 (s.d. = 0.07) vs 4.7 
                                                 
254 Bates MS, Rankin-Hill L.  Control, culture, and chronic pain.  Social Science and Medicine. 
1994;39:629-645. 
255 Lipton JA, Marbach JJ.  Ethnicity and the pain experience.  Social Science and Medicine.  
1984;19:1279-1298. 
256 Jordan MS, Lumley MA, Leisen JC.  The relationships of cognitive coping and pain control beliefs to 
pain and adjustment among African-American and Caucasian women with rheumatoid arthritis.  Arthritis 
Care and Research.  1998;11:80-88. 
257 Riley JL, Wade JB, Myers CD, Sheffield D, Papas RK, Price DD.  Racial/ethnic differences in the 
experience of chronic pain.  Pain.  2002;100:291-298. 
 106
(s.d.=0.11)], negative emotion ratings [19.6 (s.d. = 0.51) vs 17.3 (s.d.= 0.34)], and 
pain behavior ratings [19.3 (s.d. = 0.58) vs 17.7(s.d.=0.38)] compared to whites.  A 
mean difference of 1.0 on a VAS was considered clinically significant.  Education 
and duration of pain were included as control variables.  The two groups were 
compared by relaxing the constraints between successive stages of the model one at a 
time.  The two groups differed primarily on pain suffering and its association with 
pain behaviors, with African Americans demonstrating a stronger link between these 
two stages.  These results indicate that interventions focusing on management of 
emotional distress are more likely to benefit African Americans.  Depression and 
other factors that constitute pain suffering may limit activity in these patients due to 
lethargy, fatigue, and reduced motivation levels. 
 
2.3.7.2 Age 
 
 There is little knowledge about the association between age and pain, adaptation 
to pain, and response to therapy.  The chronic nature of pain, the aging population and 
the large number of elderly that experience pain necessitate the delineation of these 
associations.  Riley, Wade, and colleagues examined whether variations in pain 
processing are related to differences in age.258  Chronic pain patients were categorized 
into three groups: younger adults (age – 18 to 44, n = 820); middle-aged adults (age 
45-64, n = 596); and older adults (age ≥ 65, n = 159).  Duration of pain did not 
correlate significantly with any of the stages of pain model variables.  Univariate 
analysis indicated that all three age groups provided similar ratings for pain intensity 
and unpleasantness, however, older adults exhibited lower ratings of negative 
emotion and manifested fewer pain behaviors than the other two age groups.  
Structural equation modeling results showed a variation in the linear association 
between pain-related emotion and behavior across age categories.  Older adults were 
least likely to exhibit pain behaviors and experience the lowest levels of emotional 
                                                 
258 Riley JL, Wade JB, Robinson ME, Price DD.  The stages of pain processing across the adult life span.  
The Journal of Pain.  2000;2:162-170. 
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suffering in response to pain.  Middle-aged adults exhibited the highest levels of 
emotional distress, which was also manifest as behavior.  The authors reasoned that 
middle-age adults provided the highest negative emotion ratings and displayed pain 
related behaviors to a greater extent as they were entering a phase of their life where 
health begins to deterioration and this phase of their life was compounded by the 
chronic pain condition.  Younger adults are also more likely to experience greater 
distress and are more likely to report illness behavior due to the inability to perform 
routine activities.  
 
2.3.7.3 Gender 
 
 Riley and colleagues examined the association between gender and various 
emotions such as anxiety, depression, fear, anger, and frustration in the context of the 
first three stages of pain model.  Although women tended to provide higher pain 
intensity and unpleasant ratings than men, univariate analysis indicated no sex 
differences in ratings for depression, anxiety, and anger.  A stronger association was 
found in the linear association between pain unpleasantness and pain emotions for 
males than females.  However, these results do not indicate group differences for pain 
suffering.   In the context of the present study model, these findings suggest that 
analgesic relief would be more predictive of lower ratings in pain unpleasantness, and 
therefore, pain suffering among males than among females. Thus, the relationship 
between gender and pain suffering is mediated by pain unpleasantness. 
 
2.3.8 Dependent Variables – Measures of Attention 
 
  Measures of the dependent variable were selected to assess various aspects of an 
individual’s ability to maintain attention.  Several factors were considered in selecting 
these measures of attention: domain of attention being assessed, reliability, cost, ease of 
administration and scoring, sensitivity in a chronic non-malignant pain patient 
population.  
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2.3.8.1 Digit Span and Digit Symbol Subtest of the Wechsler Adult Intelligence 
Scale –III (WAIS-III)  
 
  The digit span subtest includes two tests, the digits forward and backward tests.  
The former is a measure of immediate recall and the latter is a measure of temporal 
ordering.   These measures have fairly high reliability scores (0.66 to 0.89) and can be 
administered in a relatively short duration of time (4 to 6 minutes).  The digit span 
test was sensitive to measures of stage III and IV of the stages of pain model.259  The 
digit span test was included as part of this study to replicate these findings. 
 The digit symbol test assesses a wide range of cognitive abilities including motor 
persistence, sustained attention, response speed, and visuomotor attention.  Motor 
function is an important aspect of daily functioning.  The test-retest reliability of the 
digit symbol test is high (0.82 to 0.88).  The test is easy to score and takes very little 
time to complete (90 seconds).  Motor function in pain patients is impaired compared 
to healthy controls.260,261  Abuse and dependence on opioids and tranquilizers was 
associated with poor performance on the digit symbol test.262  Performance on digit 
symbol test did not deteriorate with long-acting narcotic use.263  The digit symbol test 
will be included in this study since it is sensitive to the  factors being studied.  Both 
the digit span and digit symbol subtest are part of the WAIS-III making their use cost-
effective. 
 
2.3.8.2 Paced Auditory Serial Attention Test (PASAT) 
 
  The paced auditory serial attention test is a measure of information processing, 
and sustained attention.  The test is highly reliable (0.9) and validity has been 
                                                 
259 Wade JB, Hart RP.  Attention and the stages of pain processing.   Pain Medicine.  2002;3:30-38. 
260 Sletvold H, Stiles TC, Landro NI.  Information processing in primary fibromyalgia, major depression, 
and healthy controls.  The Journal of Rheumatology.  1995;22:137-142. 
261 Grace GM, Nielson WR, Hopkins M, Berg MA.  Concentration and memory deficits in patients with 
fibromyalgia syndrome.  Journal of Clinical and Experimental Neuropsychology.  1999;21:477-487. 
262 McNairy SL, Maruta T, Ivnik RJ, Swanson DW, Ilstrup DM.  Prescription medication dependence and 
neuropsychologic function.  Pain.  1984;18:169-177. 
263 Haythornthwaite JA, Lynette MA, Quatrano-Piacentini Al, Pappagallo M.  Outcome of chronic opioid 
therapy for non-cancer pain.   Journal of Pain and Symptom Management.  1998;15:185-194. 
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extensively established.  The PASAT is capable of detecting very subtle impairments 
in information processing ability; thus, one of the most commonly used measure to 
assess attention.  Performance on the PASAT in pain patients is impaired.264,265 ,266  
Performance on PASAT did not deteriorate with long-acting narcotic use.267 Since, 
the PASAT is sensitive to the factors being studied; it will be included in this study. 
 In summary, we can conclude that pain experience is adequately described by 
the stages of pain model.  Further, stage III and IV of the model are directly 
associated with cognitive processes, which may contribute to sub-normal 
performance in tasks that require concentration, memory, focus, and persistence.  The 
review in chapter 1 demonstrated that opioid analgesics tend to have a minimal 
negative association with cognitive test scores, particularly in pain patients that derive 
analgesic benefit from the drug.  
 Given this background information, the following model is proposed to examine 
the associations between stages of pain model variables, narcotic analgesic dose, 
benzodiazepine dose and cognitive function as measured through neuropsychological 
test in CNMP patients.  Figure 2.2 is a representation of all the relationships outlined 
above.  
 
                                                 
264 Sletvold H, Stiles TC, Landro NI.  Information processing in primary fibromyalgia, major depression, 
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Figure 2.2 Structural Equation Model Depicting Associations between Demographics (age, gender, 
ethnicity), Stages of Pain Model Variables, Narcotic and Benzodiazepine Dose, and the Dependent 
Variable (cognitive function test score) at Baseline 
 
 
PI – Pain Intensity, PU – Pain Unpleasantness, PS – Pain Suffering, PB -  Pain Behaviors, MED – Morphine Equivalent Dose, VED -  Valium 
Equivalent Dose, CFT – Cognitive Function Test Score, B – Baseline,                 indicates that two variables covary 
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2.4 Hypothesized Study Model  
 
Data for each variable (excluding demographics) in the proposed path model will 
be collected at baseline and follow-up.  Data for patients on each variable collected at 
baseline and follow-up are expected to be correlated.  Therefore, Figures 2.3, 2.4, and 
2.5 represent two wave models with the digit span test, digit symbol test, and paced 
auditory serial addition test as dependent variables.  Since each of these models will 
be analyzed separately, hypothesis for each model are presented after the 
representative figure. 
 112
 
  
 
Figure 2.3- Proposed Two-wave Path Diagram with Digit Span Test as the Dependent Variable 
 
 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent 
Dose, DSYT-Digit Span Test, B-Baseline, F-Follow-up 
 
DSYTB 
MEDB PIB 
PUB 
PSB 
PBB 
Gender 
Age 
Race 
VEDB 
PIF 
MEDF 
PUF 
PSF 
PBF 
DSYTF 
 113
2.4 Hypothesis  
2.4.1 Hypothesis for Digit Span Model 
The following hypothesis will be tested for the proposed two-wave path model 
(Figure 2.3) with the Digit span subtest as the dependent variable: 
¾ Ho1: There is no significant association between morphine equivalent dose 
(MEU) of short-acting narcotic analgesic agents and digit span subtest 
scores at baseline. 
¾ H2: There is a significant linear and inverse relationship between 
benzodiazepine dose and digit span subtest scores baseline. 
¾ Ho3: There is no significant direct association between pain intensity and 
digit span subtest scores at baseline. 
¾ H4: There is a significant linear and inverse association between pain 
suffering and digit span subtest scores at baseline. 
¾ H5: There is a significant linear and inverse association between frequency 
of pain behaviors and digit span subtest scores at baseline. 
¾ H6: There is a significant linear and inverse association between age and 
pain suffering at baseline. 
¾ Ho7: There is no significant difference in pain unpleasantness ratings 
between males and females at baseline. 
¾ Ho8: There is no significant association between ethnicity and pain 
suffering at baseline. 
¾ Ho9: There is no significant association between ethnicity and pain 
behavior at baseline. 
¾ Ho10: There is no significant association between age and pain behavior at 
baseline. 
¾ H11: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
¾ H12: There is linear and direct association between pain suffering and 
valium equivalent dose at baseline 
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¾ H13:  There is an inverse association between age and DST at baseline. 
¾ Ho14: There is no significant association between morphine equivalent 
dose (MEU) of long-acting narcotic analgesic agents and digit span subtest 
scores at follow-up. 
¾ H15: There is a significant linear and inverse relationship between 
benzodiazepine dose and digit span subtest scores at follow-up. 
¾ Ho16: There is no significant direct association between pain intensity and 
digit span subtest scores at follow-up. 
¾ H17: There is a significant linear and inverse association between pain 
suffering and digit span subtest scores at follow-up. 
¾ H18: There is a significant linear and inverse association between 
frequency of pain behaviors and digit span subtest scores at follow-up. 
¾ H19: There is a significant linear and inverse association between age and 
pain suffering at follow-up. 
¾ Ho20:  There is no significant difference in pain unpleasantness ratings 
between males and females at follow-up. 
¾ Ho21: There is no significant association between race and pain suffering at 
follow-up. 
¾ Ho22: There is no significant association between race and pain behavior at 
follow-up. 
¾ Ho23: There is no significant association between age and pain behavior at 
follow-up. 
¾ H24: There is an inverse association between morphine equivalent dose 
and pain intensity at follow-up. 
¾ H25: There is an inverse association between valium equivalent dose and 
pain suffering at follow-up. 
¾ H26: There is an inverse association between age and DST at follow-up. 
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Figure 2.4- Proposed Two-wave Path Diagram with Digit Symbol Test as the Dependent Variable 
 
 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent 
Dose, DSYT-Digit Symbol Test, B-Baseline, F-Follow-up 
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2.4.2 Hypothesis for Digit Symbol Model 
The following hypothesis will be tested for the proposed two-wave path model 
(Figure 2.4) with the Digit symbol subtest as the dependent variable: 
¾ Ho27: There is no significant association between morphine equivalent 
dose (MEU) of short-acting narcotic analgesic agents and digit symbol 
subtest scores at baseline. 
¾ H28: There is a significant linear and inverse relationship between 
benzodiazepine dose and digit symbol subtest scores baseline. 
¾ Ho29: There is no significant direct association between pain intensity and 
digit symbol subtest scores at baseline. 
¾ H30: There is a significant linear and inverse association between pain 
suffering and digit symbol subtest scores at baseline. 
¾ H31: There is a significant linear and inverse association between 
frequency of pain behaviors and digit symbol subtest scores at baseline. 
¾ H31: There is a significant linear and inverse association between age and 
pain suffering at baseline. 
¾ Ho32: There is no significant difference in pain unpleasantness ratings 
between males and females at baseline. 
¾ Ho33: There is no significant association between ethnicity and pain 
suffering at baseline. 
¾ Ho34: There is no significant association between ethnicity and pain 
behavior at baseline. 
¾ Ho35: There is no significant association between age and pain behavior at 
baseline. 
¾ H36: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
¾ H37: There is linear and direct association between pain suffering and 
valium equivalent dose at baseline 
¾ H38:  There is an inverse association between age and DSYT at baseline. 
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¾ Ho39: There is no significant association between morphine equivalent 
dose (MEU) of long-acting narcotic analgesic agents and digit symbol 
subtest scores at follow-up. 
¾ H40: There is a significant linear and inverse relationship between 
benzodiazepine dose and digit symbol subtest scores at follow-up. 
¾ Ho41: There is no significant direct association between pain intensity and 
digit symbol subtest scores at follow-up. 
¾ H42: There is a significant linear and inverse association between pain 
suffering and digit symbol subtest scores at follow-up. 
¾ H43: There is a significant linear and inverse association between 
frequency of pain behaviors and digit symbol subtest scores at follow-up. 
¾ H44: There is a significant linear and inverse association between age and 
pain suffering at follow-up. 
¾ Ho45:  There is no significant difference in pain unpleasantness ratings 
between males and females at follow-up. 
¾ Ho46: There is no significant association between race and pain suffering at 
follow-up. 
¾ Ho47: There is no significant association between race and pain behavior at 
follow-up. 
¾ Ho48: There is no significant association between age and pain behavior at 
follow-up. 
¾ H49: There is an inverse association between morphine equivalent dose 
and pain intensity at follow-up. 
¾ H50: There is an inverse association between valium equivalent dose and 
pain suffering at follow-up. 
¾ H51: There is an inverse association between age and DSYT at follow-up. 
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Figure 2.5- Proposed Two-wave Path Diagram with Paced Auditory Serial Addition Test as the 
Dependent Variable 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent Dose, 
PASAT-Paced Auditory Serial Addition Test, B-Baseline, F-Follow-up 
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2.4.3 Hypothesis for Paced Auditory Serial Addition Test Model 
 
The following hypothesis will be tested for the proposed two-wave path model (Figure 
2.5) with the paced auditory serial addition test (PASAT) as the dependent variable: 
¾ Ho52: There is no significant association between morphine equivalent 
dose (MEU) of short-acting narcotic analgesic agents and PASAT scores 
at baseline. 
¾ H53: There is a significant linear and inverse relationship between 
benzodiazepine dose and PASAT scores baseline. 
¾ Ho54: There is no significant direct association between pain intensity and 
PASAT scores at baseline. 
¾ H55: There is a significant linear and inverse association between pain 
suffering and PASAT scores at baseline. 
¾ H56: There is a significant linear and inverse association between 
frequency of pain behaviors and digit PASAT scores at baseline. 
¾ H57: There is a significant linear and inverse association between age and 
pain suffering at baseline. 
¾ Ho58: There is no significant difference in pain unpleasantness ratings 
between males and females at baseline. 
¾ Ho59: There is no significant association between ethnicity and pain 
suffering at baseline. 
¾ Ho60: There is no significant association between ethnicity and pain 
behavior at baseline. 
¾ Ho61: There is no significant association between age and pain behavior at 
baseline. 
¾ H62: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
¾ H63: There is linear and direct association between pain suffering and 
valium equivalent dose at baseline 
¾ H64:  There is an inverse association between age and PASAT at baseline. 
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¾ Ho65: There is no significant association between morphine equivalent 
dose (MEU) of long-acting narcotic analgesic agents and PASAT scores at 
follow-up. 
¾ H66: There is a significant linear and inverse relationship between 
benzodiazepine dose and PASAT scores at follow-up. 
¾ Ho67: There is no significant direct association between pain intensity and 
PASAT scores at follow-up. 
¾ H68: There is a significant linear and inverse association between pain 
suffering and PASAT scores at follow-up. 
¾ H69: There is a significant linear and inverse association between 
frequency of pain behaviors and PASAT scores at follow-up. 
¾ H70: There is a significant linear and inverse association between age and 
pain suffering at follow-up. 
¾ Ho71:  There is no significant difference in pain unpleasantness ratings 
between males and females at follow-up. 
¾ Ho72: There is no significant association between race and pain suffering at 
follow-up. 
¾ Ho73: There is no significant association between race and pain behavior at 
follow-up. 
¾ Ho74: There is no significant association between age and pain behavior at 
follow-up. 
¾ H75: There is an inverse association between morphine equivalent dose 
and pain intensity at follow-up. 
¾ H76: There is an inverse association between valium equivalent dose and 
pain suffering at follow-up. 
¾ H77: There is an inverse association between age and PASAT at follow-up. 
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Chapter 3: Methodology 
 
3.1 Study Design 
 
This study utilizes a prospective design in which patients will be evaluated over a 
period of four weeks. A within subjects design will be employed with measures 
obtained at two points in time.  
 
OB X OF 
 
OB – Observations at baseline 
X – Therapeutic intervention (long-acting narcotic analgesics) 
OF – Observations at follow-up 
 Participants will include chronic non-malignant pain patients that have been 
referred to Advanced Pain Management and Rehabilitation Medical Group Inc., 
Castro Valley, CA.  A convenience sampling procedure shall be used for this pre-
experimental design.  Patients with moderate to severe chronic non-malignant pain 
who have received a previous trial of short-acting narcotic analgesics (SANA) 
(hydrocodone, codeine, propoxyphene, etc.) will be recruited for the study. 
The physician has control of who will be changed from a short-acting narcotic 
analgesic to a long-acting narcotic analgesic.  This responsibility is not in control of 
the researcher.  The division of responsibilities between the clinician and researcher is 
detailed in Table 3.1.  In order for patients to be initiated on long-acting narcotic 
therapy patients must be receiving treatment with short-acting narcotic analgesics and 
meet these additional criteria:  
 Experience constant chronic pain despite adhering to SANA regimen; 
 Inadequate pain relief, which requires frequent SANA dosing; 
 Flares in pain symptoms; 
 Risk of hepatic toxicity due to excessive consumption of acetaminophen along 
with SANA therapy; 
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 Disturbed sleep patterns; 
 Lack of improvement in function with SANA. 
Typically, patients encountered at the clinic present with these characteristics and 
these patients are routinely converted to long-acting narcotic analgesic therapy after 
evaluation by the clinician.  In most cases, patients will be initiated on the lowest 
Avinza dose (30mg) and the physician will instruct patients to modify SANA dose as 
appropriate.  The determination of appropriateness of long-acting therapy is made 
solely on the basis of clinical criteria, which will in no way be influenced by the need 
to enroll patients in the study.  This decision is part of current practice in the clinic. 
Once the clinician has determined the need for initiation of long-acting narcotic 
therapy and sought their interest to participate in the study, he will introduce the 
patient to the researcher.  Figure 3.1 provides an illustration of the point at which the 
researcher will make contact with the patient.  The researcher will provide patients 
who express an interest in the study with a study flyer (See Appendix B) and seek 
interest in participation.  Patients will be enrolled in the study if they voluntarily 
agree to participate and complete an informed consent form (See Appendix C). 
Once patients agree to volunteer in the study, a convenient time will be scheduled 
to obtain measures at baseline.  The following assessments will be made at baseline: 
pain intensity, pain unpleasantness, pain suffering, pain behaviors, depression (Beck 
Depression Inventory -BDI), short-acting narcotic analgesic dose, benzodiazepine 
dose, and measures of attention.  Additionally, background information (birth date, 
medical record number, medications, diagnosis, type of pain, duration of pain and 
prior surgery) indicated in Appendix D will be obtained from patient charts.  Patients 
will be asked to report average daily dose of short-acting narcotic analgesic and 
benzodiazepine (if applicable) in the previous week.  Retrieving this information 
within the last week should not pose a significant burden on patient memory.  
Additionally, using the average daily dose of SANA and benzodiazepines within the 
last week would be suitable for the purpose of the analysis.  Unless otherwise noted, 
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this information will be obtained by self-report and verification will be obtained 
through prescription records when possible.  
 Following baseline assessments, patients will be evaluated after a two-week 
interval to assess pain relief, side effects, and need for breakthrough medication.  
Patients will have the ability to obtain appointments immediately in the event of an 
emergency.  Pain intensity assessments made for the purposes of titrating dosage and 
monitoring progress will not be included in the path model.  An example of the 
progress assessment guide can be found in Appendix G.  Dose adjustments shall be 
made in the following situations: 
 Less than 50 percent improvement in pain relief as reported by the patient; 
 Greater than four doses of breakthrough medication; 
 Intolerable or unmanageable side-effects. 
Data collection sheets used to obtain baseline data will also be used at follow-up.  
These follow-up measures will be incorporated in the two-wave path model.  An 
illustration of the flow of patients through baseline and follow-up assessments is 
presented in Figure 3.2. 
 Patients who are intolerant to Avinza or drop-out of the study due to side-
effects, or do not obtain adequate pain relief will be switched to another medication.  
Data for these patients will not be included in the two-wave model.  
  
    124
 
Table 3.1 - Division of Responsibilities between Physician/Clinic Staff and 
Researcher at Clinic Site 
Physician/Clinic Staff - Usual 
Responsibilities 
Researcher Responsibilities 
Pre-Visit 
¾ Visit Preparation 
 Referring MD (Consult) 
 Ancillary (X-rays) 
¾ Referral/Prior Authorization 
¾ Appointment Scheduled 
¾ Benefit Eligibility 
¾ Pre-registration 
¾ Insurance Verification 
¾ Medical record creation 
Check-In 
¾ Registration 
¾ Insurance verification 
¾ Co-pay collection 
¾ Clinical Intake 
Provision of Care 
¾ Clinical care 
 Assessments 
 Diagnostics 
 Treatment (Including long-
acting narcotics) 
 Ancillary Services 
 Procedures 
¾ Data collection 
¾ Documentation of care 
¾ Patient education 
¾ Care coordination  
¾ Coding  
¾ Charge Capture 
¾ Informs patient about study 
Check-Out 
¾ Charge entry 
¾ After hours care 
¾ Follow-up care (Progress 
Assessment Guide) 
Follow-up Care 
¾ Evaluation of therapy 
¾ Treatment optimization 
Pre-Visit 
¾ None 
 
 
 
 
 
 
 
Check-In 
¾ None 
 
Provision of Care 
¾ None 
 
If patient has been prescribed long-acting 
narcotic analgesic: 
¾ Researcher contacts patient once 
patient has expressed interest to 
learn more about the study.  
¾ Provide study flier 
¾ Solicit interest in participation 
¾ Schedule appointment 
 
Assessments 
 
¾ Background Information 
¾ Pain assessments 
¾ Neuropsychological testing 
 
Follow-up Assessments 
¾ Pain assessments 
¾ Neuropsychological testing 
¾ Follow-up assessment data 
obtained from progress assessment 
guide 
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Figure 3.1 – Division of Responsibilities and Point of Contact between Patients and Researcher 
 
 
Phases I to IV represent routine activities at the clinic site and are under complete control of the physician.  Patient contact 
with researcher will occur only after the decision to prescribe long-acting narcotic analgesic has occurred.  At this point, 
patient willingness to enroll in the study will be determined. 
Patient 
Enrolls/ 
Registers at 
clinic - I 
Evaluation 
and provision 
of care -II 
Need and 
appropriateness 
of long-acting 
narcotic therapy 
is determined - 
III
Patient receives 
Rx for long-
acting narcotic 
agent - IV 
Patient enrolls 
in study - V 
Contact with 
researcher 
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Figure 3.2 – Flow Chart of Study Protocol, Enrollment Criteria, Baseline and Follow-up 
Assessments 
 
 
Enrolled 
Demographics 
Enrollment Criteria: 
- CNMP Patient 
- Currently on short-
acting narcotic 
analgesics 
- 18 – 70 years old 
- English speaking 
 
Willing to 
participat
e
Baseline assessments 
- Pain intensity 
- Pain unpleasantness 
- Pain suffering 
- Pain behaviors 
- BDI 
- Short-acting narcotic 
analgesic dose 
- Benzodiazepine dose 
- Medical chart data 
- Measures of attention 
Week  2 
- Routine clinical 
assessments to 
evaluate patient 
comfort and 
titrate dosage. 
 
 
Initiate long-acting 
narcotic therapy 
Index date 
Follow-up assessments 
- Pain intensity 
- Pain unpleasantness 
- Pain suffering 
- Pain behaviors 
- BDI 
- Long-acting narcotic 
analgesic dose 
- Breakthrough pain 
medication dose 
- Benzodiazepine dose 
- Measures of attention 
 
Week 4 
  
 127
3.2 Sample Characteristics 
 
 In addition to chronic non-malignant pain (CNMP -defined as pain that has 
persisted for three or more months), patients must meet the following inclusion criteria: 
English speaking, 18-70 years of age, be under the care of physician (Ravi Panjabi, MD) 
at the clinic site mentioned above.  These patients should also be receiving treatment with 
SANA and meet criteria for being initiated on long-acting narcotic therapy. 
 Patient exclusion criteria include: pain not responding to opioids, a history of 
allergy or hypersensitivity to opioids, life threatening disease, reduced level of 
consciousness, social isolation, history of substance misuse, clinically relevant cardiac, 
nervous system, or respiratory disease.  The goal of the study is to recruit a total of 100 
patients.  In order to detect a moderate treatment effect (effect size = 0.15), the study with 
100 participants shall have sufficient power (0.80) to draw inferences at the 95 percent 
confidence level.   
 
3.2.1 Patient Recruitment  
 
 Eligible patients will be informed about the study by the physician-in-charge and 
will be requested to contact the researcher about study details if patients express an 
interest to participate in the study.  Participants will be notified that the purpose of the 
study is to assess the effects of the medications that will be prescribed to treat their pain 
and their willingness to participate or decline in the study shall in no way interfere with 
the care they receive at the clinic.  An appointment will be scheduled with patients that 
volunteer to participate in the study.  Data will be collected at baseline and a follow-up 
assessment will be made at the end of four weeks.   
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3.2.2 Sample Size Calculations 
 
The few studies that have addressed the relationship between cognitive function 
and long acting narcotic analgesics in chronic non-malignant pain have failed to address 
the issue of sample size.  An adequate sample size is necessary to enable the researcher to 
reject the null hypothesis with a certain degree of confidence, and conclude that the 
phenomenon in question does exist. 268  
The following parameters are of concern with tests of statistical inference: power 
(1 – β) i.e., power = 0.80 is considered substantial to detect treatment effect; α – 
significance level in most cases is estimated at the 0.05 level; effect size – the extent to 
which the phenomenon exists in the population, and N- sample size.  Given any of these 
three parameters, the fourth can be determined.  In estimating any of these parameters 
consideration must also be given to the statistical test employed. 
The data will be analyzed using path analysis, which utilizes several multiple 
regression equations to test the relationships specified within the model.  For the purposes 
of this study, two models have been specified.  The follow-up model includes one 
additional predictor, i.e., route of administration of long-acting narcotic agent.  Patients at 
follow-up will conceivably utilize short-acting agents for breakthrough pain.  The total 
amount of drug used at follow-up will be calculated as the average daily dose of the long-
acting and short acting narcotic analgesic in the precious week.  Path analysis is 
discussed in greater detail below. 
It is clear from the description above that in order to calculate sample size for the 
purposes of a study, effect size of the phenomenon under question must be estimated.  
There are several ways to arrive at this estimate, such as, reviewing the literature or 
utilizing conventional effect size estimates that have been proposed by Cohen: 
1. Small Effect size: R2 = 0.0196 (approximately 2 percent of the variance in the 
dependent variable) 
2.  Medium Effect size: R2 = 0.13 (13 percent of the variance in the dependent variable) 
3. Large Effect size: R2 = 0.25 (25 percent of the variance in the dependent variable) 
                                                 
268 Cohen J.  Statistical power for the behavioral sciences.  Lawrence Erlbaum Associates Inc.  New York, NY.  1982. 
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For the purposes of this study, an effect size estimate will be gauged from the 
literature.  A summary of the studies with relevant effect size estimates is provided in 
Table 3.1 below.  All of these studies examined the association between one or more 
independent variables, such as, pain intensity, depression, opioid dose, pain beliefs, pain 
behaviors and scores on cognitive tests among chronic non-malignant pain patients.  
Cohen has provided a formula to calculate sample size for a multiple regression analysis, 
which is depicted here:269 
N = λ / f2 
N = λ (1 – R2 Y.B) / R2 Y.B 
N- Sample size 
λ – non centrality parameter of the non central F- distribution 
R2 Y.B – proportion of variance accounted for by B (set of one or more independent 
variables) in dependent variable Y 
1 – R2 Y.B  - proportion of error or residual variance 
λ  is a simple function of the ES (effect size) index  and the 
numerator and denominator df (degrees of freedom), respectively u 
and v:270 
λ = f2 (u + v + 1) 
where, 
f2 = R2 Y.B  / (1 – R2 Y.B)  
 
The value for λ can be calculated from tables provided by Cohen.  This value can 
be estimated from the following parameters α, power, u (total number of independent 
variables), and v (denominator degrees of freedom).  Specific values of λ can be 
determined for four values of v (20, 60, 120, and ∞).  Linear interpolation will yield an 
accurate estimate of λ.  However, using v = 120 yields values of λ that are sufficiently 
accurate.  Use of the following parameter values: u = 15, α = 0.05, v = 120, power = 0.80 
yielded a λ value of 19.0. 
                                                 
269 Cohen J.  Statistical power for the behavioral sciences.  Lawrence Erlbaum Associates Inc.  New York, 
NY.  1982. 
270 Ibid. 
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Substituting λ =17.4 and an effect size estimate of 0.15 in equation 1 yields a sample size 
of 98. 
N = 19.0 (1 – 0.15) / 0.15  
N = 107 
A total of 130 patients shall be recruited utilizing a convenience sampling strategy and 
measures will be obtained at baseline and follow-up.  
 
Table 3.2.  Summary of Studies with Relevant Effect Size Estimates 
 
STUDY/DESCRIPTION CF TEST R2 
Haythornwaite et al. assessed cognitive function 
in patients treated with either long acting (n = 19) 
and short acting (n = 10) narcotic analgesics.   
 
 
Francis examined the effect of long term 
administration of short-acting narcotic agents on 
cognitive function in chronic pain patients 
Change in test scores were regressed on change in 
pain intensity, BDI scores, and MEU from Time 1 
to Time 2. 
 
 
Sjogren and colleagues compared 40 age-matched 
healthy controls with 40 chronic non-malignant 
pain patients treated with long-acting narcotics for 
at least 2 weeks.  SVAS, PVAS, HAD, Karnofsky 
performance status, opioid doses were measured.  
Only PVAS correlated with PASAT scores. 
 
Wade and colleagues examined the association 
between the stages of pain model and scores on 
the Digit span test (forward and backward test 
scores combined) in chronic non-malignant pain 
patients 
DST 
 
DSYT 
 
 
DSF 
 
 
DSB 
 
 
 
 
PASAT (T- 2.4 sec) 
 
PASAT (T- 2.0 sec) 
 
 
 
 
DST 
0.27 
 
0.56 
 
 
0.27 
 
 
NS 
 
 
 
 
0.18 
 
0.36 
 
 
 
 
0.11 
CF Test – Cognitive Function Test, BDI- Beck depression inventory, MEU – Morphine 
equivalent units, SVAS – Sedation visual analog scale, PVAS – pain visual analog scale, 
HAD – Hospital anxiety and depression scale, DST – Digit Span Test, DSYT – Digit 
Symbol Test, DSF – Digits Span Forwards, DSB – Digits Span Backwards, PASAT – 
Paced auditory serial addition test.  
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3.3 Instruments 
 
The background information sheet and the scales to measure the ‘stages of pain 
model’ variables are listed in Appendix D.  The items for the stages of pain model 
scales are the same as those used by Wade and colleagues in their confirmatory factor 
analysis of the model.  The following scales will be administered to patients at 
baseline as well as follow-up: 
 
3.3.1 Pain Intensity 
Pain intensity represents the first stage of the stages of pain model, and is a 
measure of perceived pain intensity.  Patients will be asked to report subjective pain 
at the highest intensity, lowest intensity, and usual intensity in the last week.   
Responses are indicated by marking along a visual analogue scale (VAS) that 
measures 15 cm in length with verbal anchors “no sensation” and “the most intense 
sensation imaginable.”  The VAS is presented in Appendix D. These three indicators 
will be used to load on the pain intensity construct, which represents stage I of the 
stages of pain model.   
 
3.3.2 Pain Unpleasantness 
Pain unpleasantness represents the second stage of the stages of pain model.  Pain 
unpleasantness encompasses a patient’s “immediate affective response to the pain 
sensation and to the context in which it occurs.271”   Patients will be asked to report 
subjective pain unpleasantness due to pain at the highest intensity, lowest intensity, and 
usual intensity in the last week.  Responses are indicated by marking along a VAS that 
measures 15 cm in length with verbal anchors “not bad at all” and “the most intense bad 
feeling possible.”  The VAS is presented in appendix D. 
Price and colleagues have used the following statement to enable patients to 
distinguish between pain intensity and pain unpleasantness:  
                                                 
271 Riley JL, Robinson ME, Wade JB, Myers CD, Price DD.  Sex differences in negative emotional 
responses to chronic pain.  The Journal of Pain.  2001;2:354-359. 
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There are two aspects of pain which we are interested in measuring: the 
intensity, how strong the pain feels, and the unpleasantness, how 
unpleasant or disturbing the pain is for you.  The distinction between 
these two aspects of pain might be made clearer if you think of listening 
to a sound, such as a radio.  As the volume of the sound increases, I can 
ask you how loud it sounds or how unpleasant it is to hear it.  The 
intensity of pain is like loudness; the unpleasantness of pain depends not 
only on intensity but also on other factors which may affect you.272 
 
These are scales for measuring each of these 2 aspects of pain.  
Although some pain sensations may be equally intense and unpleasant, 
we would like you to judge these 2 aspects of your pain 
independently.273 
 
In a comparison of numerical rating scales and mechanical visual analogue 
scales it was concluded that only the latter fulfilled the properties of being ratio 
scales, while both scales were useful in distinguishing between pain intensity 
and unpleasantness, and experimental and clinical pain.274 
 
3.3.3 Pain Suffering 
 The third stage of the stages of pain model is also referred to as pain 
suffering or pain affect.  The construct is composed of two sub-factors, namely, negative 
emotions and negative beliefs.  The following negative pain beliefs will be evaluated with 
the aid of visual analogue scales: pain interference, ability to endure pain, control over 
pain, and belief about curability.  Item statements used to assess each belief item along 
with anchors for associated VASs can be viewed in Appendix D.  Items used to assess 
pain beliefs had relatively low factor loadings (highest loading was 0.47) on the pain 
suffering construct.  Wade and colleagues found that the fit obtained by the stages of pain 
                                                 
272 Price DD, MCGrath PA, Rafii A, Buckinham B.  The validation of visual analogue scales as ration scale 
measures for chronic and experimental pain.  Pain.  1983;17:45-56. 
273 Harkins SW, Price DD, Braith J.  Effects of extraversion and neuroticism on experimental pain, clinical 
pain, and illness behavior.  Pain.  1989;36:209-218. 
274 Price DD, Bush FM, Long S, Harkins SW.  A comparison of pain measurement characteristics of 
mechanical visual analogue and simple numerical rating scales.  Pain.  1994,56:217-226. 
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model to the data without the negative belief variables was significantly better than with 
the variables included.275 
 The following negative emotions will be evaluated with the aid of visual 
analogue scales: depression, anxiety, frustration, anger, and fear.  Patients indicate 
the level of each negative emotion they experience on a scale with anchor that range 
from “none” to “the most severe imaginable.”  The nine indicator variables will be 
loaded on the pain suffering construct.   
 
3.3.4 Pain Behavior 
Pain behaviors will be assessed from five subscales adapted from the psychological pain 
inventory (PPI).  Items on the PPI are worded in an open ended format.  Spontaneous 
responses reported by the patient are recorded followed by asking the patient about all the 
behaviors listed under each item.  The authors argue that utilizing an open ended format 
in which patients are quizzed about each behavior elicits ‘complete and reliable 
information.276’  The following aspects of pain behaviors at home are recorded: patient 
actions in response to pain in the home, extent of “social reinforcement for illness 
behavior,” effect on usual activities that need to be performed at home, pain response to 
rest and minimization of activity, and observed pain behavior will be assessed.  Higher 
scores on an item indicate that a certain pain behavior is more apparent in the present 
case than in most cases of chronic pain.  The PPI was originally designed to identify and 
assess problem areas that can be targeted for intervention. 
 The degree to which patients express pain behaviors at home is directly related to 
the extent of social reinforcement for pain behavior.  It is believed that the extent to 
which pain patients relate with the sick role and the extent of reinforcement received are 
negatively correlated with desire to alter these behaviors.  In addition to noting the type 
of behavior exhibited, accounting for the frequency of these behaviors enables 
distinguishing between patients. 
                                                 
275 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
276 Heaton RK, Gettto CJ, Lehman RAW, Fordyce WE, Brauer E, Groban SE.  A standardized evaluation 
of psychosocial factors in chronic pain.  Pain.  1982;12:165-174. 
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 The item addressing the effect of pain on usual activities that need to be 
performed at home is a measure of direct change in activities that may have occurred 
subsequent to the pain problem.  The number of daytime hours spent lying down or 
resting “is a direct measurement of the role that rest and avoidance of activity may have 
in the patient’s pain.277”  Patients that exhibit overt pain behaviors during the interview 
receive high scores.  Additionally, patients who describe their pain as severe and 
persistent and do not exhibit behaviors that are concomitant with such a description 
receive high scores since the pain is exaggerated. 
 ‘Higher PPI scores predict increasing influence of psychosocial factors and poorer 
response to a treatment plan, while low scores are indicative of relatively fewer 
psychosocial factors that contribute to pain and influence outcome.’278 
 
3.3.5 Beck Depression Inventory (BDI) 
The BDI is a self-administered rating scale for the assessment of depression in 
psychiatric and non-psychiatric populations.  Beck and colleagues originally developed 
the Beck Depression Inventory (BDI), in 1961.279  The BDI is a 21-item instrument that 
has found wide application in the assessment of clinical depression.280  The instrument is 
highly internally consistent with coefficients ranging from 0.73 to 0.92 in both 
psychitriac and non-psychiatric populations.281   
The maximum score on each item is three, for a maximum score of sixty-three. 
The lowest possible score for the whole test is zero.  For the current study, the item on 
suicidal ideation will not be included and hence maximum score that patients can obtain 
                                                 
277 Getto CJ, Heaton RK.  Psychosocial pain inventory manual.  Psychological Assessment Resources, Inc.  
Lutz, FL.  1995;pp:23. 
278 Heaton RK, Gettto CJ, Lehman RAW, Fordyce WE, Brauer E, Groban SE.  A standardized evaluation 
of psychosocial factors in chronic pain.  Pain.  1982;12:165-174. 
279 Beck AT, Ward CH, Mendelson M, Mock N, Erbaugh J.  An inventory for measuring depression.  
Archives of General Psychiatry.  1961;4:561-571. 
280 Wade JB, Price DD, Hamer RM, Schwartz SM, Hart RP.  An emotional component analysis of chronic 
pain.  Pain.  1990;40:303-310. 
 
281 Beck AT, Steer RA, Garbin MG.  Psychometric properties of the Beck Depression Inventory: Twenty-
five years of evaluation. Clinical Psychology Review. 1988;8 (1), 77-100. 
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is 60.  The instrument is listed in Appendix E and was selected to screening tool for 
depression since: 
• The measures obtained on the pain suffering construct have been previously 
correlated with measures obtained on the BDI. 
• The clinic site for the study currently employs the BDI for assessing depressive 
symptoms among their patients.   
 
3.3.6 Benzodiazepine Equivalent Dose 
In assessing the effects of long-acting narcotic agents on cognitive impairment in 
chronic pain, the ideal research design would exclude all patients on benzodiazepines.  
However, numerous chronic non-malignant pain patients in clinical practice are 
maintained on benzodiazepines.  Eliminating these patients from the study would 
significantly limit the sample.  Therefore, benzodiazepine dose is included in the 
model as a control variable.  The effects of benzodiazepine on cognitive impairment 
will be controlled for statistically in the study model. 
Data on type of benzodiazepine, frequency and strength of dose will be obtained 
from patients.  Whenever possible, self-reported data will be verified using prescription 
records maintained in medical charts.  The following conversion factors will be used to 
compare patients on the different benzodiazepines that they are currently taking: 
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Table 3.3 - Drug Dose Conversion Equivalent to 60mg Diazepam (Valium)282 
Benzodiazepine Dose (mg) Diazepam(60mg) 
conversion factor 
Alprazolam(Xanax)    6 10.0 
Chlordiazepoxide (Limbitrol) 150   0.4 
Clonazepam (Klonipin)  24   2.5 
Flurazepam (Dalmane)  90   0.6 
Halazepam (Paxipam) 240   0.25 
Lorazepam (Ativan)  12 5 
Oxazepam (Serax)  60 1.0 
Temazepam (Restoril)  60 1.0 
NOTE: To find the dose of chlordiazepoxide equivalent to that of diazepam, multiply by 0.4. A dose of 150 
mg of chlordiazepoxide is equivalent to a dose of 60 mg of diazepam. A dose of 100 mg is equivalent to a 
dose of 40 mg, etc. 
 
 
3.3.7 Morphine Equivalent Dose 
Patient reported information about the type(s), dose, and dose schedule of utilized 
narcotic medications will be obtained.  Data will be verified using prescription records.  
Dose of short-acting narcotics will be converted to standardized morphine equivalent 
units.  Equianalgesic dose conversion criteria listed in Table 1.3 will be used for the 
conversions.   
 
3.3.8 Neuropsychological Tests   
 
These tests will  be administered to the patients at baseline and follow-up.  The 
neuropsychological tests can be viewed in Appendix F. 
The scales and tests will be administered in the following order.  After providing each 
patient with a description of the study and obtaining their consent, patients will be asked 
to complete the scales assessing the stages of pain model variables.  Following this, digit 
span and the digit-symbol tests well be administered in succession. Patients will then be 
asked whether they would prefer to complete the BDI or take a short break (2-3 minutes).  
After completing the BDI, patients will be provided another short break.  Finally, the 
                                                 
282 Miller NS, Gold MS.  Management of withdrawal syndromes and relapse prevention in drug and alcohol 
dependence.  American Family Physician.  1998;58:139-146. 
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PASAT, which takes about 15 minutes to complete will be administered.  It is anticipated 
that the entire process will require approximately 45-50 minutes for completion.   
 
3.3.8.1 Digit Span Test 
 
 The digit span subtest includes two tests, the digits forward and backward tests.  
For the digits forward test, patients are simply asked to repeat the series of numbers that 
was recited.  A total of eight series, each with two trials are recited.  One point is 
assigned for every series that is correctly recalled.  Thus, a maximum of 16 points can 
be scored on the digits forward test.  The total number of digits in each subsequent 
series increases from a minimum of two digits to a maximum of nine digits.  The 
number of digits in each series refers to the span.   
For the digits backward test, patients are asked to repeat the series of numbers that 
was recited in the reverse order.  A total of seven series, each with two trials are recited.  
One point is assigned for every series that is correctly recalled.  Thus, a maximum of 14 
points can be scored on the digits backward test. 
 The raw score calculated represents the number of series correctly recalled.   The raw 
scores can be converted into scaled scores based on age categories to draw comparisons 
with data from normal, healthy individuals and also draw comparisons within the 
sample.  Although Lezac, recommends analyzing scores from the two tests separately, 
scaled norm scores are available for both tests combined.  Studies have evaluated the 
validity and reliability of the test as an adequate measure of attention.283,284,285 The test 
along with scoring manual and norms data is available from the Psychological 
Corporation, San  Antonio, TX. 
 
                                                 
283 Larrabee GJ, Curtiss G. Construct validity of various verbal and visual memory tests. Journal of 
Clinical and Experimental Neuropsychology. 1995;17:536-547. 
284 Larrabee GJ, Kane RL, Schuck JR. Factor analysis of the WAIS and Wechsler Memory Scale: an 
analysis of the construct validity of the Wechsler Memory Scale. Journal of Clinical Neuropsychology. 
1983;5:159-168 
285 Snow WG, Tierney MC, Zorzitto ML, Fisher RH, Reid DW. WAIS-R test-retest reliability in a normal 
elderly sample. Journal of Clinical and Experimental Neuropsychology 1989;11:423-428. 
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3.3.8.2 Digit Symbol Test 
 
The digit symbol test is a sub-test of the Wechsler Adult Intelligence Scale and assesses 
motor function and hand-eye coordination.  A series of nine symbols corresponding to a 
number are printed on top of the record sheet.  Also provided on the sheet is a total of 
140 blank boxes along with a corresponding number.  Subjects must fill each blank box 
with the symbol from the key provided at the top with the first seven boxes serving as a 
practice.  Thus, a maximum raw score of 133 can be attained with the allotted two 
minutes for the task.  The digit symbol test assesses various aspects of psychomotor 
function such as motor persistence, sustained attention, response speed, and visuomotor 
coordination.  The digit symbol test was found to have little association (r = 0.22 to 
0.44) with other subtests of intelligence that are part of the WAIS-R indicating that the 
test is independent of mental ability. 
 
3.3.8.3 Paced Auditory Serial Addition Test  
 
  The paced auditory serial attention test is a measure of information processing, and 
sustained attention.  Subjects are presented with single digit numbers in a random order. 
and they are required to add each number to the one immediately before it.  Each subject 
undergoes four trials.  Sixty digits are presented in a trial with the speed of digit 
presentation increasing with each subsequent trial (2.4, 2.0, 1.6, 1.2 seconds).  On several 
occasions, subjects may experience difficulty with the two slower rates of presentation, in 
such a situation the two trials with 1.6 and 1.2 second digit presentation rates are not 
administered.  Spreen and Strauss provide detailed oral administration instructions, for 
example:  
“I am going to ask you to add together pairs of single-digit numbers,  You will hear a 
tape-recorded list of numbers read one after the other,  I will ask you to add the numbers 
in pairs and give your answers out loud.  Although this is really a concentration task, and 
not a test to see how well you can add, it might help to do a little adding before I explain 
the task in detail.  Please add the following pairs of numbers as fast as you can and give 
your answers out loud: 3,8(11); 4,9(13);7,8(15);…..7,6(13).  Good.  
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The task that I want you to do involves adding together pairs of numbers, just like you 
have done, except that the numbers will be read as a list, one after the other,  Let me give 
you an example with a short, easy list. Suppose I gave you the following: 1,2,3,4.  Here is 
what you would do.  After hearing the first two numbers on the list, which were 1,2, you 
would add these together and give your answer, 1+2 = 3.  The next number on the list is 
3, so when you heard it, you would add this number to the number right before it on the 
list which was 2, and give your answer, 2+3 = 5.  Are you following so far?  The last 
number you heard is 4 (remember the list is 1,2,3,4), so you would add 4 to the number 
right before it, which was 3, and give your answer, 3 + 4 = 7.  The important thing to 
remember is that you must add each number on the list to the number right before it on 
the list, and not to the answer you have just given.  You can forget your answers as soon 
as you have said them.  All you have to remember is the last digit that you have heard and 
add it to the next digit that you hear. O.K?  Let’s try that short list again, only this time 
you say the answers.  Ready? 1,2, (3), 3, (5), 4, (7).  Now let’s try another, longer 
practice list of numbers,  This time the numbers on the list won’t be in any particular 
order.  Ready? 4,6, (10), 1, (7), 8, (9), 8, (16), 4, (12), 3, (7), 8, (11), 2, (10), 7, (9).  
Good.286”   
 In addition to oral instruction, written instructions are also available for patients that 
have difficulty in understanding the test procedure.Normative data obtained from healthy 
subjects are presented below:  It is evident from the table that performance on the 
PASAT declines with increasing rate at which digits are presented. 
Table 2.3 – Mean Number of Correct Responses at Each Age Range287 
 
Age in years 
Presentation rate  
(in seconds)      
16-29 (n = 30) 
 
Mean               SD      
30-49 (n = 30) 
 
Mean               SD      
50-69 (n = 30) 
 
Mean               SD      
2.4 47.4                 10.1 43.4                 10.2 43.5                 13.6 
2.0 42.0                 12.5 41.9                 10.2 35.6                 14.6 
1.6 36.0                 13.0 33.1                 12.2 30.8                 15.9 
1.2 27.4                   9.9 24.6                 10.6 21.2                 14.4 
SD – Standard deviation 
Source: Stuss et al. (1988) provide normative data from a sample of healthy relatively well-educated 
adults, ages 16-69 years. 
                                                 
286 Spreen O, Strauss E.  A compendium of neuropsychological tests.  Administration, norms, and 
commentary.  Oxford University Press.  New York,NY. 1998; pp:244. 
287 Spreen O, Strauss E.  A compendium of neuropsychological tests.  Administration, norms, and 
commentary.  Oxford University Press.  New York,NY. 1998. 
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3.4 Data Analysis 
 
The procedures used to analyze data obtained from the sample of patients are 
discussed below.  SPSS version 11.0 and AMOS version 4.0 will be used for all the 
analyses.  All tests of statistical inference will be made at the 0.05 alpha level.  Data 
analysis will include the following: 
1. Descriptive statistics – A description of the sample on all relevant variables will be 
included by generating frequency distribution, means, and standard deviations.  
2. Normality – In order to test for normality, histograms and statistics for skewness 
and kurtosis will be generated.  Appropriate transformations will be applied to variables 
that grossly violate the normality assumption. 
3. Outlier variables will be excluded from the data. 
4. Confirmatory factor analysis/Structural equation modeling will be used to validate 
the measures used in the stages of pain model. 
5. Structural equation modeling will be used to test the hypothesized models. 
 
  Patients will be encouraged to fill all forms thoroughly during the interview data 
to minimize missing data.  Data for patients who do not complete follow-up 
assessments will not be included in the two-wave models.  Data will be screened to 
eliminate coding errors by running frequencies and descriptives for each variable.  
Skewness and kurtosis values for each variable will be examined to verify that data 
meet assumptions of normality.   
3.4.1 Analyses Plan 
 
The proposed study models will be analyzed with causal modeling techniques.  
More specifically, structural equation modeling (SEM), which is a combination of 
factor analysis and path analysis will be used to analyze collected data.  SEM is also 
commonly referred to as covariance structure modeling.   
In order to utilize causal modeling, there must be sufficient confidence in the theory 
being posited.  Prior knowledge serves as a guide to make restrictive assumptions about 
the structure of the data.  Consequently, the objective in SEM is to minimize the 
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difference between the observed covariance matrix and the restricted covariance matrix 
(i.e., the hypothesized model).   
In order to determine whether the operationalized variables of the stages of pain 
model load on the constructs they are purported to measure, a hybrid model testing the 
measurement structure and the relations between latent constructs will be analyzed with 
baseline and follow-up data.  Such an analysis will serve to confirm the measurement 
component and the structural component of the baseline and follow-up stages of pain 
models.    The models may be modified to improve fit to the data.  The evaluation of 
structural equation models are governed by numerous criteria.  A description of some 
of these criteria and how they will be applied in the current study are discussed next. 
 
3.4.2 Goodness of Fit Statistics 
  
The most common test to evaluate model fit to the data is the exact chi-square fit 
test.  The chi-square statistic tests the plausibility of a significant difference between 
the hypothesized model and a just-identified version of that model.  A non-significant 
value of the chi-square statistic (p > 0.05) indicates that fit of the over-identified model 
does not differ from fit of the null model, and the hypothesized model is acceptable.288   
Several fit indices have been developed to assist in evaluation of various aspects of 
model fit.  The Joreskog-Sorbom goodness of fit index can be considered as a parallel 
to the squared multiple correlation.  The index explains the proportion of the sample 
variance-covariance matrix accounted for by the hypothesized model.  The normed fit 
index (NFI) is indicative of the percentage improvement in fit of the hypothesized 
model over the null model. 
The standardized root mean square residual (SRMR) is most sensitive to 
misspecified factor structures while the comparative fit index (CFI), Bollen’s fit index 
(BL89), and root mean square error of approximation (RMSEA) are sensitive to poorly 
specified factor loadings.  In order to adequately assess factor loadings and latent 
                                                 
288 Kline RB.  Principles and practice of structural equation modeling.  The Gulford Press.  New York, NY. 
1998.  
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structure of the current model the following goodness of fit indices will be evaluated: 
SRMR, CFI, RMSEA.289   
Based on the fit indices, procedures such as removal of poorly loading items or 
measurement of parameters constrained to be zero may be employed.  For the purpose 
of this analysis, operationalized variables with item loadings that are not significant (p 
> 0.05) will be eliminated.   
Every model includes three types of variables, i.e., exogenous variables, 
endogenous variables, and disturbance terms, which account for error not accounted 
for by variables in the model.  A system of linear equations is used to simultaneously 
examine the association between several exogenous and endogenous variables.  These 
associations are modeled in the form of path diagrams, which enable a visual 
conceptualization of the postulated theory.290   These techniques encompass path 
analysis and structural equation modeling.    The path coefficients estimated are 
interpreted as regression coefficients in a multiple regression analysis.  Maximum 
likelihood estimation procedures will be used to estimate path coefficients for the 
proposed model. 
Causal modeling does not provide any information about the direction of the 
relationship between two variables (X & Y) or that one variable causes another except 
under the following restrictive conditions: 
• X and Y should covary; 
• The variables should exhibit some temporal order; 
• Elimination of confounders (believed to precede X & Y) should not alter the 
relationship between X and Y.291 
 
 
 
                                                 
289 Hu L, Bentler PM.  Fit indices in covariance structure modeling: sensitivity to underparametrized model 
misspecification.  Psychological Methods.  1998;3:424-453. 
290 Byrne B.  Structural equation modeling with EQA and EQS/Windows.  Basic concepts, applications, 
and programming.  Sage  Publications.  Thousand Oaks, CA.  1994. 
291 Asher HB.  Causal modeling, Sage University paper series on quantitative applications in the social 
sciences 07-003.  Newberry Park, Sage Publications, 11, 1983. 
  
 143
 
3.4.3 Advantages of Causal Modeling and Path Analysis292: 
  
There are numerous advantages of path analysis over multiple regression 
techniques. Some advantages of path analysis include: 
• Ability to separate the direct effects from the indirect effects of one variable on 
another variable. 
o Comparisons between the magnitudes of the direct and indirect effects can 
be drawn. 
• The correlation between any two variables can be split into simple and compound 
paths, which can be summated to provide the total correlation 
o A compound path can be calculated by multiplying the simple paths that 
form the compound path. 
• A comparison between observed variance-covariance matrix and that estimated 
from simple and compound paths can be used to determine the adequacy of model 
fit, i.e., goodness of fit testing. 
o Paths that have been omitted in the original model and are assumed to be 
zero can be tested by re-estimating the model with the path in question. 
• Ability to manipulate empirical data within a theoretical context. 
 
 
 
 
                                                 
292 Pedhazur EJ.  Causal Analysis, In Multiple regression in behavioral research.  CBS College Publishing.  
New York, NY. 1982.   
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The equations listed in Table 3.4 represent direct paths in the two-wave model with 
digit span test as dependent variable (Figure 2.3).  Similar equations for models in 
Figure 2.4 and 2.5 will be estimated from the data as well. 
 
Model Equations 
 
PUB =  G + PI + DPUB 
                                
PUF =  G + PIF  + PUB + DPUF 
 
PSB =  A + E + PUB + DPSB 
                     
PSF = A + E + PUF  + VED + PSB + DPSF 
                      
PBB = A + E + PSB + DPBB 
 
PBF = A + E + PSF + PBB + DPBF 
                            
VED = PSB + DVED 
 
MEDB = PIB + DMEDB 
 
MEDF = MEDB + DMEDF 
 
PIF =  PIB + MEDF  -   MEDB + DPIF 
 
DSTB  = A + PSB + PBB + MEDB + VED + PIB + DDSTB      
                    
DSTF  = PSF + PBF  + MEDF + VED +  PIF + DSTB + DDSTF    
 
A – Age, G – Gender, E – Ethnicity/Race, PI-Pain Intensity, PU-Pain 
Unpleasantness, PS-Pain Suffering, PB-Pain Behaviors, MED, Morphine 
Equivalent Dose, VED-Valium Equivalent Dose, DST-Digit Span Test, 
B-Baseline, F-Follow-up, D - Disturbance term associated with the latent 
variable 
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Chapter 4: Results 
 
 This results chapter can be summarized broadly under five sections.  Concerns 
about the integrity of the data are addressed in the first section.  This is followed by an 
overview of the demographic characteristics of the sample included in the study.  
Descriptive statistics for key variables that were assessed during the data collection phase 
are presented in section three.    The final two sections present the confirmatory factor 
analysis procedure used to determine the study models and test hypothesis that were 
postulated. 
 
4.1 Data Screening 
 
  A total of 129 patients were enrolled in the study.   Baseline and follow-up 
data were obtained on 88 of these patients.  The collected data were entered into 
a computer file.  Accuracy of data input and coding were verified by cross 
checking entries in the computer file with data collection sheets.   Item 
frequencies, and minimum and maximum scores were examined to determine 
that values were in specified ranges.  SPSS 12.0 statistical software was 
employed to conduct exploratory data analysis.  
 
4.1.1 Missing Data 
 
  Patterns of missing data may either be random or systematic.  Systematic 
missing data cannot be subjected to statistical corrections and pose greater 
problems than observations missing at random.293   
  Complete observations were obtained for all variables except the Paced 
auditory serial addition test administered at a presentation rate of 2.4 and 2.0 
seconds (PASAT 2.4 and 2.0).  A total of eight patients did not complete the 
                                                 
293 Kline RB.  Principles and practice of structural equation modeling.  The Gulford Press.  New York, NY. 
1998.  
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PASAT.  Of these, three were lost to follow-up and three experienced side-
effects.  An additional two patients who completed both baseline and follow-up 
data for all other variables excluding the PASAT were excluded from models 
evaluating the PASAT as the dependent variable.  Since there patients were 
included in models assessing the DST and DSYT as dependent variables 
(referred to as DST and DSYT models), the sample size in every model with 
PASAT as dependent variable (referred to as PASAT model) evaluated at 
baseline and follow-up included two fewer patients. 
 
4.1.2 Outliers 
 
Data were explored for univariate outliers.  Outliers and extreme values can 
significantly affect the distribution of the data.  Boxplots and standardized z-
scores were used to identify extreme values.  Tabachnik and Fidell suggest that 
cases with z-scores of │3│or greater should be excluded from the dataset.294 
Results from the exploratory analyses of baseline data identified three 
individuals whose short-acting narcotic analgesic morphine equivalent dose 
(MED) and one individual whose Valium equivalent dose (VED) exceeded the z-
score threshold of │3│.  One additional case had a morphine equivalent dose z-
score value at follow-up that exceeded the above threshold.   
Out of 129 patients who were enrolled, 30 experienced side-effects and 11 
were lost to follow-up (see Table 4.1).  Eighty-eight patients completed baseline 
and follow-up evaluations.  Four of the five patients with extreme values had 
completed both follow-ups.  Their elimination resulted in a usable sample size of 
84 patients.  An additional two patients who had baseline and follow-up data 
failed to complete the PASAT.  Thus, the sample size of patients in the PASAT 
model was 82.  Models with the digit span test and the digit symbol test as 
dependent variables included data from 84 patients.  PASAT models included 
data from 82 patients. 
                                                 
294 Tabachnick BG, Fidel LS. Using Multivariate Statistics (pp: 67). HarperCollins. New York, NY. 1996.  
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Table 4.1 – All Reasons for Subject Loss and Sample Size of Patients in 
the DSTa, DSYTb, and PASATc Models  
 n  (%) 
 
Patients enrolled in study (Total) 
 
Dropouts due to side-effects 
Dropouts due to side-effects & incomplete PASATa 
Dropouts due to side-effects & outlier Value 
 
Patients lost to follow-up 
Patients lost to follow-up & incomplete PASATa 
 
Patients who completed study (one-month follow-up) 
 
129  
 
26 
3 
1 
 
8 
3 
 
88 
 
(100.0) 
 
(20.2) 
(2.3) 
(0.8) 
 
(6.2) 
(2.3) 
 
(68.2) 
Patients who completed study (Total) 
Patients who completed study & outlier value 
DST & DSYT model sample size 
88 
4 
84  
(100.0) 
(4.5) 
(95.5) 
Patients who completed study (Total) 
Patients who completed study & outlier value 
Patients who completed study & incomplete PASAT 
PASAT model sample size 
88 
4 
2 
82 
(100.0) 
(4.5) 
(2.3) 
(93.2) 
 a DST – Digit Span Test   
b DSYT – Digit Symbol Test 
c PASAT – Paced Auditory Serial Addition Test 
 
4.1.3 Normality 
 
The maximum likelihood procedure for making unbiased parameter estimates 
in structural equation modeling assumes multivariate normality.   Univariate 
normality was assessed by means of histograms and skewness and kurtosis 
values.  Several Monte Carlo simulations have concluded that absolute values 
greater than│3│represent extremely high skew and values greater 
than│8│represent extreme kurtosis.295,296     
                                                 
295 Chou CO, Bentler PM .  Estimates and tests in structural equation modeling.  In Hoyle RH, Structural 
Equation Modeling (pp 37-55).  Thousand Oaks, CA:Sage. 1995. 
296 West SG, Finch JF, Curran PJ.  Structural equation models with non-normal variables: problems and 
remedies.  Estimates and tests in structural equation modeling.  In Hoyle RH, Structural Equation Modeling 
(pp 56-75).  Thousand Oaks, CA:Sage.  1995 
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All the modeled variables except MED at baseline (MEDB) and follow-up 
(MEDF) met the above criteria.  After excluding the outlier cases, skewness 
values for MEDB  and MEDF were 3.27 and 3.97 respectively.  The kurtosis 
values for morphine equivalent dose at baseline and follow-up were 11.08 and 
18.63 respectively.  Therefore, a log transformation was performed for MEDB 
and MEDF  values.  The skew (1.00, 0.46) and kurtosis (1.19,1.34) values for 
natural log transformations of MEDB and MEDF were well within the acceptable 
range.   
Calculated variances for variables hypothesized to be part of the model are 
presented in Table 4.2.    Bolded figures represent variances with large 
magnitudes.  According to Kline, large differences (≥10) in the magnitude of 
variances of modeled variables can lead to failure of the maximum likelihood 
iterative process.297  Additionally, the small sample size in this study may 
contribute to the failure in the iterative process.  In order to minimize the extent 
to which variances for variables being modeled differed and improve the 
possibility of model convergence, baseline and follow-up scores for the following 
variables were also transformed to their natural log values: VED, PASAT 2.0 and 
2.4, and digit symbol tests.   
 
 
 
 
 
 
 
                                                 
297 Kline RB.  Principles and Practice of  Structural Equation Modeling.  1998.  The Guilford Press.  New 
York, NY. 
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Table 4.2 Variance Estimates of Indicators Included in the Hypothesized 
Study Model for Data obtained from Evaluable Patients at Baseline and 
Follow-up 
Variance Construct Indicator 
Baseline Follow-
up 
PI – Usual level 5.3 9.0 
PI – Highest level 2.9 8.2 
Pain Intensity (PI) 
PI – Lowest level 10.8 8.2 
PU – Usual level 10.33 12.1 
PU – Highest level 4.5 10.2 
Pain Unpleasantness 
(PU) 
PU – Lowest level 19.6 12.6 
Interference due to pain 6.5 9.9 
Ability to endure pain 9.5 13.6 
Ability to control pain 12.7 10.5 
Pain Suffering (PS) – 
Negative beliefs 
Belief that pain will be cured 17.4 16.8 
Depression 20.4 18.5 
Anxiety 19.1 16.8 
Frustration 11.3 15.3 
Anger 25.6 20.9 
Pan Suffering (PS) – 
Negative emotions 
Fear 24.2 19.3 
Pain behavior at home 0.91 0.80 
Home and family related 
responsibilities 1.0 0.84 
Pain contingent down time 1.2 1.0 
Social reinforcement of PB 0.49 0.47 
Pain Behaviors (PB) 
PB during interview 1.1 1.3 
MEDa Morphine equivalent dose  3291.9 3375.3 
VED Valium equivalent dose 117.3 147.5 
DSYT Digit symbol test score 267.5 268.6 
PASAT 2.4 score 84.4 83.2 PASATb 
PASAT 2.0 score 88.9 81.4 
DST Digits span test - forward Score 4.8 5.4 
 Digits span test - backward Score 3.5 4.6 
Numbers in bold indicate variances with large magnitudes that may hinder the maximum-
likelihood iterative process 
a MED baseline – Total short acting morphine equivalent dose at baseline Med Follow-up – 
Sum of Avinza dose and total short-acting narcotic analgesic dose used for breakthrough pain 
b PASAT – Paced Auditory Serial Addition Test 
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4.2 Sample Description 
 
 A total of 129 patients were enrolled in this study.  Eighty-eight (68.2%) 
patients completed the one-month follow-up.  The proportions of patients who 
completed the study versus those who dropped out due to adverse events 
associated with Avinza® are provided in Table 4.3 below:  
 
Table 4.3 – Number and Proportion of Patients who Completed the 
Study, Dropped Out, and Failed to Follow-up 
 n  (%) 
 
Patients enrolled in study (Total) 
Patients who dropped out due to side-effects 
Patients lost to follow-up 
Patients who completed study (one-month follow-up) 
 
129 
30  
11 
88  
    
(100.0) 
(23.3) 
(8.5)      
(68.2)  
 
 
As described in the data screening section, usable data were obtained from 
124 patients at baseline, after excluding outliers.   Complete data were obtained 
from 84 patients (i.e., patients who provided both baseline and follow-up data 
after excluding outliers).  Patients who provided complete baseline and follow-
up data (n = 84) were categorized as evaluable patients.  Patients who dropped 
out of the study or were lost to follow-up (n = 40), after excluding outliers were 
categorized as non-evaluable patients. 
 
4.2.1 Adverse Events 
 
Table 4.4 presents the frequency of adverse events or reasons provided by 
patients who dropped out of the study.  The most common reasons for dropping 
out of the study were drowsiness (n = 14), fatigue (n = 8), allergies to morphine 
(n = 6), itching (n = 6), nausea (n = 5), confusion (n =4), inadequate pain control 
(n = 2), shortness of breath (n = 2), and rashes (n =2).  Several patients (n = 17) 
cited two adverse events or reasons for dropping out of the study.  Ten patients 
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cited one adverse event or reason and three patients cited three adverse events or 
reasons for dropping out of the study. 
 
 
Table 4.4 – Total Counts of Each Adverse Event or Reason 
Provided by Patients who Dropped Out of the Study (N =30)  
Adverse Event n (%) 
Drowsiness 
Fatigue 
Allergic to Morphine 
Itching 
Nausea 
Confusion 
Inadequate Pain Control 
Shortness of breath 
Rash 
Constipation 
Headaches 
Vomiting 
Dizziness 
                              Total 
14  
8  
6  
6  
   5  
   4  
   2  
   2  
   2  
   1  
   1  
   1  
   1  
  53  
(26.4) 
(15.1) 
(11.3) 
(11.3) 
(9.4) 
(7.5) 
(3.8) 
(3.8) 
(3.8) 
(1.9) 
(1.9) 
(1.9) 
(1.9) 
(100.0) 
*Total does not equal 100 due to rounding error 
 
4.2.2 Demographic Characteristics 
 
Table 4.5 presents the distribution of enrolled, evaluable and non-evaluable 
patients by age, gender, ethnicity, and education level.   The average age of 
patients enrolled in the study was 46 years.  Results from a t-test (t = -0.27, df = 
122, p = 0.78) showed that the mean age of evaluable patients (46.6 years) did 
not differ significantly from that of non-evaluable patients (47.0 years).  
Additional t-test results (t = -0.48, df = 122, p = 0.62) showed that there was no 
statistically significant difference between the average age of males (47.2 years) 
and females (46.4 years) enrolled in the study. 
A greater number of females (n = 74) than males (n = 50) were enrolled in the  
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study.  Results from a chi-square test (chi-square = 7.79, df = 1, p = 0.005) showed 
that the proportion of females who did not complete the study (n = 31, 77.5%) was 
significantly greater those who did (n = 43, 51.2%).    
A majority of enrolled patients (n = 76, 63.1%) were Caucasian.  The sample of 
enrolled patients also consisted of the following ethnic groups:  African-American (n 
= 25, 20.2%), Hispanic/Latin American (n = 12, 9.7%), American Indian (n =2, 
1.6%), Asian (n = 4, 3.2%), and other (n = 5, 4.0%).  Results from a chi-square test 
(chi-square = 1.51, df = 5, p = 0.91) showed no statistically significant difference in 
the ethnic composition of evaluable and non-evaluable patients.  
The distribution of the highest level of education achieved by patients enrolled in 
the study was as follows:  less than high school (n = 7, 5.6%) high school graduate (n 
= 41, 33.1%), some trade school or some college (n = 48, 38.7%), trade school or 
college graduate (n = 20, 16.1%), some graduate school (n = 4, 3.2%), graduate 
school (n = 4, 3.2%).  %).  Results from a chi-square test (chi-square = 2.38, df = 5, p 
= 0.79) showed no statistically significant difference between the education level of 
patients in the evaluable and non-evaluable groups.  
A comparison of evaluable and non-evaluable patients by demographic 
characteristics showed that significantly more females dropped out of the study as 
compared to males.  The results showed no significant differences between the two 
groups with respect to age, ethnicity, and education level. 
 
 
 
 
 
 
 
 
 
  
 153
Table 4.5 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Patients by Demographic Characteristics: Age, Gender, Race/Ethnicity, 
and Education Level 
Enrolled 
Patientsa  
Evaluable 
Patientsb 
Non-Evaluable 
Patientsc 
Variable 
n % n % n %
Age (years)  
 18 – 29 
 30 – 39 
 40 – 49 
 50 – 59  
 60 – 69  
 Total 
 Mean 
SD 
Range 
3 
20 
56 
35 
 10 
 124 
46.7  
9.1
19 - 68
 
(2.4)
(16.1)
(45.2)
(28.2)
(8.1)
(100.0)
1 
13 
39 
27 
    4 
  84 
  46.6
8.6 
19 - 65
 
(1.2)
(15.5)
(46.4)
(32.1)
(4.8)
(100.0)
2  
7  
17  
8  
    6  
  40  
  47.0 
10.2 
27 - 68 
 
(1.2)
(15.5)
(46.4)
(32.1)
(4.8)
(100.0)
Gender  
Female 
Male 
Total 
74 
50 
    124 
(59.7)
(40.3)
(100.0)
74 
50 
    124
   
(48.8)
(51.2)
(100.0)
 
31 
9 
40 
(77.5)
(22.5)
(100.0)
Race/Ethnicity  
Caucasian 
African-American 
Hispanic/Latin American 
American Indian 
Asian 
Other 
Total 
76 
25 
    12
2
4
5
124 
(61.3)
(20.2)
(9.7)
(1.6)
(3.2)
(4.0)
(100.0)
53
16
8
1
2
4
84
   
(63.1)
(19.0)
(9.5)
(1.2)
(2.4)
(4.8)
(100.0)
 
23 
9 
4 
1 
2 
1 
40 
(57.5)
(22.5)
(10.0)
(2.5)
(5.0)
(2.5)
(100.0)
Highest Level of 
Education 
Less then high school 
High school graduate 
Some trade school/college    
Trade school/college  
graduate 
Some graduate school 
Graduate school 
 Total 
7 
41 
    48
20
4
4
124 
(5.6)
(33.1)
(38.7)
(16.1)
(3.2)
(3.2)
(99.9*)
6
27
30
15
3
3
84
 
   
(7.1)
(32.1)
(35.7)
(17.9)
(3.6)
(3.6)
(100.0)
 
 
1 
14 
18 
5 
 
1 
1 
40 
(2.5)
(35.0)
(45.0)
(12.5)
(2.5)
(2.5)
(100.0)
* Total does not equal 100 due to rounding error 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
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4.2.3 Duration of Chronic Non-Malignant Pain 
 
Table 4.6 presents results on the distribution of patients by duration of pain.  
During the interview, patients were asked to state the amount of time (months or 
years) they had experienced the pain that was being treated (Appendix D).  The 
mean duration of pain was 5.35 years.   A majority (n = 72, 58.1%) of the 
enrolled patients had experienced pain for a duration of one to five years.  A total 
of 38 patients (30.6%) had experienced pain for more than five years, and only 
14 patients (11.3%) had experienced pain for less than one year.  Results from a 
t-test (t = 0.62, df = 122, p = 0.53) showed no statisitical difference in the mean 
duration of pain between evaluable and non-evaluable patients. 
 
Table 4.6 - Distribution of Sample by Duration of Pain  for Enrolled, 
Evaluable, and Non-Evaluable Patients 
Enrolled Patientsa Evaluable 
Patientsb 
Non-Evaluable 
Patientsc 
Duration of Pain 
(years) 
 n % n % n %
Less than one  
≥ One and ≤ Five 
> Five  
Total 
Mean 
SD 
Range 
14
72
38 
 124 
 5.3
  5.4
0.25 - 25
(11.3)
(58.1)
(30.6)
 (100.0)
7 
50 
27 
  84 
  5.5
5.7 
0.25 - 25
(8.3)
(59.5)
(32.1)
(99.9*)
7 
22 
11 
40 
4.9 
4.9 
0.25 - 20 
(17.5)
(55.0)
(27.5)
(100.0)
* Total does not equal 100 due to rounding error 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
 
4.2.4 Payment Source 
 
Table 4.7 presents the distribution of results for enrolled, evaluable, and non-
evaluable patients by payment source.  Data on payment source were obtained 
through information recorded in patient charts.  A total of 42.7 percent (n = 53) 
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of enrolled patients received medical and prescription benefits through worker’s 
compensation.  Other payment sources included HMOs (n = 17, 13.7%), PPOs (n 
= 22, 17.7%), Medicare (n = 6, 4.8%), MediCal (n = 8, 6.5%), Medicare and 
MediCal ( n =12, 9.7%).  Results from a chi-square comparison (chi-square = 
5.15, df = 7, p = 0.6) showed that the two groups did not differ statistically by 
payment source. 
 
Table 4.7 - Distribution of Sample by Payment Source  for Enrolled, 
Evaluable, and Non-Evaluable Patients 
Enrolled 
Patientsa  
Evaluable 
Patientsb 
Non-Evaluable 
Patientsc 
Payment Source 
 
n % n % n %
Worker's 
Compensation 
HMO 
PPO 
Medicare 
MediCal 
Medicare/MediCal 
Cash 
Indemnity  
Total 
         
53
17
22
6
8
12
3
3
124
 
(42.7)
(13.7)
(17.7)
(4.8)
(6.5)
(9.7)
(2.4)
(2.4)
 (100.0)
33
12
17
4
5
9
1
3
84
(39.3)
(14.3)
(20.2)
(4.8)
(6.0)
(10.7)
(1.2)
(3.6)
(100.1*)
20 
 
5 
5 
2 
3 
3 
2 
0 
40 
(50.0)
(12.5)
(12.5)
(5.0)
(7.5)
(7.5)
(5.0)
(0.0)
 (100.0)
* Total does not equal 100 due to rounding error 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
4.2.5 Diagnoses 
 
The data in Table 4.8 show that patients with a variety of diagnoses were 
included in the study.  The total count of the top five most frequently occurring 
diagnoses among evaluable patients was as follows: lumbar spondylosis (51, 
16.6%), lumbar disc disorder (47, 15.3%), radiculopathy (36, 11.7%), cervical 
spondylosis (27, 8.8%), and back pain (19, 6.2%).  The total count of the top five 
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most frequently occurring diagnoses among non-evaluable patients was as 
follows: lumbar spondylosis (23, 17.4%), lumbar disc disorder (21, 15.9%), 
radiculopathy (18, 13.6%), cervical Spondylosis (10, 7.6%), and back pain (9, 
6.8%). 
The average number of diagnoses per individual was 3.6 and 3.3 in the 
evaluable and non-evaluable groups respectively.   An eyeball comparison 
suggested that the rate at which the top five diagnoses occurred in the evaluable 
and non-evaluable groups were similar. 
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Table 4.8 Total Count of Each Diagnosis for which Evaluable (N = 84) and Non-
Evaluable (N = 40) Patients were Treated at the Study Site 
Diagnoses Evaluablea 
 n       (%) 
Non-Evaluableb
     n        (%) 
Lumbar Spondylosis 
Lumbar Disc Disorder 
Radiculopathy 
Cervical Spondylosis 
Back Pain 
Cervical Radiculopathy 
Disc Disorder Cervical Region 
Spinal Lumbar Degenerative Disc Disorder 
Post Lumbar Laminectomy Syndrome 
Disc Disorder Thoracic Region 
Spinal Stenosis 
Reflex Sympathetic Dystrophy Syndrome 
(RSD) 
Chronic Low Back Pain 
Neck Pain 
Cervical Pain 
Foot Pain 
Shoulder Pain 
Chest Wall Pain 
Fibromyalgia 
Herniated Disc Lumbar 
Hip Degenerative Joint Disease (DJD) 
Hip Pain 
Lumbar Sacral Spondylosis 
Osteoarthritis 
Post Laminectomy Syndrome Cervical Region 
Thoracic Spondylosis 
Wrist/Carpal Tunnel Syndrome 
Extremity Pain 
Hemarthrosis - Ankle 
Intravertebral Herniation 
Lumbar Compression Fracture 
Lumbar Vertebral Syndrome 
Migraine Headache 
Osteomyelitis 
Plantar Fascitis 
Rheumatoid Arthritis 
51    (16.6) 
47    (15.3) 
36    (11.7) 
27     (8.8) 
19     (6.2) 
15     (4.9) 
15     (4.9) 
10     (3.2) 
  9     (2.9) 
  7     (2.3) 
  7     (2.3) 
  6     (1.9) 
  5     (1.6) 
  5     (1.6) 
  4     (1.3) 
  4     (1.3) 
  4     (1.3) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  2     (0.6) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
  1     (0.3) 
23    (17.4) 
21    (15.9) 
18    (13.6) 
10      (7.6) 
  9      (6.8) 
  5      (3.8) 
  4      (3.0) 
  1      (0.8) 
  4      (3.0) 
  1      (0.8) 
  4      (3.0) 
  3      (2.3) 
  1      (0.8) 
  3      (2.3) 
  4      (3.0) 
  0      (0.0) 
  3      (2.3) 
  1      (0.8) 
  0      (0.0) 
  2      (1.5) 
  2      (1.5) 
  2      (1.5) 
  2      (1.5) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  2      (1.5) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
  0      (0.0) 
Total number of diagnosis exceeds 124 as each patient may have multiple diagnoses. 
aAll patients who completed baseline and follow-up assessments excluding outliers 
bAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
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Table 4.8 (Continued)  Total Count of Each Diagnosis for which Evaluable (N = 
84) and Non-Evaluable(N = 40) Patients were Treated at the Study Site 
Diagnoses Evaluablea 
n (%) 
Non-Evaluableb 
n (%) 
Sacroiliac Pain 
Sciatica Pain 
Shoulder Strain 
Spinal Lumbar Fracture 
Spinal Thoracic Degenerative Disease 
Spondylopathy Unspecified 
Thoracic Pain 
Vertebral Compression Fracture 
Abdominal Pain 
Deep Vein Thrombosis 
Edema 
Trigeminal Neuralgia 
Total 
1    (0.3) 
1    (0.3) 
1    (0.3) 
1    (0.3) 
1    (0.3) 
1    (0.3) 
1    (0.3) 
0    (0.0) 
0    (0.0) 
0    (0.0) 
     0    (0.0) 
0    (0.0) 
308 (100.0) 
1     (0.8) 
0     (0.0) 
0     (0.0) 
0     (0.0) 
0     (0.0) 
1     (0.8) 
0     (0.0) 
1     (0.8) 
1     (0.8) 
1     (0.8) 
1     (0.8) 
1     (0.8) 
132 (100.0) 
Total number of diagnosis exceeds 124 as each patient may have multiple diagnoses. 
aAll patients who completed baseline and follow-up assessments excluding outliers 
bAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
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4.3 Results of Key Model Variables 
 
This section of the results chapter provides descriptive statistics for the key 
variables examined in the structural equation models.  A brief description explaining 
the measurement technique for the variable will also be included. 
 
4.3.1 Morphine Equivalent Dose (MED) 
 
Patients enrolled in the study used a variety of short-acting narcotic analgesic 
medications.  The dose of the narcotic medication used by enrolled patients was 
converted to a standard morphine milligram equivalent unit, which was labeled 
as morphine equivalent dose for the purposes of this study.  The conversion 
criteria applied to convert the short-acting narcotic analgesic doses to standard 
morphine equivalent units can be viewed in Table 1.1 (page 26). 
During the interview at baseline, patients were asked to provide the names 
and doses of prescription narcotic analgesic medications that they used to obtain 
pain relief.  Patients were asked to recall the average number of narcotic 
analgesic doses taken per day in the previous week to obtain pain relief.  The 
average daily short-acting narcotic analgesic dose used by the patient was 
calculated by multiplying the strength of the medications used with the number 
of doses.  This average daily short-acting narcotic analgesic dose was converted 
to a morphine equivalent dose.  
A similar procedure was utilized at follow-up.  The average daily morphine 
equivalent dose at follow-up for each patient was calculated by adding the 
average daily Avinza® dose and the average daily short-acting narcotic dose used 
for breakthrough pain.  Dose calculation for Avinza®, which is  a long-acting 
morphine agent, did not require conversion to morphine equivalent units.  The 
average daily dose of short-acting breakthrough pain medication at follow-up 
was calculated in a similar fashion to the short-acting narcotic analgesic 
morphine equivalent dose at baseline.  Thus, the total narcotic analgesic dose at 
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follow-up was calculated as the sum of the Avinza® dose and the morphine 
equivalent dose (MED) of breakthrough pain medication at follow-up. 
Table 4.9 presents the distribution of patients by brand name of primary 
short-acting narcotic analgesic used at baseline. A majority of enrolled patients 
(67.0%, n = 83) used various combinations of the short acting narcotic 
hydrocodone in combination with acetaminophen [ Vicodin® (n = 27), Vicodin 
ES® (n = 26), Norco® (n = 22), and Lortab® (n = 8)].  Other short-acting narcotic 
analgesics commonly used by enrolled patients included methadone (10.5%, n  = 
13), Ultram® (7.2%, n = 9), Darvocet® (5.6%, n = 7). and Tylenol #4® (2.4%, n = 
3).  Tylenol #3®, morphine sulfate immediate release (MSIR), Actiq®, and 
Oxycodone® were used by two patients each. 
Three categories of primary short-acting narcotic analgesic brands were 
created to assess differences in their use between evaluable and non-evaluable 
patients.  One category of brands included all drugs in which the active 
ingredients were hydrocodone and acetaminophen.  The second category of 
brands included drugs with methadone as the active ingredient, while the third 
category was an amalgam of brands with all other active ingredients.  Results 
from a chi-square test (chi-square = 9.38 df = 2,  p = 0.01) showed that there was 
a significant difference among  primary narcotic analgesics used by evaluable 
and non-evaluable patients.  The proportion of evaluable patients (72.6%) who 
utilized medications with hydrocodone/acetaminophen as active ingredients was 
higher than non-evaluable patients (55.0%).  As compared to evaluable patients 
(4.8%), the proportion of patients in the non-evaluable group (22.5%) who used 
methadone was greater.  The proportion of patients who utilized “other” brand 
names in each of the groups was similar (22.6% and 22.5%).  
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Table 4.9 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Patients by Brand of Primary  Short-Acting Narcotic Analgesic Used to 
Treat Pain at Baseline 
 
Narcotic Analgesic Brand 
Name 
 
Enrolled 
Patientsc  
    n      (%) 
Evaluable 
Patientsd 
  n      (%) 
Non-Evaluable 
Patientse 
   n       (%) 
Tylenol® #3 
Tylenol® #4 
Vicodin® 5/500 
Vicodin ES®,a 7.5/750mg 
Norco® 10/325mg 
Lortab® 10/500mg 
Ultram® 50mg                
Methadone  10mg 
MSIRb  15mg 
Actiq®  200ug 
Percodan 5mg 
Oxycodone®  5mg 
Darvocet® /Propoxyphene  
100mg 
Total 
    2     (1.6) 
    3     (2.4) 
  27   (21.8) 
  26   (21.0) 
  22   (17.7) 
    8     (6.5) 
    9     (7.2) 
  13   (10.5) 
    2     (1.6) 
    2     (1.6) 
    1     (0.8) 
    2     (1.6) 
    7     (5.6) 
 
124   (99.9*) 
  2     (2.4) 
  3     (3.6) 
20   (23.8) 
20   (23.8) 
15   (17.9) 
  6     (7.1) 
  5     (6.0) 
  4     (4.8) 
  1     (1.2) 
  2     (2.4) 
  0     (0.0) 
  2     (2.4) 
  4     (4.8) 
 
84  (100.2*) 
   0      (0.0) 
   0      (0.0) 
   7    (17.5) 
   6    (15.0) 
   7    (17.5) 
   2      (5.0) 
   4    (10.0) 
   9    (22.5) 
   1      (2.5) 
   0      (0.0) 
   1      (2.5) 
   0      (0.0) 
   3      (7.5) 
 
 40   (100.0) 
* Total does not equal 100 due to rounding error 
aES – Extra Srength 
bMSIR – Morphine Sulfate Immediate Release 
cAll patients enrolled in the study at baseline excluding outliers 
dAll patients who completed baseline and follow-up assessments excluding outliers 
eAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
 
Table 4.10 presents the distribution of enrolled, evaluable, and non-evaluable 
patients who used a second short-acting narcotic analgesic at baseline.  A total of 
12 patients (9.6%) used a second narcotic analgesic medication at enrollment.  
Among enrolled patients, five patients used Norco, two patients used Ultram, and 
one patient each used Vicodin, Vicodin ES, MSIR, Percocet, and Darvocet as a 
secondary narcotic analgesic.  A similar proportion of patients in the evaluable 
(92.0%) and non-evaluable groups (87.5%) did not utilize a secondary narcotic 
analgesic. 
 
 
 
  
 162
 
Table 4.10 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Patients by Brand of  Secondary Short-Acting Narcotic Analgesic Used to 
Treat Pain at Baseline 
 
Narcotic Analgesic Brand 
Name 
 
Enrolled 
Patientsc  
    n        (%) 
Evaluable 
Patientsd 
   n       (%) 
Non-Evaluable 
Patientse 
     n        (%) 
Vicodin® 5/500 
Vicodin ES®,a 7.5/750mg 
Norco® 10/325mg 
Ultram® 50mg                
MSIRb 15mg  
Percocet® 
Darvocet® /Propoxyphene  
100mg 
Patients not on 2nd analgesic 
Total 
    1       (0.8) 
    1       (0.8) 
    5       (4.0) 
    2       (1.6) 
    1       (0.8) 
    1       (0.8) 
    1       (0.8) 
 
112     (90.3) 
124   (100.0) 
   0      (0.0) 
   0      (0.0) 
   3      (3.6) 
   1      (1.1) 
   1      (1.1) 
   1      (1.1) 
   1      (1.1) 
 
 77    (91.7) 
 84  (100.0) 
     1       (2.5) 
     1       (2.5) 
     2       (5.0) 
     1       (2.5) 
     0       (0.0) 
     0       (0.0) 
     0       (0.0) 
 
   35     (87.5) 
   40   (100.0) 
aES – Extra Strength 
bMSIR – Morphine Sulfate Immediate Release 
cAll patients enrolled in the study at baseline excluding outliers 
dAll patients who completed baseline and follow-up assessments excluding outliers 
eAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
Table 4.11 presents the distribution of enrolled, evaluable, and non-evaluable 
patients by average daily morphine equivalent dose of short-acting narcotic analgesic 
at baseline.   The categories were formed to correspond with the most commonly 
available Avinza dosage units (30mg, 60mg, 90mg and 120mg).  A total of 40.3 
percent (n = 50) of enrolled patients took an average daily MED that was less than or 
equal to 30 morphine milligram equivalents at baseline.  Another 33.9 percent (n = 
42) of enrolled patients used an average daily MED of short-acting narcotics that 
ranged from 30.1 to 60 morphine milligram equivalents.  A total of 18 enrolled 
patients (14.5%) used an average daily MED that ranged from 60.1 to 120 morphine 
milligram equivalents.   A total of 14 patients (11.3%) used an average daily MED 
that was greater than 120 morphine milligram equivalents.  The number of non-
evaluable patients (n = 9, 22.5%) who utilized a MED of short-acting narcotic 
analgesic at baseline that was greater than 180 mg was twice the number of evaluable 
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patients (n = 4, 4.8%).  The average daily morphine equivalent short-acting narcotic 
analgesic dose utilized by enrolled patients at baseline was 76.56mg. 
Results from an independent samples t-test (t = -3.64, df = 122, p < 0 .01) showed 
that the average daily MED taken by evaluable patients (mean MED = 52.3, sd = 
57.3) was significantly lower than the average daily MED of short-acting narcotic 
analgesics taken by non-evaluable patients (mean MED  = 128.9, sd = 175.1) at 
baseline. 
 
Table 4.11 Distribution of Enrolled, Evaluable, and Non-Evaluable Patients 
by Average Daily Morphine Equivalent Dose (MED) of Short-Acting 
Narcotic Analgesic at Baseline 
 
MED (mg) Enrolled Patientsa  
       n        (%) 
Evaluable Patientsb 
     n         (%) 
Non-Evaluable 
Patientsc 
     n         (%) 
0 to 30 
30.1 to 60 
60.1 to 90 
90.1 to 120 
120.1 to 180 
> 180 
Total 
Mean  
SD 
Range 
      50     (40.3) 
      42     (33.9) 
      13     (10.5) 
        5       (4.0) 
        1       (0.8) 
      13     (10.5) 
    124   (100.0) 
 76.5 
115.1 
5 to 675 
    38      (45.2) 
    32      (38.1) 
      7        (8.3) 
      2        (2.4) 
      1        (1.2) 
      4        (4.8) 
    84    (100.0) 
52.3 
57.3 
10 to 400 
    12      (30.0) 
    10      (25.0) 
      6      (15.0) 
      3        (7.5) 
      0        (0.0) 
      9      (22.5) 
    40    (100.0) 
128.9 
175.1 
5 to 675 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding 
outliers 
 
 
Table 4.12 presents the distribution of evaluable patients by average daily MED 
at follow-up.  The table provides the distributions for average daily Avinza dose, 
MED of short acting narcotic breakthrough pain medication, and MED of total 
narcotic analgesic, which was calculated as the sum of Avinza and breakthrough pain 
medication doses.   
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A total of 37 patients (44.1%) used an average daily Avinza dose that was less 
than or equal to 30mg, while 68 patients (81%) used an average daily breakthrough 
pain medication dose that was less than or equal to 30mg units of morphine.  Only 5 
patients used a total narcotic dose that was less than or equal to 30mg units of 
morphine at follow-up. 
A total of 33 patients (39.3%) utilized an average daily Avinza dose that ranged 
between 30.1mg and 60mg.  A total of 11 (13.1%) patients utilized an average daily 
Avinza dose that was greater than 60 mg and less than or equal to 120 mg.  Three 
patients (3.6%) utilized an average daily Avinza dose that was in excess of 120mg.  
The average daily Avinza dose utilized by patients at follow-up was 59.1mg (sd = 
48.0). 
A total of 12 patients (14.3%) utilized an average daily morphine equivalent 
breakthrough pain medication dose that ranged between 30.1mg and 60mg.  Four 
patients (4.8%) utilized an average daily morphine equivalent breakthrough pain 
medication dose that exceeded 60mg.  The average daily morphine equivalent 
breakthrough pain medication dose utilized by patients at follow-up was 23.6mg (sd 
= 32.4). 
A total of 39.3 percent (n = 33) , 27.4 percent  (n = 23), and 15.5 percent  (n = 13) 
of patients utilized a total daily morphine equivalent narcotic dose at follow-up that 
ranged from 30.1mg to 60mg, 60.1mg to 90mg, and 90.1mg to 120mg, respectively.  
Ten patients (10.8%) of patients utilized a total daily morphine equivalent narcotic 
dose at follow-up that exceeded 120mg.  The average total daily morphine equivalent 
narcotic dose utilized by patients at follow-up was 82.7mg (sd = 58.0). 
Results form a paired sample t-test (t = -6.6, df = 83, p < 0.01) showed that the 
average daily morphine equivalent total narcotic dose (mean = 82.7, sd = 58.0) 
utilized by evaluable patients at follow-up was significantly greater than the average  
daily morphine equivalent short-acting narcotic dose at baseline (mean  = 52.3, sd = 
57.3). 
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Table 4.12 Distribution of Evaluable Patients by Average Daily Morphine 
Equivalent Dose (MED) of Avinza, Short-Acting Breakthrough Narcotic 
Analgesic, and Total Narcotic Analgesic at Follow-up 
 
MED (mg)        Avinza 
      n         (%) 
Breakthrough 
Narcotic Analgesic 
      n        (%) 
Total Narcotic 
Analgesica 
        n        (%) 
0 to 30 
30.1 to 60 
60.1 to 90 
90.1 to 120 
120.1 to 180 
> 180 
Total 
Mean  
SD 
          Range 
     37      (44.1) 
     33      (39.3) 
       7        (8.3) 
       4        (4.8) 
       1        (1.2) 
       2        (2.4) 
     84    (100.1*) 
59.1 
48.0 
15 to 360 
     68     (81.0) 
     12     (14.3) 
       2       (2.4) 
       0       (0.0) 
       1       (1.2) 
       1       (1.2) 
     84   (100.1*) 
23.6┼ 
32.4 
0 to 225 
        5       (6.0) 
      33     (39.3) 
      23     (27.4) 
      13     (15.5) 
        6       (7.2) 
        4       (3.6) 
      84   (100.0)  
82.7┼ 
58.0 
15 to 420 
* Total exceeds 100 due to rounding error 
a  Total Narcotic Analgesic = (Avinza + Breakthrough Narcotic Analgesic) 
         ┼ p < 0.05 
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4.3.2 Valium Equivalent Dose (VED) 
 
Patients enrolled in the study used a variety of benzodiazepine medications.  
The dose of the benzodiazepine medication used by enrolled patients was 
converted to a standard Valium milligram equivalent unit, which was labeled as 
valium equivalent dose (VED) for the purposes of this study.  The conversion 
criteria applied to convert the benzodiazepine medication doses to standard 
valium equivalent units can be viewed in Table 3.3 (page 47). 
At baseline, patients were asked during the interview to provide the names 
and doses of prescription benzodiazepine medications that were used.  Patients 
were asked to recall the average number of benzodiazepine doses taken per day 
in the previous week.  The average daily benzodiazepine dose used by the patient 
was calculated by multiplying the strength of the medications used by the 
number of daily doses.  This average daily benzodiazepine dose was converted to 
VED.  Information provided by the patients was verified through prescription 
records maintained in the medical charts. 
A similar procedure was utilized at follow-up.  Patients reported no changes 
in benzodiazepine medication use at follow-up.  Thus, the VED utilized by 
evaluable patients at baseline and follow-up was a constant. 
Table 4.13 presents the distribution of enrolled, evaluable, and non-evaluable 
patients by brand name of benzodiazepine medication utilized at baseline.  A 
similar proportion of enrolled (64.5%), evaluable (65.5%), and non-evaluable 
(62.5%) patients did not utilize benzodiazepines.  Valium was the most 
frequently utilized benzodiazepine among enrolled (n = 18, 14.5%), evaluable (n 
= 11, 13.1%) and non-evaluable (n = 7, 17.5%)patients. 
The distribution of enrolled patients across other commonly utilized 
benzodiazepines was as follows: Xanax® (n = 7, 5.6%), Ativan® (n = 7, 5.6%), 
Klonipin® (n = 6, 4.8% ), Restoril® (n = 3, 2.4%), and Serax® (n = 3, 2.4% ).  The 
distribution of evaluable patients across commonly utilized benzodiazepines other 
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than Valium was as follows: Xanax® (n = 5, 6.0%), Ativan® (n = 3, 3.6%), Klonipin® 
(n = 4, 4.8% ), Restoril® (n = 3, 3.6%), and Serax® (n = 3, 3.6% ).   
The distribution of non-evaluable patients across commonly utilized 
benzodiazepines other than Valium was as follows: Xanax (n = 2, 5.0%), Ativan (n = 
4, 10.0%), and Klonipin, (n = 2, 5.0%). 
Results from a chi-square test (chi-square = 0.10, df = 1, p = 0.74) showed no 
statistically significant difference between the proportion of evaluable and non-
evaluable patients who used benzodiazepine medications. 
 
Table 4.13 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Patients by Brand of  Benzodiazepine Medication at Baseline 
 
Benzodiazepine Medication 
Brand Name 
 
Enrolled 
Patientsa  
   n       (%) 
Evaluable 
Patientsb 
  n       (%) 
Non-Evaluable 
Patientsc 
    n       (%) 
Valium® 
Xanax® 
Ativan® 
Klonipin® 
Restoril® 
Serax® 
Did not use Benzodiazepines 
Total 
  18    (14.5) 
    7      (5.6) 
    7      (5.6) 
    6      (4.8) 
    3      (2.4) 
    3      (2.4) 
  80    (64.5) 
124  (100.3) 
 11    (13.1) 
   5      (6.0) 
   3      (3.6) 
   4      (4.8) 
   3      (3.6) 
   3      (3.6) 
 55    (65.5) 
 84  (100.2) 
    7     (17.5) 
    2       (5.0) 
    4     (10.0) 
    2       (5.0) 
    0       (0.0) 
    0       (0.0) 
   25    (62.5) 
   40  (100.0) 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding 
outliers 
 
 
Information on duration of benzodiazepine medication use was also obtained 
from patients who took the drugs listed in Table 4.13.  Patients recalled from memory 
the duration of benzodiazepine use in terms of months or years.  Table 4.14 presents 
the distribution of enrolled, evaluable, and non-evaluable patients who took 
benzodiazepines by duration of use.  Duration of use categories were developed on 
the basis of relatively short-term use (≤ one year), long-term use (> one and ≤ five 
years), and persistent use that was greater than five years. 
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 A total of 44 enrolled patients utilized benzodiazepines.  Within this group, a total 
of 40.9 percent (n = 18) patients utilized benzodiazepines for less than or equal to one 
year.  Another 38.6 percent (n = 17) utilized benzodiazepines for greater than one and 
less than or equal to five years, and 20.5 percent (n = 9) utilized these medications for 
greater than five years.  The average benzodiazepine duration of use was 3.8 years. 
A total of 29 evaluable patients utilized benzodiazepines.  Within this group, a 
total of 48.3 percent (n = 14) patients utilized benzodiazepines for less than or equal 
to one year.  Another 31.0 percent (n = 9) utilized benzodiazepines for greater than 
one and less than or equal to five years, and 20.7 percent (n = 6) utilized these 
medications for greater than five years.   
A total of 15 non-evaluable patients utilized benzodiazepines.  Within this group, 
a total of 26.7 percent (n = 4) patients utilized benzodiazepines for less than or equal 
to one year.  Another 53.3 percent (n = 8) utilized benzodiazepines for greater than 
one and less than or equal to five years, and 20.0 percent (n = 3) utilized these 
medications for greater than five years.   
 Results from an independent samples t-test (t = -0.14, df = 42, p = 0.88) showed 
no statistically significant difference in the mean duration of benzodiazepine use 
between evaluable (3.8 years) and non-evaluable (4.0 years) patients. 
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Table 4.14 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Patients who Use  Benzodiazepine Medications by Duration of Use 
 
Benzodiazepine Medication 
Duration of Use (years) 
 
Enrolled 
Patientsa  
  n       (%) 
Evaluable 
Patientsb 
 n       (%) 
Non-Evaluable 
Patientsc 
   n       (%) 
≤ one  
> one  and ≤ five 
> five 
Total 
Mean 
SD 
Range 
 18    (40.9) 
 17    (38.6) 
   9    (20.5) 
 44  (100.0) 
3.8 
5.3 
0.08 to 25 
14    (48.3) 
  9    (31.0) 
  6    (20.7) 
29  (100.0) 
3.8 
5.9 
0.08 to 25 
   4     (26.7) 
   8     (53.3) 
   3     (20.0) 
 15   (100.0) 
4.0 
4.1 
0.5 to 15 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding 
outliers 
 
Table 4.15 presents the distribution of enrolled, evaluable, and non-evaluable 
benzodiazepine users by VED.   The average daily VED taken by enrolled patients 
who used benzodiazepine was 16.5mg.  Among enrolled patients who used 
benzodiazepines, 47.7 percent (n = 21) utilized a daily VED that ranged from 2.5mg 
to 10mg.   Another 27.3 percent (n = 12) of enrolled patients utilized a daily VED 
that was greater than 10mg and less than or equal to 20mg.  Finally, 25.0 percent (n = 
11) of enrolled benzodiazepine users utilized a daily VED that exceeded 20mg. 
Among evaluable patients who used benzodiazepines, 48.3 percent (n = 14) 
utilized a daily VED that ranged from 2.5mg to 10mg.   Another 27.6 percent (n = 8) 
of evaluable patients utilized a daily VED that was greater than 10mg and less than or 
equal to 20mg.  Finally, 24.1 percent (n = 7) of evaluable benzodiazepine users 
utilized a daily VED that exceeded 20mg. 
Among non-evaluable patients who used benzodiazepines, 46.6 percent (n = 7) 
utilized a daily VED that ranged from 2.5mg to 10mg.   Another 26.7 percent (n = 4) 
of non-evaluable patients utilized a daily VED that was greater than 10mg and less 
than or equal to 20mg.  Finally, 26.7 percent (n = 4) of non-evaluable benzodiazepine 
users utilized a daily VED that exceeded 20mg.  
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Results from a t-test (t = -0.19, df = 42, p = 0.85) showed that there was no 
statistically significant difference in the average daily valium equivalent dose 
between evaluable (mean = 16.8 mg, sd = 10.8) and non-evaluable patients (mean = 
16.1, sd = 10.3). 
 
Table 4.15 Distribution of Enrolled, Evaluable, and Non-Evaluable 
Benzodiazepine Users by Valium Equivalent Dose at Baseline 
 
Valium Equivalent Dose 
(mg) 
Enrolled 
Patientsa  
    n       (%) 
Evaluable 
Patientsb 
   n        (%) 
Non-Evaluable 
Patientsa 
        n       (%) 
≤ ten 
> ten  and ≤ twenty 
> twenty 
Total 
Mean  
SD 
Range 
   21    (47.7) 
   12    (27.3) 
   11    (25.0) 
   44  (100.0) 
16.5 
10.5 
2.5 to 40.0 
  14     (48.3) 
    8     (27.6) 
    7     (24.1) 
  29   (100.0) 
16.8 
10.8 
2.5 to 40.0 
        7     (46.6) 
        4     (26.7) 
        4     (26.7) 
      15   (100.0) 
16.1 
10.3 
2.5 to 30.0 
a All patients enrolled in the study at baseline excluding outliers 
b All patients who completed baseline and follow-up assessments excluding outliers 
c All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
 
4.3.3 Pain Intensity (PI) 
  
Pain intensity was defined as “Stage I” of the stages of pain model.  During 
the interview at baseline and follow-up, patients were asked to indicate the pain 
intensity experienced in the previous week at three levels: highest, lowest, and 
usual.  In order to assess pain intensity at each of the three levels, patients were 
presented with three visual analogue scales that measured 15 centimeters (cm) in 
length.  Each scale was anchored at the two ends by the following statements: 
“no sensation” and “the most intense sensation imaginable.” 
Table 4.16 presents the mean pain intensity ratings and corresponding 
standard deviations at highest, lowest, and usual levels for enrolled, evaluable, 
and non-evaluable patients.  The mean pain ratings at the highest intensity level 
provided by enrolled (mean = 12.7 cm, sd = 1.7), evaluable (mean = 12.7 cm, sd 
= 1.7), and non-evaluable patients (mean = 12.6 cm, sd = 1.8) at baseline were 
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similar.    Results from an independent sampless t-test (t = 0.04, df = 122, p = 
0.96) showed that mean pain intensity ratings for highest pain intensity level 
between evaluable and non-evaluable patients were not statistically different at 
baseline. Results from a paired-samples t-test (t = 6.99, df = 83, p < 0.01) showed 
that the mean pain intensity rating provided by evaluable patients for highest pain 
intensity level at follow-up (mean = 10.9, sd = 2.8) was significantly lower 
(mean difference = 1.8 cm, sd = 2.3) than at baseline, one month after treatment 
with Avinza®.  
The mean pain ratings at the lowest intensity level provided by enrolled 
(mean = 6.7 cm, sd = 3.0), evaluable (mean = 6.7 cm, sd = 3.3), and non-
evaluable patients (mean = 6.8 cm, sd = 2.5) at baseline were similar.    Results 
from an independent samples t-test (t = -0.14, df = 122, p = 0.88) showed that 
mean pain intensity ratings for lowest pain intensity level between evaluable and 
non-evaluable patients were not statistically different at baseline.  Results from a 
paired-samples t-test (t = 6.41, df = 83, p < 0.01) showed that the mean pain 
intensity rating provided by evaluable patients for lowest pain intensity level at 
follow-up (mean = 4.5, sd = 2.8) was significantly lower than at baseline (mean 
difference = 2.2 cm, sd = 3.1), one month after treatment with Avinza®.  
The mean pain ratings at the usual intensity level provided by enrolled (mean 
= 9.9 cm, sd = 2.4), evaluable (mean = 10.0 cm, sd = 2.3), and non-evaluable 
patients (mean = 9.9 cm, sd = 2.8) at baseline were similar.    Results from an 
independent samples t-test (t = 0.18, df = 122, p = 0.85) showed that mean pain 
intensity ratings for usual pain intensity level between evaluable and non-
evaluable patients were not statistically different at baseline.  Results from a 
paired-samples t-test (t = 8.19, df = 83, p < 0.01) showed that mean pain intensity 
rating provided by evaluable patients for usual pain intensity level at follow-up 
(mean = 7.6 cm, sd = 3.0) was significantly lower than at baseline (mean 
difference = 2.3 cm, sd = 2.6), one month after treatment with Avinza®.   
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Internal consistency reliability of the items used to form the pain intensity 
construct at baseline (Cronbach’s α = 0.79) and follow-up (Cronbach’s α = 0.83) 
was adequate. 
 
Table 4.16 Means and Standard Deviations for Items Assessing Highest, 
Lowest, and Usual Pain Intensity Levels for Enrolled, Evaluable, and 
Non-Evaluable Patients at Baseline and Follow-up 
Pain Intensity  
VASg – 15 cm 
 
Enrolled  
Patientsd 
n = 124  
Baseline 
Scores 
Evaluable  
Patientse 
n = 84 
Baseline 
Scores 
Non-Evaluable 
 Patientsf 
n = 40 
Baseline 
Scores 
Evaluable 
Patientse 
n = 84 
Follow-up 
Scores 
Highest Pain Intensitya 
Mean 
SD 
 
    12.7 
1.7 
 
      12.7* 
1.7 
 
    12.6 
1.8 
 
     10.9* 
2.8 
Lowest Pain Intensityb 
Mean 
SD 
 
6.7 
3.0 
 
6.7* 
3.3 
 
6.8 
2.5 
 
4.5* 
2.8 
Usual Pain Intensityc 
Mean 
SD 
 
9.9  
2.4 
 
      10.0* 
        2.3 
 
9.9 
2.8 
 
7.6* 
3.0 
a Indicate along the scale below the intensity of the painful sensation at its highest intensity 
during the past week. 
b Indicate along the scale below the intensity of the painful sensation at its lowest intensity 
during the past week. 
c Indicate along the scale below the intensity of the painful sensation at its usual intensity during 
the past week. 
d All patients enrolled in the study at baseline excluding outliers 
e All patients who completed baseline and follow-up assessments excluding outliers 
f All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
g VAS – 15cm – Visual Analogue Scale, length 15 centimeters 
VAS Anchors: 0 cm – No Sensation, 15cm – The most intense sensation imaginable 
* p < 0.01 
4.3.4 Pain Unpleasantness (PU) 
 
 
Pain Unpleasantness was defined as “Stage II” of the stages of pain model.  
During the interview at baseline and follow-up, patients were asked to indicate 
the pain unpleasantness experienced in the previous week at the highest, lowest, 
and usual pain intensity levels.  In order to assess pain unpleasantness at each of 
the three levels, patients were presented with three visual analogue scales that 
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measured 15 centimeters (cm) in length.  Each scale was anchored at the two 
ends by the following statements: “not bad at all” and “the most intense bad 
feeling possible.”   
Table 4.17 presents the mean pain unpleasantness ratings and corresponding 
standard deviations at highest, lowest, and usual levels for enrolled, evaluable, 
and non-evaluable patients.  
The mean pain unpleasantness ratings at the highest pain intensity level 
provided by enrolled (mean = 12.9 cm, sd = 1.9), evaluable (mean = 12.8 cm, sd 
= 2.1), and non-evaluable patients (mean = 13.3 cm, sd = 1.5) at baseline were 
similar.  Results from an independent samples t-test (t = -1.39, df = 122, p = 
0.16) showed that the mean pain unpleasantness ratings at highest pain intensity 
level between evaluable and non-evaluable patients were not statistically 
different at baseline.  Results from a paired-samples t-test (t = 5.74, df = 83, p < 
0.01) showed that mean pain unpleasantness rating provided by evaluable 
patients for highest pain intensity level at follow-up (mean = 11.0, sd = 3.2) was 
significantly lower (mean difference = 1.7 cm, sd = 2.7) than the mean 
unpleasantness rating for highest pain intensity level at baseline.   
The mean pain unpleasantness ratings at the lowest pain intensity level 
provided by enrolled (mean = 6.8 cm, sd = 4.2), evaluable (mean = 6.5 cm, sd = 
4.4), and non-evaluable patients (mean = 7.4 cm, sd = 3.8) at baseline were 
similar.  Results from an independent samples t-test (t = -1.15, df = 122, p = 
0.25) showed that the mean pain unpleasantness ratings at lowest pain intensity 
level between evaluable and non-evaluable patients were not statistically 
different at baseline.  Results from a paired-samples t-test (t = 5.08, df = 83, p < 
0.01) showed that mean pain unpleasantness rating provided by evaluable 
patients for lowest pain intensity level at follow-up (mean = 4.0, sd = 3.5) was 
significantly lower (mean difference = 2.4 cm, sd = 4.4) than the mean 
unpleasantness rating for lowest pain intensity level at baseline.     
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The mean pain unpleasantness ratings at the usual pain intensity level 
provided by enrolled (mean = 9.7 cm, sd = 3.1), evaluable (mean = 9.6 cm, sd = 
3.2), and non-evaluable patients (mean = 10.0 cm, sd = 2.9) at baseline were 
similar.  Results from an independent samples t-test (t = -0.57, df = 122, p = 
0.56) showed that the mean pain unpleasantness ratings at usual pain intensity 
level between evaluable and non-evaluable patients were not statistically 
different at baseline.  Results from a paired-samples t-test (t = 7.09, df = 83, p < 
0.01) showed that the mean pain unpleasantness rating provided by evaluable 
patients for usual pain intensity level at follow-up (mean = 7.2, sd = 3.4) was 
significantly lower (mean difference = 2.3 cm, sd = 3.0) than the mean 
unpleasantness rating for usual pain intensity level at baseline.   Internal 
consistency reliability of the items used to form the pain unpleasantness construct 
at baseline (Cronbach’s α = 0.81) and follow-up (Cronbach’s α = 0.83) was 
adequate. 
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Table 4.17 Means and Standard Deviations for Items Assessing Highest, 
Lowest, and Usual Pain Unpleasantness (PU)  Levels for Enrolled, 
Evaluable, and Non-Evaluable Patients at Baseline and Follow-up 
Pain Unpleasantness 
(PU) at various levels of 
Pain Intensity (PI) 
VASg – 15 cm 
 
Enrolled  
Patientsd  
n = 124 
Baseline 
Scores 
Evaluable  
Patientse 
n = 84 
Baseline 
Scores 
Non-Evaluable 
 Patientsf 
n = 40 
Baseline 
Scores 
Evaluable 
Patientse 
n = 84 
Follow-up 
Scores 
PU at Highest PIa 
Mean 
SD 
 
    12.9 
1.9 
 
      12.8* 
2.1 
 
13.3 
  1.5 
 
     11.0* 
3.2 
PU at Lowest PIb 
Mean 
SD 
 
6.8  
4.2 
 
6.5  
4.4 
 
  7.4 
  3.8 
 
4.0 
3.5 
PU at Usual PIa 
Mean 
SD  
 
9.7 
3.1 
 
9.6* 
3.2 
 
10.0 
  2.9 
 
7.2* 
3.4 
a Indicate along the scale below how unpleasant or disturbing your pain was when it was at its 
highest intensity during the past week. 
b Indicate along the scale below how unpleasant or disturbing your pain was when it was at its 
lowest intensity during the past week. 
c Indicate along the scale below how unpleasant or disturbing your pain was when it was at its 
usual intensity during the past week. 
d All patients enrolled in the study at baseline excluding outliers 
e All patients who completed baseline and follow-up assessments excluding outliers 
f All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
g VAS – 15cm – Visual Analogue Scale, length 15 centimeters 
VAS Anchors: 0 cm – Not bad at all, 15cm – The most intense bad feeling possible 
*  p < 0.01 
 
4.3.5 Pain Suffering (PS) 
 
Pain suffering was defined as “Stage III” of the stages of pain model.  The 
pain suffering construct was composed of negative emotion items and negative 
belief items.   
 
4.3.5.1 Negative Emotions 
 
The following negative emotions were evaluated: depression, anxiety, 
frustration, anger, and fear.  During the interview at baseline and follow-up, 
patients were asked to indicate the intensity of each negative emotion as it related 
to their pain in the previous week on visual analogue scale (length = 15cm).  The 
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anchors for the scales assessing each emotion were: “none” and “the most severe 
imaginable.”  
Table 4.18 presents mean ratings for each of the negative emotions and the 
corresponding standard deviations for enrolled, evaluable, and non-evaluable 
patients.   
The mean rating for all enrolled patients on the depression scale was 9.0 cm 
(sd = 4.4).  Results from an independent samples t-test (t = -2.58, df = 122, p = 
0.01) showed that the mean rating on the depression scale from evaluable 
patients (mean = 8.3 cm, sd = 4.5) was significantly lower than the mean 
depression rating from non-evaluable patients (mean = 10.5 cm, sd = 3.9) at 
baseline.  Results from a paired-samples t-test (t = 2.73, df = 83, p < 0.01) 
showed that the mean depression rating provided by evaluable patients at follow-
up (mean = 7.08, sd = 4.3) was significantly lower (mean difference = 1.2 cm, sd 
= 4.23) than the mean depression rating at baseline.       
The mean rating for all enrolled patients on the anxiety scale was 9.1 cm (sd 
= 4.2).  Results from an independent samples t-test (t = -2.32, df = 122, p = 0.02) 
showed that the mean rating on the anxiety scale provided by evaluable patients 
(mean = 8.5 cm, sd = 4.3) was significantly lower than the mean anxiety rating 
provided by non-evaluable patients (mean = 10.3 cm, sd = 3.5).  Results from a 
paired-samples t-test (t = 4.20, df = 83, p < 0.01) showed that the mean anxiety 
rating provided by evaluable patients at follow-up (mean = 6.7 cm, sd = 4.1) was 
significantly lower (mean difference = 1.7 cm, sd = 3.8) than the mean anxiety 
rating at baseline.       
The mean rating for all enrolled patients on the frustration scale was 11.1 cm 
(sd = 3.1).  Results from an independent samples t-test (t = -2.19, df = 122, p = 
0.03) showed that the mean frustration rating from evaluable patients (mean = 
10.7 cm, sd = 3.3) was significantly lower than the mean frustration rating from 
non-evaluable patients (mean = 12.0 cm, sd = 2.5).  Results from a paired-
samples t-test (t = 4.80, df = 83, p < 0.01) showed that the mean frustration rating 
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provided by evaluable patients at follow-up (mean = 8.6 cm, sd = 3.9) was 
significantly lower (mean difference = 2.0 cm, sd = 3.8) than the mean frustration 
rating at baseline.       
The mean rating for all enrolled patients on the anger scale was 8.6 cm (sd = 
4.8).  Results from an independent samples t-test (t = -3.0, df = 122, p < 0.01) 
showed that the mean anger rating from evaluable patients (mean = 7.7 cm, sd = 
5.0) was significantly lower than the mean anger rating from non-evaluable 
patients (mean = 10.4 cm, sd = 3.6).  Results from a paired-samples t-test (t = 
4.83, df = 83, p < 0.01) showed that the mean anger rating provided by evaluable 
patients at follow-up (mean = 5.4 cm, sd = 4.5) was significantly lower (mean 
difference = 2.2 cm, sd = 3.8) than the mean anger rating at baseline.       
  The mean rating for all enrolled patients on the fear scale was 6.6 cm (sd = 
4.8).  Results from an independent samples t-test (t = -1.6, df = 122, p = 0.09) 
showed that the mean fear rating from evaluable patients (mean = 6.1 cm, sd = 
4.9) was not significantly different than the mean fear rating from non-evaluable 
patients (mean = 7.7 cm, sd = 3.6).  Results from a paired-samples t-test (t = 
1.96, df = 83, p = 0.05) showed that the mean fear rating provided by evaluable 
patients at follow-up (mean = 5.2 cm, sd = 4.4) was significantly lower (mean 
difference = 0.9 cm, sd = 4.5) than the mean fear rating at baseline.  Internal 
consistency reliability of the items used to form the negative emotions construct 
at baseline (Cronbach’s α = 0.84) and follow-up (Cronbach’s α = 0.91) was 
adequate. 
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Table 4.18 Means and Standard Deviations for Items Assessing Negative 
Emotions for Enrolled, Evaluable, and Non-Evaluable Patients at 
Baseline and Follow-up 
Negative Emotions 
VASe – 15 cm 
 
Enrolled  
Patientsb  
n = 124 
Baseline 
Scores 
Evaluable  
Patientsc 
n = 84 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n = 40 
Baseline 
Scores 
Evaluable 
Patientsc 
n = 84 
Follow-up 
Scores 
Depressiona 
Mean 
SD 
 
 9.0 
 4.4 
 
       8.3* 
       4.5 
 
10.5 
  3.9 
 
7. 0* 
4.3 
Anxietya 
Mean 
SD 
 
 9.1 
 4.2 
 
       8.5* 
       4.3 
 
10.3 
  3.5 
 
6.7*  
4.1 
Frustrationa 
Mean 
SD 
 
    11.1 
3.1 
 
     10.7* 
       3.3 
 
12.0 
  2.5 
 
8.6* 
3.9 
Angera 
Mean 
SD 
 
8.6 
4.8 
 
       7.7* 
       5.0 
 
     10.4 
 3.6 
 
5.4* 
4.5 
Feara 
Mean 
SD 
 
 6.6 
      4.8 
 
       6.1┼ 
       4.9 
 
7.7 
4.6 
 
5.2┼ 
       4.4 
aWhat kind of negative feelings accompany your pain? Check along each scale below the 
intensity of each feeling as it has related to your pain over the past week 
bAll patients enrolled in the study at baseline excluding outliers 
cAll patients who completed baseline and follow-up assessments excluding outliers 
dAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
eVAS – 15cm – Visual Analogue Scale, length 15 centimeters 
VAS Anchors: 0 cm – None, 15cm – The most severe imaginable 
       *p < 0.01 
       ┼p < 0.05 
 
 4.3.5.2 Negative Beliefs 
  
Negative beliefs were assessed through four items.  During the interview at 
baseline and follow-up, patients were asked to indicate along a visual analogue scale 
(length = 15cm) with anchors, the extent to which they believed that pain interfered 
in their life, the extent to which patients could endure pain and control pain, and the 
extent to which patients believed that pain will be removed or cured.    
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Table 4.19 presents mean ratings for each of the negative beliefs and the 
corresponding standard deviations for enrolled, evaluable, and non-evaluable 
patients.    
The mean ratings on the scale assessing pain interference provided by 
enrolled (mean = 11.9 cm, sd = 2.6), evaluable (mean = 11.9 cm, sd = 2.5), and 
non-evaluable patients (mean = 11.8 cm, sd = 2.7) at baseline were similar.  
Results from an independent samples t-test (t = 0.32, df = 122, p = 0.74) showed 
that the mean rating on the scale assessing pain interference provided by 
evaluable patients was not significantly different from the mean rating provided 
by non-evaluable patients.  Results from a paired-samples t-test (t = 7.05, df = 
83, p < 0.01) showed that the mean rating on the scale assessing pain interference 
provided by evaluable patients at follow-up (mean = 9.3, sd = 3.1) was 
significantly lower (mean difference = 2.6 cm, sd = 3.4) than the mean rating on 
the scale assessing pain interference at baseline.         
 The mean ratings on the scale assessing ability to endure pain provided by 
enrolled (mean = 11.3 cm, sd = 2.8), evaluable (mean = 11.0 cm, sd = 3.0), and non-
evaluable patients (mean = 11.8 cm, sd = 2.4) at baseline were similar.  Results from 
an independent samples t-test (t = -1.30, df = 122, p = 0.19) showed that the mean 
rating on the scale assessing ability to endure pain provided by evaluable patients was 
not significantly different from the mean rating provided by non-evaluable patients.   
Results from a paired-samples t-test (t = 6.02, df = 83, p < 0.01) showed that the 
mean rating on the scale assessing ability to endure pain provided by evaluable 
patients at follow-up (mean = 8.8, sd = 3.6) was significantly lower (mean difference 
= 2.2 cm, sd = 3.4) than the mean rating on the scale assessing ability to endure pain 
at baseline.         
The mean rating for all enrolled patients on the scale assessing ability to control 
pain was 6.2 cm (sd = 3.4).  Results from an independent samples t-test (t = 2.27, df = 
122, p = 0.02) showed that the mean rating on the scale assessing ability to control 
pain provided by evaluable patients (mean = 6.7 cm, sd = 3.5) was significantly 
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higher than the mean rating on the scale assessing ability to control pain provided by 
non-evaluable patients (mean = 5.2 cm, sd = 2.9).  Results from a paired-samples t-
test (t = -4.25, df = 83, p < 0.01) showed that the mean rating on the scale assessing 
ability to control pain provided by evaluable patients at follow-up (mean = 8.5 cm, sd 
= 3.2) was significantly higher (mean difference = 1.8 cm, sd = 4.0) than the mean 
rating provided at baseline.         
  The mean ratings on the scale assessing the belief that pain will be removed or 
cured provided by enrolled (mean = 6.2 cm, sd = 4.4), evaluable (mean = 6.2 cm, sd = 
4.1), and non-evaluable patients (mean = 6.3 cm, sd = 4.9) at baseline were similar.  
Results from an independent samples t-test (t = -0.02, df = 122, p = 0.97) showed that 
the mean rating on the scale assessing the belief that pain will be removed or cured 
provided by evaluable patients was not significantly different from the mean rating 
provided by non-evaluable patients.  Results from a paired-samples t-test (t = -0.72, 
df = 83, p = 0.14) showed that the mean rating on the scale assessing the belief that 
pain will be removed or cured provided by evaluable patients at follow-up (mean = 
7.01, sd = 4.1) was not significantly different than the mean rating on the scale 
assessing the belief that pain will be removed or cured at baseline.         
Internal consistency reliability of the items used to form the negative beliefs 
construct at baseline (Cronbach’s α = 0.36) was very low.  Concbach’s α for the 
same items at follow-up was 0.70. 
A possible explanation for the low reliability values is misinterpretation of 
the scale.  The item which assessed ability to control pain had the following 
anchors: 0 cm - 0% I cannot reduce it at all, and 15 cm – 100% I can reduce it 
completely.  Some patients may have misinterpreted zero percent as the ability to 
reduce pain to zero. 
Some patients may have misinterpreted the item assessing the belief that pain 
may be removed or cured.  In some instances, patients may have provided a 
rating on the hope or expectation that Avinza would provide significant relief.  
These discrepancies may have contributed to low reliability scores. 
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Table 4.19 Means and Standard Deviations for Items Assessing 
Negative Beliefs  for Enrolled, Evaluable, and Non-Evaluable Patients 
at Baseline and Follow-up 
Negative Beliefs 
VASh – 15 cm 
 
Enrolled  
Patientse 
n = 124  
Baseline 
Scores 
Evaluable  
Patientsf 
n = 84 
Baseline 
Scores 
Non-Evaluable 
 Patientsg 
n = 40 
Baseline 
Scores 
Evaluable 
Patientsf 
n = 84 
Follow-up 
Scores 
Pain Interferencea  
                          Mean 
                              SD 
 
11.9 
2.6 
 
11.9 * 
2.5 
 
11.8 
2.7 
 
9.3 * 
3.1 
Ability to Endure 
Painb                  Mean 
                              SD 
 
11.3 
2.8 
 
11.0 * 
3.0 
 
11.8 
2.4 
 
8.8 * 
3.6 
Ability to Control 
Painc                  Mean 
                             SD 
 
6.2 
3.4 
 
6.7 * 
3.5 
 
5.2 
2.9 
 
8.5 * 
3.2 
Belief that Pain Will 
be Removed/Curedd     
                           Mean 
                              SD 
 
 
6.2 
4.4 
 
 
6.2 
4.1 
 
 
6.3 
4.9 
 
 
7.0 
4.1 
aIndicate along the scale below how: how much does your pain prevent your from doing what you 
want to do?  Scale Anchors: 0 cn - No interference and 15cm - Complete Interference – Cannot do 
anything 
bIndicate along the scale below how difficult is it to endure the pain over time?  Scale Anchors: 0cm - 
Not difficult at all and 15 cm -  The most difficult imaginable 
cIndicate along the scale below how much can you reduce the intensity of your pain if you want?  
Scale Anchors: 0 cm - zero percent, I cannot reduce it all and 15 cm - 100 percent, I can reduce it 
completely  
dIndicate along the scale below how likely do you feel that your pain will be removed or cured? 
Scale Anchors: 0 cm - Impossible and 15 cm - Certain.  
eAll patients enrolled in the study at baseline excluding outliers 
fAll patients who completed baseline and follow-up assessments excluding outliers 
gAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
hVAS – 15cm – Visual Analogue Scale, length 15 centimeters 
      * p < 0.01 
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4.3.6 Pain Behaviors (PB) 
 
Pain behavior was assessed through five subscales that were adapted from the 
Psychosocial Pain Inventory.298  The following aspects of pain behavior and their 
frequency were assessed: “pain behavior” in the home, “social reinforcement for pain 
behavior,” “home or family related responsibilities that were disrupted,” “pain 
contingent down time,” and “interview behavior.” 
A total score that ranges from zero to three was calculated for each of the five 
items listed above.  The score for each item was calculated by summing the number 
of points associated with every sub-item endorsed by the patient (Appendix D).  The 
total score for each item is then converted to a scaled score (range – 0 to 3).    
 
4.3.6.1 Pain Behavior at Home 
Pain behavior at home was assessed by asking patients about the pain behaviors 
they display at home.  During the interview, patients were presented with a list of 
pain behaviors and were asked about the frequency with which they engaged in the 
endorsed pain behaviors.  Pain behavior scores were calculated as follows: 
Pain behavior - First add up the points associated with the behaviors 
checked, and then use this sum to a figure a rating as follows (0 to 
3)299: 
 
0 = 0 to 4 points   2 = 10 to 14 points 
1 = 5 to 9 points   3 = 15 or more points 
 
Table 4.20 presents the frequency distribution and descriptive statistics for the 
item which assessed pain behaviors at home for enrolled, evaluable, and non-
evaluable patients at baseline and follow-up.  A higher score on this item implies a 
greater frequency of pain behaviors.   
                                                 
298 Getto CJ, Heaton RK.  Psychosocial Pain Inventory.   Psychological Assessment Resources.  Lutz, FL.  
1995. 
299 Ibid 
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A very small proportion of enrolled (4.0%, n = 5), evaluable (4.8%, n = 4) and 
non-evaluable patients (2.5%, n  = 5) scored a zero on the item which assessed 
frequency of pain behaviors at home.  The proportion of evaluable patients (9.5%, n 
= 8) who scored a zero (0) on this item almost doubled at follow-up.  The proportion 
of evaluable patients (34.5%, n = 29) who received a score of one (1) on the item 
which assessed pain behaviors at home was nearly twice the proportion of non-
evaluable patients (17.5%, n = 7) who received a score of one (1) on this item at 
baseline.  The total number of evaluable patients (n = 36, 42.8%) who received a 
score of one on the same item increased at follow-up.  Although a greater number of 
evaluable patients at follow-up (n = 25, 29.8%) in comparison with baseline (n = 20, 
23.8%) received a score of two (2) on the item which assessed pain behavior at 
home, more than twice the proportion of patients received a score of three (3) at 
baseline (36.9%, n = 31) than at follow-up (17.9%, n = 15).  A score of three (3) 
represented the category with the highest frequency of pain behaviors at home. 
Results from an independent samples t-test (t = -1.74, df = 122,  p = 0.08) showed 
that baseline mean score on the item which assessed pain behavior at home for 
evaluable patients (mean = 1.92 sd = 0.9) was not significantly different from the 
mean score for non-evaluable patients (mean  = 2.23, sd = 0.8) at the 95 percent 
confidence level.  Results from a paired-samples t-test (t = 3.99, df = 83, p < 0.01) 
showed that the mean score provided by evaluable patients at follow-up (mean = 
1.55, sd = 0.9) on the item which assessed pain behavior at home was significantly 
lower than the mean score provided at baseline (mean difference = 0.36 sd = 0.8).  
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Table 4.20 Frequency Distribution and Descriptive Statistics of Pain 
Behaviors at Home  for Enrolled, Evaluable, and Non-Evaluable Patients 
at Baseline and Follow-up 
Pain Behavior  
– Homea 
 
Enrolled  
Patientsb  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsc 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
0 
1 
2 
3 
 Total 
 Mean 
SD 
    5      (4.0) 
  37    (29.8) 
  33    (26.6) 
  49    (39.5) 
124   (99.9*) 
2.0 
0.9 
  4      (4.8) 
29    (34.5) 
20    (23.8) 
31    (36.9) 
84  (100.0) 
1.9 * 
0.9 
  1      (2.5) 
  7    (17.5) 
14    (35.0) 
18    (45.0) 
40  (100.0) 
2.2 
0.8 
  8      (9.5) 
36    (42.8) 
25    (29.8) 
15    (17.9) 
84  (100.0) 
1.5 * 
0.8 
* Total does not equal 100 due to rounding error 
a “When you are at home and the pain is really bad, how can your family tell that you hurt that 
way?”  Check each pain behavior which occurs with the frequency indicated.  Patients who live 
alone will be assigned a “0.” 
 Hold or grasp the area that hurts, 3 times a day or more =1 
 Wince or cringe, 3 times a day or more =2 
 Call a doctor, once a month or more = 3 
 Cry, once a week or more = 3 
 Moan, once a week or more = 3 
 Say it hurts, once a day or more.  Ask how this is done, and specify whether it is done with  
 no affect = 1 
 some affect = 2 
 much affect = 3 
 Pace, three times a week or more = 2 
 Go into another room by self, 3 times a week or more = 2 
 Lie down more than once a day = 2 
 If this happens at work too with any frequency = 3 
 Sit down, more than 3 times per day = 1 
 Change position frequently = 0  
 Scream, if at all = 3 
 Take medications = 0 (unless addicted; then =3) 
 Ask for help with things that patient would normally be able to do himself/herself, once a 
day or more = 3 
 Gets angry or irritable, 3 times per week or more = 2 
 Other (specify): _____________________________________ 
bAll patients enrolled in the study at baseline excluding outliers 
cAll patients who completed baseline and follow-up assessments excluding outliers 
dAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
0 = 0 to 4 points,  1 = 5 to 9 points, 2 = 10 to 14 points, 3 = 15 or more points 
Higher score implies greater frequency of pain behaviors at home 
      * p < 0.01 
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4.3.6.2 Social Reinforcement for Pain Behavior 
 
Social reinforcement for pain behavior was assessed by asking patients about the 
response of family members to their behaviors.  During the interview, patients were 
presented with a list of responses and were asked about the frequency with which 
family members responded to the items endorsed.  Social reinforcement for pain 
behavior scores were calculated as follows: 
Social reinforcement for pain behavior - First add up points associated 
with checked responses, and then use the sum to figure the rating as 
follows (0 to 3)300: 
 
0 = 0 to 3 points   2 = 8 to 11 points 
1 = 4 to 7 points   3 = 12 or more points 
 
Table 4.21 presents the frequency distribution and descriptive statistics for the 
item which assessed social reinforcement of pain behavior for enrolled, evaluable, 
and non-evaluable patients at baseline and follow-up.  A higher score on this item 
implies a greater frequency of social reinforcement. 
A majority of enrolled patients (54.0%, n =67), evaluable patients at baseline 
(56.0%, n = 47) and follow-up (61.9%, n = 52), and non-evaluable patients (50.0%, n 
= 20) received a score of zero (0) on the item which assessed social reinforcement for 
pain behavior.  The distribution of patients who received a score of one (1) on the 
item which assessed social reinforcement for pain behavior was as follows:  enrolled 
patient (33.1%, n = 41), evaluable patients at baseline (32.1%,  n =27) and follow-up 
(27.4%, n =23), and non-evaluable patients (35.0%, n = 14).  As compared to 
evaluable patients at baseline (n = 10, 11.9%), one less patient received a score of 
two (2) on the item which assessed social reinforcement for pain behavior at follow-
up (n = 9, 10.7%).   None of the evaluable patients at either baseline (n = 0) or 
                                                 
300 Ibid 
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follow-up (n = 0) received a score of three on the item which assessed social 
reinforcement for pain behavior. 
Results from an independent samples t-test (t = -0.82, df = 122,  p = 0.41) showed 
that baseline mean score on the item which assessed social reinforcement for pain 
behavior provided by evaluable patients (mean = 0.5 sd = 0.7) was not significantly 
different from the mean score for non-evaluable patients (mean  = 0.6, sd = 0.7) at the 
95 percent confidence level.  Results from a paired-samples t-test (t = 1.75, df = 83, p 
= 0.08) showed that the mean score provided by evaluable patients at follow-up 
(mean = 0.48, sd = 0.6) on the item which assessed social reinforcement for pain 
behavior was not significantly different than the mean score provided at baseline 
(mean difference = 0.07 sd = 0.37).  
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Table 4.21 Frequency Distribution and Descriptive Statistics of Social 
Reinforcement of Pain Behavior for Enrolled, Evaluable, and Non-
Evaluable Patients at Baseline and Follow-up 
Social 
Reinforcementa 
 
Enrolled  
Patientsb  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsc 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
0 
1 
2 
3 
 Total 
 Mean 
SD 
 67      (54.0) 
 41      (33.1) 
 15      (12.1) 
   1        (0.8) 
124    (100.0) 
0.6 
0.7 
 47    (56.0) 
 27    (32.1) 
 10    (11.9) 
   0      (0.0) 
 84  (100.0) 
0.5 
0.7 
20    (50.0) 
14    (35.0) 
  5    (12.5) 
  1      (2.5) 
40  (100.0) 
0.6 
0.7 
 52    (61.9) 
 23    (27.4) 
   9    (10.7) 
   0      (0.0) 
 84  (100.0) 
0.4 
0.6 
a Ask in relation to the pain behaviors considered generally: “When other family members see 
you doing these things, and hurting especially badly, how do they respond to you?”  Again, ask 
about any response that is not mentioned spontaneously, determine the general frequency with 
which each response occurs, and check each response that occurs with the frequency indicated. 
 Express sympathy verbally, daily or almost everyday = 2 
 Withdraws from patient, daily or almost everyday = 0 (unless MMPI-SI 60; then = 2) 
 Encourages patient to take remedial action (i.e., to take meds, lie down, apply heating pad,  
call doctor, etc.) daily or almost every day = 1 
 Helps patient take remedial action (i.e., gets the meds or heating pad, draws bath, calls doctor, etc) 
daily or almost everyday = 2 
 Actually administers remedial medication (i.e., gives back rub, holds patient, gives injection, etc.) 
daily or almost every day = 3 
 Offers to do whatever work the patient is either attempting to do or scheduled to do, when this is 
something the patient usually feels capable of doing, daily or almost every day = 3 
 Complains = 0 
 Does nothing (ignores patient) = 0 
 Other (specify): ________________________ 
bAll patients enrolled in the study at baseline excluding outliers 
cAll patients who completed baseline and follow-up assessments excluding outliers 
dAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
0 = 0 to 3 points,  1 = 4 to 7 points, 2 = 8 to 11 points, 3 = 12 or more points 
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4.3.6.3 Home or Family Related Responsibilities 
 
 
Effect of pain on home and family related responsibilities was assessed by 
asking patients about their responsibilities before the pain problem and in 
their current state.  During the interview, patients were asked to indicate 
whether the extent to which they performed responsibilities prior to the pain 
was “less now” or “never performed now.”  The score for this item was 
calculated as follows: 
Home or family related responsibilities - Give one point for each 
previously discharged responsibility that is done less now, and two 
points for each which is never done now.  Add the points and use the 
sum to figure out a rating as follows (0 to 3)301: 
 
0 = 0 points    2 = 3 to 6 points 
1 = 1 or 2 points   3 = 7 or more points 
 
Table 4.22 presents the frequency distribution and descriptive statistics for the 
item which assessed the effect of pain on home and family related responsibilities for 
enrolled, evaluable, and non-evaluable patients at baseline and follow-up.  A higher 
score on this item implies a greater reduction in home or family related 
responsibilities.  
A very small proportion of enrolled patients (6.5%, n = 8) and evaluable patients 
at baseline (9.5%, n = 8) patients at baseline received a score of zero on the item 
which assessed the effect of pain on home and family related responsibilities.  The 
proportion of evaluable patients (6.0%, n = 5) who received this score at follow-up 
declined.  The number of evaluable patients who received a score of one (1) on this 
item increased from baseline (n = 9, 10.7%) to follow-up (n = 12, 14.2%).  None of 
the patients in the non-evaluable group (n = 0) received a score of either zero (0) or 
one (1).  A large majority of non-evaluable patients (n = 35, 87.5%) received a score 
of three (3), which suggested that these patients experienced the highest level of 
                                                 
301 Ibid 
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reduction in home and family related responsibilities due to their pain.   A majority 
of evaluable patients at baseline (61.9%, n = 52) and follow-up (51.2%, n = 43) 
experienced a similar level of reduction in home and family related responsibilities 
Results from an independent samples t-test (t = -3.38, df = 122,  p < 0.01) showed 
that baseline mean score on the item which assessed the effect of pain on home or 
family related responsibilities for evaluable patients (mean = 2.3,  sd = 1.0) was 
significantly lower than the mean score for non-evaluable patients (mean  = 2.8, sd = 
0.3) at the 95 percent confidence level.   Results from a paired-samples t-test (t = 
1.09, df = 83, p = 0.27) showed that the mean score provided by evaluable patients at 
follow-up (mean = 2.2, sd = 0.8) on the item which assessed effect of pain on home 
and family related responsibilities was not significantly different than the mean score 
provided at baseline (mean difference = 0.1, sd = 0.3).  
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Table 4.22 Frequency Distribution and Descriptive Statistics of Home or 
Family Related Responsibilities for Enrolled, Evaluable, and Non-
Evaluable Patients at Baseline and Follow-up 
Home or 
Family Related 
Responsibiltiesa 
 
Enrolled  
Patientsb 
n (%)  
Baseline 
Scores 
Evaluable  
Patientsc 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
0 
1 
2 
3 
 Total 
 Mean 
SD 
    8       (6.5) 
    9       (7.3) 
 20     (16.1) 
 87     (70.2) 
 124  (100.1*) 
2.5 
0.8 
   8      (9.5) 
   9    (10.7) 
 15    (17.9) 
 52    (61.9) 
 84  (100.0) 
2.3 
1.0 
  0        (0.0) 
  0        (0.0) 
  5      (12.5) 
 35     (87.5) 
 40   (100.0) 
2.8 
0.3 
   5      (6.0) 
 12    (14.2) 
 24    (28.6) 
 43    (51.2) 
 84   100.0) 
2.2 
0.8 
*Total does not equal 100 due to rounding error 
aUse the following checklist to indicate what home or family related responsibilities the patient 
discharged prior to the pain problem as compared to now.  Under “ Before” check only those 
activities that the patient did at least half of the time before (i.e., it must have been primarily the 
patient’s responsibility – not mostly someone else’s in the family).  Check under “Less now” if, 
due to the pain, the frequency with which the patient does the activity has decreased but by no 
more than 50 percent.  Check under “Never now” if the frequency has decreased by more than 50 
percent.  Give one point for each previously discharged responsibility that is done less now, and 
two points for each which is never done now.  Add the points and use the sum to figure out a 
rating as follows (0 to 3): 
Responsibility  Before Less Now  Never Now 
Housecleaning ________ ________  ________ 
Clothes washing ________ ________  ________ 
Clothes ironing     ________     ________  ________ 
Shopping      ________     ________  ________ 
Cooking      ________     ________  ________ 
Repair work (home)     ________     ________  ________ 
Repair work (car)     ________     ________  ________ 
Yard work      ________     ________  ________ 
Errands      ________     ________  ________ 
Caring for children     ________     ________  ________ 
Disciplining children    ________     ________  ________ 
Driving other family members  ________        ________  ________ 
Family finances     ________     ________  ________ 
Family correspondence    ________     ________  ________ 
Other (specify): 
bAll patients enrolled in the study at baseline excluding outliers 
cAll patients who completed baseline and follow-up assessments excluding outliers 
dAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
0 = 0 to 3 points,  1 = 4 to 7 points, 2 = 8 to 11 points, 3 = 12 or more points 
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4.3.6.4 Pain Contingent Down Time 
 
Pain contingent down time was assessed by asking patients to indicate the amount 
of time they spend laying down because of their pain.  The following categories were 
formed to calculate scores: 
 
0 = No more than 1 hour/day 2 = Two to four hours/day 
1 = > one and < two hours/day 3 = Greater than four hours/day 
 
 
Table 4.23 presents the frequency distribution and descriptive statistics for the 
item which assessed pain contingency down time for enrolled, evaluable, and non-
evaluable patients at baseline and follow-up.  A higher score on this item implies a 
greater amount time that patients spend lying down due to pain. 
The distribution of patients who reported that they spend less than one hour per 
day lying down was as follows: enrolled patients (n =21, 16.9%), evaluable patients 
at baseline (n = 16, 19.0%) and follow-up (n = 15, 17.9%), and non-evaluable 
patients (n = 5, 12.5%).  The total number of evaluable patients who reported that 
they spend greater than one but less than two hours per day lying down was 16 
(19.0%) at baseline and 17 at follow-up (20.2%).  The proportion of enrolled patients 
(37.1%, n = 46), evaluable patients (36.9%, n = 31), and non-evaluable patients 
(37.5%, n = 15) who spend greater than four hours per day lying down at baseline 
was similar.  A smaller proportion of evaluable patients at follow-up (23.8%, n = 20) 
spend as much time lying down because of their pain. 
Results from an independent samples t-test (t = -1.06, df = 122,  p = 0.28) showed 
that baseline mean score on the item which assessed pain contingent down time for 
evaluable patients (mean = 1.82 sd = 1.1) was not significantly different from the 
mean score for non-evaluable patients (mean  = 2.05, sd = 0.9) at the 95 percent 
confidence level.   Results from a paired-samples t-test (t = 1.23, df = 83, p = 0.22) 
showed that the mean score provided by evaluable patients at follow-up (mean = 
1.67, sd = 1.0) on the item which assessed pain contingency down time was not 
  
 192
significantly different than the mean score provided at baseline (mean difference = 
0.15 sd = 0.8).  
 
 
Table 4.23 Frequency Distribution and Descriptive Statistics of Pain 
Contingent Down Tine  for Enrolled, Evaluable, and Non-Evaluable 
Patients at Baseline and Follow-up 
Pain 
Contingent 
Down Timea 
 
Enrolled  
Patientsb  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsc 
 n (%) 
Baseline 
 Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
0 
1 
2 
3 
 Total 
 Mean 
SD 
  21     (16.9) 
  19     (15.3) 
  38     (30.6) 
  46     (37.1) 
124  (100.1*) 
1.8 
1.1 
 16     (19.0) 
 16     (19.0) 
 21     (25.0) 
 31     (36.9) 
 84    (99.9*)  
1.8 
1.1 
   5     (12.5) 
   3       (7.5) 
 17     (42.5) 
 15     (37.5) 
 40   (100.0) 
2.0 
0.9 
 15    (17.9) 
 17    (20.2) 
 32    (38.1) 
 20    (23.8) 
 84  (100.0) 
1.6 
1.0 
* Total does not equal 100 due to rounding error 
a Determine about how many daytime hours are spent lying sown because of pain these days? 
Less than one hour per day = 0 
Greater than one but less than two hours per day = 1 
Two to four hours per day = 2 
More than four hours per day = 3 
b All patients enrolled in the study at baseline excluding outliers 
c All patients who completed baseline and follow-up assessments excluding outliers 
d All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
 
 
4.3.6.5 Observed Pain Behaviors 
 
Observed pain behaviors were defined as those behaviors observed by the 
interviewer during the interview.  Various pain behaviors were listed on the data 
collection sheet.  Observed pain behaviors were endorsed on the sheet.  The score for 
observed pain behaviors was calculated as follows: 
Interview behavior: Score is highest rating corresponding to an 
endorsed item (i.e., the rating of the most dramatic pain behavior); or 
score 3 points if pain behavior clearly varied with topic being 
discussed.302 
                                                 
302 Ibid. 
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Table 4.24 presents the frequency distribution and descriptive statistics for the 
item which assessed observed pain behaviors for enrolled, evaluable, and non-
evaluable patients at baseline and follow-up.  The distribution of patients who 
received a score of zero (0) on the item which assessed observed pain behaviors was 
as follows: enrolled patients (n = 16, 12.9%), evaluable patients at baseline (n = 12, 
14.3%) and follow-up (n = 28, 33.3%), and non-evaluable patients (n = 4, 10.0%).  
The distribution of patients who received a score of one (1) on the item which 
assessed observed pain behaviors was as follows: enrolled patients (n = 36, 29.0%), 
evaluable patients at baseline (n = 22, 26.2%) and follow-up (n = 22, 26.2%), and 
non-evaluable patients (n = 14, 35.0%).  The distribution of patients who received a 
score of two (2) on the item which assessed observed pain behaviors was as follows: 
enrolled patients (n = 32, 25.8%), evaluable patients at baseline (n = 22, 26.2%) and 
follow-up (n = 15, 17.9%), and non-evaluable patients (n = 10, 25.0%).  The 
distribution of patients who received a score of three (3) on the item which assessed 
observed pain behaviors was as follows: enrolled patients (n = 40, 32.3%), evaluable 
patients at baseline (n = 28, 33.3%) and follow-up (n = 19, 22.6%), and non-
evaluable patients (n = 12, 30.0%). 
Results from an independent samples t-test (t = 0.17, df = 122,  p = 0.85) showed 
that the baseline mean score on the item which assessed observed pain behaviors for 
evaluable patients (mean = 1.79 sd = 1.0) was not significantly different from the 
mean score for non-evaluable patients (mean  = 1.75, sd = 1.0) at the 95 percent 
confidence level.  Results from a paired-samples t-test (t = 3.40, df = 83, p < 0.01) 
showed that the mean score provided by evaluable patients at follow-up (mean = 
1.29, sd = 1.1) on the item which assessed observed pain behavior was significantly 
lower than the mean score provided at baseline (mean difference = 0.49 sd = 1.3).  
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Table 4.24 Frequency Distribution and Descriptive Statistics of Observed 
Pain Behaviors for Enrolled, Evaluable, and Non-Evaluable Patients at 
Baseline and Follow-up 
Observed Pain 
Behaviorsa 
 
Enrolled  
Patientsb  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsc 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
0 
1 
2 
3 
 Total 
 Mean 
SD 
16     (12.9) 
36     (29.0) 
32     (25.8) 
40     (32.3) 
124 (100.0) 
1.7 
1.0 
12      (14.3) 
22      (26.2) 
22      (26.2) 
28      (33.3) 
84    (100.0) 
1.7 * 
1.0 
  4      (10.0) 
14      (35.0) 
10      (25.0) 
12      (30.0) 
40    (100.0) 
1.7 
1.0 
28      (33.3) 
22      (26.2) 
15      (17.9) 
19      (22.6) 
84    (100.0) 
1.2 * 
1.1 
aDescribe the patient’s pain behavior that you observed in the interview: 
 Held or grasped the area that hurt = 1 
 Winced or cringed = 2 
 Moaned = 3  
 Paced = 3  
 Changed position frequently = 1  
 Took medications = 3 
 Became irritable = 2 
 Asked to stop interview = 3 
 Said it hurt, not in direct response to a question or statement by the interview, with 
 
 much affect = 3 
 little affect = 2  
 some affect = 2  
 no affect = 1 
 Asked to call doctor = 3 
 No pain behavior was observed = 3 (0  if patient is currently getting very much or total relief from 
treatment). 
Score is highest rating corresponding to an endorsed item (i.e., the rating of the most dramatic 
pain behavior); or score 3 points if pain behavior clearly varied with topic being discussed.303 
bAll patients enrolled in the study at baseline excluding outliers 
cAll patients who completed baseline and follow-up assessments excluding outliers 
dAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
       *  p < 0.01 
 
 
 
 
   
                                                 
303 Ibid. 
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4.3.7 Digit Span Test (DST) 
 
The digit span test consists of two subtests, the digits span forwards and backwards.  
In the digits forward test, subjects are required to repeat the numbers in the same 
sequence as the examiner. Eight sequences of numbers are presented, with sequences 
ranging from two to nine numbers.  For each sequence, two trials are presented.  The 
procedure is followed until the patient fails to correctly repeat two trials of the same 
sequence.  Total score is the number of sequences correctly repeated.   
 Table 4.25 presents the frequency distributions and descriptive statistics of the 
digits forward and backward test for enrolled, evaluable, and non-evaluable patients 
at baseline and follow-up.   
The distribution of patients who received a raw score ranging from one to four on 
the digits forward test was as follows: enrolled patients (n = 1, 0.8%), evaluable 
patients at baseline (n = 1, 1.2%) and follow-up (n = 0, 0.0%), and non-evaluable 
patients (n = 0, 0.0%).  The distribution of patients who received a raw score ranging 
from five to eight on the digits forward test was as follows: enrolled patients (n = 46, 
37.1%), evaluable patients at baseline (n = 28, 33.3%) and follow-up (n = 24, 28.5%), 
and non-evaluable patients (n = 18, 45.0%).  An equal number (n = 47, 56.0%) of 
evaluable patients at baseline and follow-up obtained a score on the digits forward 
test that ranged from nine to twelve. 
 Results from an independent samples t-test (t = 0.56, df = 122, p = 0.57) showed 
that the mean score of evaluable patients on the digits span forward test at baseline 
(mean = 9.42, sd = 2.2) was not significantly different from that of non-evaluable 
patients (mean = 9.17, sd = 2.6).   Results from a paired-samples t-test (t = 4.31, df = 
83, p < 0.01) showed that the mean score of evaluable patients on the digits span 
forward test at follow-up (mean = 10.20, sd = 2.3) was significantly greater than that 
at baseline (mean difference = 0.77, sd = 1.6). 
Participants can receive a maximum score of 16 on the digits forward test.  Average 
span in the normal population is 6 (sd = 1.0).  Patients with a span that is five or 
greater are considered to have a normal span of attention, a span of 4 is indicative of 
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borderline impairment, and a span of 3 indicates impairment.304  A mean score of 
9.42 indicates that the average span among evaluable patients at baseline was in the 
four to five range.  At follow-up, the span was slightly above five. 
For the digits span backward test, participants are expected to recall presented 
numbers in the reverse order.  Seven sequences of numbers are presented, with 
sequences ranging from two to eight numbers.  Total score is the number of 
sequences correctly repeated.  Participants can receive a maximum score of 14 on this 
test. 
Results from table 4.25 showed that the number of evaluable patients who 
received a score of one to four on the digits backward test at baseline (n = 8, 9.5%) 
was twice that at follow-up (n = 4, 4.8%).  The distribution of patients who received a 
raw score ranging from five to eight on the digits backward test was as follows: 
enrolled patients (n = 89, 71.8%), evaluable patients at baseline (n = 63, 75.0%) and 
follow-up (n = 57, 67.9%), and non-evaluable patients (n = 26, 65.0%).  The 
proportion of evaluable patients who received a raw score ranging from nine to 
twelve on the digits backward test increased from baseline (n = 13, 15.5%) to follow-
up (n =21, 25.0%) 
Results from an independent samples t-test (t = 0.98, df = 122, p = 0.32) showed 
that the mean score of evaluable patients on the digits span backward test at baseline 
(mean = 6.72, sd = 1.8) was not significantly different from that of non-evaluable 
patients (mean = 6.32, sd = 2.5).  Results from a paired-samples t-test (t = 3.34, df = 
83, p < 0.01) showed that the mean score of evaluable patients on the digits span 
backward test at follow-up (mean = 7.40, sd = 2.1) was significantly greater than that 
at baseline (mean difference = 0.67, sd = 1.8).  The test-retest reliability coefficients 
for the digit span forward and backward tests were 0.74 and 0.58 respectively. 
 
                                                 
304 Ibid 
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Table 4.25 Frequency Distribution and Descriptive Statistics of Digit 
Span Test for Enrolled, Evaluable, and Non-Evaluable Patients at 
Baseline and Follow-up 
Digit Span Test Enrolled  
Patientsc  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsd 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientse 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsd 
n (%) 
Follow-up 
Scores 
Digits Span 
Forwarda 
1 to 4 
5 to 8 
9 to 12 
13 to 16 
Total 
Mean 
SD 
 
 
    1       (0.8) 
  46     (37.1) 
  63     (50.8) 
  14     (11.3) 
124   (100.0) 
9.3 
2.3 
 
 
  1       (1.2) 
28     (33.3) 
47     (56.0) 
  8       (9.5) 
84   (100.0) 
9.4┼ 
2.2 
 
 
  0       (0.0) 
18     (45.0) 
16     (40.0) 
 6      (15.0) 
40   (100.0) 
9.1 
2.6 
 
 
  0        (0.0) 
24      (28.5) 
47      (56.0) 
13      (15.5) 
84    (100.0) 
       10.2┼ 
2.3 
Digits Span 
Backwardb 
1 to 4 
5 to 8 
9 to 12 
13 to 14 
Total 
Mean 
SD 
 
 
  14     (11.3) 
  89     (71.8) 
  20     (16.1) 
    1       (0.8) 
124   (100.0) 
6.5 
2.1 
 
 
  8       (9.5) 
63     (75.0) 
13     (15.5) 
  0       (0.0) 
84   (100.0) 
6.7┼ 
1.8 
 
 
  6     (15.0) 
26     (65.0) 
  7     (17.5) 
  1       (2.5) 
40   (100.0) 
6.3 
2.5 
 
 
  4       (4.8) 
57      (67.9) 
21      (25.0) 
  2        (2.4) 
84   (100.1*) 
7.4┼ 
2.1 
*Total does not equal 100 due to rounding error 
a Digits span forward test – Maximum score is 16 points 
b Digits span backward test – Maximum score is 14 points 
c All patients enrolled in the study at baseline excluding outliers 
d All patients who completed baseline and follow-up assessments excluding outliers 
e All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
      ┼ p < 0.01 
 
4.3.8 Digit Symbol Test (DSYT) 
 
The test comprises a series of boxes labeled with random numbers ranging from 
one to nine, along with nine symbols that are also identified by numbers.  The subject’s 
task is to copy the appropriate symbol for each corresponding number.  Test score is 
calculated as the total number of symbols that were correctly copied within two minutes. 
Table 4.26 presents the frequency distribution and descriptive statistics of the digit 
symbol test for enrolled, evaluable, and non-evaluable patients at baseline and follow-up.  
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The distribution of patients who received a raw score ranging from one to thirty on the 
test was as follows: enrolled patients (n = 3, 2.4%), evaluable patients at baseline (n = 1, 
1.2%) and follow-up (n = 2, 2.4%), and non-evaluable patients (n = 2, 5.0%).   The 
distribution of patients who received a raw score ranging from 31 to 60 on the digit 
symbol test was as follows: enrolled patients (n = 61, 49.2%), evaluable patients at 
baseline (n = 40, 47.6%) and follow-up (n = 32, 38.0%), and non-evaluable patients (n = 
21, 52.5%).  The distribution of patients who received a raw score ranging from 61 to 90 
on the digit symbol test was as follows: enrolled patients (n = 52, 41.9%), evaluable 
patients at baseline (n = 37, 44.1%) and follow-up (n = 46, 54.8%), and non-evaluable 
patients (n = 15, 37.5%). 
Results from an independent samples t-test (t = 1.56, df = 122, p = 0.12) showed 
that the mean score of evaluable patients on the digit symbol test at baseline (mean = 
62.1, sd = 16.3) was not significantly different from that of non-evaluable patients (mean 
= 56.9, sd = 18.6).  Results from a paired-samples t-test (t = - 3.81, df = 83, p < 0.01) 
showed that the mean score of evaluable patients on the digit symbol test at follow-up 
(mean = 65.4, sd = 16.3) was significantly greater than that at baseline (mean difference 
= 3.3, sd = 8.1).  The test-retest reliability coefficient for the DSYT test was 0.87. 
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Table 4.26 Frequency Distribution and Descriptive Statistics of Digit 
Symbol for Enrolled, Evaluable, and Non-Evaluable Patients at Baseline 
and Follow-up 
Digit Symbol 
Testa 
Enrolled  
Patientsb  
n (%) 
Baseline 
Scores 
Evaluable  
Patientsc 
n (%) 
Baseline 
Scores 
Non-Evaluable 
 Patientsd 
n (%) 
Baseline 
Scores 
Evaluable 
Patientsc 
n (%) 
Follow-up 
Scores 
Digits Symbol 
Test 
1 to 30 
31 to 60 
61 to 90 
91 to 133 
Total 
Mean 
SD 
 
 
    3       (2.4) 
  61     (49.2) 
  52     (41.9) 
    8       (6.5) 
124   (100.0) 
60.4 
17.2 
 
 
   1      (1.2) 
 40    (47.6) 
 37    (44.1) 
   6      (7.1) 
 84  (100.0) 
62.1* 
16.3 
 
 
   2       (5.0) 
 21     (52.5) 
 15     (37.5) 
   2       (5.0) 
 40   (100.0) 
56.9 
18.6 
 
 
   2       (2.4) 
 32     (38.0) 
 46     (54.8) 
   4       (4.8) 
 84   (100.0) 
65.4* 
16.3 
a Digit symbol test – Maximum score is 133 points 
b All patients enrolled in the study at baseline excluding outliers 
c All patients who completed baseline and follow-up assessments excluding outliers 
d All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
      * p < 0.01 
 
4.3.9 Paced Auditory Serial Addition Test (PASAT) 
 
 The paced auditory serial attention test is a measure of information processing, 
and sustained attention.  Subjects are required to add each successive pair of numbers that 
that are presented in a sequence of fifty numbers. Two PASAT tests were administered, 
in which the presentation rate of each number was set at 2.4 and 2.0 seconds.  Scores for 
each test were calculated as the correct number of responses to each test. 
 Table 4.27 presents the frequency distribution and descriptive statistics of the two 
PASAT tests.  A total of 13 (10.5%) enrolled patients, 6 evaluable patients (7.3%), and 7 
non-evaluable patients (17.5%) responded correctly to 40 percent or fewer items on the 
PASAT 2.4 at baseline.  Among evaluable patients, a larger proportion of patients 
responded correctly to greater than 82 percent of items on the PASAT 2.4 at follow-up (n 
= 39, 46.4%) as compared to baseline (n = 24, 29.3%). 
Results from an independent samples t-test (t = 1.33, df = 114, p = 0.18) showed that the 
mean score of evaluable patients (mean  = 33.7, sd = 9.1) on the PASAT 2.4  was not 
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significantly different from non-evaluable patients (mean = 31.0, sd = 10.8) at baseline.  
Results from a paired-samples t-test (t = -7.15, df = 81, p < 0.01) showed that mean score 
of evaluable patients on PASAT 2.4 at follow-up (mean = 38.4, 9.1) was significantly 
greater (mean difference = 4.6, sd = 5.9) than at baseline. 
The distribution of patients who responded correctly to 40 percent or fewer items 
on the PASAT 2.0 was as follows: enrolled patients (n = 16, 12.9%), evaluable patients at 
baseline (n = 8, 9.7%) and follow-up (n = 3, 3.6%), and non-evaluable patients (n = 8, 
20%).  The distribution of patients who responded correctly to at least 82 percent of the 
items on the PASAT 2.0 was as follows enrolled patients (n = 23, 18.5%), evaluable 
patients at baseline (n = 18, 22.0%) and follow-up (n = 32, 38.1%), and non-evaluable 
patients (n = 5, 12.5%).  Results from an independent samples t-test (t = 2.42, df = 114, p 
= 0.01) showed that the mean score of evaluable patients (mean  = 32.8, sd = 9.4) on 
PASAT 2.0 was significantly higher than non-evaluable patients (mean = 28.09, sd = 9.9) 
at baseline.  Results from a paired sample t-test (t = -5.64, df = 81, p < 0.01) showed that 
mean score of evaluable patients at follow-up (mean = 36.72, 9.0) on PASAT 2.0 was 
significantly greater (mean difference = 3.89, sd = 6.2) than that at baseline. 
 The average score on the PASAT 2.4 and 2.0 tests improved from baseline to 
follow-up.  The test-retest reliability coefficients for the PASAT 2.4 and 2.0 tests were 
0.78 and 0.77 respectively. 
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Table 4.27 Frequency Distribution and Descriptive Statistics of Paced 
Auditory Serial Addition Test  for Enrolled, Evaluable, and Non-
Evaluable Patients at Baseline and Follow-up 
Paced Auditory 
Serial Addition 
Test 
Enrolled  
Patientsc  
n (%) 
Baseline 
Scores 
 
Evaluable  
Patientsd 
n (%) 
Baseline 
Scores 
 
Non-Evaluable 
 Patientse 
n (%) 
Baseline 
Scores 
 
Evaluable 
Patientsd 
n (%) 
Follow-up 
Scores 
 
PASAT 2.4a 
1 to 10 
11 to 20 
21 to 30 
31 to 40 
41 to 50 
Missing 
Total 
Mean  
SD 
 
    0     (0.0) 
  13   (10.5) 
  39   (31.5) 
  30   (24.2) 
  34   (27.4) 
    8     (6.4) 
124 (100.0) 
32.9 
9.7 
 
    0     (0.0) 
    6     (7.3) 
  27   (32.9) 
  25   (30.5) 
  24   (29.3) 
    2     (2.4) 
  84 (100.0) 
33.7 
9.1 
 
   0      (0.0) 
   7    (17.5) 
 12    (30.0) 
   5    (12.5) 
 10    (25.0) 
   6    (15.0) 
 40  (100.0) 
 31.0  
10.8 
 
    0     (0.0) 
    3     (3.6) 
  16   (19.0) 
  24   (28.6) 
  39   (46.4) 
    2     (2.4) 
  84 (100.0) 
38.4 
9.1 
PASAT 2.0b 
1 to 10 
11 to 20 
21 to 30 
31 to 40 
41 to 50 
Missing 
Total 
Mean  
SD 
 
    1     (0.8) 
  15   (12.1) 
  43   (34.7) 
  34   (27.4) 
  23   (18.5) 
    8     (6.5) 
124 (100.0) 
31.4 
9.7 
 
    1     (1.2) 
    7     (8.3) 
  29   (34.5) 
  27   (32.1) 
  18   (21.4) 
    2     (2.4) 
  84 (100.0) 
32.8* 
9.4 
 
   0      (0.0) 
   8    (20.0) 
 14    (35.0) 
   7    (17.5) 
   5    (12.5) 
   6    (15.0) 
 40  (100.0) 
28.0  
9.9 
 
    0     (0.0) 
    3     (3.6) 
  20   (23.8) 
  27   (32.1) 
  32   (38.1) 
    2     (2.4) 
  84 (100.0) 
36.7* 
9.0 
a PASAT 2.4  – Paced Auditory Serial Addition Test with a presentation rate of one number every 
2.4 seconds. Maximum score is 50 points 
b PASAT 2.0  – Paced Auditory Serial Addition Test with a presentation rate of one number every 
2.0seconds. Maximum score is 50 points 
c All patients enrolled in the study at baseline excluding outliers 
d All patients who completed baseline and follow-up assessments excluding outliers 
e All enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
      * p < 0.01 
 
A comparison of PASAT scores from a normal sample and the current sample of 
evaluable pain patients in Table 4.28 suggested that as age increased performance on the 
test worsened.  Pain patients in all three age groups (16 to 29, 30 to 49, and 50 to 69) had 
lower mean scores on both the PASAT 2.4 and 2.0 as compared to the normal sample.  
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These results indicated that as a group, pain patients have a compromised information 
processing ability and reduced ability to maintain sustained attention. 
 
 
Table 4.28 Comparison between a Normal Sample and Evaluable 
Patients at Baseline and Follow-up on the Mean Number of Correct 
Responses to the PASAT 2.4 and 2.0 by Age Group 
16-29  30-49  50-69  Test Study Group 
Mean (SD) Mean (SD) Mean (SD)
Normal Sample (N = 90) 
 
47.4   (10.1)
n = 30 
43.4   (10.2) 
n = 30 
43.5    (13.6)
n = 30 
Evaluable Patients c – 
Baseline (N = 82) 
42       (NA)
n = 1 
33.2     (9.2) 
n = 50 
34.2      (9.2)
n = 31 
PASAT 2.4 a 
Evaluable Patients c - 
Follow-up (N = 82) 
45       (NA)
n = 1 
39.0     (8.9) 
n = 50 
37.2     (9.5)
n = 31 
 
Normal Sample (N = 90) 42.0(12.5) 
n = 30 
41.9   (10.2) 
n = 30 
35.6   (14.6)
n = 30 
Evaluable Patients c – 
Baseline (N = 82) 
40.0    (NA)
n = 1 
32.7     (8.4) 
n = 50 
32.8   (11.0)
n = 31 
PASAT 2.0 b 
Evaluable Patients c - 
Follow-up (N = 82) 
39      (NA)
n = 1 
37.1     (8.1) 
n = 50 
36.0     (9.7)
n = 31 
aPASAT 2.4  – Paced Auditory Serial Addition Test with a presentation rate of one number every 
2.4 seconds. Maximum score is 50 points 
bPASAT 2.0  – Paced Auditory Serial Addition Test with a presentation rate of one number every 
2.0 seconds. Maximum score is 50 points 
cAll patients who completed baseline and follow-up assessments excluding outliers 
 
 
4.4 Beck Depression Inventory (BDI) 
 
The Beck Depression Inventory (BDI) was administered to assess depression.  The 
BDI was originally composed of 22 items.  However, for this study the item assessing 
suicidal ideation was not included.  Thus, the total score on the BDI was calculated 
based on responses to 21 items.  Each item on the inventory includes four responses, 
which are scored from zero to three.  Table 4.29 presents the frequency distribution of 
the sample by categories that enable clinical interpretation of scores.   
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The distribution of patients who were classified with mild mood disturbance was 
as follows: enrolled patients (n = 33, 26.6%), evaluable patients at baseline (n = 27, 
32.1%) and follow-up (n = 25, 29.8%), and non-evaluable patients (n = 6, 15.0%).  A 
greater proportion of non-evaluable patients (27.5%, n =11) as compared to evaluable 
patients at baseline (20.2%, n = 17) and follow-up (16.7%, n = 14) were classified 
with borderline clinical depression. 
The distribution of patients who were classified with moderate depression was as 
follows: enrolled patients (n = 31, 25.0%), evaluable patients at baseline (n = 22, 
26.2%) and follow-up (n = 16, 19.0%), and non-evaluable patients (n = 9, 22.5%).  
The number of non-evaluable patients (n = 12, 30.0%) who were categorized with 
severe depression was three times the number of evaluable patients (n = 4, 4.8%) in 
that category at baseline. 
Results from an independent samples t-test (t = -2.67, df = 122, p < 0.01) showed 
that the mean score of evaluable patients (mean  = 18.7, sd = 9.0) on the BDI was 
significantly lower than non-evaluable patients (mean = 23.2, sd = 8.1) at baseline.  
Results from a paired sample t-test (t = 5.22, df = 83, p < 0.01) showed that the mean 
score of evaluable patients at follow-up (mean = 14.5, sd = 8.8) was significantly 
lower (mean difference = 4.2, sd = 7.3) than that at baseline. 
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Table 4.29  Frequency Distribution and Descriptive Statistics of Beck 
Depression Inventory for Enrolled, Evaluable, and Non-Evaluable 
Patients at Baseline and Follow-up 
Beck Depression 
Inventory 
Enrolled  
Patientsa 
n (%)  
Baseline 
Scores 
 
Evaluable  
Patientsb 
n (%) 
Baseline 
Scores 
 
Non-Evaluable 
 Patientsc 
n (%) 
Baseline 
Scores 
 
 
Evaluable 
Patientsb 
n (%) 
Follow-up 
Scores 
 
These ups and downs 
are considered normal 
(0 to 10) 
 
14   (11.3) 
 
  12   (14.3) 
 
   2    (5.0) 
 
 
  26  (30.9) 
Mild mood disturbance 
(11 to 16) 
 33   (26.6)   27   (32.1)    6  (15.0)   25  (29.8) 
Borderline clinical 
depression (17 to 20) 
 28   (22.6)   17   (20.2)  11  (27.5)   14  (16.7) 
Moderate depression  
(21 to 30) 
 31   (25.0)   22   (26.2)  9  (22.5)   16  (19.0) 
Severe depression  
(31 to 40) 
 16   (12.9)    4      (4.8)  12  (30.0)     2    (2.4) 
Extreme depression  
(41 or greater) 
   2     (1.6)    2      (2.4)    0    (0.0)     1    (1.2) 
Total 124 (100.0)   84  (100.0) 40 (100.0)  84 (100.1) 
Mean  
SD 
20.21 
9.0 
18.75* 
9.0 
23 .28 
 8.1 
14.54* 
 8.8 
aAll patients enrolled in the study at baseline excluding outliers 
bAll patients who completed baseline and follow-up assessments excluding outliers 
cAll enrolled patients who dropped out of the study or were lost to follow-up excluding outliers 
      * p < 0.01 
Results from a multiple regression analysis (F = 11.21, p < 0.001) showed that items 
on the negative emotions scale (depression, anxiety, frustration, anger, and fear) 
explained a third of the variance (R2 = 0.32) in Beck Depression Inventory scores.   
The “depression” item accounted for 25.4 percent of the variance (R2 = 0.25) in the BDI 
scores.  The results suggest that there is some overalap between BDI scores and the 
negative emotions scale.   The relative ease and quickness with which the negative 
emotions scale can be administered may justify its use as a supplement to the BDI 
inclinical settings.   
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4.5 Structural Equation Modeling 
 
 
This section of the results chapter addresses the measurement and factor structure 
of the stages of pain model.  A structural equation modeling (SEM) procedure was used 
to determine fit of the current data to the stages of pain model.  An overview of some 
general modeling conventions is presented below.  The stages of pain model will be 
addressed subsequently 
SEM is a statistical technique, which relies on existing information to postulate 
the causal structure of a given set of data.305  The methodology serves to confirm 
relationships between unobserved variables (construct/factor/latent) and items believed to 
represent it.  The latent variable can be measured indirectly through observed phenomena 
or behaviors, which are referred to as indicators.   This procedure is commonly referred 
to as a confirmatory factor analysis and represents the measurement portion of a SEM.  
Additionally, relationships between latent variables may be examined.  This portion of 
the model is referred to as the structural model (Figure 4.1). 
In Figure 4.1, the variable “F” represents a latent construct.  The variables 
denoted as “V” are observed indicators that load on the latent.  The terms labeled “E” 
refer to measurement error associated with the observed indicators, while “D” represents 
the disturbance term associated with the regression of one latent on another.  The 
associations modeled in Figure 4.1 may be represented with the following set of 
equations: 
  F2 = F1 + D2 
  V1 = F1 + E1 
  V2 = F1 + E2 
  V3 = F1 + E3 
  V4 = F2 + E4 
  V5 = F2 + E5 
                                                 
305 Byrne BM.  Structural Equation Modeling with EQS and EQS/Windows.  Sage Publications Inc.  
Thousand Oaks, CA.  1994. 
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  V6 = F2 + E6 
Figure 4.1 – Components of a Structural Equation Model306 
 
 
The fit of the hypothesized model to the data is compared with that of the null 
model (i.e., no structure imposed on the data).  Overall model fit is usually determined on 
the basis of the exact chi-square test.  Model modifications may be performed to improve 
fit to the data.  
A non-significant value of the chi-square statistic (p > 0.05) indicates that fit of 
the over-identified model does not differ from fit of the null model, and the hypothesized 
                                                 
306 Ibid 
F1 
V1 
V2 
V3 
F2 V5
V4
V6
E1 
E2 
E3 
E4 
E5 
E6 
D2
Structural Model
Measurement Model
F1, F2 – Unobserved latent variable (factor) 
V1 to V6 – Observed variable 
F          V – Path coefficient for regression of observed variables onto factor 
F          F – Path coefficient for regression of one factor onto another 
D          F – Residual error (disturbance) in prediction of factor  
E          V – Measurement Error Associated with Observed Variable 
E          E – Measurement Error between V4 and V5 is correlated 
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model is acceptable.307  In order to adequately assess factor loadings and latent structure 
of the current model, the following goodness of fit indices were utilized: comparative fit 
index (CFI), standardized root mean square residual (SRMR), root mean square error of 
approximation (RMSEA), normed fit index (NFI), and goodness of fit index (GFI).308  
The recommended cutoff values for goodness of fit indices considered for this study are 
provided in Table 4.30 below309: 
 
  
Table 4.30 Cutoff Values for Fit Indices 
 
Fit Index 
 
Cutoff Values 
Bentler-Bonett Normed Fit Index (NFI) 0.90 
Comparative Fit Index (CFI) 0.95 
Joreskog-Sorbom Goodness of Fit Index (GFI) 0.95 
Standardized Root Mean Square Residual (SRMR) 0.08 
Root Mean Square Error of Approximation (RMSEA) 0.06 
 
4.5.1 Overview of Modeling Approach 
  
 The overall approach to obtain fit of the stages of pain model (SOPM) to current 
data is outlined below.  The hypothesized (original) SOPM was tested first.  This model 
included all the stages of pain model variables.  Since this model did not fit the baseline 
data adequately, modifications were made to resemble a previously published model.  
Even though this model fit the baseline data adequately, fit improvements were made by 
allowing the correlation between errors of two indicators to be estimated freely.  
However, errors were encountered when this model (i.e., model resembling the 
previously published SOPM with correlated errors) was fit to follow-up data.  
Consequently, offending indicators were removed and the model was tested with both 
baseline and follow-up data.  Although the model with correlated errors fit baseline data, 
                                                 
307 Kline RB.  Principles and practice of structural equation modeling.  The Gulford Press.  New York, NY. 
1998.  
308 Hu L, Bentler PM.  Fit indices in covariance structure modeling: sensitivity to underparametrized model 
misspecification.  Psychological Methods.  1998;3:424-453. 
309 Hu L, Bentler PM.  Cutoff criteria for fit indexes in covariance structural analysis: conventional criteria 
versus new alternatives.  Structural Equation Modeling.  1999;6:1-55. 
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the procedure for removing indicators was followed to maintain equality in the 
measurement and structural portions of the model for both waves of data.  Removal of the 
offending indicators resulted in excellent model fit.  In order to assess model reliability, 
the final model with baseline and follow-up data were subjected to simultaneous 
constraints.   
 Adequate reliability enabled the construction of two-wave models, which 
controlled for autocorrelation between baseline and follow-up data.  The subsequent 
section addresses two-wave models.  
4.5.2 Baseline Stages of Pain Model - Original 
 
The original stages of pain model was composed of four latent variables or 
factors: pain intensity, pain unpleasantness, pain suffering, and pain behaviors.     The 
pain intensity factor was composed of three items, i.e., pain intensity at the highest, 
lowest and usual levels in the previous week.  The pain unpleasantness factor was 
composed of three items, i.e., pain unpleasantness experienced at the three pain intensity 
levels in the previous week.  The pain suffering factor was composed of negative 
emotions (depression, anxiety, frustration, anger, and fear) and negative beliefs (pain 
interference, ability to endure pain, ability to control pain, and belief that pain will be 
cured).  The pain behaviors factor was composed of five factors: pain behavior at home, 
social reinforcement of pain behavior, family or home related responsibilities, pain 
contingent down time, and observed pain behaviors. 
Table 4.31 shows that factor loadings estimated for the original stages of pain 
model in the current study were comparable to those estimated in a previous confirmatory 
factor analysis.310  The measurement and structural components of the stages of pain 
model can be viewed in Figure 4.2.  The chi-square value for the original stages of pain 
model was 349.6 with 167 degrees of freedom ( p < 0.001).  The goodness of fit statistics 
(Table 4.32) suggested that the data do not fit the model adequately. 
                                                 
310 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
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Three indicators were dropped from subsequent analysis, since weak factor 
loading estimates were observed: belief that pain will be cured (-0.02), social 
reinforcement for pain behavior (0.17), and observed pain behaviors (0.29).  
Table 4.31 Comparison of Factor Loadings for Pain Intensity, Pain 
Unpleasantness, Pain Suffering, and Pain Behavior Constructs between 
Current Study and Wade et al. Study 
 
Factor Loading Construct Indicator 
Current 
Study 
Wade et 
al.311 
Study 
PI – Highest Level 0.62 0.45 
PI – Lowest Level 0.81 0.69 
Pain Intensity (PI) 
PI – Usual Level 0.87 0.89 
 
PU – Highest Level 0.59 0.60 
PU – Lowest Level 0.85 0.64 
Pain Unpleasantness 
(PU) 
PU – Usual Level 0.88 0.95 
 
Pain Suffering (PS)    
Pain Interference 0.38 0.43 
Ability to Endure Pain 0.63 0.47 
Ability to Control Pain -0.38 0.14 
Negative Beliefs 
Belief that Pain will be Cured -0.02 0.15 
 
Depression 0.70 0.78 
Anxiety 0.75 0.68 
Frustration 0.78 0.75 
Fear 0.54 0.57 
Negative Emotions 
Anger 0.68 0.62 
 
Pain Behaviors (PB) Pain Behavior at Home 0.73 0.52 
Social Reinforcement of Pain 
Behavior 
0.17 0.55 
Home and Family Related 
Responsibilities 
0.56 0.49 
Pain Contingent Down Time 0.38 0.26 
 
Observed Pain Behaviors 0.29 0.35 
 
                                                 
311 Ibid 
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Figure 4.2 Standardized Parameter Estimates of Original Baseline 
Stages of Pain Confirmatory Factor Model 
 
PI-pain intensity, PU-pain unpleasantness, Pain Endurance – ability to endure pain, Pain control-ability to 
control pain, Pain Cure-belief that pain will be cured, PBHome-pain behavior at home, SR-social 
reinforcement of pain behavior, Responsibility-home and family responsibilities, sleep-pain contingent 
down time, pi/uh- pain intensity/unpleasantness at highest level, pi/ul-pain intensity/unpleasantness at 
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lowest level, pi/uu-pain intensity/unpleasantness at usual level, pin-pain interference, pe-pain endurance, 
pr-pain reduction, pc-pain cure, d-depression, a-anxiety, fr-frustration, an-anger, f-fear, pbh- pain behavior 
at home, resp-responsibility, sr-social reinforcement of pain, pbo- observed pain behavior.          
 
 
NFI – Bentler-Bonett Normed Fit Index 
CFI – Comparitive Fit Index 
GFI – Lisrel GFI Fit Index 
SRMR – Standardized Root Mean Square Residual 
RMSEA – Root Mean Square Error of Approximation 
90%CI – 90 percent Confidence Interval 
 
4.5.3 Baseline Stages of Pain Model - Modified 
 
The next step in the analysis was to estimate a measurement model that was 
similar to the model which provided Wade and colleagues the best fit to their data.  
Wade’s best fitting model excluded the following indicators from the original model: 
negative belief indicators, pain intensity and unpleasantness indicators at highest and 
lowest pain intensity levels, and the pain contingent down time indicator.   
Thus, a model that closely resembled Wade’s best fitting model was constructed.  
The modified model was referred to as the baseline stages of pain model – modification 1 
(See Figure 4.3).  This model included four factors: pain intensity, pain unpleasantness, 
pain suffering, and pain behaviors.  The pain intensity factor was composed of a single 
indicator, i.e., pain intensity at the usual level.  The pain unpleasantness factor was 
Table 4.32 Goodness of Fit Statistics for the Stages of Pain Model 
 
Variable 
 
Chi square, df 
       p – value 
NFI CFI GFI SRMR RMSEA 90%CI 
RMSEA 
Baseline  
Original Model 
349.5,  167 
 p < 0.001 
0.69 0.80 0.77 0.08 0.09 0.08,   0.10 
Baseline 
Modification_1 
32.4, 34 
 p = 0.54 
0.92 1.00 0.95 0.05 0.00 0.00,   0.06 
Baseline 
Modification_2  
27.5, 33 
 p = 0.73 
0.93 1.00 0.95 0.05 0.00 0.00,   0.04 
Follow-up 
Modification_2 
54.8, 33 
p = 0.01 
0.88 0.95 0.89 0.07 0.08 0.04,   0.12 
Baseline 
Final Model 
9.8, 12 
P = 0.63 
0.95 1.00 0.98 0.03 0.00 0.00,   0.07 
Follow-up  
Final Model 
19.5, 12 
p = 0.10 
0.91 0.96 0.94 0.07 0.07 0.00,   0.14 
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composed of a single indicator, i.e., pain unpleasantness at the usual level.  The pain 
suffering factor was composed of the negative emotions (depression, anxiety, frustration, 
anger, and fear).  The pain behaviors construct was composed of three indicators, namely, 
pain behaviors at home, home and family related responsibilities, and pain contingent 
down time.   The model evaluated with the current baseline data in this step was similar 
to Wade’s best fitting model except for the indicators used to estimate the pain behavior 
factor.  The previous best fitting model had excluded the “pain contingent down time” 
indicator, while including the observed pain behaviors and social reinforcement for pain 
behaviors indicators. The latter two indicators were dropped from this analysis due to 
non-significant factor loadings as described above.    
In order to estimate any meaningful model, the degrees of freedom in the model 
being tested should be greater than the corresponding null model.  Models containing 
factors with single indicators may be over-identified by fixing measurement error 
variance to zero or by providing reasonable start values or best guess estimates.  Fixing 
error variance to zero assumes that the indicator has been measured perfectly.  Since the 
pain intensity and pain unpleasantness factors were composed of single indicators, the 
measurement error variance estimates of each indicator generated in the previous run of 
the model were utilized as “best guess estimates” of measurement error variances for the 
average pain intensity and pain unpleasantness indicators in subsequent models. 
Model fit improved significantly for the baseline stages of pain model – 
modification 1 (chi-square = 32.4, df = 34, p = 0.54).  The chi-square and goodness of fit 
statistics indicate that the model fits the data well (Table 4.30).  Results from the 
modification indices suggested that the chi-square statistic would decrease further by 
freely estimating the covariance between measurement errors of the “pain contingent 
down time” and “home or family related responsibilities” indicators.  The resulting 
modified model, which was referred to as baseline stages of pain model – modification 2 
can be viewed in Figure 4.4.  The results indicated a significant improvement in model fit 
(chi-square = 27.5, df = 33, p = 0.73).    Goodness of fit statistics for this model are 
presented in Table 4.30. 
 
  
 213
 
 
 
Figure 4.3 Unstandardized Parameter Estimates of Baseline Stages of 
Pain Confirmatory Factor Model – Modification 1 
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Figure 4.4 Unstandardized Parameter Estimates of  Baseline Stages of 
Pain Confirmatory Factor Model – Modification 2 
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4.5.4 Follow-up Stages of Pain Model – Modification 2 
 
A model similar to the baseline stages of pain model – modification 2 was 
estimated with the follow-up data.  The measurement and structural components of 
the follow-up stages of pain model – modification 2 can be viewed in Figure 4.5.  The 
results from the follow-up data indicated that the model failed to fit the data 
adequately and should be rejected (chi square = 54.8, d.f. = 33, p = 0.01). 
An examination of the residual covariance matrix showed that residual variances 
for three indicators of the pain suffering construct (frustration, anger, and fear) were 
negative.  The magnitude of the negative variances for frustration, anger, and fear 
indicators were -0.62, -0.01, and -0.01 respectively.  Negative residual variance is 
indicative of multicollinearity, which may contribute to model misspecification.312  
Additionally, these indicators would have contributed to estimation problems in 
subsequent models.  Thus, these indicators were dropped from the follow-up and 
baseline models. 
Removal of the offending indicators resulted in excellent model fit for both the 
baseline and follow-up models.   The model without the three indicators will be 
referred to as the stages of pain model – final model.  The measurement and structural 
components of the stages of pain – final model at baseline and follow-up can be 
viewed in Figures 4.6 and 4.7, respectively.    
The chi-square fit test showed that the stages of pain - final model at baseline 
(chi-square = 9.8, df = 12, p = 0.63) and follow-up (chi-square = 19.5, df = 12, p = 
0.10) fit the data adequately.  Goodness of fit indices for these models can be viewed 
in Table 4.30. 
 
 
 
 
                                                 
312 Estimator conditioning diagnostics for covariance structure models.  Sociological Methods and 
Research.  1994;23:200-229. 
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Figure 4.5 Unstandardized Parameter Estimates of Follow-up Stages 
of Pain Confirmatory Factor Model – Modification 2 
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Figure 4.6 Unstandardized Parameter Estimates of Baseline Stages of 
Pain Confirmatory Factor Model – Final Model 
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Figure 4.7 Unstandardized Parameter Estimates of Follow-up Stages of Pain 
Confirmatory Factor Model – Final Model 
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In order to determine the stability of the stages of pain model –final model from 
baseline to follow-up, the two models were compared simultaneously with and without 
constraints (Table 4.33).  In each step, additional constraints such as equal 
measurement weights, equal measurement intercepts, equal structural weights, equal 
structural intercepts, equal structural means, equal structural covariances, equal 
structural residuals, and equal measurement residuals were imposed on the two models 
simultaneously. 
Simultaneous analysis of the baseline and follow-up final models showed that 
model fit to the data was adequate when factor loadings at baseline and follow-up were 
constrained to be equal (Table 4.33 – model with factor loadings constrained to be 
equal).  The results suggested that the constructs being measured at baseline and 
follow-up are reliable.  The baseline and follow-up stages of pain model can be 
described as having partial measurement invariance.313  
                                                 
313 Byrne BM, Shavelson RJ, Muthen B.  Testing for the equivalence of factor covariance and mean 
structures:  The issue of partial measurement invariance.  Psychological Bulletin.  1989;105:456-466. 
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Table 4.33 Results of the Simultaneous Comparison of  Baseline and 
Follow-up Stages of Pain – Final Models  
Model (Type of 
Constraint) Chi-square DF P Chi-square/DF 
Unconstrained 32.272 24 .120 1.345 
Model 1a 34.510 27 .152 1.278 
Model 2 b 67.801 34 .001 1.994 
Model 3 c 68.483 37 .001 1.851 
Model 4 d 68.483 37 .001 1.851 
Model 5 e 68.483 37 .001 1.851 
Model 6 f 73.737 38 .000 1.940 
Model 7 g 73.737 38 .000 1.940 
Model 8 h 73.737 38 .000 1.940 
Saturated model .000 0   
Independence model 396.297 42 .000 9.436 
aFactor loadings are constrained to be equal 
bFactor loadings and measurement intercepts are constrained to be equal 
cFactor loadings, measurement intercepts, and structural weights are constrained to be equal 
dFactor loadings, measurement intercepts and structural weights and intercepts are constrained to be 
equal 
e Factor loadings, measurement intercepts, structural weights and intercepts, and structural means are 
constrained to be equal 
f Factor loadings, measurement intercepts, structural weights and intercepts, and structural means and 
covariances are constrained to be equal 
gFactor loadings, measurement intercepts, structural weights and intercepts, and structural means and 
covariances, and structural residuals are constrained to be equal 
hFactor loadings, measurement intercepts, structural weights and intercepts, and structural means and 
covariances, and structural and measurement residuals are constrained to be equal 
 
 
4.6 Two-Wave Models 
 
It was demonstrated above that indicators at baseline and follow-up were reliable 
measures of the latent constructs they were believed to represent.  Thus, this section of 
the results chapter is concerned with the analysis of data collected at baseline and 
follow-up simultaneously.  All two-wave models incorporated data from only patients 
who completed both baseline and follow-up assessments.  Data collected for the same 
individuals over two or more time periods are often correlated.  In order to analyze the 
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effects of an intervention, the effects of baseline variables on corresponding follow-up 
variables should be controlled.  
Data collected over two waves may be modeled with synchronous and/or lagged 
effects. 
Equation 4.1 represents a basic regression model: 
Yt = β0 + β1Xt + εt  ……………………4.1 
 
Yt = β0 + β1Xt + β2Yt-1 + εt  ………..…4.2 
Yt in equation 4.2 is assumed to be predicted from exogenous variable (Xt), the lagged 
dependent variable (Yt-1) and a random error term with constant variance, with no 
autocorrelation and no correlation with any of the predictor terms in the equation.  
Panel data represented in equation 4.2 model only the synchronous or co-temporal 
effect. An implicit assumption of the model is that the effect of X on Y is almost 
immediate.  “It cannot be claimed that X causes Y instantaneously, but rather the causal 
lag for X to influence Y is short, relative to the time elapsed between waves of 
measurement.”314 
For situations in which there is a lag or delay between the effect of X on Y, and the 
interval between two measurements exceeds the delay, a lagged model may be more 
appropriate.  In a lagged model, Xt would be replaced by Xt-1 in equation 4.2.   The 
identification of the lagged causal structure is a complex issue due to a general lack of 
knowledge about the time required by one variable to influence another and the relation 
of this lag to the time intervals in which data is measured.  Therefore, Finkel suggests 
that specification of the lag structure should be influenced by theory first and data next.  
Models with both synchronous and lag effects may be estimated together.  Such a 
model would be represented as: 
 
Yt = β0 + β1Xt + β2Yt-1 + β3Xt-1 εt  ……4.3 
  
                                                 
314 Finkel SE.  Causal analysis with panel data.  Sage Publications. 1995.   Thousand Oaks, CA.  pp 12. 
  
 222
In the present study, long-acting morphine therapy was introduced at the time of 
baseline assessments as part of the therapeutic strategy.  The objective of the study was 
to evaluate the effects of long-acting morphine therapy on pain and cognitive function 
at follow-up.  In order to evaluate this objective, a synchronous effects model of the 
two-wave data seemed most appropriate. 
 
4.6.1 Stages of Pain – Two Wave Model 
 
The best fitting baseline and follow-up stages of pain models (final models) were 
combined to form a longitudinal (two-wave) model.  As described above, only 
synchronous effects were analyzed in this model.  Paths from each factor at baseline to 
the corresponding factor at follow-up were estimated.  The covariance paths between 
measurement errors of the same indicator at baseline and follow-up were also estimated 
to account for autocorrelation.  The resulting model is depicted in Figure 4.8.  Although 
measurement error paths were estimated, they are not drawn in the figure due to space 
considerations.  No additional constraints were imposed on this model.  According to 
the exact chi-square fit test (chi square = 72.2, df = 65,  p 0.25), the data fit the two-
wave stages of pain model adequately.   
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Figure 4.8 Unstandardized Parameter Estimates of the Two-Wave Stages of Pain Confirmatory Factor Model – Final Model 
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4.6.2 Hypothesized Study Model 
 
 
The next step in the analysis was to determine fit of the hypothesized study 
model.  A total of three tests, digit span test (DST), digit symbol test (DSYT), and paced 
auditory serial addition test (PASAT), which assess cognitive function were administered 
to patients.  Thus, three models, each evaluating the associations between a test of 
cognitive function and various exogenous and endogenous variables, were constructed.   
Except for the dependent variables, all three models (DST, DSYT, and DSYT) 
included common factors.  Each model included the following factors: 
• Age 
o This factor was formed with a single indicator, i.e. reported age.  In order 
to estimate a factor with a single indicator, the error variance associated 
with a single indicator may be estimated or assumed to be zero.  Age was 
assumed to have been measured perfectly, and thus, the error variance 
associated with this indicator was fixed to zero. 
• Gender 
o Gender was reported in a dichotomous fashion, i.e., male or female.  This 
factor was composed of a single indicator.  Gender was assumed to have 
been measured perfectly, and thus, the error variance associated with this 
indicator was fixed to zero. 
• Ethnicity/Race 
o Patients reported their ethnicity during the interview.  A majority of the 
respondents (n = 53, 61%) were Caucasian.  For the SEM analysis, this 
variable was dichotomized to represent two groups, i.e., Caucasians and 
others.  The reported ethnicity indicator used to form this construct was 
assumed to have been measured perfectly.  Thus, the error variance 
associated with this indicator was fixed to zero. 
• Stages of pain model factors – Final Model: 
o The stages of pain final model included the following constructs at 
baseline and follow-up: pain intensity, pain unpleasantness, pain suffering 
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and pain behaviors.  The measurement and structural portions of the 
SOPM were described above. 
• Valium equivalent dose (VED) 
o VED was calculated by converting patient-reported average daily 
benzodiazepine dose into standard valium equivalent units.  Thus, an 
average daily valium equivalent dose was calculated.  A natural log 
transformation was applied to this variable.  The purpose of the 
transformation was to minimize the magnitude of difference in the 
variance of modeled variables as described in Section 4.1.3 (See Table 
4.2).    Thus, the natural log transformations of the VED (lnVED) served 
as the indicator for the VED factor.  Measurement error variance 
associated with the lnVED indicator was calculated using the formula: 
 
Measurement Error variance = (1 – reliability) * Variance…. 4.4 
 
Based on the values in Table 4.34, measurement error variance associated 
with lnVED was estimated to be 0.17. 
• Morphine Equivalent Dose at baseline (MEDB) and follow-up (MEDF) 
o MEDB and MEDF were calculated by converting the average daily 
narcotic analgesic doses at baseline and follow-up into morphine 
equivalent units.  As described in the data screening procedures, large 
skewness and kurtosis values were observed for MEDB and MEDF, 
which suggested that these variables did not follow a normal 
distribution.  Therefore, natural log transformations were applied to 
MEDB and MEDF  values. These transformed values, i.e., lnMEDB and 
lnMEDF served as single indicators for MEDB and MEDF factors.  
Measurement error variance for lnMEDB (0.15) and lnMEDF (0.10) 
was estimated by substituting values from Table 4.34 in equation 4.3. 
The formation of the dependent variable factors will be discussed separately, 
along with the results for each model. 
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Table 4.34 Measurement Error Variance Estimates of Single Indicators 
Utilized in the Hypothesized Models 
 
Variable      Variance Test- Re-test 
Reliability 
(Cronbach’s α) 
Measurement 
Errora 
lnMED 
Baseline 
Follow-up 
 
0.44 
0.28 
 
0.65 
0.65 
 
0.150 
0.100 
 
lnVED 
 
 
1.7 
 
0.9* 
 
0.170 
lnDST 
Baseline 
Follow-up 
 
0.08 
0.07 
 
0.87 
0.87 
 
0.010 
0.009 
* Although lnVED was a constant from baseline to follow-up, random error was assumed to be 0.1  
a Measurement Error variance = (1 – reliability) * Variance 
 
In order to estimate models with single indicators, the error variance associated 
with a single indicator may be assumed to take a value of zero.  Alternatively, the error 
variance for single indicatory may be estimated.  The factor loadings for each of the 
exogenous single indicators (age, gender, ethinicity/race) were fixed to one (1) and the 
error variance estimate was assumed to be zero.  The exogenous factors were assumed to 
have been measured perfectly.   
An alternate conceptualization of latent constructs of single indicators involves 
estimating the measurement error associated with these indicators.  Estimates of 
reliability may be generated from the literature or the sample data.  Measurement error 
variance of a single indicator used to form a latent factor was estimated with the 
following formula:315,316 
 
 Measurement Error variance = (1 – reliability) * Variance 
 
 
 
                                                 
315  Hayduk L.  Structural Equation Modeling with LISREL: Essentials and Advances(pages 119-122).  
1987 Johns Hopkins University Press. 
316 Hayduk L.  LISREL Issues Debates and Strategies (pages25-30).  1996, Hopkins University Press. 
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4.6.2.1 Autocorrelated Errors 
 
This section continues to address the measurement component of the two-wave 
study model. 
Since data for all variables except age, gender, ethnicity, and VED varied from 
baseline to follow-up, measurement error terms of corresponding indicators at 
baseline and follow-up were assumed to be autocorrelated.  Thus covariance paths 
between each indicator at baseline and follow-up were freely estimated. 
However, lnMEDB and lnMEDF were not assumed to be autocorrelated.  The 
measure at baseline was composed of total morphine equivalent dose of short-acting 
narcotic analgesic.  The measure at follow-up was the sum of Avinza dose and short-
acting narcotic morphine equivalent dose used for breakthrough pain at follow-up.  
The error estimate between baseline and follow-up MED doses were not assumed to 
be autocorrelated for the following reasons: 
• All patients were started on the lowest Avinza dose available (30mg/day), 
regardless of short-acting narcotic dose.  Exceptions were made only in 
instances where patients were on exceedingly large doses of short-acting 
narcotic medications. 
• Patient response to Avinza and the need for breakthrough narcotic dose was 
variable. 
• The baseline dose was composed of only the short acting narcotic, while the 
follow-up dose comprised of the Avinza and breakthrough medication dose.  
 
 
 
 
 
 
 
  
 228
 
 
 
4.6.3 Hypothesized Digit Span Test (DST) Model 
 
The dependent variable for the DST model was the digit span test factor at 
baseline (DSTB) and follow-up (DSTF).  The DSTB factor was composed of two 
indicators, namely, digits span forward test and digits span backward test at baseline.  
The DSTF factor was composed of two indicators, i.e., digits span forward test and 
digits span backward test at follow-up.  The structural component of the DST model 
can be viewed in Figure 4.9.  Structural equation modeling results (chi square = 
183.96, df = 212, p = 0.91) showed that the data were an excellent fit to the model.  
Goodness of fit indices for the model can be viewed in Table 4.35. 
 
NFI- Normed Fit Index 
CFI – Comparitive Fit Index 
SRMR – Standardized Root Mean Square Residual 
RMSEA – Root Mean Square Error of Approximation 
90%CI – 90% Confidence Interval 
 
Unstandardized parameter estimates of modeled associations are presented in Table 
4.36. 
 
 
 
Table 4.35  Goodness of Fit Indices for the Hypothesized DST, DSYT, and 
PASAT Models 
 
Variable 
 
Chi sq,  df      
p 
NFI CFI 
 
SRMR RMSEA 90%CI 
RMSEA 
Two-wave Digit 
Span Model  
183.9, 212 
0.91 
0.82 1.00 0.08 0.00 0.00, 0.01 
Two-wave Digit 
Symbol Model  
189.8, 174 
0.19 
0.80 0.97 0.09 0.03 0.00, 0.06 
Two-wave 
PASAT Model –  
204.2,  212 
0.65 
0.82 1.00 0.08 0.00 0.00, 0.03 
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Table 4.36 Table of Unstandardized Model Equations and Squared 
Multiple Correlations for the Hypothesized Digit Span Model 
Model Equations 
 
R2 
PUB =  0.28G + 1.21***PI + 2.45**DPUB 
                                
PUF =  - 0.02G + 0.94***PIF  + 0.28*PUB + 1.53*DPUF 
 
PSB =  0.01A – 2.07**E + 0.60***PUB+ 9.55***DPSB 
                     
PSF = -0.01A – 0.90E + 0.47***PUF  + 0.36VED + 0.46***PSB + 
4.77***DPSF 
                      
PBB = 0.02*A + 0.03E + 0.14***PSB + 0.55***DPBB 
 
PBF = 0.00A + 0.03E + 0.09**PSF + 0.39**PBB + 0.39***DPBF 
                            
VED = 0.05PSB + 1.56**DVED 
 
MEDB = 0.04PIB + 0.27***DMEDB 
 
MEDF = 0.64***MEDB + 0.07*DMEDF 
 
PIF =  0.70***PIB + 6.38*MEDF  -  4.97* MEDB + 2.35DPIF 
 
DSTB  = - 0.03^^A -0.05PSB – 0.39*PBB + 0.68^MEDB - 0.01VED –  
0.06PIB + 1.00D*DSTB      
                    
DSTF  = -0.02PSF + 0.28PBF  - 0.38MEDF - 0.05VED +  0.02PIF + 
1.55***DSTB + 0.40DDSTF    
 
0.69 
 
0.84 
 
0.29 
 
0.61 
 
 
0.36 
 
0.47 
 
0.02 
 
0.03 
 
0.63 
 
0.66 
 
0.34 
 
 
0.88 
 
A – Age, G – Gender, E – Ethnicity/Race, PI-Pain Intensity, PU-Pain 
Unpleasantness, PS-Pain Suffering, PB-Pain Behaviors, MED, Morphine 
Equivalent Dose, VED-Valium Equivalent Dose, DST-Digit Span Test, B-
Baseline, F-Follow-up, D - Disturbance term associated with the latent variable 
***p < 0.001, **p<0.01, *p<0.05 ^p = 0.08 ^^ p = 0.06
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Figure 4.9 Hypothesized Two-Wave Digit Span Test Structural Model 
 
 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent 
Dose, DST – Digit Span Test Factor, B-Baseline, F-Follow-up 
 
 
 
DSTB 
MEDB PIB 
PUB 
PSB 
PBB 
Gender 
Age 
Race 
VEDB 
PIF 
MEDF 
PUF 
PSF 
PBF 
DSTF 
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4.6.3.1 Hypothesis Testing – Digit Span Model 
 
In this section, associations between age, stages of pain model factors, 
MED, VED, and  Digit Span Test (DST) as the dependent variable  are presented.  
The proposed hypothesis and corresponding results are listed in order.  All 
parameter estimates are expressed as unstandardized units unless specified 
otherwise. 
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Table 4.37 presents a summary of the relationships examined in this section. 
Table 4.37 Summary of Hypothesized Relationships for the Digit Span 
Model 
Model  
Component 
 
Regression 
Weight 
Significance  
Level 
Hypothesis Hypothesis 
Supported 
MEDB → DSTB 
VED → DSTB 
PIB → DSTB 
PSB → DSTB 
PBB → DSTB 
A → PSB 
G → PUB 
E → PSB 
E → PBB 
A → PBB 
PIB → MEDB 
PSB → VED 
A → DSYTB 
 
MEDF → DSTF 
VED → DSTF  
PIF → DSTF 
PSF → DSTF 
PBF → DSTF  
A → PSF 
G → PUF 
E → PSF 
E → PBF 
A → PBF 
MEDF → PIF 
VED → PSF 
A → DSYTB 
 
 0.68 
-0.01 
-0.06 
-0.05 
-0.39 
  0.01 
-0.28 
-2.07 
0.03 
0.02 
0.04 
0.05 
-0.03 
 
-0.38 
-0.05 
 0.02 
-0.02 
 0.28 
-0.01 
-0.02 
-0.90 
0.03 
0.00 
6.38 
0.36 
0.02 
0.08 
0.91 
0.61 
0.46 
0.05 
0.83 
0.60 
0.01 
0.84 
0.06 
0.21 
0.20 
0.06 
 
0.53 
0.70 
0.78 
0.70 
0.29 
0.72 
0.95 
0.21 
0.84 
0.31 
0.04 
0.17 
0.33 
Ho1 
H2 
Ho3 
H4 
H5 
H6 
Ho7 
Ho8 
Ho9 
Ho10 
H11 
H12 
H13 
 
Ho14 
H15 
 Ho16 
H17 
H18 
H19 
Ho20 
Ho21 
Ho22 
Ho23 
H24 
H25 
H26 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
Yes 
No 
No 
No 
 
Yes 
No 
Yes 
No 
No 
No 
Yes 
Yes  
Yes  
Yes 
Yes 
No 
No 
 
A – Age, G – Gender, E – Ethnicity/Race, PI-Pain Intensity, PU-Pain 
Unpleasantness, PS-Pain Suffering, PB-Pain Behaviors, MED, Morphine 
Equivalent Dose, VED-Valium Equivalent Dose, DST-Digit Span Test, B-
Baseline, F-Follow-up 
 
¾ Ho1: There is no association between morphine equivalent dose (MED) of 
short-acting narcotic analgesic agents and digit span test scores at baseline. 
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Results from the two-wave digit span model showed that there was a 
positive but insignificant association between MED and digit span test 
scores at baseline (MEDB Æ DSTB = 0.68, SE = 0.40, p = 0.08).  Since a 
log transformation was applied to the MEDB indicator, the coefficient 
implies that a one percent change in MEDB is associated with a 0.0068 
unit change in DST scores. 
The hypothesis was supported 
¾ H2: There is a linear and inverse relationship between benzodiazepine dose 
and digit span test scores at baseline. 
Results from the two-wave digit span model showed that there was no 
statistical association between valium equivalent dose of benzodiazepines 
taken by patients and digit span test scores at baseline (VED Æ DSTB =  - 
0.01, SE = 0.12, p = 0.91).  Since a log transformation was applied to the 
VED indicator, the coefficient implies that a one percent change in VED 
is associated with a – 0.0001 unit change in DST scores. 
The hypothesis was not supported. 
¾ Ho3: There is no direct association between pain intensity and digit span 
scores at baseline. 
Results from the two-wave digit span model showed that statistically, 
there was no direct effect of pain intensity on the digit span test scores at 
baseline (PIBÆ DSTB = -0.06, SE = 0.13, p = 0.61).   
The hypothesis was supported. 
¾ H4: There is a linear and inverse association between pain suffering and digit 
span subtest scores at follow-up. 
Results from the two-wave digit span model showed that there was no 
statistical association between pain suffering and digit span test scores at 
baseline (PSBÆ DSTB = -0.05, SE = 0.07, p = 0.46). 
The hypothesis was not supported. 
¾ H5: There is a linear and inverse association between frequency of pain 
behaviors and digit span subtest scores at baseline. 
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Results from the two-wave digit span model showed that there was a 
linear and inverse association between frequency of pain behaviors and 
digit span test scores at baseline (PBBÆ Digit Span = -0.39, SE = 0.20, 
p = 0.05). 
The hypothesis was supported. 
¾ H6: There is a linear and inverse association between age and pain suffering. 
Results from the two-wave digit span model showed that there was no 
statistical association between pain suffering and age at baseline (Age 
Æ PSB = 0.01, SE = 0.04, p = 0.83). 
The hypothesis was not supported. 
¾ Ho7: There is no difference in baseline pain unpleasantness ratings between 
males and females. 
Results from the two-wave digit span model showed that there was no 
statistical difference in pain unpleasantness ratings between males and 
females (Gender Æ PUB  = -0.28, SE = 0.53, p = 0.60). 
The hypothesis was supported. 
¾ Ho8: There is no significant association between ethnicity and pain suffering at 
baseline. 
 Results from the two wave model with the DST as the dependent 
variable showed that Caucasians provided significantly lower pain 
suffering ratings than patients belonging to other ethnic groups at 
baseline.  (Ethnicity Æ PSB  = -2.07, SE = 0.88, p < 0.01).  
¾ Ho9: There is no significant association between ethnicity and pain behavior at 
baseline. 
Results from the two wave model with the DST as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
baseline.  (Ethnicity Æ PBB  = 0.03, SE = 0.20, p = 0.84).  
The hypothesis was supported. 
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¾ Ho10: There is no significant association between age and pain behavior at 
baseline. 
Results from the two-wave model with the DST as the dependent 
variable showed that the association between pain behavior and age at 
baseline approached statistical significance (Age Æ PBB = 0.02, SE = 
0.01, p = 0.06). 
The hypothesis was supported. 
¾ H11: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
Results from the two-wave DST model showed that there was no 
statistical association between pain intensity and MED at baseline 
(PIBÆ MEDB = 0.04, SE = 0.03, p = 0.21).  Since a natural log 
transformation was applied to the MED indicator, the regression 
coefficient implies that a unit change in PI is associated with a four 
percent change in MED. 
The hypothesis was not supported. 
¾ H12: There is linear and direct association between pain suffering and valium 
equivalent dose at baseline 
Results from the two-wave DST model showed that there was no 
statistical association between pain suffering and VED at baseline 
(PSBÆ VEDB = 0.05, SE = 0.04, p = 0.20).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a unit change in PS is associated with a five 
percent change in VED. 
 The hypothesis was not supported. 
¾ H13:  There is an inverse association between age and DST at follow-up. 
Results from the two-wave DST model showed that association 
between age and DST at baseline approached statistical significance 
(Age Æ DSTB = -0.03, SE = 0.01, p = 0.06).   
The hypothesis was not supported. 
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¾ Ho14: There is no association between morphine equivalent dose (MED) of 
Avinza® plus breakthrough medication dose and digit span test scores at 
follow-up. 
Results from the two-wave digit span model showed that there is no 
association between the latent factor composed of natural log of 
Avinza® dose and morphine equivalent dose of short-acting narcotic 
breakthrough pain medication and digit span test scores at follow-up 
(MEDF  Æ DSTF = - 0.38, SE = 0.61, p = 0. 53).  Since a log 
transformation was applied to the MEDF indicator, the coefficient 
implies that a one percent change in MEDF is associated with a -0.0038 
unit change in DST scores. MEDF and DSTF scores were controlled by 
their corresponding scores at baseline. 
The hypothesis was supported. 
¾ H15: There is a linear and inverse relationship between benzodiazepine dose 
and digit span subtest scores at follow-up. 
Results from the two-wave digit span model showed that there was no 
association between theVED and digit span test scores at follow-up 
(VEDF Æ DSTF = -0.05, SE = 0.14, p = 0.70). Since a log 
transformation was applied to the VED indicator, the coefficient implies 
that a one percent change in VED is associated with a -0.0005 unit 
change in DST scores. Digit span test score at follow-up was controlled 
by its corresponding score at baseline. 
The hypothesis was not supported. 
¾ Ho16: There is no direct association between pain intensity and digit span 
subtest scores at follow-up. 
Results from the two-wave digit span model showed that there is no 
association between PI and digit span test scores at follow-up (PIF Æ 
DSTF = 0.02 SE = 0.09, and p = 0.78).  Pain intensity and DST at 
follow-up were controlled by their corresponding scores at baseline. 
The hypothesis was supported. 
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¾ H17: There is a linear and inverse association between pain suffering and digit 
span subtest scores at follow-up. 
Results from the two-wave digit span model showed that there is no 
statistical relationship between pain suffering and digit span test scores 
at follow-up, controlling for pain suffering and digit span test scores at 
baseline.  (PSF  Æ DSTF = -0.02 SE = 0.07, and p = 0.70).   
The hypothesis was not supported. 
¾ H18: There is a linear and inverse association between frequency of pain 
behaviors and digit span subtest scores. 
Results from the two-wave digit span model showed that there is no 
statistical relationship between frequency of pain behaviors and digit 
span test scores at follow-up, controlling for pain behaviors and digit 
span test scores at baseline.  (PBF  Æ DSTF = 0.28 SE = 0.26, and p = 
0.29).   
The hypothesis was not supported. 
¾ H19: There is a linear and inverse association between age and pain suffering 
at follow-up. 
Results from the two-wave digit span model showed that there was no 
statistical association between pain suffering and age at follow-up (Age 
Æ PSF = - 0.01, SE = 0.03, p = 0.72). 
The hypothesis was not supported. 
¾ H o20: There is no difference in follow-up pain unpleasantness ratings between 
males and females. 
Results from the two-wave digit span model showed that there was no 
statistical difference in pain unpleasantness ratings between males and 
females (Gender Æ PUF = - 0.02, SE = 0.43, p = 0.95). 
The hypothesis was supported. 
¾ Ho21: There is no significant association between race and pain suffering at 
follow-up. 
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Results from the two wave model with the DST as the dependent 
variable showed no significant difference in pain suffering ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PSF  = -0.90, SE = 0.71, p < 0.21).  
The hypothesis was supported. 
¾ Ho22: There is no significant association between race and pain behavior at 
follow-up. 
Results from the two wave model with the DST as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PBF  = 0.03, SE = 0.16, p = 0.84).  
The hypothesis was supported. 
¾ Ho23: There is no significant association between age and pain suffering at 
follow-up. 
Results from the two-wave model with the DST as the dependent 
variable showed that there was no statistical association between pain 
behavior and age at follow-up (Age ÆPBF= 0.00, SE = 0.00, p = 0.31). 
The hypothesis was supported. 
¾ H24: There is a linear and direct association between morphine equivalent 
dose and pain intensity at follow-up. 
Results from the two-wave DST model showed that there was a 
statistically significant direct association between pain intensity and 
MED at follow-up (MEDF  Æ PIF  = 6.38, SE = 3.01, p = 0.04).  Since a 
log transformation was applied to the MEDF indicator, the coefficient 
implies that a one percent change in MEDF is associated with a 0.06 
unit change in pain intensity ratings.   
¾ H25: There is a linear and direct association between valium equivalent dose 
and pain suffering at follow-up. 
Results from the two-wave DST model showed that there was no 
statistical association between pain suffering and VED at follow-up 
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(VEDF  Æ PSF = 0.36, SE = 0.26, p = 0.17).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a one percent change in VED is associated with 
a 0.03 unit change in PS. 
The hypothesis was not supported. 
¾ H26: There is an inverse association between age and DST at follow-up. 
Results from the two-wave DST model showed that there was no 
statistically significant association between age and DST at follow-up 
(Age Æ DSTF = 0.02, SE = 0.02, p = 0.33).   
The hypothesis was not supported. 
 
4.6.4 Hypothesized Digit Symbol Test (DSYT) Model 
 
The dependent variable for the DSYT model was the digit symbol test factor at 
baseline (DSYTB) and follow-up (DSYTF).  The DSYTB and DSYTF factors were 
each composed of a single indicator, i.e., digit symbol test score at baseline and 
follow-up.  A natural log transformation was applied to the test scores.  The purpose 
of the transformation was to minimize the magnitude of difference in the variance of 
modeled variables (Table 4.2 presents the observed variance for digit symbol test 
scores at baseline and follow-up).  Thus, the natural log transformations of the DSYT 
scores at baseline (lnDSYT B) and follow-up (ln DSYTF) served as indicators for the 
DSYTB  and DSYTF  factors, respectively.  Measurement error variance associated 
with the lnDSYTB (0.016) and lnDSYTF (0.014) indicators was estimated by 
substituting values from Table 4.34 in equation 4.3.  The structural component of the 
DSYT model can be viewed in Figure 4.10.  Structural equation modeling results (chi 
square = 189.85, df = 174, p = 0.19) showed that the data were an excellent fit to the 
model.  Goodness of fit indices for the model can be viewed in Table 4.35. 
Unstandardized parameter estimates of modeled associations are presented in 
Table 4.38. 
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Table 4.38 Table of Unstandardized Model Equations and Squared 
Multiple Correlations for the Modified Digit Symbol Model 
 
Model Equations R2 
PUB = 0.31G + 1.20***PIB + 2.52**DPUB 
 
PUF =  - 0.04G + 0.93***PIF  + 0.31*PUB + 1.39DPUF   
                          
PSB = 0.01A – 1.32*E + 0.32**PUB+ 5.77**DPSB 
 
PSF = - 0.01A – 0.85E + 0.41***PUF + 0.51***PSB+ 0.35VED + 
3.38***DPSF 
                      
PBB =  0.007A – 0.02E + 0.06**PSB + 0.09*DPBB 
 
PBF =  - 0.007*A – 0.02E    0.03*PSF + 0.40**PBB + 0.01DPBF 
                            
VED = 0.04PSB + 1.58***DVED 
 
MEDB = 0.04PIB + 0.27***DMEDB 
 
MEDF = 0.61***MEDB + 0.07*DMEDF 
 
PIF = 0.68***PIB + 5.77*MEDF – 4.38MEDB + 2.46*DPIF 
 
 
DSYTB  =  -0.007*A + 0.002PSB –  0.13PBB + 0.07MEDB - 0.05*VED - 
0.007PIB + 0.05***DDSYTB     
 
DSYTF  =  0.003PSF – 0.03PBF - 0.008MEDF + 0.012VED - 0.00PIF + 
0.87***DSYTB + 0.01*DDSYTB    
 
0.69 
 
0.86 
 
0.18 
 
0.60 
 
0.29 
 
0.76 
 
0.01 
 
0.03 
 
0.58 
 
0.61 
 
 
0.21 
 
 
0.83 
A – Age, G – Gender, E – Ethnicity/Race, PI-Pain Intensity, PU-Pain 
Unpleasantness, PS-Pain Suffering, PB-Pain Behaviors, MED, Morphine 
Equivalent Dose, VED-Valium Equivalent Dose, DSYT-Digit Symbol Test, B-
Baseline, F-Follow-up, D - Disturbance term associated with the latent variable 
***p < 0.001, **p<0.01, *p<0.05 
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Figure 4.10  Hypothesized Two-Wave Digit Symbol Test Measurement Model 
 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent 
Dose, DSYT – Digit SymbolTest Factor, B-Baseline, F-Follow-up 
 
 
DSYTB 
MEDB PIB 
PUB 
PSB 
PBB 
Gender 
Age 
Race 
VEDB 
PIF 
MEDF 
PUF 
PSF 
PBF 
DSYTF 
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4.6.4.1 Hypothesis Testing – Digit Symbol Model 
 
In this section, associations between age, stages of pain model factors, MED, 
VED, and  Digit Symbol Test (DSYT) as the dependent variable  are presented.  
The proposed hypothesis and corresponding results are listed in order.  All 
parameter estimates are expressed as unstandardized units unless specified 
otherwise. 
A summary of the examined relationships is presented in Table 4.39. 
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Table 4.39 Summary of Hypothesized Relationships for the Digit Symbol 
Model 
 
Model  
Component 
 
Regression 
Weight 
Significance  
Level 
Hypothesis Hypothesis 
Supported 
MEDB → DSYTB 
VED → DSYTB 
PIB → DSYTB 
PSB → DSYTB 
PBB → DSYTB 
A → PSB 
G → PUB 
E → PSB 
E → PBB 
A → PBB 
PIB → MEDB 
PSB → VED 
A → DSYTB 
MEDF → DSYTF 
VED → DSYTF  
PIF → DSYTF 
PSF → DSYTF 
PBF → DSYTF  
A → PSF 
G → PUF 
E → PSF 
E → PBF 
A → PBF 
MEDF → PIF 
VED → PSF 
A → DSYTB 
 
 
 
0.075 
-0.05 
-0.007 
0.002 
-0.13 
0.01 
0.31 
-1.32  
-0.02  
0.007  
0.04  
0.04  
-0.007   
-0.008 
0.012 
0.00 
 0.003 
-0.03 
-0.01 
-0.04 
-0.85  
-0.02  
0.003  
5.72  
0.35  
-0.003  
0.23 
0.03 
0.70 
0.90 
0.16 
0.55 
0.56 
0.02 
0.73 
0.10 
0.23 
0.30 
0.03 
0.85 
0.33 
0.94 
0.722 
0.75 
0.60 
0.92 
0.11 
0.64 
0.40 
0.02 
0.09 
0.15 
Ho27 
H28 
Ho29 
H30 
H31 
H32 
Ho33 
Ho34 
Ho35 
Ho36 
H37 
H38 
H39 
Ho40 
H41 
Ho42 
H43 
H44 
H45 
Ho46 
Ho47 
Ho48 
Ho49 
H50 
H51 
H52 
 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
* This relationship may be considered significant. 
- The hypothesis was not testable 
A- Age, G – Gender, PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain 
Suffering, PB-Pain Behaviors, MED, Morphine Equivalent Dose, VED-Valium 
Equivalent Dose, DSYT-Digit Symbol Test, B-Baseline, F-Follow-up 
 
¾ Ho27: There is no association between morphine equivalent dose (MED) of 
short-acting narcotic analgesic agents and digit symbol test scores at baseline. 
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Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was a positive but insignificant 
association between MED and DSYT at baseline (MEDBÆ DSYTB = 
0.075, SE = 0.06, p = 0.23).  Since a log transformation was applied to 
indicators of both DSYT and MED at baseline, the coefficient implies that 
a one percent change in MEDB is associated with a 0.075 percent change 
in DSYT scores. 
The hypothesis was supported. 
¾ H28: There is a linear and inverse relationship between benzodiazepine dose 
and digit symbol subtest scores. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was a significant inverse association 
between VED and DSYTB at baseline (VEDÆ DSYTB = -0.05, SE = 
0.02, p = 0.03).  Since a natural log transformation was applied to 
indicators of both DSYT and VED, the regression coefficient implies that 
a one percent change in VED is associated with 0.05 percent reduction in 
DSYT scores. 
The hypothesis was supported. 
¾ Ho29: There is no direct association between pain intensity and digit symbol 
test scores at baseline. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was an insignificant association 
between pain intensity and digit symbol test at baseline (PIB Æ DSYTB = 
-0.007, SE = 0.01, p = 0.70).  Since a natural log transformation was 
applied to the DSYT indicator, the regression coefficient implies that a 
unit change in PI is associated with a 0.7 percent reduction in digit 
symbol subtest scores. 
The hypothesis was supported. 
¾ H30: There is a linear and inverse association between pain suffering and digit 
symbol test scores at baseline 
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Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical association 
between pain suffering and digit symbol test at baseline (PSB Æ DSYTB = 
0.002, SE = 0.01, p = 0.90).  Since a natural log transformation was 
applied to the DSYT indicator, the regression coefficient implies that a 
unit change in PS is associated with a 0.2 percent increase in digit symbol 
subtest scores. 
The hypothesis was not supported. 
¾ H31: There is a linear and inverse association between frequency of pain 
behaviors and digit symbol subtest scores. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was an inverse, but insignificant  
statistical association between frequency of pain behaviors and digit 
symbol test at baseline (PBB Æ DSYTB = -0.13, SE = 0.09, p = 0.16).  
Since a natural log transformation was applied to the DSYT indicator, 
the regression coefficient implies that a unit increase in pain behavior 
frequency is associated with a 13 percent reduction in digit symbol 
subtest scores. 
The results imply a large, practically important association between 
pain behaviors and digit symbol test scores; however, the hypothesis 
was not supported. 
¾ H32: There is a linear and inverse association between age and pain suffering 
at baseline. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical association 
between age and pain suffering at baseline (Age Æ PSB = 0.01, SE = 
0.03, p = 0.55) 
The hypothesis was not supported. 
¾ Ho33: There is no difference in pain unpleasantness ratings between males and 
females at baseline. 
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Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical difference in 
pain unpleasantness ratings between males and females at baseline 
(Gender Æ PUB = 0.31, SE = 0.53, p = 0.56) 
The hypothesis was supported. 
¾ Ho33: There is no association between ethnicity and pain suffering at baseline. 
Results from the two wave model with the DSYT as the dependent 
variable showed that Caucasians provided significantly lower pain 
suffering ratings than patients belonging to other ethnic groups at 
baseline.  (Ethnicity Æ PSB  = -1.32, SE = 0.58, p = 0.02).  
The hypothesis was not supported. 
¾ Ho34: There is no association between ethnicity and pain behavior at baseline. 
Results from the two wave model with the DSYT as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
baseline.  (Ethnicity Æ PBB  = -0.02, SE = 0.07, p = 0.73). 
The hypothesis was supported. 
¾ Ho35: There is no significant association between age and pain behavior at 
baseline. 
   Results from the two-wave model with the DSYT as 
the dependent variable showed that there no statistical association 
between pain behavior and age at baseline (Age ÆPBB = 0.007, SE = 
0.004, p = 0.10). 
The hypothesis was supported. 
¾ H36: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
Results from the two-wave DSYT model showed that there was no 
statistical association between pain intensity and MED at baseline 
(PIBÆ MEDB = 0.04, SE = 0.03, p = 0.23).  Since a natural log 
transformation was applied to the MED indicator, the regression 
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coefficient implies that a unit change in PI is associated with a four 
percent change in MED. 
The hypothesis was not supported. 
¾ H37: There is linear and direct association between pain suffering and 
valium equivalent dose at baseline. 
Results from the two-wave DSYT model showed that there was no 
statistical association between pain suffering and VED at baseline 
(PSBÆ VEDB = 0.04, SE = 0.05, p = 0.30).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a unit change in PS is associated with a four 
percent change in VED. 
¾ H38:  There is an inverse association between age and DSYT at baseline. 
Results from the two-wave DSYT model showed that there was a 
statistically significant association between age and DSYT at baseline 
(Age Æ DSYTB = -0.007, SE = 0.01, p < 0.05).  Since a log 
transformation was applied to the DSYT indicator, the regression 
coefficient implies that a one year increase in age is associated with a 
0.7 percent reduction in DSYT. 
The hypothesis was supported. 
¾ Ho39: There is no association between morphine equivalent dose (MED) of 
Avinza® plus breakthrough medication dose and digit symbol test scores at 
follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was an insignificant association 
between MED and digit symbol test at follow-up (MEDF Æ DSYTF = -
0.008, SE = 0.04, p = 0.85).  Since natural log transformations were 
applied to indicators of both DSYT and MED at follow-up, the 
regression coefficient implies that a one percent change in MED is 
associated with a 0.008 percent reduction in DSYT scores at follow-up.  
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DSYTF and MEDF scores were controlled by their corresponding scores 
at baseline. 
The hypothesis was supported. 
¾ H40: There is a linear and inverse relationship between benzodiazepine dose 
and digit symbol subtest scores at follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical association 
between VED and digit symbol test at follow-up (VED Æ DSYTF = 
0.012, SE = 0.01, p = 0.33).  DSYTF  score at follow-up was controlled 
by its corresponding scores at baseline.  Since natural log 
transformations were applied to indicators of both DSYT and VED at 
follow-up, the regression coefficient implies that a one percent change 
in VED is associated with a 0.01 percent increase in DSYT scores at 
follow-up.   
The hypothesis was not supported. 
¾ Ho41: There is no direct association between pain intensity and digit symbol 
subtest scores at follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no association between pain 
intensity scores and digit symbol test at follow-up (PIF Æ DSYT =  0.00 
SE = 0.007, p = 0.94).  DSYTF  and PIF scores at follow-up were 
controlled by their corresponding scores at baseline. 
  The hypothesis was supported. 
¾ H42: There is a linear and inverse association between pain suffering and digit 
symbol subtest scores at follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no significant association 
between pain suffering scores and digit symbol test at follow-up (PSF Æ 
DSYTF = 0.003, SE = 0.008, p = 0.72).  Since a log transformation was 
applied to the DSYT indicator, the regression coefficient implies that a 
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unit change in PS scores at follow-up was associated with a 0.3 percent 
increase in DSYT scores.  DSYTF and PSF  scores were controlled by 
their corresponding scores at baseline. 
  The hypothesis was not supported. 
¾ H43: There is a linear and inverse association between frequency of pain 
behaviors and digit symbol subtest scores at follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was a statistically insignificant 
inverse association between PB scores and digit symbol test at follow-
up (PBF Æ DSYTF = -0.03, SE = 0.09, p = 0.675).  Since a log 
transformation was applied to the DSYT indicator, the regression 
coefficient implies that a unit increase in pain behavior frequency at 
follow-up was associated with a 3 percent reduction in DSYT scores.   
DSYTF and PBF scores at follow-up were controlled by their 
corresponding scores at baseline. 
The hypothesis was supported. 
¾ H44: There is a linear and inverse association between age and pain suffering 
at follow-up. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical association 
between age and pain suffering at baseline (Age Æ PSF = -0.01, SE = 
0.02, p = 0.60) 
The hypothesis was not supported. 
¾ Ho45: There is no difference on follow-up pain unpleasantness ratings between 
males and females. 
Results from the two wave model with the digit symbol test as the 
dependent variable showed that there was no statistical difference in 
pain unpleasantness ratings between males and females at baseline 
(Gender Æ PUB = - 0.04, SE = 0.41, p = 0.92) 
The hypothesis was supported. 
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¾ Ho46: There is no significant association between race and pain suffering at 
follow-up. 
Results from the two wave model with the DSYT as the dependent 
variable showed no significant difference in pain suffering ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PSF  = -0.85, SE = 0.54, p = 0.11). 
The hypothesis was supported. 
¾ Ho47: There is no significant association between race and pain behavior at 
follow-up. 
Results from the two wave model with the DSYT as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PBF  = – 0.02, SE = 0.05, p = 0.64). 
The hypothesis was supported. 
¾ Ho48: There is no significant association between age and pain behavior at  
 follow-up. 
Results from the two-wave model with the DSYT as the dependent 
variable showed that there no statistical association between pain 
behavior and age at follow-up (Age ÆPBF = 0.003, SE = 0.003, p = 
0.40). 
The hypothesis was supported. 
¾ H49: There is a linear and direct association between morphine equivalent 
dose and pain intensity at follow-up. 
Results from the two-wave DSYT model showed that there was a 
statistically significant direct association between pain intensity and 
MED at follow-up (P MEDF  Æ PIF  = 5.77, SE = 2.52, p = 0.02).  Since 
a log transformation was applied to the MEDF indicator, the coefficient 
implies that a one percent change in MEDF is associated with a 0.057 
unit change in pain intensity ratings.   
The hypothesis was supported. 
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¾ H50: There is a linear and direct association between valium equivalent dose 
and pain suffering at follow-up. 
Results from the two-wave DSYT model showed that there was no 
statistical association between pain suffering and VED at baseline 
(VEDF  Æ PSF = 0.35, SE = 0.21, p = 0.09).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a one percent change in VED is associated with 
a 0.03 unit change in PS. 
¾ H51: There is an inverse association between age and DST at follow-up. 
Results from the two-wave DSYT model showed that there was no 
statistically significant association between age and DSYT at follow-up 
(Age Æ DSYTF = -0.003, SE = 0.02, p = 0.15).  Since a log 
transformation was applied to the DSYT indicator, a one year increase 
in age is associated with a 0.3% reduction in DSYT scores. 
 The hypothesis was not supported. 
 
 
4.6.5 Hypothesized Paced Auditory Serial Addition Test (PASAT) Model 
 
The dependent variable for the PASAT model was the paced auditory serial 
attention test factor at baseline (PASATB) and follow-up (PASATF).  The PASATB  
factor was composed of two indicators, namely, lnPASAT 2.4 and lnPASAT 2.0 at 
baseline.  The PASATF  factor was composed of two indicators, namely, lnPASAT 
2.4 and lnPASAT 2.0 at follow-up.  The structural component of the PASAT model 
can be viewed in Figure 4.11. 
Structural equation modeling results (chi square = 204.20, df = 212, p = 0.65) showed 
that the data were an excellent fit to the model.  Goodness of fit indices for the model 
can be viewed in Table 4.35.   
Unstandardized parameter estimates of modeled associations are presented in 
Table 4.40 
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Table 4.40 Table of Unstandardized Model Equations and Squared Multiple 
Correlations of Paced Auditory Serial Addition Test Model 
 
Model Equations R2 
PUB =  0.30G + 1.21***PIB + 2.57**DPUB 
 
PUF =  - 0.02G + 0.95***PIF  + 0.26*PUB + 1.60*DPUF   
                          
PSB = 0.01A – 2.0**E + 0.59***PUB+ 10.15***DPSB 
 
PSF = -0.01A – 0.76E + 0.47***PUF + 0.50***PSB+ 0.33VED + 4.97***DPSF 
                      
PBB = 0.01A + 0.009E + 0.13***PSB + 0.58***DPBB 
 
PBF = 0.009A - 0.01E + 0.08***PSF + 0.38***PBB + 0.40***DPBF 
                            
VED = 0.05PSB + 1.57***DVED 
 
MEDB = 0.05PIB + 0.26***DMEDB 
 
MEDF = 0.64***MEDB + 0.12***DMEDF 
 
PIF =  0.68***PIB + 3.65**MEDF  – 3.13**MEDB + 3.00**DPIF 
 
PASATB  = -0.004PSB – 0.034PBB + 0.06MEDB - 0.064**VED - 0.017PIB + 
0.05***DPASATB     
 
PASATF  =  -0.008PSF – 0.022PBF  - 0.033MEDF  + 0.006VED - 0.005PIF + 
0.80***PASATB + 0.01*DPASATF    
 
0.69 
 
0.83 
 
0.24 
 
0.62 
 
0.33 
 
0.44 
 
0.02 
 
0.03 
 
0.47 
 
0.53 
 
0.18 
 
 
0.84 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain 
Behaviors, MED, Morphine Equivalent Dose, VED-Valium Equivalent Dose, 
PASAT-Paced Auditory Serial Addition Test, B-Baseline, F-Follow-up, D – 
Disturbance term associated with the latent variable 
***p < 0.001, **p<0.01, *p<0.05 
 
 
 
 
 
 
 
 
  
 253
 
 
Figure 4.11 Hypothesized Two-Wave PASAT  Measurement Model 
 
 
 
 
 
 
PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, PB-Pain Behavior, MED-Morphine Equivalent Dose, VED-Valium Equivalent Dose, 
PASAT – Paced Auditory Serial Addition Test Factor, B-Baseline, F-Follow-up 
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4.6.5.1 Hypothesis Testing – Paced Auditory Serial Addition Test 
 
Results from the two-wave longitudinal model with Paced Auditory Serial 
Addition Test (PASAT) as the dependent variable: 
The proposed hypothesis and corresponding results are listed in order.  All 
parameter estimates are expressed as unstandardized units unless specified 
otherwise. 
A summary of the examined relationships is presented in Table 4.41: 
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- Hypothesis not testable 
A- Age, G – Gender, PI-Pain Intensity, PU-Pain Unpleasantness, PS-Pain Suffering, 
PB-Pain Behaviors, MED, Morphine Equivalent Dose, VED-Valium Equivalent 
Dose, PASAT-Paced Auditory Serial Addition Test, B-Baseline, F-Follow-up 
 
 
 
Table 4.41 Summary of Hypothesized Relationships for the Paced 
Auditory Serial Addition Test Model 
 
Model  
Component 
 
Regression 
Weight 
Significance 
Level 
Hypothesis Hypothesis 
Supported 
MEDB → PASATB 
VED → PASATB 
PIB → PASATB 
PSB → PASATB 
PBB → PASATB 
A → PSB 
G → PUB 
E → PSB 
E → PBB 
A → PBB 
PIB → MEDB 
PSB → VED 
A → PASATB 
 
MEDF → PASATF 
VED → PASATF 
PIF → PASATF 
PSF → PASATF 
PBF → PASATF 
A → PSF 
G → PUF 
E → PSF 
E → PBF 
A → PBF 
MEDF → PIF 
VED → PSF 
A → PASATB 
0.06 
-0.06 
-0.017 
-0.004 
-0.03 
0.01 
0.30 
-2.00 
0.00 
0.01 
0.05 
0.05 
-0.002 
 
-0.03 
0.006 
-0.005 
-0.008 
-0.022 
-0.01 
-0.02 
-0.76 
-0.01 
0.009 
3.65 
0.33 
-0.003 
(0.002) 
0.33 
  0.008 
0.34 
0.71 
0.38 
0.83 
0.57 
0.01 
0.96 
0.06 
0.19 
0.24 
0.56 
 
0.37 
0.66 
0.55 
0.21 
0.30 
0.73 
0.94 
0.27 
0.95 
0.29 
0.01 
0.20 
0.16 
Ho53 
H54 
Ho55 
H56 
H57 
H58 
Ho59 
Ho60 
Ho61 
Ho62 
H63 
H64 
H65 
 
Ho66 
H67 
Ho68 
H69 
H70 
H71 
Ho72 
Ho73 
Ho74 
Ho75 
H76 
H77 
H78 
 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
Yes 
No 
No 
No 
 
Yes 
No 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
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¾ Ho53: There is no association between morphine equivalent dose (MED) of 
short-acting narcotic analgesic agents and PASAT scores at baseline. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there is no significant association 
between MED and PASAT scores at baseline (MEDB Æ PASATB = 
0.06, SE = 0.06, p = 0.33).  Since a log transformation was applied to 
indicators of both PASAT and MED at baseline, the coefficient implies 
that a one percent change in MEDB is associated with a 0.06 percent 
change in PASAT scores. 
The hypothesis was supported. 
¾ H54: There is a linear and inverse relationship between benzodiazepine dose 
and PASAT scores at baseline. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there is a significant inverse association 
between VED and PASAT scores at baseline (VED Æ PASATB = -
0.06, SE = 0.02,  p = 0.008).  Since a log transformation was applied to 
indicators of both PASAT and VED at baseline, the coefficient implies 
that a one percent change in VED is associated with a 0.06 percent 
reduction in PASAT scores. 
The hypothesis was supported. 
¾ Ho55: There is no direct association between pain intensity and PASAT scores 
at baseline. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there was no significant association 
between  pain intensity ratings and PASAT scores at baseline (PIB Æ 
PASATB = -0.017, SE = 0.018, p = 0.34).  Since indicators for the 
PASAT factor were transformed utilizing a natural log transformation, 
the regression coefficient implies that a unit change in PI scores 
corresponds with a 1.8 percent reduction in PASAT scores. 
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The hypothesis was supported. 
¾ H56: There is a linear and inverse association between pain suffering and 
PASAT scores at baseline. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there is a non-significant association 
between  pain suffering ratings and PASAT scores at baseline (PSBÆ 
PASATB = -0.004, SE = 0.01, p = 0.71). Since indicators for the 
PASAT factor were transformed utilizing a natural log transformation, 
the regression coefficient implies that a unit change in PS scores 
corresponds with a 0.4 percent reduction in PASAT scores. 
The hypothesis was not supported. 
¾ H57: There is a linear and inverse association between frequency of pain 
behaviors and PASAT scores at baseline. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there is a inverse but non significant 
association between frequency of pain behaviors and PASAT scores at 
baseline (PBB Æ PASATB = -0.03, SE = 0.03, p = 0.38).  Since 
indicators for the PASAT factor were transformed utilizing a natural log 
transformation, the regression coefficient implies that a unit change in 
PB scores corresponds with a three percent reduction in PASAT scores. 
The hypothesis was not supported. 
¾ H58: There is a linear and inverse association between age and pain suffering 
scores at baseline. 
Results from the two wave model with the PASAT as the dependent 
variable showed that there was no statistical association between age 
and pain suffering at baseline (Age Æ PSB = 0.01, SE = 0.04, p = 0.83) 
The hypothesis was not supported. 
¾ Ho59: There is no difference in baseline pain unpleasantness ratings between 
males and females at baseline. 
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 Results from the two wave model with the PASAT as the 
dependent variable showed no difference in pain unpleasantness ratings 
between males and females (Gender Æ PUB = 0.30, SE = 0.54, p = 
0.57) 
The hypothesis was supported. 
¾ Ho60: There is no association between ethnicity and pain suffering at baseline. 
Results from the two-wave model with the PASAT as the dependent 
variable showed that Caucasians provided significantly lower pain 
suffering ratings than patients belonging to other ethnic groups at 
baseline.  (Ethnicity Æ PSB  = -2.0, SE = 0.54, p = 0.01).  
 The hypothesis was not supported. 
¾ Ho61: There is no association between ethnicity and pain behavior at baseline. 
Results from the two wave model with the PASAT as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
baseline.  (Ethnicity Æ PBB  = 0.009, SE = 0.19, p < 0.96). 
The hypothesis was supported. 
¾ Ho62: There is no significant association between age and pain behavior at 
baseline. 
Results from the two-wave model with the PASAT as the dependent 
variable showed that there no statistical association between pain 
behavior and age at baseline (Age ÆPBB = 0.01, SE = 0.01, p = 0.06). 
The hypothesis was supported. 
¾ H63: There is linear and direct association between pain intensity and 
morphine equivalent dose at baseline. 
Results from the two-wave PASAT model showed that there was no 
statistical association between pain intensity and MED at baseline 
(PIBÆ MEDB = 0.05, SE = 0.03, p = 0.19).  Since a natural log 
transformation was applied to the MED indicator, the regression 
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coefficient implies that a unit change in PI is associated with a five 
percent change in MED. 
The hypothesis was not supported. 
¾ H64: There is linear and direct association between pain suffering and valium 
equivalent dose at baseline. 
Results from the two-wave PASAT model showed that there was no 
statistical association between pain suffering and VED at baseline 
(PSBÆ VEDB = 0.05, SE = 0.04, p = 0.24).  ).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a unit change in PS is associated with a five 
percent change in VED. 
The hypothesis was not supported 
¾ H65:  There is an inverse association between age and PASAT at baseline. 
Results from the two-wave PASAT model showed that there was no 
statistically significant association between age and PASAT at baseline 
(Age Æ PASATB = -0.002, SE = 0.003, p = 0.57).  Since a log 
transformation was applied to the PASAT indicator, the regression 
coefficient implies that a one year increase in age is associated with a 
0.2 percent reduction in DSYT. 
The hypothesis was not supported. 
¾ Ho66: There is no association between morphine equivalent dose (MED) of 
Avinza® plus breakthrough medication dose and PASAT scores at follow-up. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there is a negative but non significant 
association between MED and PASAT scores at follow-up (MEDF Æ 
PASATF = - 0.03, SE = 0.03, p = 0.37).  Since a log transformation was 
applied to indicators of both PASAT and MED at baseline, the 
coefficient implies that a one percent change in MEDF is associated 
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with a 0.03 percent reduction in PASAT scores. MEDF and PASATF 
scores were controlled by their corresponding scores at baseline. 
The hypothesis was supported. 
¾ H67: There is a linear and inverse relationship between benzodiazepine dose 
and PASAT scores at follow-up. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there was no statisitical  association 
between VED and PASAT scores at follow-up. (VED Æ PASATFU = 
0.006, SE = 0.01, p = 0.66).  Since a log transformation was applied to 
indicators of both PASAT and VED at baseline, the coefficient implies 
that a one percent change in VED is associated with a 0.6 percent 
increase in PASAT scores.  PASATF score was controlled by its 
corresponding score at baseline. 
The hypothesis was not supported. 
¾ Ho68: There is no direct association between pain intensity and PASAT scores 
at follow-up. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there was a non-significant association 
between PASAT scores and pain intensity ratings at follow-up. (PIFU Æ 
PASATFU = - 0.005, SE = 0.008, p = 0.55).  Since a log transformation 
was applied to PASAT indicators, the coefficient implies that a one 
percent change in PI at follow-up is associated with a 0.5 percent 
reduction in PASAT scores.  PASAT and PI scores at follow-up were 
controlled by their corresponding score at baseline. 
The hypothesis was not supported. 
¾ H69: There is a linear and inverse association between pain suffering and 
PASAT scores at follow-up. 
Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there was a non-significant association 
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between pain suffering ratings and PASAT scores at follow-up. (PSFU 
Æ PASATFU = - 0.008, SE = 0.007, p = 0.21).  Since a log 
transformation was applied to PASAT indicators, the coefficient implies 
that a one percent change in PS at follow-up is associated with a 0.7 
percent reduction in PASAT scores.  PASAT and PS scores at follow-up 
were controlled by their corresponding score at baseline. 
The hypothesis was not supported 
¾ H70: There is a linear and inverse association between frequency of pain 
behaviors and PASAT scores at follow-up. 
 Results from the two-wave model with PASAT scores modeled as the 
dependent variable showed that there was a non-significant inverse 
association between frequency of pain behavior ratings and PASAT 
scores at follow-up. (PBFU Æ PASATFU = -0.022, SE = 0.02, p = 0.30).  
Since a log transformation was applied to PASAT indicators, the 
coefficient implies that a one percent change in PB at follow-up is 
associated with a 2.8 percent reduction in PASAT scores.  PASAT and 
PB scores at follow-up were controlled by their corresponding score at 
baseline. 
 The hypothesis was supported. 
¾ H71: There is a linear and inverse association between age and pain suffering 
at follow-up. 
 Results from the two wave model with the PASAT as the dependent 
variable showed that there was no statistical association between age 
and pain suffering atfollow-up (Age Æ PSF = -0.01, SE = 0.03, p = 
0.73) 
 The hypothesis was not supported. 
¾ Ho72: There is no difference in follow-up pain unpleasantness ratings between 
males and females. 
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 Results from the two wave model with the PASAT as the dependent 
variable showed no difference in pain unpleasantness ratings between 
males and females (Gender Æ PUF = - 0.02, SE = 0.42, p = 0.94) 
 The hypothesis was supported. 
¾ Ho73: There is no association between ethnicity and pain suffering at follow-
up. 
Results from the two wave model with the PASAT as the dependent 
variable showed no significant difference in pain suffering ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PSF  = -0.76, SE = 0.69, p = 0.27). 
The hypothesis was supported. 
¾ Ho74: There is no association between ethnicity and pain behavior at baseline. 
 Results from the two wave model with the PASAT as the dependent 
variable showed no significant difference in pain behavior ratings 
between those provided by Caucasians and other ethnic groups at 
follow-up.  (Ethnicity Æ PBF  = -0.01, SE = 0.16, p= 0.95). 
The hypothesis was supported. 
¾ Ho75: There is no significant association between age and pain behavior at 
follow-up. 
 Results from the two-wave model with the PASAT as the dependent 
variable showed that there no statistical association between pain 
behavior and age at follow-up (Age ÆPBF = 0.009, SE = 0.009, p = 
0.29). 
The hypothesis was supported. 
¾ H24: There is a linear and direct association between morphine equivalent 
dose and pain intensity at follow-up. 
Results from the two-wave PASAT model showed that there was no 
statistical association between pain intensity and MED at follow-up 
(MEDF  Æ PIF    = 3.65, SE = 1.12, p < 0.01).  Since a log 
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transformation was applied to the MEDF indicator, the coefficient 
implies that a one percent change in MEDF is associated with a 0.036 
unit change in pain intensity ratings.   
The hypothesis was supported 
¾ H25: There is a linear and direct association between valium equivalent dose 
and pain suffering at follow-up. 
Results from the two-wave PASAT model showed that there was no 
statistical association between pain suffering and VED at baseline 
(VEDF  Æ PSF = 0.33, SE = 0.26, p = 0.20).  Since a natural log 
transformation was applied to the VED indicator, the regression 
coefficient implies that a one percent change in VED is associated with 
a 0.03 unit change in PS. 
The hypothesis was not supported. 
¾ H76: There is an inverse association between age and PASAT at follow-up. 
Results from the two-wave PASAT model showed that there was no 
statistically significant association between age and PASAT at follow-
up (Age Æ PASATF = -0.003, SE = 0.02, p = 0.16).  Since a log 
transformation was applied to the PASAT indicator,    
 The hypothesis was not supported. 
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Chapter 5: Discussion and Conclusion 
 
The purpose of this section is to interpret the results from the previous section.  
The findings from the current study will be compared and contrasted with contemporary 
research in the field.   The relevance of the findings will be discussed in reference to 
chronic pain patients and the pain management community at large.  The chapter is 
composed of a discussion of all the modeled variables.  This discussion is followed by a 
contrast of the stages of pain model confirmed by the current data with Wade’s 
previously published model.  Subsequently, the associations between the dependent 
variables for each model, i.e., DST, DSYT, and PASAT models and their predictors are 
examined.  Finally, limitations of the study are addressed, and conclusions drawn from 
the aforementioned discussion. 
5.1 Study Withdrawals 
 
The proportion of patients who withdrew from this study (21.7%, n = 28) due to 
an adverse event (excluding inadequate pain control) was similar to a double-blind, 
placebo controlled study which assessed the safety and efficacy of Avinza®.  The 
proportion of patients who withdrew due to an adverse event (excluding “lack of 
efficacy”) from the latter study was 23.9 percent.317   
Common adverse events that contributed to withdrawals from the study were 
drowsiness (n = 14), fatigue (n= 8), and nausea (n = 5).  The frequent incidence of an 
allergic type reaction [allergies to morphine (n = 6), itching (n = 6), shortness of breath (n 
= 2), and rashes (n = 2)) suggested that  pain patients should be screened for morphine 
sensitivity prior to treatment with Avinza® or other morphine agents. 
Except for gender, evaluable and non-evaluable patients were comparable on 
demographic characteristics such as age, ethnicity, and education.  Non-evaluable 
                                                 
317 Caldwell JR, Rapoport RJ, Davis JC et al.  Efficacy and safety of a once-daily morphine formulation in 
chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-
blind trial and an open-label extension trial.  Journal of Pain and Symptom Management.  2002;23:278-
291. 
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patients used significantly higher doses of short-acting narcotics at baseline than 
evaluable patients.  Patients who withdrew from the study reported significantly higher 
ratings on items assessing negative emotions than patients who completed the study.  
These patients reported a significantly greater reduction in home- and family-related 
responsibilities.  Non-evaluable patients tended to score lower on the administered tests 
of attention; a significant difference was observed between evaluable and non-evaluable 
patients on the PASAT 2.0.   
These differences do not suggest systematic differences between evaluable and 
non-evaluable patients.  It can be speculated that the lack of a significant statistical 
association between pain suffering and tests of cognitive function may be attributable to 
patients who were lost to follow-up. 
 
5.2 Key model Variables 
 
5.2.1 Morphine Equivalent Dose (MED) 
 
All patients enrolled in the study were utilizing a short-acting narcotic dose at the 
time of enrollment.  The average short-acting narcotic analgesic morphine equivalent 
dose (MED) utilized by evaluable patients at baseline was 52.39 mg.   The average 
narcotic dose from baseline to follow-up increased by 58.0 percent.  At the end of one-
month follow-up, patients had been stabilized on an average Avinza® dose of 59.11mg.  
Average breakthrough pain medication MED at follow-up was 23.68mg.   
 
5.2.2 Valium Equivalent Dose (VED) 
 
Benzodiazepines are frequently prescribed in the treatment of chronic non-
malignant pain.  Greater than a third of evaluable patients (34.7%) were prescribed 
benzodiazepines.  The average daily Valium equivalent dose (VED) utilized by evaluable 
patients at baseline and follow-up was 16.81 mg.  A negative dose-response association 
between benzodiazepine use and performance on tests of cognitive function has been 
  
 266
established.318,319  Previous studies that examined the association between narcotic use 
and cognitive function failed to control for the confounding effects of 
benzodiazepines.320,321  Inclusion of this confounder in the present analysis enabled the 
delineation of associations between narcotics and cognitive function while controlling for 
the effects of benzodiazepine dose.   
 Results from this study indicated a negative association between benzodiazepine 
dose and tests of cognitive function (digit symbol and paced auditory serial addition test).  
These associations are addressed later in the chapter. 
 
5.2.3 Pain Intensity 
 
Baseline and follow-up assessments of patient-reported pain intensity at the 
highest, lowest, and usual levels in the previous week were made.  Following a four-week 
trial with Avinza, evaluable patients reported an average reduction of 14.2 percent, 32.2 
percent, and 23.7 percent in pain at the highest, lowest, and usual pain intensity levels, 
respectively.   The average pain intensity levels reported at follow-up were significantly 
lower (p < 0.05) than those reported at baseline. 
The results were comparable with an efficacy study, which showed an average 
reduction of 26.7 percent (qAM dosing) and 22.8 percent (qPM dosing) after a four-week 
trial with Avinza.322  All patients in the current study were recommended to follow an 
“AM” dosing schedule.   
 
                                                 
318 Scheman J, Aker R, Covington E.  Cognitive effects of opioid and benzodiazepine weaning.  Abstract.  
American Pain Society. 2003;Poster# 859.  http://www.ampainsoc.org/abstract/2003/data/859/index.html.  
Accessed:Jun 11, 2003. 
319 Curran KC, Marks HN, Basoglu M.  Long-term effects of alprazolam on memory: a 3.5 year follow-up 
of agrophobia/panic patients.  Psychological Medicine.  1999;29:225-231. 
320 Haythornthwaite JA, Lynette MA, Quatrano-Piacentini Al, Pappagallo M.  Outcome of chronic opioid 
therapy for non-cancer pain.   Journal of Pain and Symptom Management.  1998;15:185-194. 
321 Francis SE.  The effects of long term opioid therapy on neuropsychological functioning in chronic pain 
patients. California Institue of Integral Studies.  Dissertation.  June 1999; 130p  
322 Caldwell JR, Rapoport RJ, Davis JC et al.  Efficacy and safety of a once-daily morphine formulation in 
chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-
blind trial and an open-label extension trial.  Journal of Pain and Symptom Management.  2002;23:278-
291. 
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5.2.4 Pain Unpleasantness 
 
Baseline and follow-up assessments of patient-reported pain unpleasantness at the 
highest, lowest, and usual pain intensity levels in the previous week were made.  
Following a four-week trial with Avinza, evaluable patients reported an average 
reduction of 13.6 percent, 37.6 percent, and 24.7 percent in pain unpleasantness at the 
highest, lowest and usual pain intensity levels, respectively.  The average pain 
unpleasantness levels reported at follow-up were significantly lower (p < 0.05) than those 
reported at baseline. 
 
5.2.5 Pain Suffering 
 
The original pain suffering construct was composed of negative emotions and negative 
beliefs. 
 
5.2.5.1 Negative Emotions 
 
Negative emotions were assessed by asking patients to rate the intensity of each 
emotion, i.e., depression, anxiety, frustration, anger, and fear in the context of their pain.  
A significant reduction (p < 0.05) in the average rating for each emotion was observed at 
follow-up.  Following a four-week trial with Avinza, evaluable patients reported an 
average reduction of 15.1 percent in depression, 20.5 percent in anxiety, 19.0 percent in 
frustration, 29.6 percent in anger, and 15.7 percent in fear. 
 
5.2.5.2 Negative Beliefs 
 
On average, the levels of negative beliefs at follow-up were lower than those 
reported at baseline.  Evaluable patients believed that, on average, interference due to 
pain reduced by 22.2 percent and difficulty to endure pain reduced by 20.2 percent.  
Treatment with Avinza, a long-acting morphine agent, enhanced patients’ belief in their 
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ability to control pain.  Patients reported that their ability to control pain following a four-
week trial with Avinza increased by 28.0 percent.   
 
5.2.6 Pain Behaviors 
 
Pain Behaviors were assessed through five items on the psychological pain 
inventory (PPI).  Of these five items, a significant (p < 0.05) reduction from baseline to 
follow-up was seen for frequency of pain behaviors at home (mean reduction = 0.36) and 
observed pain behaviors (mean reduction = 0.48).  The average reduction/improvement in 
pain behaviors observed for the other indicators was small and not significant.  The 
average reduction in mean scores for social reinforcement of pain behaviors, home or 
family related responsibilities, and pain contingent down time was 0.08, 0.07, and 0.15, 
respectively. 
As described in the results section, raw scores for each pain behavior indicator 
were collapsed to form categories that ranged from zero to three.  Often, meaningful 
information may not be discernable when continuous data is collapsed to form categories.  
A comparison between baseline and follow-up raw scores before data were collapsed into 
categories showed meaningful differences for the two other indicators used to form the 
pain behaviors construct.  A paired-samples t-test ( t = 3.55, df = 83, p < 0.001) showed 
that patient mean scores on the pain or family related responsibilities scale were 
significantly lower at follow-up (mean  = 7.45, sd = 4.5) compared to baseline (mean  = 
8.30, sd = 5.1).  Similarly, a paired sample t-test showed that there was a significant 
decrease (t = 4.02, df = 83,  p < 0.01) in average scores on the item which assessed pain 
contingent down time.  The mean pain contingent downtime decreased from baseline 
(mean = 3.71 hours) to follow-up (mean = 2.55 hours).  
 
5.2.7 Digit Span Test (DST) 
 
The digit symbol test (DST) is composed of the digits forward and backward 
tests.  Scores for each test are calculated as the total number of series recalled correctly 
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before an individual fails to recall two consecutive series of numbers with the same 
length.  A total score for the test is calculated by summing the scores of the two 
individual tests. 
A significant (t = 5.17, df = 83, p < 0.01) improvement in total span was observed 
from baseline to follow-up.  Average total span on the test  increased from 16.14 at 
baseline to 17.60 at follow-up for evaluable patients. 
 Since this study did not employ a control group, the improvement in scores from 
baseline to follow-up may be an artifact due to the effect of regression to the mean.  In 
order to test for this effect, baseline and follow-up scores on the digits forward and 
backward tests were compared for participants who scored one standard deviation above 
and below the mean score for each test at baseline.  This strategy was undertaken since 
post-test scores have a tendency to regress to the mean, i.e., cases with below average 
pre-intervention test scores tend to have higher post-intervention test scores and cases 
with above average pre-intervention test scores tend to the mean on the posttest. 
 Data in Table 5.1 suggests that a small regression to the mean effect may be 
operating.  Regression to the mean is a function of the initial score (deviation from mean) 
and the test retest reliability or lack thereof.  An estimate of the retest score can be 
calculated using the formula323: 
Estimated SF = CM + R (ScoreF – ScoreB)…………Eqn 5.1 
CM or common mean is the average of mean scores at baseline and follow-up.  R 
is a measure of test-retest reliability obtained from the literature. SF  represents the 
estimated score at follow-up or retest score.  The subscripts F and B denote follow-up and 
baseline scores.  The common mean for the digits forward and backward tests were 9.81 
and 7.06, respectively.  The test-retest reliability for the tests reported in the literature 
range from 0.66 to 0.89 (Table 1.2). 
An estimated retest score was calculated for each individual with a baseline mean 
score that was ≥ one standard deviation above the baseline mean score for both tests.  The 
mean estimated retest score for this group of individuals on the digits forward test ranged 
                                                 
323 Streiner DL.  Regression toward the mean: its etiology, diagnosis, and treatment.  Canadian Journal of 
Psychiatry.  2001;46:72-77. 
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from 11.86 to 12.53 using 0.66 and 0.89 as reliability estimates, respectively.  The 
average estimated retest score for patients with mean baseline digits backward test scores 
that were ≥ one standard deviation above the mean ranged from 9.0 to 9.67.  In the case 
of both tests, the observed means (Table 5.1) were slightly greater than the upper limit of 
the estimated retest scores.  Since the observed retest score was greater than the upper 
limit of the predicted score, it may be concluded that effects of regression to the mean in 
this sample for digit span test scores are limited.   
 
Table 5.1 Mean Baseline and Follow-up Scores of Evaluable Patients with 
Scores that were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) 
the Mean Sample Baseline Digits Span Forwards and Backwards Test Scores 
 
 Patients who Scored 1 SD 
Above Sample Mean 
Patients who Scored 1 SD Below 
Sample Mean 
 MeanB  MeanF  MeanB  MeanF  
DST - Forward 12.92  12.64 6.43  7.93 
DST - Backward 10.0 9.69 3.87 5.0 
SD – standard deviation 
B – Baseline 
F- Follow-up 
DST – Digit Span Test 
 
5.2.8 Digit Symbol Test (DSYT) 
 
The digit symbol test (DSYT), like the DST, is a subtest of the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS – III).  The average score on the DSYT 
increased by 5.4 percent, which was statistically significant (p < 0.01).  Baseline and 
follow-up scores on the digit symbol test were compared for participants who scored one 
standard deviation above and below the mean digit symbol test score for all participants 
at baseline.  Again, data presented in Table 5.2 suggest that a regression to the mean 
effect may be operating here. 
Thus, an estimated retest score was calculated for patients with mean baseline 
scores that were greater than or equal to one standard deviation above the mean baseline 
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DSYT score.  The common mean for the baseline and follow-up tests was 63.8 and test-
retest reliability estimates ranged from 0.82 to 0.89.  
Using equation 5.1, estimates of the average retest scores ranged from 82.99 to 
84.63 with reliability estimates ranging from 0.82 and 0.89, respectively.   Since the 
observed retest score (table 5.2) was greater than the upper limit of the predicted score, 
the possibility of a regression to the mean effect was questionable.   
 
 
Table 5.2 Mean Baseline and Follow-up Scores of Evaluable Patients with 
Scores that were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) 
the Mean Sample Baseline Digits Symbol Test Scores 
 
 Patients who Scored ≥ 1 SD over 
Sample Mean 
Patients who Scored ≤ 1 SD 
Below Sample Mean 
 MeanB MeanF MeanB MeanF 
DSYT 87.21 85.36 38.0 42.08 
SD – standard deviation 
B – Baseline 
F- Follow-up 
DSYT – Digit Symbol Test 
 
5.2.9 Paced Auditory Serial Addition Test (PASAT) 
 
The PASAT tests were assessed at two presentation rates, i.e., 2.4 and 2.0 second 
presentation rates.  The number of correct responses at baseline and follow-up were 
calculated for each presentation rate.  The score on the PASAT 2.4 improved 
significantly from baseline to follow-up (mean difference = 4.69, t = 7.15, df = 81, p < 
0.01).  Similarly, the score on the PASAT 2.0 improved significantly from baseline to 
follow-up (mean difference = 3.89, t = 5.6, df = 81, p < 0.01). 
Baseline and follow-up scores on the PASAT 2.4 and 2.0 were compared for 
participants who scored one standard deviation above and below the mean PASAT 2.4 
and 2.0 scores for all participants at baseline.  As shown in table 5.3, follow-up mean 
PASAT 2.4 scores was higher than baseline scores for both groups of individuals.  Thus, 
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it can be concluded that the effect of regression to the mean was not operating in this 
instance.   
In the case of the PASAT 2.0, there was a very small decline (-0.13) in mean 
follow-up scores of individuals with baseline mean scores that were greater than one 
standard deviation above the mean baseline score of all participants.  This result 
suggested that the effect of regression to the mean was not operating.   
 
 
Table 5.3 Mean Baseline and Follow-up Scores of Evaluable Patients with 
Scores that were One Standard Deviation Above and below (1SD ≥ Mean ≤ 1SD) 
the Mean Sample Baseline PASAT 2.4 and 2.0 Scores 
 
 Patients who Scored 1 SD Above 
Sample Mean 
Patients who Scored 1 SD Below 
Sample Mean 
 MeanB MeanF MeanB MeanF 
PASAT 2.4 45.94 47.22 21.50 28.22 
PASAT 2.0 45.69 45.56 19.5 26.29 
SD – standard deviation 
B – Baseline 
F- Follow-up 
 
In summary, follow-up measures of pain intensity, pain unpleasantness, pain suffering 
and pain behaviors were lower than those reported at baseline.  Average daily narcotic 
dose increased from baseline to follow-up.  There was an improvement in performance 
on tests assessing cognitive function.  The improvement in test scores from baseline to 
follow-up was not entirely independent of the effects of regression to the mean.   
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5.3 Stages of Pain Model 
 
This section is confined to the discussion of results from the confirmatory factor 
analysis procedure of the stages of pain model.  Results from the current data supported a 
four factor structure for the stages of pain model.  The four factors that represent different 
stages of the model are: pain intensity (stage I), pain unpleasantness (stage II), pain 
suffering (stage III) and pain behaviors (stage IV).  However, the measurement 
components of the model varied from previously published measurement models of the 
stages of pain model. 
 Wade and colleagues confirmed a four factor solution for the stages of pain 
model.324  The pain intensity and pain unpleasantness factors were composed of average 
pain intensity and average pain unpleasantness in the previous week, respectively.  The 
pain suffering factor was composed of five indicators, namely, depression, frustration, 
anxiety, anger and fear.   Pain behavior in the home, social reinforcement of pain 
behavior, home or family related responsibilities and observed pain behaviors represented 
the pain behavior factor. 
 In a subsequent study, Riley, Wade and colleagues examined the association 
between race/ethnic background and stages of pain model variables.325  The composition 
of the pain behavior factor in this study varied slightly from the previously confirmed 
model.  The ‘observed pain behaviors’ indicator was replaced by the indicator which 
assessed ‘pain contingent down time.’   
The results from this study found support for a re-specification of the stages of 
pain models described above.  The stages of pain model – modification 2 with baseline 
data was similar to the above models, except for the indicators used to form the pain 
behavior factor.  The pain behavior factor for this model (modification 2) included three 
                                                 
324 Wade JB, Dougherty LM, Archer CR, Price DD.  Assessing the stages of pain processing: a multivariate 
analytical approach.  Pain.  1996;68:157-167. 
 
325 Riley JL, Wade JB, Myers CD et al.  Racial/ethnic differences in the experience of chronic pain.  Pain.  
2002;100:291-298. 
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indicators: pain behaviors at home, home or family related responsibilities, and pain 
contingent down time. 
The stages of pain model – modification 2 did not fit the data at follow-up.  At 
follow-up, residual variances for three indicators of the pain suffering construct were 
negative (frustration, anger, fear).  The negative variances were contributing to model 
misspecification.  The final model specified without these indicators was found to fit the 
data well.   
Thus, the final stages of pain model determined from the data in this study 
differed from previously confirmed models with respect to the pain suffering and pain 
behavior constructs.  The pain suffering factor predicted two indicators: depression and 
anxiety. The pain behaviors factor predicted three indicators: pain behaviors at home, 
home or family related responsibilities, and pain contingent down time.  It is likely that a 
larger sample (n > 300) may have resulted in the confirmation of previously published 
models. 
.  
5.3.1 Pain Intensity and Pain Unpleasantness 
 
Pain intensity (stage I) is composed of the sensory-discriminative aspect of pain.  
Pain unpleasantness (stage II) is composed of the immediate concern regarding the pain 
on an individual’s mental state.  These two factors comprise the sensory-affective 
dimension of pain.  A significant direct association between pain intensity and pain 
unpleasantness was found at baseline (β = 1.11, p < 0.01) and follow-up (β = 1.08, p < 
0.01).   
 
5.3.2 Pain Suffering 
 
Pain suffering (stage III) is a cognitive process reflective of the emotional 
disruption due to chronic pain.  The results showed that this stage is distinctly different 
from the immediate negative affect described above.  A strong association was found 
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between pain affect/unpleasantness and pain suffering at baseline (β = 0.69, p < 0.01) and 
follow-up (β = 0.65, p < 0.01).   
It was postulated that negative emotions arising due to chronic pain are 
accompanied by an individual’s belief about the impact of pain in their life.  This 
hypothesis was not supported by the current model.   
This does not imply that the relationship between pain suffering and pain beliefs 
does not exist.  Numerous studies have shown the association between these two 
constructs.326,327,328  Low reliability (cronbach’s α = 0.36) for items used to measure the 
pain beliefs construct at baseline highlights the deficiency of the  pain beliefs scale used 
in this study.    
The stages of pain model could improve significantly by utilizing a reliable and 
valid measure of pain beliefs such as the pain beliefs and perceptions inventory (PBPI). 
The PBPI was correlated with pain related anxiety, depressive symptoms, and subjective 
reports of pain.329  
The causal direction of the relationship between pain suffering and pain beliefs is 
not apparent.  Most often, pain beliefs are conceptualized as influencing psychological 
symptoms.  Negative beliefs and emotions may arise together influencing each other 
simultaneously.  Thus, future studies utilizing the stages of pain model should attempt to 
elucidate the association between pain beliefs and pain suffering in larger samples. 
 
5.3.3 Pain Behaviors 
 
 To a large extent, pain behaviors are the only observable components of the pain 
process.  Functional impairment, disability, and withdrawal from usual responsibilities 
may be used to operationalize the concept of pain behaviors. There was a weak 
                                                 
326 Williams DA, Robinson ME, Geisser ME.  Pain beliefs: assessment and utility.  Pain.  1994;59:71-78. 
327 Gibson JS, Helme RD.  Cognitive factors and the experience of pain and suffering in older persons.  
Pain.  2000;85:375-383. 
328 Ashgari A, Nicholas MK.  Pain self-efficacy beliefs and pain behaviors.  A prospective study.  Pain. 
2001;94:85-100. 
329 Williams DA, Robinson ME, Geisser ME.  Pain beliefs: assessment and utility.  Pain.  1994;59:71-78. 
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relationship between pain suffering and pain behaviors at baseline (0.13) and follow-up; 
however, the associations at both points in time were significant (p < 0.01).   
In order to visualize the association between pain behaviors and the indicators of 
the pain suffering construct, a composite pain behavior variable at baseline was created 
using the three indicators used to form the pain behavior construct.  The composite was 
created by summing scores of individuals for frequency of pain behaviors at home, home- 
or family-related responsibilities, and pain continent down time.  The sum of scores was 
divided by three.  Greater frequency of pain behaviors (higher scores on the composite) 
was associated with higher levels of depression and anxiety.  This trend was observed 
across all levels of pain behavior except for the groups of  patients with a pain behavior 
composite score that equaled one (Figure 5.1).  This groups consisted of only two 
patients, and corresponding data were skewed since one patient provided maximum 
ratings on both the depression and anxiety scales.   
 
Figure 5.1 Plot of Depression and Anxiety by Pain Behavior Composite at Baseline 
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Prior research has also demonstrated that patients with positive perceptions about 
pain or patients demonstrating higher levels of self efficacy were less likely to engage in 
pain behaviors.330,331  The results from this study echoed the findings from the literature.   
This statement can be verified graphically from the plot of the pain behavior 
composite by pain belief indicators (Figure 5.2).  The pain belief indicators depicted here 
are difficulty in enduring pain and ability to control pain.  The plot clearly shows that 
patients with a higher frequency of pain behaviors believe that it is more difficult to 
endure pain and also believe that they lack the ability to endure pain.  Again, an anomaly 
in the trend was observed for the group with a pain behavior composite score that equaled 
one due to extreme scores provided by one out of two patients in the group. 
 
Figure 5.2 Plot of Ability to Endure Pain and Reduce Pain by Pain  Behavior 
Composite at Baseline 
 
                                                 
330 Denison E, Asenlof P, Lindberg P.  Self-efficacy, fear avoidance, and pain intensity as predictors of 
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Thus, Figures 5.1 and 5.2 clearly show the associations between pain suffering, 
pain beliefs, and pain behaviors.  In addition to experiencing immediate negative affect, 
disability due to pain occurs almost immediately.  A plausible alternate hypothesis is that 
pain behaviors and pain beliefs arise simultaneously. Thus, an alternative progression of 
these relationships may exist in the context of chronic pain.   
Patients with high self-efficacy levels and positive beliefs obtain control over 
their environment through behavioral and cognitive means.332  The perceived control 
enables these patients to minimize stress and the level of threat associated with stressful 
events.  Consequently, self-efficacious pain patients can motivate themselves to minimize 
the impact of pain on their behaviors and thereby limit functional impairment.  
Conversely, pain patients with low self-efficacy levels experience constant pain and lack 
an ability to control the pain.  As a result, inefficacious patients are overwhelmed by 
stress and the associated threat, which leads to pain behaviors and functional impairment.  
Threat has also been shown to capture attention, thereby diverting cognitive resources.333 
The constant stress over time, lack of control, and functional impairments contribute to 
distress and pain suffering.   This reasoning suggests that the stages of pain model in its 
current form may not be a reasonable explanation for “real-world” phenomena. 
 An alternative specification would be to model pain behaviors as a predictor of 
suffering.  It could be hypothesized that disability due to pain may have a significant 
impact on an individual’s psychological well-being.  Empirical tests of these cause-effect 
relationships would enable practitioners to root cause problems and manage patients 
effectively by targeting the source of the problem. Secondly, inclusion of measures of 
pain beliefs or self-efficacy in such a model is critical, since self efficacy mediates the 
association between pain, functional impairment or disability, and psychological 
functioning in pain patients. 
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5.4 Hypothesized Models 
 
This section examines the associations between the dependent variables in the 
study, i.e., tests of cognitive function and their predictors.  Thus, for each of the three 
hypothesized models (DST, DSYT, and PASAT), associations between each predictor 
variable (MED, VED, pain intensity, pain suffering, and pain behaviors) and the 
dependent variable is examined.  The association between age and tests of cognitive 
function, gender and pain unpleasantness, and ethnicity and pain suffering will be 
delineated as well. 
 
5.4.1 Association between Morphine Equivalent Dose and Tests of Cognitive 
Function (DST, DSYT, and PASAT) 
 
The primary purpose of this study was to examine the association between Avinza and 
performance on tests of cognitive function.   
Two-Wave Digit Span Test Model 
Results from the two-wave DST model showed a positive association between short-
acting narcotic dose and DST scores, which approached significance (p = 0.06) at 
baseline.  A ten percent change in MED was associated with a 0.068 unit change in DST 
scores.  A statistically insignificant (p = 0.53) negative association was found between 
follow-up narcotic dose (sum of Avinza and breakthrough pain medication morphine 
equivalent dose) and DST scores.  A ten percent change in MED was associated with a 
0.038 reduction in DST scores.  The results suggest that narcotics used in this study to 
manage chronic pain did not impair performance on the digit span test. 
Two-Wave Digit Symbol Test Model 
 Results from the two-wave DSYT model showed a positive non-significant (p = 
0.23) association between short-acting narcotic dose and DSYT scores. A ten percent 
change in MED at baseline was associated with a 0.7 percent change in DSYT scores.   
The association between narcotic dose at follow-up (sum of Avinza and breakthrough 
pain medication morphine equivalent dose) and DSYT scores was negative, but 
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statistically insignificant (p = 0.85).  A ten percent increase in MED at follow-up was 
associated with a 0.08 percent reduction in DSYT scores. The results suggested that 
narcotics used in this study to manage chronic pain did not impair performance on the 
digit symbol test. 
Two-Wave Paced Auditory Serial Addition Test Model 
Results from the two-wave PASAT model showed a positive and non-significant 
association between short-acting narcotic dose and PASAT scores ( p = 0.33) at baseline.  
A ten percent change in MED scores at baseline was associated with a 0.6 percent change 
in PASAT scores.  The association between narcotic dose at follow-up (sum of Avinza 
and breakthrough pain medication morphine equivalent dose) and PASAT scores was 
negative, but statistically insignificant (p = 0.37).  A ten percent change in MED at 
follow-up was associated with a 0.3 percent reduction in PASAT scored.  The results 
suggest that narcotics used in this study to manage chronic pain did not impair 
performance on the paced auditory serial addition test. 
There was no significant direct association between morphine equivalent dose 
(MED) of either short-acting or long-acting narcotics and measures of attention (DST, 
DSYT, and PASAT) while controlling for pain intensity, pain unpleasantness, pain 
suffering, pain behaviors and benzodiazepine dose.  This finding was consistent with 
recent literature, which has demonstrated that narcotic analgesics do not impair cognitive 
function.334,335,336,337  Additionally, a recent review of studies which examined the 
association between opioid use and cognitive function reinforced support for the finding 
that narcotic agents do not have detrimental effect on neuropsychological functioning.338 
 
                                                 
334 Lorenz J, Beck H, Bromm B.  Cogntive performance, mood and experimental pain before and during 
morphine-induced analgesia in patients with chronic non-malignant pain.  Pain.  1997;73:369-375. 
335 Haythornthwaite JA, Lynette MA, Quatrano-Piacentini Al, Pappagallo M.  Outcome of chronic opioid 
therapy for non-cancer pain.   Journal of Pain and Symptom Management.  1998;15:185-194. 
336 Rowbotham MC, Twilling L, Davies PS, et al.  Oral opioid therapy for chronic peripheral and central 
neuropathic pain.  New England Journal of Medicine.  2003;348:12223-1232. 
337 Raja SN, Haythornthwaite JA, Pappagallo M, et al.  Opioids versus antidepressants in postherpetic 
neuralgia: A randomized placebo-controlled trial.  Neurology.  2002;59:1015-1021. 
338 Ersek M, Cherrier MM, Overman SS, Irving GA.  The cognitive effects of opioids.  Pain Management 
Nursing.   2004;5:75-93. 
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5.4.2 Association between Valium Equivalent Dose, DST, DSYT, and PASAT 
 
The second objective in this study was to examine the association between 
benzodiazepine use and performance on tests of cognitive function.   
Two-wave Digit Span Test Model 
A ten percent increase in VED was associated with a 0.001 unit reduction in DST 
scores. The negative association between VED and DST scores at baseline was 
statistically insignificant (p = 0.91).  The direction and magnitude of the association did 
not change appreciably at follow-up.  A 10 percent increase in VED was associated with 
a 0.005 unit reduction in DST scores.  The negative association between valium 
equivalent dose and DST scores at follow-up was not statistically significant (p = 0.70).   
Previous research has demonstrated that duration of benzodiazepine use is 
associated with impaired performance on neuropsychological tests.339  In order to test 
these findings, a benzodiazepine use factor was created.  The hypothesized DST model 
was modified by adding including duration of benzodiazepine use along with valium 
equivalent dose as two indicators, which were loaded on a factor named, “benzodiazepine 
use.” 
The model was retested with a benzodiazepine use factor that included 
benzodiazepine dose and duration of use as indicators.  According to the exact chi-square 
fit test (chi-square = 231.86, p = 0.54, df = 235), model fit with the benzodiazepine use 
factor was adequate.  The results from this model showed that a ten percent increase in 
this factor score was associated with a 0.003 and 0.002 reduction in DST scores at 
baseline and follow-up, respectively.  The association between benzodiazepine use factor 
and DST at baseline (0.79) and follow-up (0.09) were not significant. 
Thus, benzodiazepine use and benzodiazepine dose were not associated with an 
impaired performance on the digit span test. 
 
 
                                                 
339 Golombok S, Moodley P, Lader M.  Cognitve impairment in long-term benzodiazepine users.  
Psychological Medicine. 1988;18:365-74. 
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Two-wave Digit Symbol Test Model 
The negative association between VED and DSYT scores at baseline was 
statistically significant (p = 0.03).  A ten percent increase in VED was associated with a 
0.5 percent reduction in DSYT scores. The direction of the association (0.012) was 
positive and not significant (p = 0.33) at follow-up.   
The model was retested with the benzodiazepine use factor that included 
benzodiazepine dose and duration of use as indicators.  According to the exact chi-square 
fit test (chi-square = 232.2, p = 0.03, df = 194), model fit with the benzodiazepine use 
factor was not adequate.  The negative association between the benzodiazepine use factor 
and DSYT scores was statistically significant (p = 0.01) at baseline.  A ten percent 
increase in benzodiazepine factor scores was associated with a 0.6 percent reduction in 
DSYT scores. The direction of this association at follow-up was reversed (0.01) and the 
association was not significant (p = 0.36).   
The proportion of variance explained for the DSYT factor at baseline in the 
hypothesized model and model with benzodiazepine use factor was 0.34 and 0.23, 
respectively.  These values at follow-up were 0.88 and 0.83, respectively. 
Although the addition of the duration of use indicator increased the magnitude of 
association with DSYT scores from 0.5 to 0.6 percent, this increase was minimal.  The 
addition of a second indicator also resulted in an ill-fitting model (p < 0.05)  Thus, the 
empirical evidence suggested that the hypothesized conceptualization of the digit symbol 
model is appropriate.  The exclusion of the duration of benzodiazepine use indicator was 
justified.  The results indicated that increase in benzodiazepine dose was associated with 
an impaired performance on the digit symbol test. 
 
Two-Wave Paced Auditory Serial Addition Test Model 
 The negative association between VED and PASAT scores at baseline was 
statistically significant (p = 0.008).  A ten percent increase in VED was associated with a 
0.6 percent reduction in DSYT scores. The direction of the association (0.006) was 
positive and not significant (p = 0.66) at follow-up.   
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The model was retested with the benzodiazepine use factor, which included 
benzodiazepine dose and duration of use as indicators.  According to the exact chi-square 
fit test (chi-square = 249.1, p = 0.26, df = 236), model fit with the benzodiazepine use 
factor was adequate.  The negative association between the benzodiazepine use factor and 
DSYT scores was statistically significant (p = 0.01) at baseline.  A ten percent increase in 
benzodiazepine use factor scores was associated with a 0.6 percent reduction in DSYT 
scores.  The direction of this association at follow-up was reversed (0.004) and the 
association was not significant (p = 0.79).   
These results suggested that addition of the benzodiazepine duration of use 
indicator did not add any new information to the hypothesized model which included 
only the benzodiazepine dose indicator.  Thus, use of the benzodiazepine dose factor with 
a single indicator, i.e., valium equivalent dose, was justifiable. 
The results indicated that increase in benzodiazepine dose was associated with an 
impaired performance on the paced auditory serial addition test.  An increase in 
benzodiazepine dose adversely affects the ability to maintain visual attention and motor 
persistence (DSYT).  Additionally, an increase in  benzodiazepine dose is associated with 
an impaired ability to adequately process information and maintain sustained and divided 
attention (PASAT).  Benzodiazepine dose did not change from baseline to follow-up.  
The finding that the association between benzodiazepine dose and DST and 
benzodiazepine dose and PASAT scores at follow-up was positive and not significant 
suggests an improvement in DST and PASAT scores independent of the benzodiazepine 
dose.  The literature review showed that studies have failed to control for the effects of  
benzodiazepine use in examining the association of pain on cognitive function.  Recent 
research also fails to address this shortcoming.340,341  A strategy of solely prescribing 
benzodiazepines to address pain-related anxiety is clearly not sufficient.  Sources of 
anxiety in chronic pain and their management is an area of research in itself that must be 
addressed. 
                                                 
340 Apkarian AV, Sosa Y, Krauss B et al.  Chronic pain patients are impaired on an emotional decision 
making task.  Pain.  2004;108:129-136. 
341 Dick B, Eccleston C, Crombez G.  Attentional functioning in fibromyalgia, rheumatoid arthritis, and 
musculoskeletal pain patients.  Arthritis and Rheumatism.  2002;47:639-644. 
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5.4.3 Association between Pain Intensity, DST, DSYT and PASAT 
 
  The third objective of this study was to determine the association between pain 
intensity and cognitive function test scores. 
Two-wave DST Model 
The association between pain intensity and DST scores was not significant.  The 
direct (β = -0.06) and indirect (β = -0.05) association between pain intensity and DST 
scores at baseline were negative.  A negative indirect association (β = -0.16) was found 
between pain intensity scores at baseline on DST scores at follow-up.   The direct effect 
of pain intensity on DST scores at follow-up was positive (β = 0.02) and the indirect 
effect was zero.   
 
Two-wave DSYT Model 
 The association between pain intensity and DSYT scores was not significant. A 
unit change in the pain intensity at baseline was associated with a 0.7 percent decline in 
DSYT scores at baseline.  The indirect effect of pain intensity at baseline on DSYT 
scores at baseline was zero.  A negative indirect association was found between baseline 
pain intensity scores and follow-up DSYT scores.  A unit change in pain intensity at 
baseline resulted in a 0.5 percent reduction in DSYT scores at follow-up.  The direct 
association between follow-up pain intensity ratings and DSYT scores was zero, while 
the indirect effect was positive.  A unit change in pain intensity ratings at follow-up was 
associated with an indirect effect that resulted in a 0.1 percent change in DSYT scores. 
Two-wave PASAT Model 
The association between pain intensity and PASAT scores was not significant   A 
unit change in pain intensity at baseline was associated with a direct effect that resulted in 
a 1.7 percent decline in PASAT scores at baseline.  Due to an indirect effect, a unit 
change in pain intensity ratings at baseline resulted in a 0.6 percent decline in PASAT 
scores at baseline.  Due to an indirect effect, a unit change in pain intensity ratings at 
baseline resulted in a 2.5 percent reduction in PASAT scores at follow-up.  The total 
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effect of pain intensity ratings at follow-up on PASAT scores at follow-up was zero, 
since the direct effect (+ 0.5) and indirect effect (-0.5) cancelled each other out.   
 Similar to previous studies, no significant direct associations were found between 
pain intensity and cognitive test scores.  The direction of the direct association between 
pain intensity ratings and cognitive function test scores went from being negative at 
baseline to positive at follow-up. 
  
5.4.4. Association between Pain Suffering, DST, DSYT, and PASAT 
 
The fourth objective of the study was to determine the association between pain suffering 
and cognitive function test. 
 
Two-Wave Digit Span Test Model 
The association between pain suffering and DST scores at baseline (p = 0.46) and 
follow-up (p = 0.70) was not significant.  Although the association between pain 
suffering and digit span test scores was negative at baseline (β = - 0.05) and follow-up (β 
= - 0.02), the magnitude of the negative association declined from baseline to follow-up. 
Two-Wave Digit Symbol Test Model 
The association between pain suffering and digit symbol test scores was not 
significant at baseline (p = 0.72) and follow-up (p = 0.90).  A unit change in pain 
suffering scores at baseline was associated with a 0.2 percent increase in digit symbol test 
scores.  The direction of this association did not change at follow-up.  A unit change in 
pain suffering scores at follow-up was associated with a 0.3 percent change in digit 
symbol test scores.  Although not significant, the positive association between pain 
suffering and DST scores seemed contrary to previous research. 
A further examination of the total effects of pain suffering on DSYT scores at 
baseline showed the association to be negative.  A unit change in the total effect 
(unmediated and mediated) of pain suffering was associated with one percent reduction in 
DSYT scores at baseline.  The sum of unmediated and mediated effect of pain suffering 
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on DSYT scores at follow-up was positive.  A unit change in the total effect of pain 
suffering at follow-up was associated with a 0.2 percent change in DSYT scores. 
Two-Wave Paced Auditory Serial Addition Test Model 
The association between pain suffering and PASAT scores was not significant at 
baseline (p = 0.71) and follow-up (p = 0.21).  A unit increase in pain suffering scores at 
baseline was associated with a 0.4 percent reduction in PASAT scores at baseline.  The 
direction of this association did not change at follow-up.  A unit increase in pain suffering 
scores at follow-up was associated with a 0.8 percent reduction in PASAT scores at 
follow-up. 
The magnitude of the total effect of pain suffering on PASAT scores was larger at 
baseline than at follow-up.  A unit change in pain suffering scores at baseline resulted in 
mediated and unmediated effects that caused a 1.2 percent reduction in PASAT scores at 
baseline.  The mediated and unmediated effects of pain suffering at follow-up caused a 
one percent reduction in PASAT scores at follow-up. 
 The non-significant association between pain suffering and cognitive test scores 
found in this study is contrary to evidence presented in the literature review.  Brown et al.  
concluded that the association between pain and cognitive function was mediated by 
depressive symptoms.342  On the other hand, some empiric evidence suggests that this 
may not always be the case.343,344  Pain suffering is most commonly associated with 
impairments in information processing.345  Although not significant, our study did find a 
negative association between pain suffering and PASAT scores, which is a measure of 
information processing.    Alternatively, the addition of benzodiazepine dose as a control 
variable may have contributed to a finding that differed from previous literature.  Other 
studies have failed to examine the association between depression, anxiety, and cognitive 
                                                 
342 The relationship of pain and depression to cognitive function in rheumatoid arthritis patients.  Brown 
SC, Glass JM, Park DC.  Pain.  2002;96:279-284. 
343 Dick B, Eccleston C, Crombez G.  Attentional functioning in fibromyalgia, rheumatoid arthritis, and 
musculoskeletal pain patients.  Arthritis and Rheumatism.  2002;47:639 
344 Park DC, Glass JM, Minear M, Crofford LJ.  Cognitive function in fibromyalgia patients.  Arthritis and 
Rheumatism.  2001;44:2125-2133. 
345 Christensen H, Griffiths K, MacKinnon A, Jacomb P.  A quantitative review of cognitive deficits in 
depression and Alzheimer-type dementia.  Journal of the International Neuropsychological Society.  
1997;3:631-651. 
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functioning in chronic pain patients while controlling for benzodiazepine dose.  Thus, 
previous conclusions about the association between pain suffering and cognitive function 
may have been spurious in the absence of this control variable. 
  
5.4.5 Association between Pain Behaviors, DST, DSYT, and PASAT 
 
The final objective of the study was to determine the association between pain behaviors 
and cognitive function test. 
Two-Wave Digit Span Test Model 
There was a significant negative association (p < 0.05) between frequency of pain 
behaviors and digit span test scores.  A unit increase in frequency of pain behaviors was 
associated with a 0.39 unit reduction in digit span test scores.  The association between 
frequency of pain behaviors at follow-up and digit span test scores was positive (β = 
0.28) and not significant (p = 0.29).   
We next determined whether improvements in digit span test scores occurred 
across all levels of pain behaviors or only among those reporting the highest frequency of 
pain behaviors.  A composite pain behavior variable at baseline and follow-up was 
created using the three indicators used to form the pain behavior construct.  The 
composite was created by summing scores of individuals for frequency of pain behaviors 
at home, home or family related responsibilities, and pain continent down time.  The sum 
of scores was divided by three. 
The average total span scores at baseline and follow-up were plotted against the 
baseline and follow-up pain behavior composites (Figures 5.3 and 5.4). The plots clearly 
show that average span scores increased from baseline to follow-up across all pain 
behavior levels, supporting the conclusion that improvement in pain and reduction in pain 
behaviors was associated with an increase in digit span test scores. 
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Figure 5.3 Plot of Baseline & Follow-up Digit Span Test Scores by Pain 
Behavior Composite at Baseline 
  
 
Figure 5.4 Plot of Baseline & Follow-up Digit Span Test Scores by Pain 
Behavior Composite at Follow-up 
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Two Wave Digit Symbol Test Model 
The association between frequency of pain behaviors and digit symbol test scores 
at baseline and follow-up was negative and non-significant.  The magnitude of these 
associations in comparison with associations examined between other variables seemed 
relatively large.  A unit increase in frequency of pain behaviors was associated with a 13 
percent reduction in digit symbol test scores.  At follow-up, a unit increase in frequency 
of pain behaviors was associated with a three percent reduction in digit symbol test 
scores.   
Similar to the procedure used above, digit symbol test scores at baseline and follow-up 
were plotted against pain behavior composites at baseline and follow-up.  The plots can 
be viewed in figures 5.5 and 5.6, respectively.  The plot shows a general negative 
association between the two variables.  However, there was a lack of a consistent 
association between the two variables since patients with a pain behavior composite score 
in the range of 2.33 to 3 performed better on the DSYT than patients in the 1.67 to 1.99 
range.  This variability may account for the lack of a significant association between pain 
behaviors and DSYT scores.  Patients who accounted for the most frequent pain 
behaviors at follow-up had marginally lower average scores on the test at follow-up.  An 
improvement in test scores was observed across all other levels of pain behavior 
frequencies. 
 
 
 
 
 
 
 
 
 
 
  
 290
Figure 5.5 Plot of Baseline & Follow-up Digit Symbol Test Scores by 
Pain Behavior Composite at Baseline 
 
 
Figure 5.6 Plot of Baseline & Follow-up Digit Symbol Test Scores by 
Pain Behavior Composite at Follow-up 
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Two-Wave Paced Auditory Serial Addition Test Model 
The association between frequency of pain behaviors and paced auditory serial 
addition test scores at baseline and follow-up was negative and non-significant.  A unit 
increase in frequency of pain behaviors was associated with a 3.4 percent reduction in 
paced auditory serial addition test scores.  At follow-up, a unit increase in frequency of 
pain behaviors was associated with a 2.2 percent reduction in paced auditory serial 
addition test scores.   
Figure 5.5 and 5.6 present a plot of baseline and follow-up PASAT 2.4 scores by 
pain behavior composite at baseline and follow-up, respectively.  Although the 
association between PASAT 2.4 scores and pain behavior composite at baseline tended to 
appear linearly negative, patients with pain behavior scores in the range of 2.33 to 2.67 
had higher PASAT 2.4 scores than individuals with less frequent pain behaviors.  A 
similar observation was made in the case of PASAT 2.0 scores (figure 5.7).   These 
deviations may have contributed to the non-significant associations between PASAT 
scores and pain behaviors.  However, the results show improvements in test scores across 
all levels of pain behaviors, which support the conclusion that improvement in pain and 
pain behaviors were associated with  overall improvements in PASAT test scores. 
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Figure 5.7 Plot of Baseline & Follow-up PASAT 2.4  Scores by Pain 
Behavior Composite at Baseline 
 
 
Figure 5.8 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain 
Behavior Composite at Follow-up 
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Figure 5.9 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain 
Behavior Composite at Baseline 
 
 
 
Figure 5.10 Plot of Baseline & Follow-up PASAT 2.0  Scores by Pain 
Behavior Composite at Follow-up 
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The above findings suggest that reduction in subjectively reported pain and pain 
behaviors were associated with some improvement in cognitive function test scores.  
Previous empirical work, which has shown an inverse association between the Arthritis 
Impact Measurement scale (AIMS) and cognitive function in fibromyalgia patients lends 
support to our findings.346 AIMS is a measure of everyday dysfunction due to pain.  Our 
study extends these findings by showing that interventions capable of reducing functional 
impairment also have positive effects on neuropsychological impairment.   
These results also lend some credibility to the alternative specification of the 
SOPM model discussed above. Pain relief with Avinza may have influenced positive 
reinforcement in the ability of patients to obtain control over their pain.  Control that can 
be sustained over prolonged periods may have reduced the associated threat with pain 
and reduced pain behaviors.  Minimization of the threat could enable patients to refocus 
their cognitive resources, which led to a weakening of the association between pain 
behaviors and cognitive test scores.  
The findings indicate that opioids, particularly long acting opioids must be an 
integral component of multidisciplinary pain management programs.  Pain management 
models that ignore the utility of opioids may be able to achieve improved outcomes with 
the addition of controlled administration of sustained-release narcotic medications.   
 
5.4.6 Association between Age, DST, DSYT, and PASAT 
 
Two-Wave Digit Span Test Model 
The results showed a negative association between age and digit span test scores 
at baseline, which approached significance (β = - 0.034, p = 0.06).  At follow-up, this 
association was positive and not significant (β = 0.023, p = 0.33).   
Two-Wave Digit Symbol Test Model 
There was a significant negative association (p = 0. 03)  between age and digit symbol 
test scores at baseline.  A one year increase in age was associated with a 0.7 percent 
                                                 
346 Park DC, Glass JM, Minear M, Crofford LJ.  Cognitive function in fibromyalgia patients.  Arthritis and 
Rheumatism.  2001;44:2125-2133. 
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decrease in DSYT scores.  The magnitude of the association was weaker and not 
significant at follow-up.  A one year increase in age was associated with a 0.3 percent 
decrease in DSYT scores ( p = 0.15). 
Two-Wave Paced Auditory Serial Addition Test 
The association between age and PASAT scores at baseline and follow-up was 
negative and not significant.  A one year increase in age was associated with a 0.2 percent 
reduction in PASAT scores at baseline and a 0.3 percent reduction in scores at follow-up. 
5.4.7 Association between Gender and Pain Unpleasantness 
 
 On average, baseline pain unpleasantness ratings at the highest, lowest, and usual 
pain intensity levels for females was higher than males.  The mean pain unpleasantness 
ratings provided by females at baseline were 13.04, 7.31, and 10.07 for highest, lowest 
and usual pain intensity levels respectively.  The mean baseline ratings provided by males 
for these levels were 12.55, 5.66, and 9.22 respectively.  Results from a cross-sectional 
study showed that women provided higher pain unpleasantness ratings than males except 
at the lowest pain intensity level.347 
However, this trend was reversed at follow-up.  The mean highest pain 
unpleasantness rating at follow-up was 11.17 for males and 10.93 for females.   The mean 
lowest pain unpleasantness rating at follow-up was 4.30 for males and 3.83 for females.  
There was a very small difference in mean unpleasantness ratings at the usual pain 
intensity level between females (7.38) and males (7.16).   
 Results from the two-wave DST, DSYT, and PASAT models showed no 
significant difference in pain unpleasantness ratings between males and females.  In an 
evaluation of two separate stages of pain models for males and females, Riley and 
colleagues showed that the association between pain unpleasantness and pain suffering 
was stronger among males.348  Our sample was not large enough to generate these 
comparisons.  Data from this study showed that women tended to report larger reductions 
                                                 
347 Riley JL, Robinson ME, Wade JB, et al.  Sex differences in negative emotional responses to chronic 
pain.  The Journal of Pain..   2001;2:354-359. 
348 Ibid. 
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in pain unpleasantness levels following treatment with sustained release morphine.  This 
tendency of women to report extreme values at both ends of the scale deserves further 
study.  
 
5.4.8 Association between Pain Suffering and Ethnicity 
 
A majority of the sample (61.3%) was Caucasian.  The two other relatively large 
ethnic groups who formed this sample were African Americans (20.2%) and Hispanics 
(9.7%).    On average, the lowest levels of depression (mean  = 7.31, sd = 4.4) and 
anxiety ( mean = 7.74, sd = 4.2) at baseline were observed among Caucasians.  All other 
ethnic groups had higher scores on both these indicators.  The average score on the 
depression indicator was lower for African-Americans (9.68, sd = 4.6) than Hispanics 
(10.67, sd = 4.0).  On average, African Americans reported higher anxiety levels (10.16, 
sd = 4.9) compared to Hispanics (9.13, sd = 4.6). 
In order to determine variation in pain suffering ratings across ethnic groups, two 
groups were formed.  One group included Caucasians and the second group included all 
other ethnic groups.  Results from the hypothesized models showed that compared to 
other ethnic groups, Caucasians provided significantly (p < 0.05) lower pain suffering 
ratings at baseline.  The magnitude of the difference in the case of the DST and PASAT 
models was 2.0, while the difference in the case of the DSYT model was 1.32.  Although 
Caucasians had lower scores than other ethnic groups on the pain suffering construct at 
follow-up as well, the differences were not significant.  
Data from this study were consistent with prior research which has shown that 
African-Americans and Hispanics tend to provide higher depression and anxiety ratings 
as compared to Caucasians.349 
 
                                                 
349 Riley JL, Wade JB, Myers CD et al.  Racial/ethnic differences in the experience of chronic pain.  Pain.  
2002;100:291-298. 
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5.5 Limitations 
 
Researchers must strive to minimize the potential for bias in their studies.  Despite 
the good intentions of the researcher, potential for bias cannot be eliminated.  This study 
is no different and suffers from potential limitations. 
The sample size for this study was small (n = 129), and patient attrition prevented 
us from utilizing all the data in modeling the relationships.  Despite the small sample 
size, significant associations were found.  However, significant associations between pain 
suffering and cognitive function test variables may have been elicited with a larger 
sample size.  These data were originally to be analyzed using path analysis, and thus, 
sample size was calculated in a fashion used for a multiple regression analysis.  Kline 
recommends that models analyzed using structural equation modeling include at least 5 
subjects per parameter included in the model.  Thus, with at least 50 parameters in this 
model, future studies contemplating a similar evaluation should intend to recruit 500 
patients. 
A convenience sampling procedure was used and only patients motivated to improve 
their condition may have enrolled in the study.  Thus, patient self-selection may have 
biased the results in an upward direction.  However, most patients enrolled in the study 
experienced chronic pain for a year or longer.  The clinic specialized in interventional 
pain procedures and opioid pain management, and thus, in most cases represented a 
tertiary form of care for most patients.  
Since patients completed the study forms in the presence of the researcher, the 
possibility that patients responded in a manner that they considered socially desirable 
cannot be excluded.   
The assessment of patient behavior utilized one item requiring the judgment of the 
researcher/interviewer.  The item lists several specific behaviors that must be rated.  
According to Polit and Hungler, observing patients in this manner is termed as a 
molecular approach to evaluation, wherein highly specific behaviors form the unit of 
observation.  Thus, bias can be introduced into recording such behaviors by the 
researcher himself.  Since only one individual made these judgments, inconsistencies in 
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interpreting certain behaviors were minimized.  Additionally, this item was not 
incorporated as an indicator of the pain behavior factor for the present analysis. 
 Numerous issues were encountered with the scales.  Three indicators of the 
original pain suffering scale: frustration, anxiety, and anger caused estimation problems 
with the follow-up data.  It is likely that the problem was associated with the limited 
sample size.   
 Items assessing pain beliefs did not load on the pain suffering construct.  As 
mentioned previously, the stages of pain model probably fails to capture real world 
phenomena without an adequate characterization of pain beliefs in the process.  
 The pain behaviors construct is dated and lacks sensitivity to change.  In the case 
of the item assessing pain or family related responsibilities, patients with a raw score that 
exceeds seven are placed in a category characterized by the highest inability to perform 
previously discharged responsibilities.   The scale lacks the ability to distinguish between 
a patient who is marginally impaired on a broad range of activities and a patient with 
significant impairments on a small set of activities.  Both these patients could easily 
receive the same category score.   Thus, the lack of scale sensitivity stems from the lack 
of consideration of the range of activities performed by patients.  
Education has been associated with performance on tests of cognitive function. 
The current model did not control for the relative educational levels of participants.     
Several patients underwent interventional procedures during the follow-up phase 
of the study.  Procedures such as nerve blocks, facet joint injections, and steroid 
injections were administered to some study patients.  These procedures when effective 
contribute significantly to pain relief and reduction in functional impairment.  Exclusion 
of intervention effects may upwardly bias the treatment effect associated with Avinza.  
 However, improvement in symptoms and the consequent improvement in 
performance on neuropsychological tests were consistent with the study hypothesis that 
pain relief and associated improvement in behavioral and psychological symptoms 
contributes to improvement in cognitive function. 
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Improvement in cognitive function test scores may have been an artifact due to 
practice effects.  Practice effects have been noted, particularly if successive tests are 
administered within a week from each other.350  The one-month interval in assessments 
minimized this effect to a certain extent.  The lack of a control group is an additional 
threat to internal validity.     The true extent to which cognitive function improved cannot 
be determined without an adequate control group. 
5.6 Conclusion 
 
The sample for this study included chronic pain patients with a variety of 
diagnoses.  The patients experienced significant disability secondary to pain.  Addition of 
Avinza® to the short-acting narcotic medication regimen significantly improved 
subjectively reported outcomes of pain intensity.  Patients utilizing short-acting narcotic 
analgesic medications reported high levels of pain intensity.  Treatment and stabilization 
of patients with Avinza® resulted in reduction of average, maximum and minimum pain 
intensity levels.  Reduction in pain intensity was associated with improvements in 
subjectively reported outcomes of pain unpleasantness, pain suffering, and pain 
behaviors. 
  The range of doses observed in the study indicates a large variance between 
individuals with respect to the extent of tolerance/sensitivity to narcotic medication dose.  
Achieving an optimal dose response varies across individual patients.  The expertise and 
experience of pain management professionals are crucial to the achievement of a 
customized narcotic regimen for pain patients.  A customized regimen minimizes the 
potential for adverse events, narcotic abuse, and the associated costs while improving 
patient outcomes. 
Data from this study validated a four stage conceptualization of the pain process.   
The measurement model at baseline and follow-up were equivalent, which suggested 
reliability of the stages of pain model constructs measured at both waves. 
                                                 
350 Spreen O, Strauss E.  A compendium of neuropsychological tests.  Administration, norms, and 
commentary.  Oxford University Press.  New York. 1998. 
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Although statistical support for the stages of pain model in its current form was 
found, an alternate specification of the structural relationship may be plausible.  The 
measurement component of the model may be improved by incorporating measures of 
self-efficacy measures in the model. 
  Frequency of pain behaviors at baseline were inversely associated with 
performance on cognitive function tests designed to measure short-term memory (digit 
span test), motor skills (digit symbol test), and information processing and attention 
(PASAT).  Improvement in pain behaviors resulted in corresponding improvements in 
cognitive function test scores.  This improvement was observed at all levels of pain 
behaviors.  Thus, therapies targeted toward improving function in chronic pain patients 
may also contribute to improvements in short-term memory, motor skills, and 
information processing ability. 
 Benzodiazepine use was associated with impaired motor skills and information 
processing ability.  Thus, treatment of anxiety with benzodiazepines should be 
reconsidered in chronic non-malignant pain populations. 
 Opioid therapy, particularly, long-acting morphine therapy (Avinza) does not 
contribute to cognitive impairment in chronic pain patients.  Sustained release 
formulations of narcotics serve as one of several important tools for pain relief in a 
multidisciplinary pain management setting.  In addition to pain relief, sustained release 
narcotics may contribute to improvements in neuropsychological functioning through 
mechanisms that enhance patient beliefs and reduce pain behaviors. 
 
5.6 Future Research 
The results from this study highlighted several deficiencies associated with the 
stages of pain model, particularly in the case of the pain beliefs construct.  Prior research 
has shown that pain beliefs are predictive of numerous outcomes including depression 
and pain behaviors, thus the stages of pain model would be served better if the pain 
beliefs construct were evaluated with robust reliable and valid measures.  The 
methodology to evaluate pain behaviors were strikingly different from those used to 
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assess other stages of pain items.  Thus, an alternative means to assessing pain behaviors 
would also lead to improvements in the stages of pain model.   
 The analyses in the present study could have certainly improved with a sub-group 
analysis.  Assessment of cognitive outcomes in sub-groups such as those formed with 
patients having varying levels of education, depression, or pain behaviors may allow 
providers to design targeted interventions for patients. 
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Tabulated Summary of Literature Examining the Efficacy and Safety of Opioid Therapy in Chronic Non-Malignant Pain 
Author 
(Study Design) 
# of 
Participants 
Diagnosis Drug Treatment Duration of 
trial 
Efficacy Adverse Effects Comments 
Maier C et al. - 
2002 
Multicenter, 
prospective, 
randomized, 
double blind 
placebo-
controlled cross 
over trial 
  
 
 
 
 
 
 
 
 
 
 
 
 
Attal N et al. - 
2002. 
Randomized, 
double-blind 
placebo 
controlled 
crossover trial 
 
 
 
 
 
Group 1 – 26,  
One dropped out 
prior to drug 
administration 
 
Group 2 –23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N = 15 
 
 
 
 
 
 
 
 
 
 
 
Neuropathic 
Pain 
- Post herpetic 
neuralgia (4) 
 
- Neuralgia 
(11) 
- 
Radiculopath
y or 
myelopathy 
(12) 
- Other (6) 
Nociceptive 
Pain 
- LBP (12) 
- Other 93) 
 
 
 
 
 
Post stroke 
pain (n= 9)  
 
Spinal cord 
injury (n=6) 
 
 
 
 
 
 
 
 
SR Morphine  
 
 
Placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV Morphine 
 
0.9% Saline 
 
Open label 
sustained release 
therapy after 4 
weeks 
 
 
 
 
 
2 weeks  
Group 1 – 
Morphine – 
week 1 
Placebo – 
week 2 
Group 2 – 
Reverse order 
 
 
 
 
 
 
 
 
 
 
 
 
 
Double blind 
phase – 4 
weeks 
 
Open label 
trial - > 1 year 
 
 
 
 
 
 
Intent-to-treat analysis 
no pain or good pain 
tolerance (morphine, n – 
19) (Placebo, n - 3) 
Just bearable pain – 
(morphine, n – 17) 
(placebo, n – 16) 
 
50% pain relief – 
Morphine (n – 16) 
Placebo (n – 1) 
 
50% pain relief (NRS) 
Morphine (n – 20) 
Placebo (n – 1) 
 
Tolerability of pain 
Morphine (n – 36) 
Placebo (n – 17) 
 
 
 
Average Pain reduction 
IV Morphine – 46.2% 
Saline – 24% 
 
50% reduction in pain 
IV Morphine (n = 7) 
Saline (n = 2) 
 
Mean difference in pain 
after 4 weeks with oral 
therapy 
20 mm (n = 8) 
Tolerability of side 
effects 
Morphine 
(n – 38) 
Placebo 
(n – 41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 patients 
discontinued 
treatment due to 
adverse effects 
 
 
 
 
 
 
 
 
More patients with 
neuropathuc pain 
fulfilled criteria of 
full responders 
than patients with 
nociceptive pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Long-term opioid 
therapy was 
beneficial in a 
small proportion 
of patients 
 
 
 
 
 
 
 
Patients preferred 
treatment with the 
                                                 
351 Wilder-Smith CH, Hill L,  Spargo K, Kalla A..  Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine 
in combination with NSAIDs: a randomized study comparing analgesia, antinociception and gastrointestinal effects.  Pain.  2001;91:23-31. 
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Allan L et al. – 
2001. 
Multi-center, 
randomized, 
open-label 
crossover study 
to determine 
preference 
 
 
 
 
 
 
Wilder Smith 
CH et al351. – 
2001 
Open-label, 
randomized, 
parallel group 
study.   
 
 
 
 
 
 
 
 
 
 
 
 
Roth SH et al. – 
Randomized, 
double-blind 
placebo 
controlled trial 
followed by an 
open-label study 
 
MS Contin 
(average dose =  
133.1 mg/day) 
(n = 92) 
 
Duragesic 
(average dose =  
57.3 µg/hour)  
(n = 104) 
 
196 of 256 
patients 
completed trial 
 
Dihydrocodeine  
slow release (n 
=29)  Average 
dose day 28 = 
130 mg 
Tramadol slow 
release (n =28) 
Average dose 
day 28 = 203 mg 
NSAIDs only (n 
= 30) 
Opioid groups 
also received 
concomitant 
NSAID 
medication and 
breakthrough 
pain medication. 
 
CR Oxycodone 
(n = 44) 20 mg 
daily 
 
CR Oxycodone 
(n = 44) 40 mg 
daily 
 
Chronic non-
cancer pain 
(nociceptive 
and 
neuropathic) 
 
 
 
 
 
 
 
 
 
Osteoarthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osteoarthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dihydrocodeine 
60mg (bid) 
 
Tramadol 100mg 
bid 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data were 
collected at 
day 7, 16, and 
28 of each 
treatment 
period. 
 
 
 
 
 
 
 
One week 
observation 
followed by 4 
weeks 
treatment with 
follow-ups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Placebo 
controlled trial 
14 days 
Open label 
trial 
Follow-up 
6 months 
 
Average pain intensity 
ratings were significantly 
lower (p < 0.001) with 
fentanyl (57.8 cm, range – 
33.1 to 82.5) than with SR 
morphine (62.9, range – 
41.2 to 84.6) 
 
 
 
 
 
 
 
Pain intensity at rest  
Significantly lower in 
tramadol group (p < 0.04) 
Pain Intensity during 
movement 
- No difference between 
groups, however pain 
intensity was lower at 
follow-up 
Quality of sleep and pain 
tolerance threshold at the 
arthritic joint improved in 
the opioid treatment groups 
 
 
 
 
 
 
Patients receiving the 40mg 
dose experienced 
significant improvements in 
pain intensity over the other 
groups. 
Improvements in sleep 
quality and mood were 
 
Incidence of side-
effects was similar 
in both groups, i.e., 
fentanyl (74%) and 
MS Contin (70%). 
 
 
 
 
 
 
 
 
 
Constipation was a 
major side-effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29.5% patients 
withdrew from the 
treatment groups 
due to adverse 
effects.  
 
 
patch over oral 
opioid therapy. 
 
 
 
 
 
 
 
 
Good analgesic 
control with 
minimal side-
effects were 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement in 
pain and pain 
control was 
observed over 18 
months and 
symptoms 
returned after 
drug withdrawal. 
 
 
Treatment with 
methadone 
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for six months.  
 
 
Taylor WF et al 
– 2000 
Follow-up study 
two-years after 
initiation of 
treatment. 
 
 
 
 
 
 
 
Caldwell JR et 
al. – 1999 
Open-label 
titration 
followed by a 
randomized, 
double blind, 
placebo 
controlled trial 
for 30-days. 
 
 
 
Jamison RN et 
al. – 1998. 
Randomized, 
open, long-term, 
repeated dose 
trial. 
 
 
 
 
 
 
Placebo 
N = 59 
 
Methadone On 
N = 19 
Methadone Off 
N = 26 
Lost to follow-
up 
N = 19 
 
 
 
 
 
 
Oxycontin 10mg 
bid (n = 34) 
Percocet 
(Oxycodone/AP
AP –5/325 mg) 
qid (n = 37) 
Pacebo (n = 36) 
 
 
 
 
 
 
Randomization 
phase 
 
Naproxen – 
Maximum daily 
dose = 1000 mg 
Oxycodone 
Maximum daily 
dose =20mg 
Titrated dose 
Oxycodone + 
Sustained 
 
 
 
Chronic non-
malignant 
pain 
 
 
 
 
 
 
 
 
 
 
Osteoarthritis 
 
 
 
 
 
 
 
 
 
 
 
 
Moderately 
severe back 
pain. 
 
 
 
 
 
 
 
 
 
12 months 
18 months 
 
Average 
duration – 
18.6 months 
 
 
 
 
 
 
 
 
 
 
Titration phase 
– 30 days 
Randomizatio
n phase 
 
 
 
 
 
 
 
 
 
Randomizatio
n phase – 16 
weeks 
 
All  patients 
subsequently 
eligible for 
oxycodone 
and SR 
morphine and 
followed upto 
16 weeks. 
observed at the end of 18 
months 
 
53% ON Methadone 
returned to work 
23% OFF Methadone 
returned to work. 
 
 
 
 
 
 
 
 
 
Percocet and Oxycontin 
produced comparable result 
for pain intensity. 
All three groups reported 
mean increase in pain 
intensity, 
Placebo (1.00, s.d.= 0.13) 
Oxycontin (0.44, s.d. = 
0.13) 
Percocet (o.49, s.d. = 0.11) 
 
 
 
Average pain intensity 
ratings at 16 weeks on a 0-
100 scale 
 
Naproxen  - Increased by 
1.2  
Oxycodone – Decreased by 
7.4 points Oxycodone + SR 
Morphine – Decreased by 
15.9 
Anxiety, depression, 
irritability were 
 
 
 
12 patients in the 
OFF group 
discontinued 
therapy due to side-
effects 
 
 
 
 
 
 
 
 
53 patients 
withdrew from the 
study due to 
adverse effects (n 
=36) and poor pain 
control (n = 17) 
 
 
 
 
 
 
 
Side effects 
occurred more 
frequently in the 
groups receiving 
opioid treatment. 
 
 
 
 
 
 
 
provided relief, 
thereby allowing a 
subgroup of 
patients to return 
to work.   
Short-acting 
analgesics are 
associated with 
greater dysphoria 
 
Overall sleep 
quality improved 
on long acting 
therapy, 
worsened on 
placebo, and did 
not change with 
short-acting 
therapy. 
 
 
 
 
Although patients 
experienced 
improvement in 
pain and mood, 
they did not report 
an increase in 
activities.  
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Watson CPN, 
Babul N. - 1998 
Randomized, 
double-blind 
crossover trial 
 
 
 
 
 
 
Haythornwaite 
et al. –1998. 
Open-label, long 
acting group vs 
usual care 
 
 
 
 
 
 
 
 
 
 
 
 
Dellemjijn L et 
al. – 1998 
release 
morphine 
 
Phase 2 – All 
patients eligible 
for the 
combination 
Maximum daily 
dose = 200mg 
 
 
N = 38 
Oxycodone SR 
(10 mg) 
Placebo 
Patients 
permitted to take 
NSAIDs as 
usual. 
 
 
 
Methadone/SR 
Morphine (n = 
19) 
Short-acting 
opioids on a 
fixed-schedule 
(n = 10). 
 
 
 
 
 
 
 
 
 
 
Transdermal 
fentanyl 
 
 
 
 
 
 
 
 
 
 
 
Postherpetic 
neuralgia 
 
 
 
 
 
 
 
 
 
Chronic pain 
that persisted 
longer than  
six months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-cancer 
neuorpathic 
 
 
 
 
 
 
 
 
 
 
 
4 weeks 
 
 
 
 
 
 
 
 
 
 
Long-acting 
group – Mean 
= 5.8 months 
Short-acting 
group – Mean 
= 3.0 months. 
 
 
 
 
 
 
 
 
 
 
 
12 week trial, 
followed by a 
significantly lower for 
opioid groups compared to 
naproxen group. 
 
 
 
 
 
 
 
 
Reports on average pain 
intensity measured by VAS 
and categorical rating 
scales were significantly 
lower in the opioid groups 
(p < 0.001). 
No significant differences 
were observed on BDI 
scores 
 
 
Pain severity self-reported: 
Long-acting group 
Mean difference  = - 1.93 
Short-acting group 
Mean difference  = -0.24. 
Patients on long-acting 
opioids reported lower 
levels of anxiety and 
hostility at follow-up. 
Performance on tests of 
cognitive function did not 
decline in the long-acting 
group and improved on the 
Digit Symbol test.  
 
 
 
43.33% experienced greater 
than 50 percent relief in 
 
 
 
 
 
 
 
 
 
 
 
Five participants 
withdrew while on 
opioids and three 
while on placebo 
due to side-effects.  
 
 
 
 
 
 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most commonly 
observed side-
 
 
 
Opioid analgesics 
may be effective 
in some 
neuropathic pain 
conditions. 
 
 
 
 
 
Treatment with 
long-acting opiod 
therapy did not 
result in 
deterioration of 
performance on 
tests of cognitive 
function. 
 
 
 
 
 
 
 
 
A subgroup of 
neuropathic pain 
patients can be 
effectively treated 
with long-acting 
narcotic 
analgesics. 
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Open-label 
prospective  
study.  
 
 
 
 
 
 
 
 
 
Dellemijn PL & 
Vanneste JA. – 
1997 
Randomized 
double-blind 
active-placebo-
controlled 
crossover trial. 
 
 
 
 
 
 
 
 
 
 
Moulin DE et al. 
– 1996 
Randomized 
double-blind 
crossover study. 
 
 
 
 
 
 
Morphine SR 
(60 mg) 
N = 48, 30 
completed the 
trial 
 
 
 
 
 
 
 
Group 1 – 
Randomized to 
Fentanly 
(Average dose = 
873 µg) or 
diazepam first 
(active placebo, 
average dose 
52.1 mg) (n = 
27) 
Group 2 - 
Randomized to 
Fentany 
(Average dose = 
873 µg) or 
saline first 
 
 
SR morphine 
(Average dose = 
83.5 mg) 
Benztropine 
(Active placebo) 
N = 61 
 
 
 
 
 
pain 
 
 
 
 
 
 
 
 
 
 
 
Nociceptive 
nerve pain, 
deaffrentation 
pain, and 
mixed 
neuropathic 
pain 
 
 
 
 
 
 
 
 
 
 
 
Chronic 
persistent 
musculoskelet
al pain 
(persistent 
pain ≥ 6 
months) 
 
 
 
 
washout 
period. 
Patients were 
ten permitted 
to continue on 
the drug. 
Final 
evaluation 
made at 2 
years. 
 
 
One week 
titration phase.   
Patients were 
observed for 8 
hours after 
infusions. 
 
 
 
 
 
 
 
 
 
 
 
 
Titration phase 
– 3 weeks 
Evaluation 
Phase – 6 
weeks 
Washout 
phase 
Washout 
phase – 2 
weeks 
 
pain intensity, while the 
rest experienced less than 
50 percent relief 
 
Proportion of patients with 
≥ 50% pain relief was 
greater among those 
receiving fentanyl (65.4% 
and 50%) than among those 
receiving diazepam 
(15.4%) or saline (8.3%). 
 
Pain intensity ratings were 
significantly lower in the 
group that received 
morphine first (p < 0.02).  
Patients that received 
placebo first were not 
responsive to either 
treatment. 
 
 
 
 
 
 
 
 
 
 
Overall mean pain intensity 
measured by VAS (p = 
0.0001) and categorical 
scales (p = 0.0001) were 
significantly lower in the 
treatment group. 
Use of breakthrough 
medication was 
significantly greater in the 
placebo group (p = 0.0001). 
 
effects were: 
nausea, vomiting, 
pruritis, 
constipation. 
 
Addiction was not a 
problem 
 
 
 
 
 
Nausea, vomiting, 
dry mouth, light 
headedness, 
floating sensations, 
and itching were 
more commonly 
reported by patients 
receiving fentanyl. 
 
 
 
 
 
 
 
 
 
  
Seven patients 
withdrew while on 
codeine and one on 
placebo due to side 
effects.  
Constipation, 
nausea, 
somnolence, and 
pruritis were more 
commonly observed 
in the treatment 
 
Long-acting 
opioid therapy 
may be effective 
in patients with 
neuropathic pain 
(without 
significant 
psychological 
comorbidity) who 
have not obtained 
benefit from other 
analgesic therapy. 
 
 
 
 
Morphine reduced 
pain intensity, 
however no 
improvement in 
cognitive or 
functional status 
was observed. 
 
 
 
 
 
 
Treatment with 
long-acting opioid 
therapy provides 
sustained pain 
relief evidenced 
by a reduction in 
use of 
breakthrough pain 
medication. 
 
Management of 
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Arkinstall et al. 
– 1995.  
Randomized, 
double-blind, 
placebo 
controlled 
crossover trial. 
 
 
 
 
McQuay HJ et 
al. – 1992. 
Open-label, 
patient 
controlled 
analgesia trial 
 
Bouckoms AJ et 
al. – 1992. 
Retrospective 
review. 
 
 
 
 
 
 
Jadad AR et al. 
– 1992 
Randomized 
double-blind 
crossover 
patient 
controlled 
analgesia study 
Tennant F et al. 
– 1988. 
 
 
 
CR codeine 
(average dose = 
273 mg) 
Placebo 
Acetaminophen 
+ Codeine – 
300/30 for 
breakthrough 
pain. 
(n = 46) 
 
IV Morphine 
N = 22 
 
 
 
 
 
Oxycodone 
derivatives, 
codeine, 
meperidine, 
methadone 
N = 59 
 
 
 
 
IV Morphine 
Doses: 10mg/ml  
30mg/ml 
Average dose = 
230 mg 
10 of 13 patients 
completed the 2 
study phases 
oxycodone, 
methadone, 
 
 
 
Chronic 
nonmalignant 
(rheumatic or 
back) pain 
 
 
 
 
 
 
 
Chronic non-
malignant and 
cancer pain. 
 
 
 
 
Nociceptive 
and 
neuropathic 
pain. 
 
 
 
 
 
 
Nociceptive 
and 
neuropathic 
pain. 
 
 
 
 
Chronic 
nociceptive 
 
 
 
Patients were 
on either 
codeine or 
placebo for a 
week and then 
crossed over to 
corresponding 
treatment. 
 
 
 
24 hours 
 
 
 
 
 
 
Average 
duration of 
treatment with 
narcotic 
analgesics – 
36 months. 
 
 
 
 
Eight hours 
 
 
 
 
 
 
 
Patients were 
on narcotic 
 
 
 
Response measured by 
100mm VAS 
Greater than 70 mm 
reduction in pain – 54.54% 
<70mm and >30mm pain 
relief at two or more 
assessment times – 18.18% 
< 30mm pain relief and 
intolerable side effects – 
22.72% 
 
Pain relief: 
Complete – 34% 
Partial – 46% 
No relief – 20% 
 
 
 
Superior response was 
observed with the higher 
dose of morphine. 
Side effect frequency was 
greater with the lower dose 
of morphine. 
 
 
 
 
88.5%of patients achieved 
adequate pain control 
 
 
 
 
 
 
Adequate but incomplete 
pain relief without 
group. 
 
 
Side-effects 
observed included 
nausea, vomiting, 
sweating, itching, 
and lack of 
concentration, 
 
 
 
 
 
24% became 
addicted. 
22% developed 
tolerance to opioid 
analgesia, 
 
 
Common side 
effects were 
drowsiness, 
itchiness, and 
concentration 
difficulties. 
 
 
 
 
Constipation and 
edema were most 
commonly observed 
 
 
 
 
 
Most common side-
effects were 
neuropathic pain 
syndromes should 
not be excluded 
as a possibility. 
 
Neuropathic pain 
and comorbidities 
such as 
depression, 
abuse, and 
addiction were 
associated with a 
poor response. 
 
Bothtypes of pain 
(nociceptive and 
neuropathic) were 
responsive to 
opioid treatment. 
 
Treatment of pain 
with opioids 
should be 
considered as a 
last line of 
therapy. 
 
 
 
 
Long-term opioid 
therapy in CNMP 
patients is safe 
and effective. 
 
 
 
 
Long-term opioid 
therapy was 
associated with 
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Open-label trial 
 
 
 
 
 
 
 
Portenoy RK, 
Foley KM. – 
1986. 
Retrospective 
evaluation. 
 
 
 
 
Schofferman, 
1999. 
Open label 
opioid trial 
 
 
 
 
 
 
 
Milligan et al. – 
2001 
Open label trial 
 
codeine, 
propoxyphene, 
hydromorphone, 
meperidine, and 
hydrocodone 
Variable doses 
n = 52 
 
Methadone,  
levorphanol, 
oxycodone,  
propoxyphene, 
meperidine, 
codeine, 
pentazocine,  
N = 38 
 
Various narcotic 
analgesics 
N = 33, 
 
 
 
 
 
 
 
 
Average 
fentanyl dose = 
90 µg/hour at 
the end of the 
study 
301/532 patients 
completed the 
study. 
 
and 
neuropathic 
pain. 
 
 
 
 
 
Intractable, 
non-
malignant 
pain patients. 
 
 
 
 
 
Chronic low 
back pain 
 
 
 
 
 
 
 
 
 
Chronic non-
malignant 
pain patients 
with moderate 
response to 
other opiodis. 
analgesic 
therapy for 
varying 
lengths of 
time. 
 
 
 
Patients were 
included in the 
review if they 
had received 
opioid therapy 
for 6 or more 
months. 
 
 
6-12 weeks 
initial 
treatment; 
long-term 
follow-up in 
patients with 
improvement.  
Avg. Follow-
up duration  
was 32 months 
 
Final follow-
up 
assessments 
were made 12 
months after 
baseline. 
 
 
 
 
 
substantial improvement in 
functional status 
 
 
 
 
 
 
29% of patients reported 
adequate relief (n =11) 
 
34 % of patients reported 
partial relief (n =13). 
 
37 % of patients reported 
episodic sever pain (n = 14) 
 
Pain scores and disability 
scores improved by 3.6 and 
13.8 points measured on a 10 
and 100 point scale 
respectively (n =21). 
Seven patients did not 
respond to therapy.   
 
 
 
 
On average, patients 
reported pain  to have 
improved from severe/very 
severe to moderate. 
 
 
 
 
 
 
 
constipation and 
edema of the 
extremities. 
 
 
 
 
 
Abuse and 
diversion became 
apparent in two 
cases.  No other  
significant side-
effects were 
reported by 
patients. 
 
Five patients 
discontinued trial 
due to intolerable 
side-effects.  
Specific side-effects 
were not reported. 
 
 
 
 
 
Frequently reported 
side-effects include: 
nausea, 
constipation,  and 
somnolence. 
Respiratory 
depression,  drug 
abuse/dependence, 
and withdrawal 
were rarely 
observed. 
reduction in pain 
and disability. 
 
 
 
 
 
Fentanly use in 
chronic pain was 
associated with 
very minor 
improvements in 
quality of life 
dimensions 
(physical, mental, 
and social). 
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Chronic Pain Study 
 
Dear Patient, 
 
Chronic pain affects a significant part of society.  Often, patients do not find relief from 
pain despite attempting treatment with several pain management strategies.   Pain 
medications form an integral part of the treatment of chronic pain.  Although pain may 
originate from biological sources, psychological and social factors also constitute the pain 
process. 
 
We, Ravi Panjabi, MD (Advanced Pain Management Group Inc.), Sumeet Punjabi, B. 
Pharmacy, MS and Marvin Shepherd Ph.D. (University of Texas at Austin) are currently 
conducting a research project to examine the effects of pain medications.  The project 
involves the completion of several forms and paper-based tests to measure attention and 
ability to process information.  None of these tests are intended to be stressful, nor will 
they in any way influence your treatment.  You will not be asked to take any special 
medications or undergo any special treatments other than what your physician 
recommends for the treatment of your pain condition. 
 
Your participation in this study is voluntary.  Your decision to either participate or 
decline participation in this project will in no way influence the level of care that you 
shall receive at Advance Pain Management Group Inc. 
 
Participation will require approximately one hour of your time on two separate occasions.  
As a recognition of your time and willingness to participate in the study, you will receive 
a coupon for your medications (subject to change). 
 
Thank you for your assistance. 
 
Sincerely, 
 
Sumeet Punjabi M.S.    Marv Shepherd Ph.D. 
Doctoral Candidate    Director 
Pharmacy Administration Division   Pharmacy Administration Division 
College of Pharmacy    College of Pharmacy 
University of Texas at Austin   University of Texas at Austin 
 
 
Ravi Panjabi M.D. 
Physician & Director 
Advanced Pain Mangement Group Inc. 
Castro Valley, CA 
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IRB#  ________________ 
 
Informed Consent to Participate in Research 
 
The University of Texas at Austin 
 
You are being asked to participate in a research study.  This form provides you with 
information about the study. The Principal Investigator (the person in charge of this 
research) or his/her representative will also describe this study to you and answer all of 
your questions. Please read the information below and ask questions about anything you 
don’t understand before deciding whether or not to take part. Your participation is 
entirely voluntary and you can refuse to participate without penalty or loss of benefits to 
which you are otherwise entitled.   
 
 
Title of Research Study: 
 
Cognitive Function in Chronic Non-Malignant Pain Patients Treated with Long-Acting 
Narcotic Analgesics 
 
 
Principal Investigator(s) (include faculty sponsor), UT affiliation, and Telephone 
Number(s):   
 
Sumeet Punjabi, M.S. 
Graduate Student/Doctoral Candidate 
512-417-8006 
 
Marv Shepherd, Ph.D. 
Professor/ Director, Center for Pharmacoeconomic Studies 
512-471-8762 
 
Ravi Panjabi, M.D. 
Physician-in charge 
Advanced Pain Management and Rehab Group, Inc 
510-461-0482 
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Funding source: 
 
This study is not funded 
 
What is the purpose of this study?   
 
You are being asked to participate in this study because your physician has decided to 
switch your therapy from short-acting narcotic analgesic medications to long-acting 
narcotic analgesic medications.  The purpose of this study is to evaluate the effects of this 
switch on your pain, emotional status, usual activities, and attention.   
 
What will be done if you take part in this research study? 
 
If you decide to take part in the study, we will ask you to complete several forms that are 
intended to examine various aspects of your pain condition.  The following aspects of your 
condition will be assessed on two separate occasions: 
 Severity of pain 
 Negative emotions due to pain 
 Negative beliefs about pain 
 Interference in activities due to pain 
 Beck Depression Inventory – a screening tool designed to assess depression 
 Dose of narcotic analgesic and benzodiazepine 
 Medical chart information to assess duration of pain, type of pain, location of pain, 
and other relevant information 
 Performance on three measures of attention 
 
A portion of the interview may be taped to ensure accurate transcription of the information 
you provide.  Completion of these forms may require 45 to 60 minutes of your time on two 
occasions about one month apart.  In addition, you will be required to come into the clinic 
each week for the three intermittent weeks in order for us to monitor your progress.  Based 
on these progress assessments, dosage of the long-acting narcotic analgesic may be 
modified to achieve better pain control or minimize side-effects. 
 
You will be asked to complete the following three tests intended to assess your attention: 
digit span backwards and forwards test; digit symbol test; and the paced auditory serial 
addition test.  These assessments will evaluate your attention by asking you to complete 
some exercises using numbers and symbols on two occasions.  The total time to complete 
these tests for each visit will be approximately 20 minutes. 
 
What are the possible discomforts and risks? 
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The study poses minimal risk to you as a patient.  Most of the forms are straightforward 
and easy to complete.  One test, i.e., the PASAT is a little difficult and intensive.  The 
purpose of the test is not to evaluate your knowledge, but ability to concentrate due to 
your chronic pain condition. 
Some side-effects associated with the use of long-acting narcotic analgesics include: 
constipation, nausea, vomiting, sweating, itching, and somnolence.  It is recommended that 
alcohol not be consumed while using these narcotic analgesics.  In addition, these agents 
may produce sedative effects, and thus you should limit activities that involve driving or 
operating heavy machinery. 
 
Although the utmost precautions will be taken to maintain confidentiality, loss of 
confidentiality is a potential risk that you should be aware of.  A detailed description of the 
measures that will be taken to minimize this possibility is provided below. 
 
 
What are the possible benefits to you or to others? 
 
 One benefit of participating in the study is the routine follow-up visits that would 
enable optimal dosage titrations of the long-acting narcotic analgesic.  Side-
effects associated with the use of long-acting narcotics will be addressed sooner 
as you will be required to visit the clinic every week for four weeks as opposed to 
usual care where patients visit the clinic once every two weeks in a four week 
period. 
 Results from this study may provide health providers with information about the 
potential benefits of using long-acting opiate pain medications. 
 
 
If you choose to take part in this study, will it cost you anything? 
 
 Your choice to participate in this study will not present any additional financial burden on 
you.  Any charges that you incur would be those that would be billed to you by the clinic 
for routine treatment and would be the same if you did not participate in this study.  Your 
insurance company will be billed for the two extra visits due to the study; however, you 
will not receive copay charges for these extra visits.  You will bear no financial 
responsibility for these extra visits. 
 
Will you receive compensation for your participation in this study? 
What if you are injured because of the study?   
  
You will not receive any compensation for participation in this study.  The study does not 
pose any “known” physical risk or harm to you as a patient.  Discomfort or side-effects due 
to medications will be treated as usual by physician-in-charge.  Your insurance will be 
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charged for the provision of such care.  No payment can be provided in the event of a 
medical problem. 
Continuing medical care and/or hospitalization for research-related injuries will not be 
provided free of charge nor will financial compensation be available either from the 
physician-in-charge, researchers, or the University of Texas at Austin. 
 
 
If you do not want to take part in this study, what other options are available to 
you? 
Participation in this study is entirely voluntary. You are free to refuse to be in the study, 
and your refusal will not influence current or future relationships with The University of 
Texas at Austin. You are free to refuse to participate in the study or withdraw from the 
study at any time.  Your decision to not participate or withdraw from the study will not 
influence the medical care you receive at Advanced Pain Management and Rehab Group 
Inc or with your current physician. 
In addition to treatment with long-acting narcotic therapy, your physician will advise you 
of alternative treatments for pain relief such as injections (epidural and nerve blocks), 
prosthetic devices, transcutaneous electrical nerve stimulation, H-wave therapy, physical 
therapy, acupuncture, and massage. 
 
 
How can you withdraw from this research study and who should I call if I have 
questions? 
 
If you wish to stop your participation in this research study for any reason, you should 
contact: Sumeet Punjabi at (512) 417 8006 or Dr. Ravi Panjabi at (510) 461 0482.   You are 
free to withdraw your consent and stop participation in this research study at any time 
without penalty or loss of benefits for which you may be entitled. Throughout the study, the 
researchers will notify you of new information that may become available and that might 
affect your decision to remain in the study.  
 
In addition, if you have questions about your rights as a research participant, please 
contact Clarke A. Burnham, Ph.D., Chair, and the University of Texas at Austin 
Institutional Review Board for the Protection of Human Subjects, 512/232-4383. 
 
How will your privacy and the confidentiality of your research records be protected? 
 
 Everything we learn about you in the study will be confidential and your 
information will be maintained private.  All the information you give us including audio 
tapes with voice recordings will be kept locked in your physician’s office.    
 Your medical chart will be reviewed to obtain information on birth date, medical 
record number, medications, diagnosis, type of pain, duration of pain and prior surgery.  
Access to this information will be limited to the researchers and the charts will never 
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leave the clinic.  Any information transcribed from the medical charts will be coded and 
information that can be used to identify you removed so as to protect patient identity.  
The charts shall in all circumstances be maintained under the control of Advanced Pain 
Management and Rehab Group, Inc.  
 A voice recorder will be used to facilitate data transcription.  While at the clinic 
collecting data, all tapes will be maintained in a locked filing cabinet.  The use of the 
tapes is to ensure that the information obtained from your tests is recorded correctly.  The 
tapes will be maintained until the end of the study and subsequently erased. 
 All data will be coded at the clinic.  The data will be coded without any patient 
identifiers (name, medical record number, date of birth) using only the study 
identification number assigned to each patient to link coded data with chart information.  
Patient names, addresses, and other patient identifiers will be deleted from the file.  
Specific detailed dates, such as day, month, and year of birth will be converted to only 
the year.  Thus, any data that leaves the clinic will be de-identified.  Any data or 
information brought to the University of Texas at Austin will be in a de-identified 
fashion.  All the results from this study will be presented in an aggregated form that 
would prevent your identification.  At the University of Texas, the researcher and the 
researcher’s major professor are the only people who will have access to the data. 
 
Authorized persons from The University of Texas at Austin and the Institutional Review 
Board have the legal right to review your research records and will protect the 
confidentiality of those records to the extent permitted by law.  If the research project is 
sponsored then the sponsor also has the legal right to review your research records. 
Otherwise, your research records will not be released without your consent unless required 
by law or a court order. 
 
If the results of this research are published or presented at scientific meetings, your identity 
will not be disclosed. 
 
 
 
Will the researchers benefit from your participation in this study ? 
 
The researchers will not obtain any monetary benefit from your participation in the study. 
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Signatures: 
 
As a representative of this study, I have explained the purpose, the procedures, the benefits, 
and the risks that are involved in this research study: 
 
 
 
_____________________________________ ___       
Signature and printed name of person obtaining consent          Date 
 
You have been informed about this study’s purpose, procedures, possible benefits and 
risks, and you have received a copy of this Form. You have been given the opportunity to 
ask questions before you sign, and you have been told that you can ask other questions at 
any time. You voluntarily agree to participate in this study.  By signing this form, you are 
not waiving any of your legal rights. 
 
 
 
___________________________________________________________________ 
Printed Name of Subject                   Date 
 
 
___________________________________________________________________ 
Signature of Subject                   Date 
 
 
 
___________________________________________________________________ 
Signature of Principal Investigator                 Date  
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Instrument at Baseline and Follow-up 
 
Background Information 
 
Today’s Date: _________________ 
 
Medical Record Number*_________________  Study ID #_______________ 
 
Birth Date*______________     Gender ___Male  
 ___Female 
 
Ethnicity  
 
_____ Caucasian      _____African-American 
 
_____Hispanic/Latin American     _____American Indian 
 
_____Asian    _____Other, Please Specify: ___________________ 
 
 
Average Daily __________________ (short-acting narcotic analgesic) Dose^ 
 
Average Daily __________________ (benzodiazepine) Dose^ 
 
 
Duration of Pain __________________________________________________________ 
 
Other Medications*________________________________________________________ 
 
 
 
 
____________________________________________________________________________________________________________ 
 
Diagnosis* ____________________________ 
 
 
Type of Pain* ____Nociceptive  ____Neuropathic  ____Mixed 
 
 
Prior Surgery* ____Yes  ____No
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Pain Intensity VAS 
 
Indicate along the scale below the intensity of the painful sensation at its highest 
intensity during the past week.   
 
 
 
 
 
 
 
 
 
 
Indicate along the scale below the intensity of the painful sensation at its lowest intensity 
during the past week. 
  
 
 
 
 
 
 
 
 
 
Indicate along the scale below the intensity of the painful sensation at its usual intensity 
during the past week. 
 
 
 
 
 
 
 
 
 
 
No Sensation The most intense 
sensation imaginable 
No Sensation The most intense 
sensation imaginable 
No Sensation The most intense 
sensation imaginable 
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Pain Unpleasantness VAS 
 
"There are two aspects of pain which we are interested in measuring: the intensity, how 
strong the pain feels, and the unpleasantness, how unpleasant or disturbing the pain is  
for you.  The distinction between these two aspects of pain might be made clearer if you 
think of listening to a sound, such as a radio.  As the volume of the sound increases, I can 
ask you how loud it sounds or how unpleasant it is to hear it.  The intensity of pain is like 
loudness; the unpleasantness of pain depends not only on intensity but also on other 
factors which may affect you.352" 
 
Indicate along the scale below how unpleasant or disturbing your pain was when it was at 
its highest intensity during the past week. 
 
 
 
 
 
 
 
 
 
Indicate along the scale below how unpleasant or disturbing your pain was when it was at  
its lowest intensity during the past week. 
 
 
 
 
 
 
  
 
 
Indicate along the scale below how unpleasant or disturbing your pain when it was at its 
usual intensity during the past week. 
 
 
 
 
 
 
                                                 
352 Price DD, McGrath PA Rafii A, Buckinham B.  The validation of visual analogue scales as ratio scale 
measures for chronic and experimental pain.  Pain..  1983;17:45-56. 
Not bad at all The most intense 
bad feeling 
Not bad at all The most intense 
bad feeling 
Not bad at all The most intense 
bad feeling 
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Pain Beliefs 
 
For each of the following, indicate the extent by making a mark along the appropriate 
scale.  The further to the right, the greater the extent. 
 
1. How much does your pain prevent your from doing what you want to do? 
 
 
 
 
 
 
 
 
 
2. How difficult is it to endure the pain over time? 
 
 
 
 
 
 
 
 
 
3. In general, how much can you reduce the intensity of your pain if you want  
 
 
 
 
 
 
 
 
 
4. In general, how likely do you feel that your pain will be removed or cured? 
 
 
 
 
 
 
  
No 
Interference 
Complete interference 
Cannot do anything 
Not at all 
difficult 
The most difficult 
imaginable 
0%  I cannot 
reduce it at all 
100% I can reduce 
it completely 
Impossible Certain 
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Pain Suffering 
 
What kind of negative feelings accompany your pain? Check along each scale below the 
intensity of each feeling as it has related to your pain over the past week. 
 
1. Depression 
 
 
 
 
 
 
 
2. Anxiety 
 
 
 
 
 
 
3. Frustration 
 
 
 
 
 
 
4. Anger 
 
 
 
 
 
 
5. Fear 
 
 
 
None The most severe 
imaginable 
None The most severe 
imaginable 
None The most severe 
imaginable 
None The most severe 
imaginable 
None The most severe 
imaginable 
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Pain Behaviors 
 
Items from the Psychological Pain Inventory Assessing Pain Behaviors 
 
Ask specifically: “When you are at home and the pain is really bad, how can your 
family tell that you hurt that way?”  Ask about all pain behaviors that are not 
mentioned spontaneously.  Also ask how often the pain is bad enough that the 
patient ends up doing each of the pain behaviors he engages in.  Check each pain 
behavior which occurs with the frequency indicated.  Patients who live alone will be 
assigned a “0.” 
 
 Hold or grasp the area that hurts, 3 times a day or more =1 
 Wince or cringe, 3 times a day or more =2 
 Call a doctor, once a month or more = 3 
 Cry, once a week or more = 3 
 Moan, once a week or more = 3 
 Say it hurts, once a day or more.  Ask how this is done, and specify whether it is done 
with  
 no affect = 1 
 some affect = 2 
 much affect = 3 
 Pace, three times a week or more = 2 
 Go into another room by self, 3 times a week or more = 2 
 Lie down more than once a day = 2 
 If this happens at work too with any frequency = 3 
 Sit down, more than 3 times per day = 1 
 Change position frequently = 0  
 Scream, if at all = 3 
 Take medications = 0 (unless addicted; then =3) 
 Ask for help with things that patient would normally be able to do himself/herself, 
once a day or more = 3 
 Gets angry or irritable, 3 times per week or more = 2 
 Other (specify): _____________________________________ 
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Ask in relation to the pain behaviors considered generally: “When family members 
see you doing these things, and hurting especially badly, how do they respond to 
you?”  Again, ask about any response that is not mentioned spontaneously, 
determine the general frequency with which each response occurs, and check each 
response that occurs with the frequency indicated. 
 
 Express sympathy verbally, daily or almost everyday = 2 
 Withdraws from patient, daily or almost everyday = 0 (unless MMPI-SI 60; then 
= 2) 
 Encourages patient to take remedial action (i.e., to take meds, lie down, apply 
heating pad,  call doctor, etc.) daily or almost every day = 1 
 Helps patient take remedial action (i.e., gets the meds or heating pad, draws bath, 
calls doctor, etc) daily or almost everyday = 2 
 Actually administers remedial medication (i.e., gives back rub, holds patient, 
gives injection, etc.) daily or almost every day = 3 
 Offers to do whatever work the patient is either attempting to do or scheduled to 
do, when this is something the patient usually feels capable of doing, daily or 
almost every day = 3 
 Complains = 0 
 Does nothing (ignores patient) = 0 
 Other (specify): ________________________ 
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Use the following checklist to indicate what home or family related responsibilities 
the patient discharged prior to the pain problem as compared to now.  Under “ 
Before” check only those activities that the patient did at least half of the time before 
(i.e., it must have been primarily the patient’s responsibility – not mostly someone 
else’s in the family).  Check under “Less now” if, due to the pain, the frequency with 
which the patient does the activity has decreased but by no more than 50 percent.  
Check under “Never now” if the frequency has decreased by more than 50 percent. 
 
Responsibility  Before Less Now  Never Now 
 
Housecleaning ________ ________  ________ 
Clothes washing ________ ________  ________ 
Clothes ironing     ________     ________  ________ 
Shopping      ________     ________  ________ 
Cooking      ________     ________  ________ 
Repair work (home)     ________     ________  ________ 
Repair work (car)     ________     ________  ________ 
Yard work      ________     ________  ________ 
Errands      ________     ________  ________ 
Caring for children     ________     ________  ________ 
Disciplining children     ________     ________  ________ 
Driving other family members  ________     ________  ________ 
Family finances     ________     ________  ________ 
Family correspondence    ________     ________  ________ 
Other (specify): 
____________________    ________     ________  ________ 
____________________    ________     ________  ________ 
____________________    ________     ________  ________ 
 
 
Determine about how many daytime hours are spent lying down because of pain 
these days? 
No more than one hour per day = 0 
Greater than one but less than two hours per day = 1 
Two to four hours per day = 2 
More than four hours per day = 3 (Specify how many): ________ 
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Describe the patient’s pain behavior that you observed in the interview: 
 
 Held or grasped the area that hurt = 1 
 Winced or cringed = 2 
 Moaned = 3  
 Paced = 3  
 Changed position frequently = 1  
 Took medications = 3 
 Became irritable = 2 
 Asked to stop interview = 3 
 
 
 Said it hurt, not in direct response to a question or statement by the interview, with 
 
 much affect = 3 
 little affect = 2  
 some affect = 2  
 no affect = 1 
 
 Asked to call doctor = 3 
 No pain behavior was observed = 3 (0  if patient is currently getting very much or 
total relief from treatment). 
 
  
 329
Appendix E 
  
 330
Beck Depression Inventory 
 
Choose one statement from among the group of four statements in each question that best 
describes how you have been feeling during the past few days. Circle the number beside 
your choice.  
 
 
 
 
 
1 0 I do not feel sad.  
1 I feel sad.  
2 I am sad all the time and I can't snap out 
of   it.  
3 I am so sad or unhappy that I can't stand it. 
7 0 I don't feel disappointed in myself.  
1 I am disappointed in myself.  
2 I am disgusted with myself.  
3 I hate myself. 
2. 0 I am not particularly discouraged about 
the future.  
1 I feel discouraged about the future.  
2 I feel I have nothing to look forward to.  
3 I feel that the future is hopeless and that 
things cannot improve. 
8.  0 I don't feel I am any worse than 
anybody else.  
1 I am critical of myself for my 
weaknesses or mistakes.  
2 I blame myself all the time for my 
faults.  
3 I blame myself for everything bad that 
happens. 
3 0 I do not feel like a failure.  
1 I feel I have failed more than the average 
person.  
2 As I look back on my life, all I can see is 
a lot of failure.  
3 I feel I am a complete failure as a person. 
9 0 I don't have any thoughts of killing 
myself.  
1 I have thoughts of killing myself, but I 
would not carry them out.  
2 I would like to kill myself.  
3 I would kill myself if I had the chance. 
4 0 I get as much satisfaction out of things as 
I used to.  
1 I don't enjoy things the way I used to.  
2 I don't get any real satisfaction out of 
anything anymore.  
3 I am dissatisfied or bored with everything. 
10 0 I don't cry any more than usual.  
1 I cry more now than I used to.  
2 I cry all the time now.  
3 I used to be able to cry, but now I can't cry 
even though I want to. 
5 0 I don't feel particularly guilty.  
1 I feel guilty a good part of the time.  
2 I feel quite guilty most of the time.  
3 I feel guilty all of the time. 
11 0 I am no more irritated by things than I 
ever am.  
1 I am slightly more irritated now than 
usual.  
2 I am quite annoyed or irritated a good 
deal of the time.  
3 I feel irritated all the time now. 
6 0 I don't feel I am being punished.  
1 I feel I may be punished.  
2 I expect to be punished.  
3 I feel I am being punished. 
12 0 I have not lost interest in other people.  
1 I am less interested in other people than 
I used to be.  
2 I have lost most of my interest in other 
people.  
3 I have lost all of my interest in other 
people. 
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13 0 I make decisions about as well as I 
ever could.  
1 I put off making decisions more than I 
used to.  
2 I have greater difficulty in making 
decisions than before.  
3 I can't make decisions at all 
anymore. 
18 0 My appetite is no worse than usual.  
1 My appetite is not as good as it used 
to be.  
2 My appetite is much worse now.  
3 I have no appetite at all anymore. 
14 0 I don't feel that I look any worse than I 
used to.  
1 I am worried that I am looking old or 
unattractive.  
2 I feel that there are permanent changes 
in my appearance that make me look 
unattractive.  
3 I believe that I look ugly. 
19 0 I haven't lost much weight, if any, 
lately.  
1 I have lost more than five pounds.  
2 I have lost more than ten pounds.  
3 I have lost more than fifteen 
pounds.  
(Score 0 if you have been purposely 
trying to lose weight.) 
15 . 0 I can work about as well as before.  
1 It takes an extra effort to get started at 
doing something.  
2 I have to push myself very hard to do 
anything.  
3 I can't do any work at all. 
20 0 I am no more worried about my 
health than usual.  
1 I am worried about physical 
problems such as aches and pains, or 
upset stomach, or constipation.  
2 I am very worried about physical 
problems, and it's hard to think of 
much else.  
3 I am so worried about my physical 
problems that I cannot think about 
anything else. 
16 . 0 I can sleep as well as usual.  
1 I don't sleep as well as I used to.  
2 I wake up 1-2 hours earlier than usual 
and find it hard to get back to sleep.  
3 I wake up several hours earlier than I 
used to and cannot get back to sleep 
21 0 I have not noticed any recent 
change in my interest in sex.  
1 I am less interested in sex than I 
used to be.  
2 I am much less interested in sex 
now.  
3 I have lost interested in sex 
completely. 
17  0 I don't get more tired than usual.  
1 I get tired more easily than I used to.  
2 I get tired from doing almost anything.  
3 I am too tired to do anything 
  
  
SCORING 
 
 1 – 10: These ups and downs are considered normal. 
 11 – 16: Mild mood disturbance  
 17 – 20: Borderline clinical depression  
 21 – 30: Moderate depression  
 31 – 40: Severe depression  
 over 40: Extreme depression 
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Follow-up Dose Assessments 
 
 
Today’s Date: _________________ 
 
Medical Record Number*_________________  Study ID #_______________ 
 
 
Average Daily __________________ (long-acting narcotic) Dose in previous week^ 
 
 
Average Daily __________________ (breakthrough analgesic) Dose in previous week^ 
 
Average Daily __________________ (benzodiazepine) Dose in previous week^ 
 
 
 
 
 * Information will be obtained from patient chart 
^ Information will be obtained from patient 
 
  
 334
Appendix G 
  
 335
Digit Span Test 
 
Discontinue Rule 
Digits Forward & Backward 
Score of 0 on both trials of any item  
For both Digits Forward & Backward, administer both 
trials of each item even if Trial 1 is passed.  Administer  
Digits Backward even of examinee scores 0 on Digits 
Forward 
Scoring Rule 
Each Trial: 0 or 1 pt. for each response 
Item Score = Trial 1 + Trial 2 
 
Digits Forward 
Trial Item/response Trial Score 
Item 
Score 
(0,1, or 2) 
Digits Backward 
Trial Item/response Trial Score 
Item 
Score 
(0,1, or 2) 
1. 1 1-7     1. 1 1-7     
  2 6-3       2 6-3     
2. 1 5-8-2     2. 1 5-8-2     
  2 6-9-4       2 6-9-4     
3. 1 6-4-3-9     3. 1 6-4-3-9     
  2 7-2-8-6       2 7-2-8-6     
4. 1 4-2-7-3-1     4. 1 4-2-7-3-1     
  2 7-5-8-3-6       2 7-5-8-3-6     
5. 1 6-1-9-4-7-3     5. 1 6-1-9-4-7-3     
  2 3-9-2-4-8-7       2 3-9-2-4-8-7     
6. 1 5-9-1-7-4-2-8     6. 1 5-9-1-7-4-2-8     
  2 4-1-7-9-3-8-6       2 4-1-7-9-3-8-6     
7. 1 5-8-1-9-2-6-7-4     7. 1 5-8-1-9-2-6-7-4     
  2 3-8-2-9-5-1-7-4       2 3-8-2-9-5-1-7-4     
8. 1 2-7-5-8-6-2-5-8-4     
 
  
  2 7-1-3-9-4-2-5-6-8       
Digits Backward Total Score  
Maximum Score   
  
Digits Forward Total Score
Maximum Score        
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Digit Symbol Coding 
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